"Rank","NCT Number","Title","Acronym","Status","Study Results","Conditions","Interventions","Outcome Measures","Sponsor/Collaborators","Gender","Age","Phases","Enrollment","Funded Bys","Study Type","Study Designs","Other IDs","Start Date","Primary Completion Date","Completion Date","First Posted","Results First Posted","Last Update Posted","Locations","Study Documents","URL"
1,"NCT00523276","SARS Survivor Evaluations",,"Withdrawn","No Results Available","Coronavirus (SARS-CoV)",,"Positive serology, SARS CoV","National Institute of Allergy and Infectious Diseases (NIAID)","All","4 Years and older   (Child, Adult, Older Adult)",,"0","NIH","Observational","Observational Model: Family-Based|Time Perspective: Cross-Sectional","06-0048",,"June 2011","June 2011","August 31, 2007",,"April 29, 2013","Beijing Ditan Hospital, Beijing, Beijing, China|Beijing You'An Hospital, Beijing, Beijing, China",,"https://ClinicalTrials.gov/show/NCT00523276"
2,"NCT00533741","SARS Coronavirus Vaccine (SARS-CoV)",,"Withdrawn","No Results Available","Coronavirus (SARS-CoV)","Drug: Aluminum hydroxide|Drug: Placebo|Biological: SARS-CoV","Frequency and description of serious adverse events (SAEs).|Frequency of significant increases in serum antibody to CoV S protein in Enzyme Linked Immunosorbent Assay (ELISA) and in neutralization tests, and increases in Geometric Mean Titers (GMT)s in sera.|Frequency and severity of solicited injection site and systemic signs and symptoms and unsolicited adverse events (AE) / SAEs.|Frequency of significant serum antibody increases and increases in Geometric Mean Titers (GMT)s, as measured in neutralizing antibody tests and an ELISA against SARS-CoV S protein.","National Institute of Allergy and Infectious Diseases (NIAID)","All","18 Years to 40 Years   (Adult)","Phase 1","0","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","07-0021",,"January 2012","January 2012","September 21, 2007",,"December 3, 2012","Baylor College of Medicine - Molecular Virology and Microbiology, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00533741"
3,"NCT01376765","Phase I Dose Escalation SARS-CoV Recombinant S Protein, With and Without Adjuvant, Vaccine Study",,"Withdrawn","No Results Available","SARS","Drug: Aluminum hydroxide adjuvant (Alhydrogel®)|Other: Phosphate buffered saline Placebo|Biological: Recombinant S protein SARS vaccine","Occurrence of solicited local and systemic adverse events (AE)within 8 days after vaccination (Days 0-7 and Days 28-35)|Incidence of vaccine-related serious adverse events (SAEs) throughout the duration of the study.|Occurrence of laboratory abnormalities at 8 days after vaccination (Days 8 and 36)|Immunogenicity: Proportion of subjects achieving a detectable serum neutralizing antibody titer against SARS-CoV in each immunized group 28 days after receipt of the second dose of vaccine (approximately Day 56)|Immunogenicity: GMT of neutralizing antibody titers against SARS-CoV in each immunized group 28 days after receipt of the second dose of vaccine (Day 56). Measurement will include the Day 56 GMT and the mean fold change (GMT ratio Day 56:Day 0)|Comparison of rates of unsolicited AEs related to vaccine for all subjects between treatment groups and in the combined cohorts receiving vaccine with aluminum hydroxide adjuvant compared with those receiving vaccine with no adjuvant.|Immunogenicity: Geometric Mean Titer (GMT) of antibody titers (IgG ELISA for S protein of SARS-CoV) 28 days after receipt of the second dose of vaccine (Day 56) at each vaccine dose level, with and without adjuvant","National Institute of Allergy and Infectious Diseases (NIAID)","All","18 Years to 40 Years   (Adult)","Phase 1","0","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","09-0100",,,,"June 20, 2011",,"February 15, 2013","University of Iowa - Infectious Disease Clinic, Iowa City, Iowa, United States|Saint Louis University - Center for Vaccine Development, Saint Louis, Missouri, United States|Cincinnati Children's Hospital Medical Center - Infectious Diseases, Cincinnati, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT01376765"
4,"NCT00066209","Investigating Severe Acute Respiratory Syndrome (SARS)",,"Completed","No Results Available","SARS Virus",,,"National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC)","All","Child, Adult, Older Adult",,"400","NIH","Observational",,"030240|03-I-0240","August 4, 2003",,"May 24, 2007","August 6, 2003",,"July 2, 2017","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00066209"
5,"NCT00342524","Collection of Convalescent SARS Plasma by Apheresis",,"Completed","No Results Available","Severe Acute Respiratory Syndrome|SARS",,,"National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC)","All","18 Years and older   (Adult, Older Adult)",,,"NIH","Observational",,"999905192|05-I-N192","July 6, 2005",,"February 8, 2007","June 21, 2006",,"July 2, 2017","The Chinese University of Hong Kong, Hong Kong, China",,"https://ClinicalTrials.gov/show/NCT00342524"
6,"NCT03463031","Efficacy and Safety of GSP 301 Nasal Spray in Children (Aged 6 to Under 12 Years) With Seasonal Allergic Rhinitis (SAR)","GSP 301-305","Completed","Has Results","Seasonal Allergic Rhinitis (SAR)","Drug: GSP 301 NS|Drug: GSP 301 Placebo NS","Change From Baseline in Average AM and PM Subject-reported 12-hour Reflective Total Nasal Symptom Score ( rTNSS) Over the 14-day Treatment Period|Change From Baseline in Average AM and PM Subject-reported 12-hour Instantaneous Total Nasal Symptom Score (iTNSS) Over the 14-day Treatment Period.|Change From Baseline in the Overall Pediatric Rhinoconjunctivitis Quality of Life Questionnaire (PRQLQ) Score on Day 15 (Visit 4)|Change From Baseline in Average AM and PM Subject-reported 12-hour Reflective Total Ocular Symptom Score (rTOSS) Over the 14-day Treatment Period.","Glenmark Specialty S.A.","All","6 Years to 11 Years   (Child)","Phase 3","446","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","GSP 301-305","March 16, 2018","November 14, 2018","November 14, 2018","March 13, 2018","October 8, 2019","October 8, 2019","Glenmark Investigational Site 18, Mission Viejo, California, United States|Glenmark Investigational Site 32, Ontario, California, United States|Glenmark Investigational Site 30, Paramount, California, United States|Glenmark Investigational Site 17, San Diego, California, United States|Glenmark Investigational Site 21, Colorado Springs, Colorado, United States|Glenmark Investigational Site 13, Marietta, Georgia, United States|Glenmark Investigational Site 26, Savannah, Georgia, United States|Glenmark Investigational Site 28, Louisville, Kentucky, United States|Glenmark Investigational Site 14, Baltimore, Maryland, United States|Glenmark Investigational Site 19, Bethesda, Maryland, United States|Glenmark Investigational Site 25, Ypsilanti, Michigan, United States|Glenmark Investigational Site 12, Columbia, Missouri, United States|Glenmark Investigational Site 10, Rolla, Missouri, United States|Glenmark Investigational Site 27, Warrensburg, Missouri, United States|Glenmark Investigational Site 15, Omaha, Nebraska, United States|Glenmark Investigational Site 3, High Point, North Carolina, United States|Glenmark Investigational Site 8, Raleigh, North Carolina, United States|Glenmark Investigational Site 11, Cincinnati, Ohio, United States|Glenmark Investigational Site 29, Cincinnati, Ohio, United States|Glenmark Investigational Site 2, Edmond, Oklahoma, United States|Glenmark Investigational Site 33, Tulsa, Oklahoma, United States|Glenmark Investigational Site 4, Medford, Oregon, United States|Glenmark Investigational Site 6, Spartanburg, South Carolina, United States|Glenmark Investigational Site 5, Austin, Texas, United States|Glenmark Investigational Site 24, Kerrville, Texas, United States|Glenmark Investigational Site 1, New Braunfels, Texas, United States|Glenmark Investigational Site 7, San Antonio, Texas, United States|Glenmark Investigational Site 9, San Antonio, Texas, United States|Glenmark Investigational Site 20, Waco, Texas, United States|Glenmark Investigational Site 31, Waco, Texas, United States|Glenmark Investigational Site 22, Draper, Utah, United States|Glenmark Investigational Site 23, Greenfield, Wisconsin, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/31/NCT03463031/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/31/NCT03463031/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03463031"
7,"NCT03443102","Long-term Assessment of Organ Functions Among Survivors of Severe Acute Respiratory Syndrome",,"Recruiting","No Results Available","SARS Virus|Long-Term Survivors",,"All-cause disability|Cardiopulmonary function|Life Life quaities mental distress","Peking University People's Hospital","All","Child, Adult, Older Adult",,"150","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","2018PHB010-01","January 25, 2018","July 1, 2018","December 1, 2018","February 22, 2018",,"February 26, 2018","Peking University People's Hospital, Beijing, Beijing, China",,"https://ClinicalTrials.gov/show/NCT03443102"
8,"NCT02870205","Efficacy and Safety of GSP 301 Nasal Spray in the Treatment of Seasonal Allergic Rhinitis (SAR)","GSP 301-304","Completed","Has Results","Seasonal Allergic Rhinitis (SAR)","Drug: GSP 301 NS|Drug: GOM-NS|Drug: GMM-2 NS|Drug: GSP 301 placebo NS","Change From Baseline in Average AM and PM Subject-reported 12-hour Reflective Total Nasal Symptom Score (rTNSS)","Glenmark Specialty S.A.","All","12 Years and older   (Child, Adult, Older Adult)","Phase 3","1176","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","GPL/CT/2015/004/III|Study Number: GSP 301-304","August 2016","January 2017","January 2017","August 17, 2016","April 6, 2018","April 6, 2018","Investigational Site 406, Mission Viejo, California, United States|Investigational Site 414, Orange, California, United States|Investigational Site 435, San Diego, California, United States|Investigational Site 420, Centennial, Colorado, United States|Investigational Site 444, Colorado Springs, Colorado, United States|Investigational Site 428, Aventura, Florida, United States|Investigational Site 412, Miami, Florida, United States|Investigational Site 436, Bethesda, Maryland, United States|Investigational Site 432, South Dartmouth, Massachusetts, United States|Investigational Site 426, Minneapolis, Minnesota, United States|Investigational Site 403, Plymouth, Minnesota, United States|Investigational Site 443, Columbia, Missouri, United States|Investigational Site 441, Rolla, Missouri, United States|Investigational Site 440, Saint Louis, Missouri, United States|Investigational Site 405, Bellevue, Nebraska, United States|Investigational Site 434, Skillman, New Jersey, United States|Investigational Site 408, Rochester, New York, United States|Investigational Site 418, Rockville Centre, New York, United States|Investigational Site 402, High Point, North Carolina, United States|Investigational Site 427, Raleigh, North Carolina, United States|Investigational Site 419, Cincinnati, Ohio, United States|United States 404, Cincinnati, Ohio, United States|United States 407, Edmond, Oklahoma, United States|Investigational Site 410, Oklahoma City, Oklahoma, United States|Investigational Site 424, Tulsa, Oklahoma, United States|Investigational Site 411, Pittsburgh, Pennsylvania, United States|Investigational Site 416, Spartanburg, South Carolina, United States|Investigational Site 415, Austin, Texas, United States|Investigational Site 442, Austin, Texas, United States|Investigational Site 417, Boerne, Texas, United States|Investigational Site 421, Dallas, Texas, United States|Investigational Site 430, Dallas, Texas, United States|Investigational Site 431, El Paso, Texas, United States|Investigational Site 433, Kerrville, Texas, United States|Investigational Site 422, New Braunfels, Texas, United States|Investigational Site 401, San Antonio, Texas, United States|Investigational Site 413, San Antonio, Texas, United States|Investigational Site 425, San Antonio, Texas, United States|Investigational Site 437, San Antonio, Texas, United States|Investigational Site 400, Waco, Texas, United States|Investigational Site 409, Waco, Texas, United States|Investigational Site 423, Draper, Utah, United States|Investigational Site 439, Greenfield, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT02870205"
9,"NCT00073086","Evaluation and Treatment of Severe Acute Respiratory Syndrome (SARS)",,"Withdrawn","No Results Available","Severe Acute Respiratory Syndrome",,,"National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC)","All","18 Years and older   (Adult, Older Adult)",,"0","NIH","Observational",,"040030|04-I-0030","November 5, 2003",,"December 27, 2010","November 17, 2003",,"July 2, 2017","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00073086"
10,"NCT00578825","A Multi-centre, Double-blinded, Randomized, Placebo-controlled Trial on the Efficacy and Safety of Lopinavir / Ritonavir Plus Ribavirin in the Treatment of Severe Acute Respiratory Syndrome",,"Unknown status","No Results Available","Severe Acute Respiratory Syndrome","Drug: Lopinavir / Ritonavir plus Ribavirin","Development of severe SARS|Adverse events|SARS-CoV Viral load|Immunological profile","Hospital Authority, Hong Kong","All","18 Years and older   (Adult, Older Adult)","Not Applicable","340","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","KW/FR/04-009|HARECCTR0500028|NTWC/CREC/349/05",,,,"December 21, 2007",,"August 22, 2013","Department of Health, Hong Kong, China|Kowloon Hospital, Hong Kong, China|Prince of Wales Hospital, Hong Kong, China|Princess Margaret Hospital, Hong Kong, China|Queen Mary Hospital, Hong Kong, China|The Chinese University of Hong Kong, Hong Kong, China|The University of Hong Kong, Hong Kong, China|Tuen Mun Hospital, Hong Kong, China|United Christian Hospital, Hong Kong, China",,"https://ClinicalTrials.gov/show/NCT00578825"
11,"NCT00173459","Dynamic Profiles of Cytokine/Chemokine in Severe Acute Respiratory Syndrome",,"Completed","No Results Available","SARS",,,"National Taiwan University Hospital","All","20 Years and older   (Adult, Older Adult)",,,"Other","Observational","Observational Model: Case Control|Time Perspective: Longitudinal|Time Perspective: Retrospective","9461700671",,,,"September 15, 2005",,"September 15, 2005",,,"https://ClinicalTrials.gov/show/NCT00173459"
12,"NCT00215826","Study of Alferon® LDO (Low Dose Oral) in Normal Volunteers",,"Completed","No Results Available","Severe Acute Respiratory Syndrome","Drug: Alferon LDO","Gene expression analysis|SARS CoV Antibody|SARS-CoV infection","AIM ImmunoTech Inc.","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","10","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LDO-102","November 2004","April 2006","April 2006","September 22, 2005",,"April 17, 2013","Princess Margaret Hospital, Lai Chi Kok, Kowloon, Hong Kong",,"https://ClinicalTrials.gov/show/NCT00215826"
13,"NCT02932774","Randomized, Double Blind, Parallel Group, Placebo Controlled, Multi-Center Study of the Efficacy and Safety of Cetirizine HCl Syrup vs. Loratadine Syrup vs. Placebo in Treatment of Children With Seasonal Allergic Rhinitis (SAR)",,"Completed","No Results Available","Allergic Rhinitis|Hay Fever|SAR|Rhinitis, Allergic, Seasonal","Drug: Cetirizine|Drug: Loratadine|Other: Placebo","Change from baseline to the Overall endpoint in the subject 24-hour reflective total symptom severity complex (TSSC) score|Change from baseline to the Overall endpoint in the subject 24-hour reflective TSSC, with and without stuffy nose score|Change from baseline to the Overall endpoint in the individual rhinoconjunctivitis symptoms (reflective and instantaneous)|Investigator evaluation of rhinoconjunctivitis symptoms|Parent/legal guardian evaluation of subject's rhinoconjunctivitis symptoms|Investigator Global Evaluations of Efficacy at Visit 4/early termination|Subject/Parent/Legal Guardian Global Evaluations at Visit 4/early termination|Parent/Legal Guardian Overall Personal Satisfaction Assessment at Visit 4/early termination|Parental Burden Questionnaire","Johnson & Johnson Consumer and Personal Products Worldwide|Pfizer","All","6 Years to 11 Years   (Child)","Phase 4","683","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","A1431009","March 2001","July 2001","July 2001","October 13, 2016",,"April 20, 2017",,,"https://ClinicalTrials.gov/show/NCT02932774"
14,"NCT00150475","Contamination During Removal of Two Different Personal Protective Systems",,"Completed","No Results Available","Severe Acute Respiratory Syndrome","Procedure: Powered Air purifying respirator","The primary endpoint of this study is the presence of any detected|base clothing layer, skin, or hair contamination.|The secondary endpoints: 1) contamination episodes of any layer, and 2) protective|system donning and removal procedure violations","Queen's University|The Physicians' Services Incorporated Foundation","All","18 Years to 75 Years   (Adult, Older Adult)","Not Applicable","50","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single|Primary Purpose: Educational/Counseling/Training","PSI 04-58","January 2005",,"May 2005","September 8, 2005",,"September 8, 2005","Kingston General Hospital, Kingston, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT00150475"
15,"NCT02497885","Seroprevalence of MERS-CoV IgG in Healthcare Workers",,"Completed","No Results Available","Coronavirus Infections",,"IgG(+)","Ewha Womans University Mokdong Hospital","All","18 Years and older   (Adult, Older Adult)",,"737","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","KMSG_HCW_IgG","August 2015","October 2015","October 2015","July 15, 2015",,"October 30, 2015","Ewha womans university mokdong hospital, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT02497885"
16,"NCT03301090","A Safety, Tolerability, Pharmacokinetics and Immunogenicity Trial of Co-administered MERS-CoV Antibodies REGN3048 and REGN3051",,"Completed","No Results Available","Corona Virus Infection","Other: Placebo|Biological: REGN3048|Biological: REGN3051","Changes from baseline in abbreviated physical examination|Changes from baseline in clinical safety laboratory values|Changes from baseline in Electrocardiogram (ECG) parameters|Changes from baseline in symptom-directed physical examination|Changes from baseline in vital signs|The incidence of Adverse Events|The incidence of treatment-emergent Serious Adverse Events|The severity of Adverse Events assessed by toxicity grading criteria|The severity of treatment-emergent Serious Adverse Events assessed by toxicity grading criteria|The type of treatment-emergent Serious Adverse Events|AUC for each dose of REGN3048 measured using validated Enzyme Linked Immunosorbent Assays (ELISAs)|AUC for each dose of REGN3051 measured using validated Enzyme Linked Immunosorbent Assays (ELISAs)|AUC(0-infinity) for each dose of REGN3048 measured using validated Enzyme Linked Immunosorbent Assays (ELISAs)|AUC(0-infinity) for each dose of REGN3051 measured using validated Enzyme Linked Immunosorbent Assays (ELISAs)|CL for each dose of REGN3048 measured using validated Enzyme Linked Immunosorbent Assays (ELISAs)|CL for each dose of REGN3051 measured using validated Enzyme Linked Immunosorbent Assays (ELISAs)|CMAX for each dose of REGN3048 measured using validated Enzyme Linked Immunosorbent Assays (ELISAs)|CMAX for each dose of REGN3051 measured using validated Enzyme Linked Immunosorbent Assays (ELISAs)|K(e) for each dose of REGN3048 measured using validated Enzyme Linked Immunosorbent Assays (ELISAs)|K(e) for each dose of REGN3051 measured using validated Enzyme Linked Immunosorbent Assays (ELISAs)|t(1/2) for each dose of REGN3048 measured using validated Enzyme Linked Immunosorbent Assays (ELISAs)|t(1/2) for each dose of REGN3051 measured using validated Enzyme Linked Immunosorbent Assays (ELISAs)|The change from baseline of antibodies against REGN3048 and REGN3051 (anti-drug antibodies, ADA), as measured in serum using validated bridging assays|TMAX for each dose of REGN3048 measured using validated Enzyme Linked Immunosorbent Assays (ELISAs)|TMAX for each dose of REGN3051 measured using validated Enzyme Linked Immunosorbent Assays (ELISAs)|V(ss) for each dose of REGN3048 measured using validated Enzyme Linked Immunosorbent Assays (ELISAs)|V(ss) for each dose of REGN3051 measured using validated Enzyme Linked Immunosorbent Assays (ELISAs)","National Institute of Allergy and Infectious Diseases (NIAID)","All","18 Years to 45 Years   (Adult)","Phase 1","48","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","15-0109|HHSN272201500005I","February 12, 2018","January 19, 2019","January 19, 2019","October 4, 2017",,"February 1, 2019","WCCT Global Cypress Clinical Pharmacology Unit, Cypress, California, United States",,"https://ClinicalTrials.gov/show/NCT03301090"
17,"NCT00172263","The Interaction Between Severe Acute Respiratory Distress Syndrome Viral Proteins and Monocytes",,"Withdrawn","No Results Available","Severe Acute Respiratory Syndrome","Procedure: blood sampling",,"National Taiwan University Hospital","All","Child, Adult, Older Adult","Not Applicable","0","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)","9261701054",,,,"September 15, 2005",,"December 10, 2012","Li-Chieh Wang, MD, Taipei, Taiwan, China",,"https://ClinicalTrials.gov/show/NCT00172263"
18,"NCT01936363","Trial of Pimasertib With SAR245409 or Placebo in Ovarian Cancer",,"Completed","Has Results","Ovarian Cancer","Drug: Pimasertib once daily|Drug: Pimasertib placebo|Drug: SAR245409 placebo|Drug: SAR245409|Drug: Pimasertib twice daily","Objective Tumor Response|Progression-Free Survival|Percentage of Participants With Disease Control|Overall Survival|Health Related Quality of Life (HrQoL) Assessed Using European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC QLQ-C30)|Health Related Quality of Life (HrQoL) Assessed Using European Organization for Research and Treatment of Cancer (EORTC) Ovarian-Specific Module Quality of Life Questionnaire Ovarian Cancer Module (QLQ-OV28)|Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs, TEAEs Leading to Discontinuation of Treatment and Death|Maximum Plasma Concentration (Cmax) After Dose of Pimasertib and SAR245409|Area Under the Curve (AUC) After Dose of Pimasertib and SAR245409|Molecular Alterations in MAPK and/or PI3K Signaling Pathway Components/Modulators in Tumor Tissue and Blood","EMD Serono|Sanofi","Female","18 Years and older   (Adult, Older Adult)","Phase 2","65","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","EMR 200066_012|2013-000902-40","September 30, 2013","May 31, 2015","November 30, 2017","September 6, 2013","April 7, 2017","December 12, 2018","Research site, Augusta, Georgia, United States|Research site, Chicago, Illinois, United States|Research site, Indianapolis, Indiana, United States|Research site, Silver Spring, Maryland, United States|Research site, Boston, Massachusetts, United States|Research site, Boston, Massachusetts, United States|Research site, Ann Arbor, Michigan, United States|Research site, Detroit, Michigan, United States|Research site, Kansas City, Missouri, United States|Research site, Saint Louis, Missouri, United States|Research site, Kalispell, Montana, United States|Research site, New York, New York, United States|Research site, Cincinnati, Ohio, United States|Research site, Columbus, Ohio, United States|Research site, Middletown, Ohio, United States|Research site, Nashville, Tennessee, United States|Research site, Houston, Texas, United States|Research site, Northmead, New South Wales, Australia|Research site, Greenslopes, Queensland, Australia|Research site, Subiaco, Western Australia, Australia|Research site, Kortrijk, Belgium|Research site, Leuven, Belgium|Research site, Hamilton, Ontario, Canada|Research site, Toronto, Ontario, Canada|Research site, Montreal, Quebec, Canada|Research site, Montreal, Quebec, Canada|Research site, Quebec, Canada|Research site, Bordeaux Cedex, Gironde, France|Research site, Chorzow, Poland|Research site, Palma Mallorca, Baleares, Spain|Research site, Madrid, Spain|Research site, Madrid, Spain|Research site, Sevilla, Spain|Research site, Valencia, Spain",,"https://ClinicalTrials.gov/show/NCT01936363"
19,"NCT00807053","Dose-ranging Study to Assess the Efficacy and Safety of Ciclesonide HFA Nasal Aerosol in Adult and Adolescent Patients 12 Years and Older With Seasonal Allergic Rhinitis (SAR) (BY9010/M1-602)",,"Completed","No Results Available","Rhinitis, Allergic, Seasonal","Drug: Ciclesonide HFA|Drug: Placebo","Average of AM and PM patient-reported reflective Total Nasal Symptom Score (TNSS) over the first two weeks of treatment|Average of AM and PM patient-reported instantaneous TNSS over the first two weeks of treatment|Physician-assessed total nasal symptoms score (PNSS) over the treatment period|Rhinoconjunctivitis Quality of Life Questionaire (RQLQ) over the treatment period in patients (adolescents and adults) with impaired quality of life at Baseline defined as a RQLQ score of greater than 3.0","AstraZeneca","All","12 Years and older   (Child, Adult, Older Adult)","Phase 2","480","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","BY9010/M1-602","April 2007","June 2007","July 2007","December 11, 2008",,"December 5, 2016","Altana/Nycomed, Mission Viejo, California, United States|Altana/Nycomed, Orange, California, United States|Altana/Nycomed, San Diego, California, United States|Altana/Nycomed, Colorado Springs, Colorado, United States|Altana/Nycomed, Denver, Colorado, United States|Altana/Nycomed, Gainsville, Georgia, United States|Altana/Nycomed, Savannah, Georgia, United States|Altana/Nycomed, Stockbridge, Georgia, United States|Altana/Nycomed, Indianapolis, Indiana, United States|Altana/Nycomed, Overland Park, Kansas, United States|Altana/Nycomed, Bethesda, Maryland, United States|Altana/Nycomed, Minneapolis, Minnesota, United States|Altana/Nycomed, St. Louis, Missouri, United States|Altana/Nycomed, Lincoln, Nebraska, United States|Altana/Nycomed, Papillion, Nebraska, United States|Altana/Nycomed, Skillman, New Jersey, United States|Altana/Nycomed, West Brick, New Jersey, United States|Altana/Nycomed, Raleigh, North Carolina, United States|Altana/Nycomed, Ashland, Oregon, United States|Altana/Nycomed, Medford, Oregon, United States|Altana/Nycomed, Portland, Oregon, United States|Altana/Nycomed, Blue Bell, Pennsylvania, United States|Altana/Nycomed, Pittsburgh, Pennsylvania, United States|Altana/Nycomed, Upland, Pennsylvania, United States|Altana/Nycomed, Charleston, South Carolina, United States|Altana/Nycomed, Austin, Texas, United States|Altana/Nycomed, New Braunfels, Texas, United States|Altana/Nycomed, San Antonio, Texas, United States|Altana/Nycomed, Draper, Utah, United States|Altana/Nycomed, Burke, Virginia, United States|Altana/Nycomed, Richmond, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT00807053"
20,"NCT03331380","Technical Development of Cardiovascular Magnetic Resonance Imaging (CMR) Using a Low Specific Absorption Rate (SAR) Scanner System",,"Recruiting","No Results Available","CAD","Device: MRI scan x 1 Healthy Volunteer|Device: MRI scan x 2 Healthy Volunteer|Device: MRI scan x 2 - CAD patients|Device: MRI scan x 2- non CAD patients","Technical feasibility and Non- inferiority of the above measurements and examinations obtained using low SAR CMR versus commercial CMR in healthy volunteers and in patients with heart disease|Numerous exploratory secondary endpoints are sought around the listed measurements across MRI systems and disease states","National Heart, Lung, and Blood Institute (NHLBI)|National Institutes of Health Clinical Center (CC)","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","1600","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","180011|18-H-0011","January 5, 2018","May 31, 2022","May 31, 2022","November 6, 2017",,"January 9, 2020","National Institutes of Health Clinical Center, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT03331380"
21,"NCT03705169","Pharmacokinetics of SAR441236",,"Recruiting","No Results Available","HIV-1-infection","Biological: SAR441236|Biological: Placebo|Drug: Antiretroviral treatment","Occurrence of a Grade 3 or higher adverse event (AE) that is related to study treatment (as judged by the core safety team, blinded to active/placebo treatment in Arm A) any time from study treatment administration through the entire follow-up|Occurrence of a Grade 3 or higher AE that is related to study treatment (as judged by the core safety team, blinded to active/placebo treatment in Arm A) any time from study treatment administration through the entire follow-up|AUC12wk of SAR441236|Change in plasma HIV-1 RNA (log10 copies/mL) from baseline (defined as the last measurement taken prior to the treatment initiation) to Day 7 of monotherapy for treatment-naïve, viremic participants with HIV (Arm B cohorts)|Change in plasma HIV-1 RNA (copies/mL) from baseline and post infusion for treatment-naïve, viremic participants with HIV (Arm B cohorts)|Change in plasma HIV-1 RNA (log10 copies/mL) from baseline (defined as the last measurement taken prior to treatment initiation) to Day 14 and Day 28 of monotherapy for Arm B cohorts|Maximum reduction of plasma HIV-1 RNA during 28 days of monotherapy for treatment-naïve, viremic participants with HIV (Arm B cohorts)|Attributions of anti-SAR441236 antibodies|Change in CD4+ T cell counts (cells/mm^3) from baseline to week 12 following single dose of SAR441236 for all cohorts|Change in CD4+ T cell counts (cells/mm^3) from baseline to week 12 following each infusion for Cohort 4|Maximum concentration of SAR441236 after infusion for Cohorts 1-3 and Arm B cohorts|Trough concentration of SAR441236 after infusion for Cohorts 1-3 and Arm B cohorts|Half life of SAR441236 after infusion for Cohorts 1-3 and Arm B cohorts|Time to half life of SAR441236 after infusion for Cohorts 1-3 and Arm B cohorts|Clearance of SAR441236 after infusion for Cohorts 1-3 and Arm B cohorts|Distribution volume of SAR441236 after infusion for Cohorts 1-3 and Arm B cohorts|Maximum concentration of SAR441236 after each infusion for Cohort 4|Trough concentration of SAR441236 after each infusion for Cohort 4|Half life of SAR441236 after each infusion for Cohort 4|Time to half life of SAR441236 after each infusion for Cohort 4|Clearance of SAR441236 after each infusion for Cohort 4|Distribution volume of SAR441236 after each infusion for Cohort 4|Establish concentration (or dose)-response relationship between SAR441236 exposure and changes in plasma HIV-1 RNA from entry baseline to week 4 (or viral load nadir) for Arm B cohorts","National Institute of Allergy and Infectious Diseases (NIAID)|Sanofi","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1","60","NIH|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","ACTG A5377|38508|TDU15867","April 22, 2019","June 30, 2021","June 30, 2021","October 15, 2018",,"January 14, 2020","Alabama CRS, Birmingham, Alabama, United States|UCLA CARE Center CRS, Los Angeles, California, United States|UCSD Antiviral Research Center CRS, San Diego, California, United States|Ucsf Hiv/Aids Crs, San Francisco, California, United States|Harbor-UCLA CRS, Torrance, California, United States|University of Colorado Hospital CRS, Aurora, Colorado, United States|The Ponce de Leon Center CRS, Atlanta, Georgia, United States|Northwestern University CRS, Chicago, Illinois, United States|Rush University CRS, Chicago, Illinois, United States|Massachusetts General Hospital CRS (MGH CRS), Boston, Massachusetts, United States|Brigham and Women's Hospital Therapeutics Clinical Research Site (BWH TCRS) CRS, Boston, Massachusetts, United States|Washington University Therapeutics (WT) CRS, Saint Louis, Missouri, United States|New Jersey Medical School Clinical Research Center CRS, Newark, New Jersey, United States|Weill Cornell Chelsea CRS, New York, New York, United States|Columbia P&S CRS, New York, New York, United States|Weill Cornell Uptown CRS, New York, New York, United States|University of Rochester Adult HIV Therapeutic Strategies Network CRS, Rochester, New York, United States|Chapel Hill CRS, Chapel Hill, North Carolina, United States|Cincinnati Clinical Research Site, Cincinnati, Ohio, United States|Case Clinical Research Site, Cleveland, Ohio, United States|Ohio State University CRS, Columbus, Ohio, United States|Penn Therapeutics, CRS, Philadelphia, Pennsylvania, United States|University of Pittsburgh CRS, Pittsburgh, Pennsylvania, United States|The Miriam Hospital Clinical Research Site (TMH CRS) CRS, Providence, Rhode Island, United States|Vanderbilt Therapeutics (VT) CRS, Nashville, Tennessee, United States|University of Washington AIDS CRS, Seattle, Washington, United States|Puerto Rico AIDS Clinical Trials Unit CRS, San Juan, Puerto Rico",,"https://ClinicalTrials.gov/show/NCT03705169"
22,"NCT00173576","Clinical Study of SARS in Children",,"Completed","No Results Available","Epidemiology",,,"National Taiwan University Hospital|National Science Council, Taiwan","All","1 Month to 18 Years   (Child, Adult)",,"800","Other","Observational","Primary Purpose: Screening|Time Perspective: Cross-Sectional|Time Perspective: Retrospective/Prospective","9461700732|NSC92-2751-B-002-013-Y","April 2003",,"March 2005","September 15, 2005",,"October 27, 2005",,,"https://ClinicalTrials.gov/show/NCT00173576"
23,"NCT02635243","A Study to Evaluate Safety, Pharmacokinetics, and Pharmacodynamics of a Single Dose of SAR438544 in Comparison to Glucagon in Type 1 Diabetes Mellitus Patients Under Induced Hypoglycemia",,"Withdrawn","No Results Available","Type 1 Diabetes Mellitus","Drug: SAR438544|Drug: r-glucagon|Drug: insulin","Time to reach a smoothed blood glucose of 70 mg/dL after initial administration of investigational medicinal product|Assessment of PD parameter: continuous monitoring of blood glucose levels over a period of 6 hours post-dose|Assessment of PD parameter: area under plasma concentration of the BG-time curve between IMP dosing and time t (BG-AUC0-t)|Assessment of PD parameter: BG-maximum concentration (BG-Cmax)|Assessment of PD parameter: BG-time to Cmax (BG-tmax)|Assessment of PK parameter (recombinant glucagon and SAR438544): Cmax|Assessment of PK parameter (recombinant glucagon and SAR438544): tmax|Assessment of PK parameter (recombinant glucagon and SAR438544): tlast|Assessment of PK parameter (recombinant glucagon and SAR438544): terminal half-life|Assessment of PK parameter (recombinant glucagon and SAR438544): area under curve from zero time until the last measurable concentration (AUClast)|Assessment of PK parameter (recombinant glucagon and SAR438544): AUC|Assessment of PK parameter (recombinant glucagon and SAR438544): partial AUCs (AUC0-t)|Number of patients with adverse events|Time to reach a smoothed blood glucose of 90 mg/dL after initial administration of investigational medicinal product","Sanofi","All","18 Years to 60 Years   (Adult)","Phase 1","0","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double|Primary Purpose: Basic Science","PDY14452|U1111-1172-1152","April 2016","November 2016","November 2016","December 18, 2015",,"September 2, 2016",,,"https://ClinicalTrials.gov/show/NCT02635243"
24,"NCT03889639","Dose-finding Study for SAR442168 in Relapsing Multiple Sclerosis",,"Completed","No Results Available","Relapsing Multiple Sclerosis","Drug: SAR442168|Drug: Placebo|Drug: Locally approved intravenous contrast medium for contrast enhanced MRI","Number of new Gd-enhancing T1 hyperintense lesions|Number of new or enlarging T2 lesions|Total number of Gd-enhancing T1 hyperintense lesions|Number of participants experiencing adverse events|Percentage of participants experiencing adverse events","Sanofi","All","18 Years to 55 Years   (Adult)","Phase 2","128","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","DRI15928|2018-003927-12|U1111-1220-0572","March 29, 2019","January 2, 2020","January 2, 2020","March 26, 2019",,"January 13, 2020","Investigational Site Number 8400005, Cullman, Alabama, United States|Investigational Site Number 8400002, Maitland, Florida, United States|Investigational Site Number 8400004, Sunrise, Florida, United States|Investigational Site Number 8400009, Tampa, Florida, United States|Investigational Site Number 8400007, Savannah, Georgia, United States|Investigational Site Number 8400001, Northbrook, Illinois, United States|Investigational Site Number 8400008, Dayton, Ohio, United States|Investigational Site Number 8400006, Westerville, Ohio, United States|Investigational Site Number 8400003, Knoxville, Tennessee, United States|Investigational Site Number 1240002, Gatineau, Canada|Investigational Site Number 1240001, Greenfield Park, Canada|Investigational Site Number 1240003, Vancouver, Canada|Investigational Site Number 2030007, Brno, Czechia|Investigational Site Number 2030004, Hradec Kralove, Czechia|Investigational Site Number 2030003, Jihlava, Czechia|Investigational Site Number 2030005, Ostrava - Poruba, Czechia|Investigational Site Number 2030006, Pardubice, Czechia|Investigational Site Number 2030001, Praha 2, Czechia|Investigational Site Number 2030002, Praha 5 - Motol, Czechia|Investigational Site Number 2330001, Tallinn, Estonia|Investigational Site Number 2500004, Nancy Cedex, France|Investigational Site Number 2500001, Nantes Cedex 1, France|Investigational Site Number 2500002, Strasbourg Cedex, France|Investigational Site Number 2500003, Toulouse Cedex 9, France|Investigational Site Number 5280001, Amsterdam, Netherlands|Investigational Site Number 5280002, Sittard-Geleen, Netherlands|Investigational Site Number 6430006, Kazan, Russian Federation|Investigational Site Number 6430003, Moscow, Russian Federation|Investigational Site Number 6430002, Moscow, Russian Federation|Investigational Site Number 6430001, Saint-Petersburg, Russian Federation|Investigational Site Number 6430005, St-Petersburg, Russian Federation|Investigational Site Number 6430004, St-Petersburg, Russian Federation|Investigational Site Number 6430007, Tyumen, Russian Federation|Investigational Site Number 7030001, Bratislava, Slovakia|Investigational Site Number 7030002, Martin, Slovakia|Investigational Site Number 7240006, Barakaldo, Spain|Investigational Site Number 7240002, Barcelona, Spain|Investigational Site Number 7240001, Madrid, Spain|Investigational Site Number 7240004, Murcia, Spain|Investigational Site Number 7240005, Salt, Spain|Investigational Site Number 7240003, Sevilla, Spain|Investigational Site Number 8040002, Chernivtsi, Ukraine|Investigational Site Number 8040005, Dnipro, Ukraine|Investigational Site Number 8040001, Lviv, Ukraine|Investigational Site Number 8040006, Lviv, Ukraine|Investigational Site Number 8040009, Odesa, Ukraine|Investigational Site Number 8040003, Vinnytsya, Ukraine|Investigational Site Number 8040007, Zhytomyr, Ukraine",,"https://ClinicalTrials.gov/show/NCT03889639"
25,"NCT02575781","A Study of SAR428926 in Patients With Advanced Solid Tumors",,"Completed","No Results Available","Neoplasm Malignant","Drug: SAR428926","Number of patients with dose limiting adverse events (Escalation cohort)|Number of patients with corneal adverse events impacting study treatment (Escalation cohort)|Assessment of overall response rate using standard imaging and RECIST v1.1 criteria (Expansion cohort)|Number of treatment emergent adverse events|Assessment of PK parameter: maximum concentration (Cmax)|Assessment of PK parameter: time to reach maximum concentration (tmax)|Assessment of PK parameter: trough plasma concentration (Ctrough)|Assessment of PK parameter: area under the plasma concentration curve versus time curve between 1 and 14 days (AUC0-14 day)|Assessment of PK parameter: mean systemic clearance (CL)|Assessment of PK parameter: clearance at steady state (CLss)|Assessment of PK parameter: accumulation ratio on AUC0-14|Assessment of PK parameter: accumulation ratio on Cmax|Preliminary tumor response by RECIST v1.1 (Escalation)|Number of corneal events according to the presence or not of preventive measures","Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 1","34","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TED14147|2015-001441-92|U1111-1168-4706","October 5, 2015","June 2018","June 2018","October 15, 2015",,"August 22, 2018","Investigational Site Number 2080001, København Ø, Denmark|Investigational Site Number 2500001, Villejuif Cedex, France|Investigational Site Number 7240001, Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT02575781"
26,"NCT02283775","SAR650984, Pomalidomide and Dexamethasone in Combination in RRMM Patients","PomdeSAR","Active, not recruiting","No Results Available","Plasma Cell Myeloma","Drug: Isatuximab SAR650984|Drug: Pomalidomide|Drug: Dexamethasone","Dose Limiting Toxicities (DLTs)|Number of patients with adverse events and clinically significant changes in laboratory tests and vital signs according to the National Cancer Institute - Common Toxicity Criteria (NCI-CTC) version 4.03 grade scaling|Incidence of grade ≥3 IARs according to the NCI-CTC version 4.03 grade scaling|Overall response rate|Pharmacokinetics: Partial area under the serum concentration time curve (AUC)|Pharmacokinetics: maximum observed concentration (Cmax)|Immune response: levels of human anti-human antibodies (ADA)|Duration of response - Time|Clinical Benefit rate|Infusion duration|Safety of isatuximab administration from fixed volume|Relationship between clinical effect and CD38 receptor density","Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 1","89","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TCD14079|U1111-1155-7484","May 15, 2015","November 2020","November 2020","November 5, 2014",,"March 28, 2019","Investigational Site Number 840001, Scottsdale, Arizona, United States|Investigational Site Number 840006, Duarte, California, United States|Investigational Site Number 840018, New Haven, Connecticut, United States|Investigational Site Number 840011, Decatur, Illinois, United States|Investigational Site Number 840004, Boston, Massachusetts, United States|Investigational Site Number 840104, Boston, Massachusetts, United States|Investigational Site Number 840010, Chapel Hill, North Carolina, United States|Investigational Site Number 840003, Charlotte, North Carolina, United States|Investigational Site Number 840014, Canton, Ohio, United States|Investigational Site Number 840016, Charleston, South Carolina, United States|Investigational Site Number 840015, Salt Lake City, Utah, United States|Investigational Site Number 840005, Seattle, Washington, United States|Investigational Site Number 840017, Milwaukee, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT02283775"
27,"NCT01440179","SAR3419 in Acute Lymphoblastic Leukemia","MYRALL","Terminated","No Results Available","Acute Lymphocytic Leukaemia","Drug: SAR3419","Number of participants achieving an Objective Response Rate|Number of participants with Adverse Events|Assessment of PK parameter - maximum concentration (Cmax)|Assessment of PK parameter - area under curve (AUC)|Assessment of PK parameter - half-life (T1/2)|Assessment of PK parameter - clearance|Assessment of PK parameter - volume in steady state (Vss)|Assessment of minimal residual disease (MRD)","Sanofi","All","16 Years and older   (Child, Adult, Older Adult)","Phase 2","100","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EFC11603|U1111-1118-0642|2012-002961-36","October 2011","May 2014","May 2014","September 26, 2011",,"August 27, 2014","Investigational Site Number 840006, Denver, Colorado, United States|Investigational Site Number 840003, Nashville, Tennessee, United States|Investigational Site Number 840001, Houston, Texas, United States|Investigational Site Number 840002, San Antonio, Texas, United States|Investigational Site Number 840004, Milwaukee, Wisconsin, United States|Investigational Site Number 250006, Amiens, France|Investigational Site Number 250001, Paris Cedex 10, France|Investigational Site Number 250002, Pessac, France|Investigational Site Number 250008, Pierre Benite, France|Investigational Site Number 250004, Rennes, France|Investigational Site Number 250005, Strasbourg, France",,"https://ClinicalTrials.gov/show/NCT01440179"
28,"NCT02332850","SAR650984 in Combination With Carfilzomib for Treatment of Relapsed or Refractory Multiple Myeloma",,"Unknown status","No Results Available","Multiple Myeloma","Drug: SAR650984|Drug: Carfilzomib","Adverse Events|Maximum Tolerated Dose|Immunogenicity of SAR650984|Overall response rate|Clinical benefit response|Overall survival (OS)|Progression Free Survival (PFS)|Time To Progression (TTP)|Duration of Response (DOR)|CD38 receptor density levels|Receptor density levels|Receptor occupancy","University of California, San Francisco","All","up to 18 Years   (Child, Adult)","Phase 1","42","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","139511","December 2014","December 2018","December 2019","January 7, 2015",,"September 18, 2017","UCSF, 400 Parnassus Ave, San Francisco, California, United States",,"https://ClinicalTrials.gov/show/NCT02332850"
29,"NCT02855268","Study of SAR339375 in Patients With Alport Syndrome","HERA","Recruiting","No Results Available","Alport's Syndrome","Drug: SAR339375|Drug: Placebo","Number of participants with adverse events|Annualized change in estimated glomerular filtration rate eGFR from baseline|Pharmacokinetics (PK) : Maximum concentration in plasma (Cmax)|Pharmacokinetics (PK) : Trough plasma concentration (Ctrough)|Number of participants with anti-drug antibodies (ADAs)|Number of participant with adverse events associated to ADAs|Percent change in eGFR values|Proportion of subjects who reach end staged renal disease (ESRD)","Genzyme, a Sanofi Company|Sanofi","All","18 Years to 55 Years   (Adult)","Phase 2","45","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","ACT16248|2019-004394-10|U1111-1223-4466|RG012-03","November 2, 2019","April 2023","April 2023","August 4, 2016",,"January 31, 2020","Investigational Site Number 8400001, Cleveland, Ohio, United States|Investigational Site Number 0360003, Herston, Australia",,"https://ClinicalTrials.gov/show/NCT02855268"
30,"NCT03324113","Evaluation of SAR408701 in Japanese Patients With Advanced Malignant Solid Tumors",,"Recruiting","No Results Available","Neoplasm Malignant","Biological: SAR408701|Drug: dexamethasone|Drug: naphazoline|Drug: diphenhydramine","IMP-related dose limiting toxicities (DLT)|Treatment emergent adverse events|Maximum observed concentration (Cmax) of SAR408701|Cmax of DM4 and Me-DM4|Time to reach maximum concentration (Tmax) of SAR408701|Tmax of DM4 and Me-DM4|Area under the concentration-time curve (AUC) of SAR408701|AUC of DM4 and Me-DM4|Assessment of PDy effect|Assessment of anti-tumor activity|Detection of anti-SAR408701 antibody","Sanofi","All","20 Years and older   (Adult, Older Adult)","Phase 1","63","Industry","Interventional","Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TCD15054|U1111-1191-5464","October 17, 2017","August 2021","August 2021","October 27, 2017",,"July 5, 2019","Investigational Site Number 3920003, Kashiwa-Shi, Japan|Investigational Site Number 3920002, Nagoya-Shi, Japan|Investigational Site Number 3920001, Sunto-Gun, Japan",,"https://ClinicalTrials.gov/show/NCT03324113"
31,"NCT03996291","Long Term Safety and Efficacy Study of SAR442168 in Participants With Relapsing Multiple Sclerosis",,"Recruiting","No Results Available","Relapsing Multiple Sclerosis","Drug: SAR442168","Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)|Number of Participants with Potentially Clinically Significant Abnormalities|Number of new gadolinium (Gd)-enhancing T1 hyperintense lesions|Number of new or enlarging T2 lesions|Total number of Gd-enhancing T1-hyperintense lesions|Number of participants wih relapse (Annualized Relapse rate)|Change in Expanded Disability Status Scale (EDSS) from baseline over time","Sanofi","All","18 Years to 55 Years   (Adult)","Phase 2","105","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LTS16004|2018-004731-76|U1111-1223-4256","September 23, 2019","January 2025","January 2025","June 24, 2019",,"January 29, 2020","Investigational Site Number 8400005, Cullman, Alabama, United States|Investigational Site Number 8400002, Maitland, Florida, United States|Investigational Site Number 8400009, Tampa, Florida, United States|Investigational Site Number 8400007, Savannah, Georgia, United States|Investigational Site Number 8400001, Northbrook, Illinois, United States|Investigational Site Number 8400008, Dayton, Ohio, United States|Investigational Site Number 8400006, Westerville, Ohio, United States|Investigational Site Number 8400003, Knoxville, Tennessee, United States|Investigational Site Number 1240001, Greenfield Park, Canada|Investigational Site Number 1240003, Vancouver, Canada|Investigational Site Number 2030007, Brno, Czechia|Investigational Site Number 2030004, Hradec Kralove, Czechia|Investigational Site Number 2030003, Jihlava, Czechia|Investigational Site Number 2030005, Ostrava - Poruba, Czechia|Investigational Site Number 2030006, Pardubice, Czechia|Investigational Site Number 2030001, Praha 2, Czechia|Investigational Site Number 2030002, Praha 5 - Motol, Czechia|Investigational Site Number 2330001, Tallinn, Estonia|Investigational Site Number 2500004, Nancy Cedex, France|Investigational Site Number 5280001, Amsterdam, Netherlands|Investigational Site Number 6430001, Saint-Petersburg, Russian Federation|Investigational Site Number 7240002, Barcelona, Spain|Investigational Site Number 7240001, Madrid, Spain|Investigational Site Number 7240004, Murcia, Spain|Investigational Site Number 7240005, Salt, Spain|Investigational Site Number 7240003, Sevilla, Spain",,"https://ClinicalTrials.gov/show/NCT03996291"
32,"NCT02187848","Evaluation of SAR408701 in Patients With Advanced Solid Tumors",,"Recruiting","No Results Available","Neoplasm Malignant","Drug: SAR408701","Number of dose limiting adverse events (every 2 week cycle)|Assessment of overall response rate using standard imaging and RECIST 1.1 criteria|Number of dose limiting adverse events (every 3 week cycle)|Number of treatment emergent adverse events|Maximum concentration (Cmax)|Time to reach maximum concentration (tmax)|Trough plasma concentrations (Ctrough)|Area under the plasma concentration versus time curve between 0 and 14 days (AUC0-14day) for Q2W or between 0 and 21 days (AUC-21 day) for Q3W|Mean systemic clearance (CL)|Clearance at steady state (CLss)|Accumulation ratio (Rac) on AUC0-14day and Cmax|Detection of the development of anti-SAR408701 antibody|Duration of response|Time to Progression","Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","337","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TED13751|2014-001130-29","July 23, 2014","June 2021","June 2021","July 11, 2014",,"January 10, 2020","Investigational Site Number 840006, Bakersfield, California, United States|Investigational Site Number 840003, Santa Monica, California, United States|Investigational Site Number 840002, New Haven, Connecticut, United States|Investigational Site Number 840105, Boston, Massachusetts, United States|Investigational Site Number 840005, Boston, Massachusetts, United States|Investigational Site Number 840001, Hackensack, New Jersey, United States|Investigational Site Number 840004, Milwaukee, Wisconsin, United States|Investigational Site Number 124001, Toronto, Canada|Investigational Site Number 250003, Bordeaux Cedex, France|Investigational Site Number 250006, Dijon, France|Investigational Site Number 250004, Marseille Cedex 5, France|Investigational Site Number 250007, Rennes, France|Investigational Site Number 250005, Saint Mande, France|Investigational Site Number 250002, Toulouse Cedex 9, France|Investigational Site Number 250001, Villejuif Cedex, France|Investigational Site Number 410002, Seoul, Korea, Republic of|Investigational Site Number 410005, Seoul, Korea, Republic of|Investigational Site Number 410003, Seoul, Korea, Republic of|Investigational Site Number 410004, Seoul, Korea, Republic of|Investigational Site Number 410001, Seoul, Korea, Republic of|Investigational Site Number 724001, Barcelona, Spain|Investigational Site Number 724007, Madrid, Spain|Investigational Site Number 724004, Madrid, Spain|Investigational Site Number 724006, Madrid, Spain|Investigational Site Number 724003, Madrid, Spain|Investigational Site Number 724002, Majadahonda, Spain",,"https://ClinicalTrials.gov/show/NCT02187848"
33,"NCT04154956","SAR408701 Versus Docetaxel in Previously Treated, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Positive Metastatic Non-squamous Non-small Cell Lung Cancer Patients","CARMEN-LC03","Recruiting","No Results Available","Non-small Cell Lung Cancer Metastatic","Drug: SAR408701|Drug: Docetaxel","Progression free survival (PFS)|Overall Survival (OS)|Objective response rate (ORR)|Health related quality of life (HRQOL) - disease related symptoms|Health related quality of life (HRQOL) - physical function|Health related quality of life (HRQOL) - role function|Number of participants with treatment emergent adverse events (TEAEs) and serious adverse events (SAEs)|Duration of response (DOR)","Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 3","554","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EFC15858|2019-001273-81|U1111-1233-0781","November 26, 2019","March 2024","March 2024","November 7, 2019",,"January 28, 2020","Investigational Site Number 8400007, Bakersfield, California, United States|Investigational Site Number 0360002, Blacktown, Australia|Investigational Site Number 0360003, Waratah, Australia|Investigational Site Number 0360001, Woolloongabba, Australia|Investigational Site Number 1240004, Montreal, Canada|Investigational Site Number 3920001, Hirakata-Shi, Japan|Investigational Site Number 6430003, Saint -Petersburg, Russian Federation|Investigational Site Number 7920004, Ankara, Turkey|Investigational Site Number 7920003, Edirne, Turkey|Investigational Site Number 7920005, Istanbul, Turkey|Investigational Site Number 7920001, Istanbul, Turkey|Investigational Site Number 7920009, Malatya, Turkey",,"https://ClinicalTrials.gov/show/NCT04154956"
34,"NCT04191382","Study of SAR439859 Versus Letrozole in ER Positive, HER2 Negative Pre-operative Post-menopausal Primary Breast Cancer",,"Recruiting","No Results Available","Breast Cancer","Drug: SAR439859|Drug: letrozole","Ki67|Ki67≥50%|ER Expression|Adverse Events (AEs)/Serious Adverse Events (SAEs)|Clinical Laboratory Test Abnormalities","Sanofi","Female","18 Years and older   (Adult, Older Adult)","Phase 2","126","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","ACT16106|2019-002015-26|U1111-1228-9473","November 20, 2019","October 27, 2020","November 20, 2020","December 9, 2019",,"December 9, 2019","Investigational Site Number 8400018, Fort Wayne, Indiana, United States|Investigational Site Number 8400007, Hato Rey, Puerto Rico",,"https://ClinicalTrials.gov/show/NCT04191382"
35,"NCT01749969","SAR650984 (Isatuximab), Lenalidomide, and Dexamethasone in Combination in RRMM Patients",,"Active, not recruiting","No Results Available","Plasma Cell Myeloma","Drug: isatuximab SAR650984|Drug: lenalidomide|Drug: dexamethasone","Number of patients with adverse events when treated with SAR650984 (isatuximab) in combination with LD|Preliminary assessment of overall response rate|Preliminary assessment of progression-free survival (PFS)|Assessment of PK parameters - maximum concentration (Cmax)|Assessment of PK parameters - time to reach Cmax (Tmax)|Assessment of PK parameters - concentration observed at end of infusion (Ceoi)|Assessment of PK parameters - area under the plasma concentration versus time curve over the dosing interval (AUCtau)|Assessment of PK parameters - plasma concentration observed just before treatment administration during repeated dosing (Ctrough)|Number of CD38 receptors occupied by SAR650984 (isatuximab)|CD38 receptor density|Immunogenicity: Number of anti-SAR650984 (isatuximab) antibodies in response to SAR650984 (isatuximab)","Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 1","60","Industry","Interventional","Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TCD11863|U1111-1119-3107","February 6, 2013","June 2020","June 2020","December 17, 2012",,"November 20, 2019","Investigational Site Number 840004, San Francisco, California, United States|Investigational Site Number 840001, Tampa, Florida, United States|Investigational Site Number 840002, Saint Louis, Missouri, United States|Investigational Site Number 840005, New York, New York, United States|Investigational Site Number 840003, Columbus, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT01749969"
36,"NCT01636479","Phase 1 Safety Testing of SAR405838",,"Completed","No Results Available","Neoplasm Malignant","Drug: SAR405838","SAR405838 Maximum tolerated dose (MTD)|In MTD cohort, clinical benefit|Adverse events (eg, number of patients experiencing AEs)|PK parameters (Cmax, Tmax, AUC)|Biomarkers|Clinical response|Drug administration compliance","Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 1","77","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TED12318|2012-000733-39|U1111-1127-2911","July 13, 2012","March 5, 2018","March 5, 2018","July 10, 2012",,"May 17, 2018","Investigational Site Number 840101, Boston, Massachusetts, United States|Investigational Site Number 840001, Boston, Massachusetts, United States|Investigational Site Number 840002, New York, New York, United States|Investigational Site Number 250001, Villejuif, France|Investigational Site Number 528001, Amsterdam, Netherlands|Investigational Site Number 528003, Rotterdam, Netherlands|Investigational Site Number 528002, Utrecht, Netherlands",,"https://ClinicalTrials.gov/show/NCT01636479"
37,"NCT04171310","Study of Excretion Balance and Pharmacokinetics of [14C]-SAR442168 in Healthy Male Subjects",,"Completed","No Results Available","Multiple Sclerosis","Drug: SAR442168","Percentage of radioactive dose excreted in urine and feces|Number of subjects with Adverse events|Blood/plasma radioactivity ratio|Plasma SAR442168 /radioactivity ratio","Sanofi","Male","30 Years to 65 Years   (Adult, Older Adult)","Phase 1","6","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BEX16018|2019-001069-33|U1111-1223-4541","November 13, 2019","December 30, 2019","December 30, 2019","November 20, 2019",,"January 21, 2020","Investigational Site Number 8260001, Nottingham, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04171310"
38,"NCT03436498","Safety Assessment of SAR341402 and NovoLog® Used in Continuous Subcutaneous Insulin Infusion for Type 1 Diabetes Mellitus Patients",,"Completed","No Results Available","Type 1 Diabetes Mellitus","Drug: Insulin aspart SAR341402|Drug: Insulin aspart","Infusion set occlusions|Unexplained hyperglycemia|Intervals for infusion set changes|Number of patients with insulin pump alarms for ""non-delivery""|Patient observation of infusion set occlusion|Adverse events and serious adverse events|Number of patients with hypoglycemic events","Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 1","45","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PDY15083|U1111-1200-1241","May 10, 2018","October 6, 2018","October 6, 2018","February 19, 2018",,"December 7, 2018","Investigational Site Number 8400001, Little Rock, Arkansas, United States|Investigational Site Number 8400002, Denver, Colorado, United States|Investigational Site Number 8400003, West Des Moines, Iowa, United States",,"https://ClinicalTrials.gov/show/NCT03436498"
39,"NCT01836705","Effect of SAR302503 on ECG Activity in Patients With Solid Tumors",,"Completed","No Results Available","Neoplasm Malignant","Drug: SAR302503 (TG101348)|Drug: Placebo SAR302503|Drug: Panolosetron","QTc Friderica (QTcF) parameter|Electrocardiographic parameters (Heart Rate)|Electrocardiographic parameters (QT)|Electrocardiographic parameters (QTcBazett)|Electrocardiographic parameters (QTcN)|Electrocardiographic parameters (PR interval)|Electrocardiographic parameters (QRS interval)|Anti-tumor activity|Number of participants with Adverse Events|Pharmacokinetic parameter: Cmax, AUC0-24, Tmax, Tmax, Ctrough","Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 1","60","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","TES13519|2012-005642-38|U1111-1115-7323","May 2013","November 2013","May 2014","April 22, 2013",,"June 4, 2014","Investigational Site Number 840003, Los Angeles, California, United States|Investigational Site Number 840007, Augusta, Georgia, United States|Investigational Site Number 840002, Detroit, Michigan, United States|Investigational Site Number 840001, St Louis, Missouri, United States|Investigational Site Number 840004, Cincinnati, Ohio, United States|Investigational Site Number 840005, Philadelphia, Pennsylvania, United States|Investigational Site Number 840006, San Antonio, Texas, United States|Investigational Site Number 840008, San Antonio, Texas, United States|Investigational Site Number 056001, Bruxelles, Belgium|Investigational Site Number 056002, Gent, Belgium",,"https://ClinicalTrials.gov/show/NCT01836705"
40,"NCT02921971","Effectiveness and Safety of SAR156597 in Treating Diffuse Systemic Sclerosis",,"Completed","No Results Available","Systemic Sclerosis","Drug: SAR156597 (ACT14604)|Drug: Placebo","Change from baseline in mRSS|Change from baseline in Health Assessment Questionnaire Disability Index (HAQ-DI), assessed with SHAQ|Change from baseline in respiratory function as measured by observed Forced Vital Capacity (FVC)|Change from baseline in observed Carbon Monoxide Diffusing Lung Capacity (DLco [corrected for hemoglobin])","Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 2","97","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ACT14604|2016-001028-80|U1111-1179-4690","November 23, 2016","January 14, 2019","April 1, 2019","October 3, 2016",,"January 14, 2020","Investigational Site Number 8400006, San Francisco, California, United States|Investigational Site Number 8400005, Washington, District of Columbia, United States|Investigational Site Number 8400002, Cleveland, Ohio, United States|Investigational Site Number 8400007, Houston, Texas, United States|Investigational Site Number 0320003, Buenos Aires, Argentina|Investigational Site Number 0320002, Caba, Argentina|Investigational Site Number 0320005, Capital Federal, Argentina|Investigational Site Number 0320001, San Miguel De Tucuman, Argentina|Investigational Site Number 0560001, Gent, Belgium|Investigational Site Number 0560002, Leuven, Belgium|Investigational Site Number 2330001, Tallinn, Estonia|Investigational Site Number 2500003, Montpellier, France|Investigational Site Number 2500004, Paris Cedex 14, France|Investigational Site Number 2500002, Strasbourg Cedex, France|Investigational Site Number 2760003, Bad Nauheim, Germany|Investigational Site Number 2760001, Berlin, Germany|Investigational Site Number 2760002, Köln, Germany|Investigational Site Number 2760004, Ulm, Germany|Investigational Site Number 3800004, Genova, Italy|Investigational Site Number 3800001, Milano, Italy|Investigational Site Number 3800005, Milano, Italy|Investigational Site Number 3800006, Orbassano, Italy|Investigational Site Number 4840001, Chihuahua, Mexico|Investigational Site Number 4840005, Guadalajara, Mexico|Investigational Site Number 4840002, Guadalajara, Mexico|Investigational Site Number 4840003, Monterrey, Mexico|Investigational Site Number 6160001, Poznan, Poland|Investigational Site Number 6160002, Warszawa, Poland|Investigational Site Number 6160003, Wroclaw, Poland|Investigational Site Number 6420003, Bucharest, Romania|Investigational Site Number 6420004, Bucharest, Romania|Investigational Site Number 6420005, Bucuresti, Romania|Investigational Site Number 6420001, Cluj Napoca, Romania|Investigational Site Number 6420002, Targu Mures, Romania|Investigational Site Number 6430002, Kemerovo, Russian Federation|Investigational Site Number 6430005, Moscow, Russian Federation|Investigational Site Number 6430001, Moscow, Russian Federation|Investigational Site Number 6430004, Moscow, Russian Federation|Investigational Site Number 6430003, Ufa, Russian Federation|Investigational Site Number 8040001, Kyiv, Ukraine|Investigational Site Number 8040002, Kyiv, Ukraine|Investigational Site Number 8040004, Kyiv, Ukraine|Investigational Site Number 8040003, Kyiv, Ukraine|Investigational Site Number 8260001, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02921971"
41,"NCT03874715","Comparison of SAR341402 to NovoLog in Adult Patients With Type 1 Diabetes Mellitus Also Using Insulin Glargine","GEMELLI X","Active, not recruiting","No Results Available","Type 1 Diabetes Mellitus","Drug: Insulin Aspart SAR341402|Drug: Insulin Aspart|Drug: Insulin glargine U100","Similarity in pharmacokinetics (PK) of SAR341402 and NovoLog:AUClast|Similarity in pharmacokinetics (PK) of SAR341402 and NovoLog: AUC|Similarity in pharmacokinetics (PK) of SAR341402 and NovoLog: Cmax|Immunogenicity: Number of participants with treatment-emergent anti-insulin aspart antibodies (AIAs)|Safety: Hypoglycemic event|Safety: Number of hypoglycemic events per participant per year|Safety: Adverse Events|Comparison of PK parameters between the two arms (alternating administration of SAR341402 and NovoLog and continuous use of NovoLog)","Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 3","184","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EFC15178|U1111-1197-7811","March 11, 2019","June 2020","June 2020","March 14, 2019",,"January 27, 2020","Investigational Site Number 8400014, Concord, California, United States|Investigational Site Number 8400001, Temecula, California, United States|Investigational Site Number 8400015, Ventura, California, United States|Investigational Site Number 8400010, Aurora, Colorado, United States|Investigational Site Number 8400029, Waterbury, Connecticut, United States|Investigational Site Number 8400038, Doral, Florida, United States|Investigational Site Number 8400030, Miami, Florida, United States|Investigational Site Number 8400032, New Port Richey, Florida, United States|Investigational Site Number 8400026, Ocoee, Florida, United States|Investigational Site Number 8400033, Palm Harbor, Florida, United States|Investigational Site Number 8400012, Atlanta, Georgia, United States|Investigational Site Number 8400005, Columbus, Georgia, United States|Investigational Site Number 8400009, Roswell, Georgia, United States|Investigational Site Number 8400019, Crystal Lake, Illinois, United States|Investigational Site Number 8400028, Des Moines, Iowa, United States|Investigational Site Number 8400018, Lexington, Kentucky, United States|Investigational Site Number 8400023, Baltimore, Maryland, United States|Investigational Site Number 8400003, Rockville, Maryland, United States|Investigational Site Number 8400013, Waltham, Massachusetts, United States|Investigational Site Number 8400004, Flint, Michigan, United States|Investigational Site Number 8400021, Kansas City, Missouri, United States|Investigational Site Number 8400031, Washington, Missouri, United States|Investigational Site Number 8400036, Omaha, Nebraska, United States|Investigational Site Number 8400017, Las Vegas, Nevada, United States|Investigational Site Number 8400007, New York, New York, United States|Investigational Site Number 8400006, Morehead City, North Carolina, United States|Investigational Site Number 8400035, Rocky Mount, North Carolina, United States|Investigational Site Number 8400034, Jefferson City, Tennessee, United States|Investigational Site Number 8400040, Dallas, Texas, United States|Investigational Site Number 8400042, El Paso, Texas, United States|Investigational Site Number 8400027, Houston, Texas, United States|Investigational Site Number 8400016, Mesquite, Texas, United States|Investigational Site Number 8400041, Waco, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03874715"
42,"NCT01985191","A Safety and Efficacy Study of SAR405838 and Pimasertib in Cancer Patients",,"Completed","No Results Available","Neoplasm Malignant","Drug: SAR405838|Drug: Pimasertib","SAR405838 (pimasertib) RP2D assessed by dose-limiting toxicities and pharmacological activities|Changes of tumor dimension by imaging|Overall safety profile of SAR405838 (pimasertib), number of participants with adverse events|Pharmacokinetic parameters for both SAR405838 (pimasertib): the maximum concentration in blood (Cmax)|Pharmacokinetic parameters for both SAR405838 (pimasertib): time to the maximum concentration (Tmax)|Pharmacokinetic parameters for both SAR405838 (pimasertib): area under the curve (AUC), etc.|Biomarker changes in response to SAR405838 (pimasertib) treatment|Genetic status in tumor tissue|Change of the genetic status of circulating tumor DNA","Sanofi|Merck KGaA, Darmstadt, Germany","All","18 Years and older   (Adult, Older Adult)","Phase 1","26","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TCD13388|2013-002325-33|U1111-1144-8349","November 2013","February 2016","February 2016","November 15, 2013",,"February 25, 2016","Investigational Site Number 250001, Villejuif Cedex, France|Investigational Site Number 528001, Amsterdam, Netherlands|Investigational Site Number 528003, Rotterdam, Netherlands|Investigational Site Number 528002, Utrecht, Netherlands",,"https://ClinicalTrials.gov/show/NCT01985191"
43,"NCT01086254","SAR240550 in Combination With Gemcitabine/Cisplatin in Non-small Cell Lung Cancer",,"Completed","No Results Available","Non-small Cell Lung Cancer Stage IV","Drug: Iniparib|Drug: gemcitabine|Drug: cisplatin","overall response rate (ORR) that is defined in the RECIST 1.1 version, as: complete response rate + partial response rate|progression free survival|overall survival","Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 2","119","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TCD11420|2009-017270-21|U1111-1116-5404","May 2010","December 2011","December 2011","March 15, 2010",,"September 24, 2013","Sanofi-Aventis Investigational Site Number 250002, Caen Cedex, France|Sanofi-Aventis Investigational Site Number 250003, Marseille Cedex 09, France|Sanofi-Aventis Investigational Site Number 250004, Toulouse, France|Sanofi-Aventis Investigational Site Number 250001, Villejuif, France|Sanofi-Aventis Investigational Site Number 276003, Essen, Germany|Sanofi-Aventis Investigational Site Number 276002, Gauting, Germany|Sanofi-Aventis Investigational Site Number 276001, Großhansdorf, Germany|Sanofi-Aventis Investigational Site Number 380003, Livorno, Italy|Sanofi-Aventis Investigational Site Number 380001, Orbassano, Italy|Sanofi-Aventis Investigational Site Number 380002, Rozzano, Italy|Sanofi-Aventis Investigational Site Number 724001, Badalona, Spain|Sanofi-Aventis Investigational Site Number 724002, Barcelona, Spain|Sanofi-Aventis Investigational Site Number 826001, Newcastle Upon Tyne, United Kingdom|Sanofi-Aventis Investigational Site Number 826002, Wolverhampton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01086254"
44,"NCT03211858","Comparison of SAR341402 to NovoLog/NovoRapid in Adult Patients With Diabetes Mellitus Also Using Insulin Glargine","GEMELLI 1","Completed","Has Results","Type 1 Diabetes Mellitus-Type 2 Diabetes Mellitus","Drug: Insulin aspart|Drug: Novolog/Novorapid|Drug: Insulin glargine (HOE901)","Change in Glycated Hemoglobin A1c (HbA1c) From Baseline to Week 26|Change in HbA1c From Baseline to Week 52|Percentage of Participants With HbA1c <7% at Week 26 and Week 52|Change in Fasting Plasma Glucose (FPG) From Baseline to Week 26 and Week 52|Change in the Mean 24-hour Plasma Glucose Concentration From Baseline to Week 26 and Week 52|Change in Postprandial Plasma Glucose (PPG) Excursion From Baseline to Week 26 and Week 52|Change in 7-Point SMPG Profiles From Baseline to Week 26 and Week 52 Per Time Point|Number of Participants With at Least One Hypoglycemic Event|Number of Hypoglycemia Events Per Participant-Year|Percentage of Participants With Hypersensitivity Reactions and Injection Site Reactions|Percentage of Participants With at Least One Positive Anti-Insulin Aspart Antibodies (AIA) Sample|Percentage of Participants With Treatment Induced, Treatment-Boosted and Treatment-Emergent Anti-insulin Aspart Antibodies (AIAs)","Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 3","597","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EFC15081|2017-000091-28|U1111-1191-5775","August 2, 2017","July 16, 2018","January 12, 2019","July 7, 2017","August 8, 2019","January 13, 2020","Investigational Site Number 8400040, Little Rock, Arkansas, United States|Investigational Site Number 8400012, Concord, California, United States|Investigational Site Number 8400002, Escondido, California, United States|Investigational Site Number 8400030, Fresno, California, United States|Investigational Site Number 8400004, Greenbrae, California, United States|Investigational Site Number 8400014, La Jolla, California, United States|Investigational Site Number 8400043, Los Angeles, California, United States|Investigational Site Number 8400036, Pomona, California, United States|Investigational Site Number 8400011, Santa Barbara, California, United States|Investigational Site Number 8400013, Ventura, California, United States|Investigational Site Number 8400037, Aurora, Colorado, United States|Investigational Site Number 8400018, Englewood, Colorado, United States|Investigational Site Number 8400031, New Port Richey, Florida, United States|Investigational Site Number 8400027, Ocoee, Florida, United States|Investigational Site Number 8400007, Atlanta, Georgia, United States|Investigational Site Number 8400022, Columbus, Georgia, United States|Investigational Site Number 8400032, Roswell, Georgia, United States|Investigational Site Number 8400038, Arlington Heights, Illinois, United States|Investigational Site Number 8400005, Des Moines, Iowa, United States|Investigational Site Number 8400041, Metairie, Louisiana, United States|Investigational Site Number 8400015, Rockville, Maryland, United States|Investigational Site Number 8400042, Waltham, Massachusetts, United States|Investigational Site Number 8400019, Flint, Michigan, United States|Investigational Site Number 8400003, Omaha, Nebraska, United States|Investigational Site Number 8400024, Henderson, Nevada, United States|Investigational Site Number 8400028, New York, New York, United States|Investigational Site Number 8400025, Morehead City, North Carolina, United States|Investigational Site Number 8400010, Wilmington, North Carolina, United States|Investigational Site Number 8400023, Fargo, North Dakota, United States|Investigational Site Number 8400029, Bend, Oregon, United States|Investigational Site Number 8400033, Chattanooga, Tennessee, United States|Investigational Site Number 8400044, Austin, Texas, United States|Investigational Site Number 8400009, Dallas, Texas, United States|Investigational Site Number 8400035, Dallas, Texas, United States|Investigational Site Number 8400021, Dallas, Texas, United States|Investigational Site Number 8400017, Houston, Texas, United States|Investigational Site Number 8400001, Houston, Texas, United States|Investigational Site Number 8400020, Houston, Texas, United States|Investigational Site Number 8400016, Mesquite, Texas, United States|Investigational Site Number 8400034, Salt Lake City, Utah, United States|Investigational Site Number 8400008, Renton, Washington, United States|Investigational Site Number 8400039, Bridgeport, West Virginia, United States|Investigational Site Number 2460006, Jyväskylä, Finland|Investigational Site Number 2460002, Kuopio, Finland|Investigational Site Number 2460004, Pori, Finland|Investigational Site Number 2460003, Seinäjoki, Finland|Investigational Site Number 2760001, Berlin, Germany|Investigational Site Number 2760006, Essen, Germany|Investigational Site Number 2760004, Heidelberg, Germany|Investigational Site Number 2760005, Oldenburg In Holstein, Germany|Investigational Site Number 2760002, Pirna, Germany|Investigational Site Number 3480012, Balatonfüred, Hungary|Investigational Site Number 3480011, Budapest, Hungary|Investigational Site Number 3480008, Budapest, Hungary|Investigational Site Number 3480001, Budapest, Hungary|Investigational Site Number 3480005, Budapest, Hungary|Investigational Site Number 3480004, Budapest, Hungary|Investigational Site Number 3480007, Debrecen, Hungary|Investigational Site Number 3480003, Nagykanizsa, Hungary|Investigational Site Number 3480010, Nyíregyháza, Hungary|Investigational Site Number 3480009, Szentendre, Hungary|Investigational Site Number 3920009, Fukuyama-Shi, Japan|Investigational Site Number 3920008, Higashiosaka-Shi, Japan|Investigational Site Number 3920007, Kashiwara-Shi, Japan|Investigational Site Number 3920001, Koriyama-Shi, Japan|Investigational Site Number 3920005, Kumamoto-Shi, Japan|Investigational Site Number 3920003, Mito-Shi, Japan|Investigational Site Number 3920010, Osaka-Shi, Japan|Investigational Site Number 3920002, Sagamihara-Shi, Japan|Investigational Site Number 3920004, Shinjuku-Ku, Japan|Investigational Site Number 3920006, Ushiku-Shi, Japan|Investigational Site Number 6160004, Bialystok, Poland|Investigational Site Number 6160003, Krakow, Poland|Investigational Site Number 6160005, Krakow, Poland|Investigational Site Number 6160007, Lublin, Poland|Investigational Site Number 6160006, Nowy Sacz, Poland|Investigational Site Number 6160001, Poznan, Poland|Investigational Site Number 6160002, Warszawa, Poland|Investigational Site Number 6430002, Samara, Russian Federation|Investigational Site Number 6430003, Saratov, Russian Federation|Investigational Site Number 6430001, St. Petersburg, Russian Federation|Investigational Site Number 6430004, Tomsk, Russian Federation","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/58/NCT03211858/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/58/NCT03211858/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03211858"
45,"NCT02843035","GZ/SAR402671 in Combination With Cerezyme in Adult Patients With Gaucher Disease Type 3","LEAP","Recruiting","No Results Available","Gaucher Disease Type 1-Gaucher Disease Type 3","Drug: GZ402671","Number of patients with adverse events|Assessment of pharmacodynamic (PD) parameter: Lyso-glucosylceramide (lyso-GL1)|Assessment of pharmacodynamic (PD) parameter:Glucosylceramide (GL-1) in cerebrospinal fluid (CSF)|Assessment of pharmacodynamic (PD) parameter:Glucosylceramide (GL-1) in plasma|Assessment of pharmacokinetic parameter: Plasma maximum concentration (Cmax)|Assessment of pharmacokinetic parameter: Time at Cmax (Tmax)|Assessment of pharmacokinetic parameter: Area under the curve (AUC)|Assessment of pharmacokinetic parameter: plasma trough concentration (Ctrough)|Assessment of pharmacokinetic parameter: CSF maximum concentration (Cmax)|Assessment of pharmacokinetic parameter: CSF time at Cmax (Tmax)|Assessment of pharmacokinetic parameter: CSF area under the curve (AUC)|Immunogenicity testing as needed for IAR (Cerezyme)","Genzyme, a Sanofi Company|Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 2","10","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PDY13949|2014-002550-39|U1111-1156-4278","January 4, 2017","May 2024","May 2024","July 25, 2016",,"December 13, 2019","Investigational Site Number 840002, New Haven, Connecticut, United States|Investigational Site Number 840001, Dallas, Texas, United States|Investigational Site Number 276001, Mainz, Germany|Investigational Site Number 392001, Minato-Ku, Japan|Investigational Site Number 826003, Cambridge, United Kingdom|Investigational Site Number 826001, London, United Kingdom|Investigational Site Number 826002, Salford, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02843035"
46,"NCT02345070","Efficacy and Safety of SAR156597 in the Treatment of Idiopathic Pulmonary Fibrosis","ESTAIR","Completed","No Results Available","Idiopathic Pulmonary Fibrosis","Drug: SAR156597|Drug: placebo","Absolute change from baseline in percent predicted Forced Vital Capacity (FVC)|Proportion of patients with disease progression|Number of deaths (all causes)","Sanofi","All","40 Years and older   (Adult, Older Adult)","Phase 2","327","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","DRI11772|2014-003933-24|U1111-1154-6083","May 1, 2015","May 22, 2017","August 14, 2017","January 26, 2015",,"June 15, 2018","Investigational Site Number 840003, Phoenix, Arizona, United States|Investigational Site Number 840020, Jacksonville, Florida, United States|Investigational Site Number 840022, Loxahatchee Groves, Florida, United States|Investigational Site Number 840017, Atlanta, Georgia, United States|Investigational Site Number 840008, Decatur, Georgia, United States|Investigational Site Number 840010, Louisville, Kentucky, United States|Investigational Site Number 840009, Minneapolis, Minnesota, United States|Investigational Site Number 840006, Rochester, Minnesota, United States|Investigational Site Number 840026, Chesterfield, Missouri, United States|Investigational Site Number 840001, Lebanon, New Hampshire, United States|Investigational Site Number 840002, Summit, New Jersey, United States|Investigational Site Number 840015, Jamaica, New York, United States|Investigational Site Number 840023, Mineola, New York, United States|Investigational Site Number 840012, New York, New York, United States|Investigational Site Number 840013, Stony Brook, New York, United States|Investigational Site Number 840014, Philadelphia, Pennsylvania, United States|Investigational Site Number 840011, Dallas, Texas, United States|Investigational Site Number 840024, Everett, Washington, United States|Investigational Site Number 032009, Caba, Argentina|Investigational Site Number 032005, Caba, Argentina|Investigational Site Number 032001, La Plata, Argentina|Investigational Site Number 032004, Mendoza, Argentina|Investigational Site Number 032002, San Miguel De Tucumán, Argentina|Investigational Site Number 032007, Vicente Lopez, Argentina|Investigational Site Number 036005, Camperdown, Australia|Investigational Site Number 036004, Darlinghurst, Australia|Investigational Site Number 036002, Frankston, Australia|Investigational Site Number 036003, Murdoch, Australia|Investigational Site Number 036001, Nundah, Australia|Investigational Site Number 124003, Toronto, Canada|Investigational Site Number 124002, Vancouver, Canada|Investigational Site Number 152003, Quillota, Chile|Investigational Site Number 152001, Santiago, Chile|Investigational Site Number 152004, Santiago, Chile|Investigational Site Number 152006, Santiago, Chile|Investigational Site Number 152002, Talca, Chile|Investigational Site Number 152007, Viña Del Mar, Chile|Investigational Site Number 170004, Armenia, Colombia|Investigational Site Number 170001, Bogota, Colombia|Investigational Site Number 170005, Cali, Colombia|Investigational Site Number 203002, Hradec Kralove, Czechia|Investigational Site Number 203004, Olomouc, Czechia|Investigational Site Number 203003, Praha 2, Czechia|Investigational Site Number 203001, Praha 4, Czechia|Investigational Site Number 208002, Aarhus C, Denmark|Investigational Site Number 208001, Hellerup, Denmark|Investigational Site Number 250007, Bobigny, France|Investigational Site Number 250002, Lille Cedex, France|Investigational Site Number 250001, Lyon, France|Investigational Site Number 250009, Marseille, France|Investigational Site Number 250005, Montpellier, France|Investigational Site Number 250004, Nice, France|Investigational Site Number 250006, Paris, France|Investigational Site Number 250008, Toulouse, France|Investigational Site Number 250003, Tours, France|Investigational Site Number 276003, Coswig, Germany|Investigational Site Number 276002, Donaustauf, Germany|Investigational Site Number 276004, Gießen, Germany|Investigational Site Number 276005, Hannover, Germany|Investigational Site Number 276001, Heidelberg, Germany|Investigational Site Number 300001, Heraklion, Greece|Investigational Site Number 376001, Haifa, Israel|Investigational Site Number 376004, Kfar Saba, Israel|Investigational Site Number 376002, Petah-Tikva, Israel|Investigational Site Number 376005, Rehovot, Israel|Investigational Site Number 376003, Tel Hashomer, Israel|Investigational Site Number 380003, Catania, Italy|Investigational Site Number 380001, Forlì, Italy|Investigational Site Number 380005, Milano, Italy|Investigational Site Number 380002, Orbassano, Italy|Investigational Site Number 380006, Pisa, Italy|Investigational Site Number 380004, Siena, Italy|Investigational Site Number 410005, Bucheon-Si, Korea, Republic of|Investigational Site Number 410001, Incheon, Korea, Republic of|Investigational Site Number 410006, Seongnam, Korea, Republic of|Investigational Site Number 410002, Seoul, Korea, Republic of|Investigational Site Number 410003, Seoul, Korea, Republic of|Investigational Site Number 410004, Seoul, Korea, Republic of|Investigational Site Number 484002, Mexico City, Mexico|Investigational Site Number 484001, Monterrey, Mexico|Investigational Site Number 484005, Monterrey, Mexico|Investigational Site Number 484003, San Juan Del Rio, Mexico|Investigational Site Number 620003, Porto, Portugal|Investigational Site Number 620004, Vila Nova De Gaia, Portugal|Investigational Site Number 724003, Barcelona, Spain|Investigational Site Number 724002, Barcelona, Spain|Investigational Site Number 724001, Hospitalet De Llobregat, Spain|Investigational Site Number 724004, Lugo, Spain|Investigational Site Number 724006, Majadahonda, Spain|Investigational Site Number 724005, Palma De Mallorca, Spain|Investigational Site Number 724007, Sabadell, Spain|Investigational Site Number 792005, Ankara, Turkey|Investigational Site Number 792006, Istanbul, Turkey|Investigational Site Number 792001, Istanbul, Turkey|Investigational Site Number 792004, Istanbul, Turkey|Investigational Site Number 792003, Istanbul, Turkey|Investigational Site Number 792002, Izmir, Turkey|Investigational Site Number 826002, Cambridge, United Kingdom|Investigational Site Number 826003, Exeter, United Kingdom|Investigational Site Number 826004, Leicester, United Kingdom|Investigational Site Number 826001, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02345070"
47,"NCT03920007","Study of Subretinally Injected SAR439483 Administered in Patients With Leber Congenital Amaurosis Caused by Biallelic Mutations in GUCY2D",,"Recruiting","No Results Available","Leber's Congenital Amaurosis","Drug: SAR439483|Drug: SAR439483 Diluent Solution|Drug: Prednisone|Drug: Triamcinalone Acetonide|Drug: 1% Prednisolone|Drug: Trimethoprim/polymyxin B","Number of participants with adverse events (AEs) from baseline up to the end of the observation period|Number of participants with AEs from baseline up to the end of the safety follow-up period|Change in best -corrected visual acuity (BCVA)|Change in sensitivity","Sanofi","All","6 Years and older   (Child, Adult, Older Adult)","Phase 1|Phase 2","15","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DFI14738|U1111-1200-1308","September 12, 2019","March 2021","March 2022","April 18, 2019",,"November 27, 2019","Investigational Site Number 8400001, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT03920007"
48,"NCT04000282","First-in-human Single Agent Study of SAR442085 in Relapsed or Refractory Multiple Myeloma",,"Recruiting","No Results Available","Plasma Cell Myeloma","Drug: SAR442085","The maximum tolerated dose (MTD) of SAR442085 (Part A)|Recommended Phase 2 dose (RP2D) (Part A)|Overall response rate (Part B)|Treatment-emergent adverse events (AEs)/serious adverse events (SAE) (Both Part A and B)|PK parameters of SAR442085: Cmax (Both Part A and B)|PK parameters of SAR442085: Tmax (Both Part A and B)|PK parameters of SAR442085: AUC (Both Part A and B)|Anti-drug antibody (ADA) against SAR442085 (Both Part A and B)|Progression-free survival (Part B)|Duration of response (Part B)","Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 1","78","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TED16132|2019-001018-40|U1111-1223-4410","June 13, 2019","February 2022","February 2022","June 27, 2019",,"January 27, 2020","Investigational Site Number 8400002, Duarte, California, United States|Investigational Site Number 8400005, Rochester, Minnesota, United States|Investigational Site Number 8400001, New York, New York, United States|Investigational Site Number 8400004, Milwaukee, Wisconsin, United States|Investigational Site Number 2500001, Toulouse Cedex 9, France|Investigational Site Number 7240002, Hospitalet De Llobregat, Spain|Investigational Site Number 7240001, Salamanca, Spain",,"https://ClinicalTrials.gov/show/NCT04000282"
49,"NCT01307319","Study of an Investigational Nasal Aerosol or Placebo Nasal Aerosol in Children (Ages 6-11) With Seasonal Allergies",,"Completed","Has Results","Seasonal Allergic Rhinitis|SAR","Drug: BDP HFA|Drug: Placebo nasal aerosol","Change From Baseline in the Average Morning (AM) and Evening (PM) Subject-Reported Reflective Total Nasal Symptom Score (rTNSS) During the Two Weeks of Treatment|Change From Baseline in the Average Morning (AM) and Evening (PM) Subject-Reported Instantaneous Total Nasal Symptom Score (iTNSS) During the Two Weeks of Treatment","Teva Branded Pharmaceutical Products, R&D Inc.|Teva Pharmaceutical Industries","All","6 Years to 11 Years   (Child)","Phase 3","715","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","BDP-AR-305","March 2011","July 2011","August 2011","March 2, 2011","February 20, 2015","February 20, 2015","Teva Clinical Study Site, Oxford, Alabama, United States|Teva Clinical Study Site, Bell, California, United States|Teva Clinical Study Site, Costa Mesa, California, United States|Teva Clinical Study Site, Mission Viejo, California, United States|Teva Clinical Study Site, Orange, California, United States|Teva Clinical Study Site, Paramount, California, United States|Teva Clinical Study Site, San Diego, California, United States|Teva Clinical Study Site, San Diego, California, United States|Teva Clinical Study Site, Stockton, California, United States|Teva Clinical Study Site, Centennial, Colorado, United States|Teva Clinical Study Site, Colorado Springs, Colorado, United States|Teva Clinical Study Site, Gainesville, Georgia, United States|Teva Clinical Study Site, Lawrenceville, Georgia, United States|Teva Clinical Study Site, Savannah, Georgia, United States|Teva Clinical Study Site, Stockbridge, Georgia, United States|Teva Clinical Study Site, Indianapolis, Indiana, United States|Teva Clinical Study Site, Bethesda, Maryland, United States|Teva Clinical Study Site, Minneapolis, Minnesota, United States|Teva Clinical Study Site, Plymouth, Minnesota, United States|Teva Clinical Study Site, Columbia, Missouri, United States|Teva Clinical Study Site, Rolla, Missouri, United States|Teva Clinical Study Site, Warrensburg, Missouri, United States|Teva Clinical Study Site, Bozeman, Montana, United States|Teva Clinical Study Site, Brick, New Jersey, United States|Teva Clinical Study Site, High Point, North Carolina, United States|Teva Clinical Study Site, Oklahoma City, Oklahoma, United States|Teva Clinical Study Site, Portland, Oregon, United States|Teva Clinical Study Site, Blue Bell, Pennsylvania, United States|Teva Clinical Study Site, Collegeville, Pennsylvania, United States|Teva Clinical Study Site, Philadelphia, Pennsylvania, United States|Teva Clinical Study Site, Pittsburgh, Pennsylvania, United States|Teva Clinical Study Site, Charleston, South Carolina, United States|Teva Clinical Study Site, Orangeburg, South Carolina, United States|Teva Clinical Study Site, Austin, Texas, United States|Teva Clinical Study Site, Dallas, Texas, United States|Teva Clinical Study Site, Dallas, Texas, United States|Teva Clinical Study Site, El Paso, Texas, United States|Teva Clinical Study Site, Ft. Worth, Texas, United States|Teva Clinical Study Site, Houston, Texas, United States|Teva Clinical Study Site, Kerrville, Texas, United States|Teva Clinical Study Site, New Braunfels, Texas, United States|Teva Clinical Study Site, San Antonio, Texas, United States|Teva Clinical Study Site, Waco, Texas, United States|Teva Clinical Study Site, Burke, Virginia, United States|Teva Clinical Study Site, Richmond, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT01307319"
50,"NCT03376802","A Clinical Study to Investigate the Effect of SAR425899 on Energy Expenditure in Obese Subjects",,"Completed","No Results Available","Type 2 Diabetes Mellitus","Drug: SAR425899|Drug: Placebo","Sleep energy expenditure|Total daily energy expenditure|Resting energy expenditure|Basal energy expenditure|Respiratory quotient (RQ)|Fat mass and fat-free mass|Diet Induced Thermogenesis (DIT)|Fasting plasma glucose|HbA1c|Lipid biomarker (free fatty acids, triglycerides, total cholesterol, HDL-/LDL-cholesterol)|Ketone bodies|Adverse events|Pharmacokinetics","Sanofi","All","18 Years to 50 Years   (Adult)","Phase 1","24","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","PDY15012|U1111-1191-5658","April 18, 2018","December 27, 2018","December 27, 2018","December 19, 2017",,"March 5, 2019","Investigational Site Number 8400001, Orlando, Florida, United States|Investigational Site Number 8400002, Baton Rouge, Louisiana, United States",,"https://ClinicalTrials.gov/show/NCT03376802"
51,"NCT00936520","SAR 1118 in Human Subjects Undergoing Pars Plana Vitrectomy",,"Terminated","No Results Available","Diabetic Macular Edema (DME)|Pars Plana Vitrectomy","Drug: SAR 1118 0.1%|Drug: SAR 1118 1.0%|Drug: SAR 1118 5.0%","Primary outcome variable: frequency of ocular and non-ocular adverse events judged related to administration of SAR 1118 Ophthalmic Solution, or of inability to tolerate the medication.|Secondary outcome variable: concentrations of SAR 1118 in aqueous and vitreous on the day of vitrectomy.","Johns Hopkins University|SARcode Bioscience","All","18 Years and older   (Adult, Older Adult)","Phase 1","30","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","NA_00029830","August 2009","May 2010","May 2010","July 10, 2009",,"May 10, 2017","Johns Hopkins University, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00936520"
52,"NCT01472887","SAR3419 as Single Agent in Relapsed-Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Patients","STARLYTE","Completed","No Results Available","Diffuse Large B-cell Lymphoma","Drug: SAR3419","Number of participants achieving an Objective Response Rate|Number of participants with Adverse Events|Response duration - Time|Progression Free Survival - Time|Overall Survival - Time","Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 2","61","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ARD10248|2011-003657-26|U1111-1115-3349","January 2012","September 2016","September 2016","November 17, 2011",,"January 25, 2018","Investigational Site Number 840001, Denver, Colorado, United States|Investigational Site Number 840003, Augusta, Georgia, United States|Investigational Site Number 840005, Boise, Idaho, United States|Investigational Site Number 056002, Gent, Belgium|Investigational Site Number 056001, Leuven, Belgium|Investigational Site Number 203002, Brno, Czechia|Investigational Site Number 203003, Praha 10, Czechia|Investigational Site Number 203001, Praha 2, Czechia|Investigational Site Number 376003, Jerusalem, Israel|Investigational Site Number 376002, Tel Hashomer, Israel|Investigational Site Number 380002, Bergamo, Italy|Investigational Site Number 380004, Bologna, Italy|Investigational Site Number 380008, Mestre, Italy|Investigational Site Number 380001, Milano, Italy|Investigational Site Number 380007, Modena, Italy|Investigational Site Number 380003, Palermo, Italy|Investigational Site Number 380006, Pavia, Italy|Investigational Site Number 616003, Brzozow, Poland|Investigational Site Number 616002, Kielce, Poland|Investigational Site Number 616001, Warszawa, Poland|Investigational Site Number 724002, Barcelona, Spain|Investigational Site Number 724004, Barcelona, Spain|Investigational Site Number 724001, Madrid, Spain|Investigational Site Number 724003, Valencia, Spain|Investigational Site Number 792003, Izmir, Turkey|Investigational Site Number 792001, Izmir, Turkey|Investigational Site Number 826001, Leicester, United Kingdom|Investigational Site Number 826002, Manchester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01472887"
53,"NCT02973321","A Study to Assess the Safety and Efficacy of SAR425899 in Patients With Type 2 Diabetes Mellitus",,"Completed","No Results Available","Type 2 Diabetes Mellitus","Drug: SAR425899|Drug: Placebo|Drug: Liraglutide|Drug: Metformin","Change in HbA1c|Change in body weight|Percentage of patients achieving predefined HbA1c targets of <7%|Percentage of patients achieving predefined HbA1c targets of <6.5%|Percentage of patients achieving ≥5% body weight loss|Percentage of patients achieving ≥10% body weight loss|Change in Fasting Plasma Glucose (FPG)|Change in postprandial plasma glucose (PPG) in response to a standardized meal test in up to 50% subset of all patients|Percentage of patients requiring rescue therapy|Change from baseline in postprandial insulin in response to a standardized meal test in up to 50% subset of all patients|Change from baseline in proinsulin in response to a standardized meal test in up to 50% subset of all patients|Change from baseline in C-peptide in response to a standardized meal test in up to 50% subset of all patients|Change in fasting lipid profile|Change in pharmacodynamic biomarkers|Assessment of PK parameter: oral clearance (CL/F)|Assessment of PK parameter: volume distribution after non-intravenous infusion (Vz/F)|Assessment of PK parameter: terminal half-life (T1/2)","Sanofi","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","296","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","DRI13940|2016-001328-77|U1111-1179-4786","December 2, 2016","December 27, 2017","December 27, 2017","November 25, 2016",,"December 7, 2018","Investigational Site Number 8400028, Sheffield, Alabama, United States|Investigational Site Number 8400002, Huntington Park, California, United States|Investigational Site Number 8400024, Los Angeles, California, United States|Investigational Site Number 8400001, Los Angeles, California, United States|Investigational Site Number 8400012, Port Hueneme, California, United States|Investigational Site Number 8400027, Denver, Colorado, United States|Investigational Site Number 8400025, Miami, Florida, United States|Investigational Site Number 8400007, Palm Harbor, Florida, United States|Investigational Site Number 8400013, Chicago, Illinois, United States|Investigational Site Number 8400016, Wichita, Kansas, United States|Investigational Site Number 8400023, Wichita, Kansas, United States|Investigational Site Number 8400018, New Orleans, Louisiana, United States|Investigational Site Number 8400019, Rockville, Maryland, United States|Investigational Site Number 8400014, Flint, Michigan, United States|Investigational Site Number 8400003, Troy, Michigan, United States|Investigational Site Number 8400020, Linden, New Jersey, United States|Investigational Site Number 8400022, New York, New York, United States|Investigational Site Number 8400005, Fargo, North Dakota, United States|Investigational Site Number 8400004, Austin, Texas, United States|Investigational Site Number 8400006, Dallas, Texas, United States|Investigational Site Number 8400021, Houston, Texas, United States|Investigational Site Number 8400026, San Antonio, Texas, United States|Investigational Site Number 8400017, Sugar Land, Texas, United States|Investigational Site Number 1240008, Quebec, Canada|Investigational Site Number 1240005, Sainte-Foy, Canada|Investigational Site Number 1240002, Sherbrooke, Canada|Investigational Site Number 1240001, Toronto, Canada|Investigational Site Number 1240003, Vancouver, Canada|Investigational Site Number 2030003, Ceske Budejovice, Czechia|Investigational Site Number 2030001, Krnov, Czechia|Investigational Site Number 2030004, Praha 10 - Uhrineves, Czechia|Investigational Site Number 2030002, Praha 9 - Klanovice, Czechia|Investigational Site Number 2760003, Berlin, Germany|Investigational Site Number 2760001, Dresden, Germany|Investigational Site Number 2760006, Hohenmölsen, Germany|Investigational Site Number 3480001, Balatonfüred, Hungary|Investigational Site Number 3480002, Budapest, Hungary|Investigational Site Number 3480008, Budapest, Hungary|Investigational Site Number 3480005, Budapest, Hungary|Investigational Site Number 3480006, Budapest, Hungary|Investigational Site Number 3480007, Budapest, Hungary|Investigational Site Number 4840004, Actopan, Mexico|Investigational Site Number 4840001, Guadalajara, Mexico|Investigational Site Number 4840003, Guadalajara, Mexico|Investigational Site Number 4840002, Monterrey, Mexico|Investigational Site Number 4840006, San Juan Del Rio, Mexico|Investigational Site Number 6430003, Saratov, Russian Federation|Investigational Site Number 6430002, St-Petersburg, Russian Federation|Investigational Site Number 6430001, St-Petersburg, Russian Federation|Investigational Site Number 6430004, St. Petersburg, Russian Federation|Investigational Site Number 6430005, Voronezh, Russian Federation|Investigational Site Number 7240005, Barcelona, Spain|Investigational Site Number 7240007, Ferrol, Spain|Investigational Site Number 7240001, La Coruña, Spain|Investigational Site Number 7240006, Las Palmas De Gran Canaria, Spain|Investigational Site Number 7240002, Madrid, Spain|Investigational Site Number 7240003, Málaga, Spain|Investigational Site Number 7240004, Málaga, Spain|Investigational Site Number 7240008, Sevilla, Spain",,"https://ClinicalTrials.gov/show/NCT02973321"
54,"NCT03437720","Assessment of the Safety and Effect of SAR425899 Versus Placebo for the Treatment of Non-alcoholic Fatty Liver Disease","Restore","Withdrawn","No Results Available","Non-alcoholic Steatohepatitis|Type 2 Diabetes Mellitus","Drug: SAR425899|Drug: Placebo","Resolution of Non-alcoholic steatohepatitis (NASH)|No hepatocyte ballooning, lobular inflammation score 0 or 1, without worsening of fibrosis|Change in overall NAFLD activity score (NAS)|Change in NAS individual components|Change in fibrosis score|Major adverse cardiac events|Change in Magnetic Resonance Imaging-determined Proton Density Fat Fraction (MRI-PDFF)|Improvement of fibrosis without worsening of hepatocyte ballooning component of NAS|Change in body weight|Change in waist circumference|Change in hip circumference|Change in waist to hip ratio|Assessment of pharmacokinetic (PK) parameter: AUC0-24|Assessment of PK parameter: Cmax|Assessment of PK parameter: Ctrough","Sanofi","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","0","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ACT15067|2017-002371-26|U1111-1191-5486","May 23, 2019","August 25, 2021","August 25, 2021","February 19, 2018",,"April 8, 2019",,,"https://ClinicalTrials.gov/show/NCT03437720"
55,"NCT01357330","Oral SAR245408 (XL147) and Oral MSC1936369B in Patients With Locally Advanced or Metastatic Solid Tumors",,"Completed","No Results Available","Solid Tumors","Drug: SAR245408 (XL147)|Drug: MSC1936369B","Identification of maximum tolerated dose|Number of participants with treatment emergent adverse events|Pharmakokinetic parameters of SAR245408: Cmax|Pharmakokinetic parameters of SAR245408: Tmax|Pharmakokinetic parameters of SAR245408:AUCι|Pharmakokinetic parameters of MSC1936369B: Cmax|Pharmakokinetic parameters of MSC1936369B: Tmax|Pharmakokinetic parameters of MSC1936369B: AUCι","Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 1","18","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)","TCD11742|U1111-1117-9893","May 2011","June 2012","June 2012","May 20, 2011",,"April 1, 2016","Investigational Site Number 840001, Boston, Massachusetts, United States|Investigational Site Number 840002, Boston, Massachusetts, United States|Investigational Site Number 840003, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT01357330"
56,"NCT03816839","Evaluation of Orally Administered SAR439859 in Japanese Postmenopausal Patients With Advanced Breast Cancer",,"Recruiting","No Results Available","Breast Cancer","Drug: SAR439859","Investigational medicinal product (IMP)-related dose limiting toxicities (DLTs)|Safety: Adverse Events (AEs)|Assessment of Pharmacokinetic parameter of SAR439859: tlag|Assessment of Pharmacokinetic parameter of SAR439859: tmax|Assessment of Pharmacokinetic parameter of SAR439859: Cmax|Assessment of Pharmacokinetic parameter of SAR439859: AUC0-24h or AUC0-10h and/or AUC0-12h|Assessment of Pharmacokinetic parameter of SAR439859: Ctrough|Assessment of antitumor activity: Objective response rate (ORR)|Assessment of antitumor activity: Clinical benefit rate (CBR)|Assessment of antitumor activity: Duration of response|Assessment of antitumor activity: Non-progression rate","Sanofi","Female","20 Years and older   (Adult, Older Adult)","Phase 1","12","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TED15954|U1111-1217-2758","March 25, 2019","June 2020","October 2020","January 25, 2019",,"January 13, 2020","Investigational Site Number 3920002, Chuo-Ku, Japan|Investigational Site Number 3920001, Kashiwa-Shi, Japan|Investigational Site Number 3920003, Nagoya-Shi, Japan",,"https://ClinicalTrials.gov/show/NCT03816839"
57,"NCT03387852","Evaluation of SAR440340 and as Combination Therapy With Dupilumab in Moderate-to-Severe Asthma Patients",,"Completed","No Results Available","Asthma","Drug: SAR440340/REGN3500|Drug: Dupilumab|Drug: Fluticasone or Fluticasone/salmeterol combination|Drug: Placebo for SAR440340 (REGN3500)|Drug: Placebo for dupilumab","Loss of asthma control (LOAC) events|Change in forced expiratory volume in 1 second (FEV1)","Sanofi|Regeneron Pharmaceuticals","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","297","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ACT15102|2017-003289-29|U1111-1194-2185","March 12, 2018","August 7, 2019","August 7, 2019","January 2, 2018",,"September 13, 2019","Investigational Site Number 8400026, Birmingham, Alabama, United States|Investigational Site Number 8400004, Long Beach, California, United States|Investigational Site Number 8400020, Los Angeles, California, United States|Investigational Site Number 8400001, Rolling Hills Estates, California, United States|Investigational Site Number 8400013, San Jose, California, United States|Investigational Site Number 8400009, Stockton, California, United States|Investigational Site Number 8400016, Colorado Springs, Colorado, United States|Investigational Site Number 8400021, Ann Arbor, Michigan, United States|Investigational Site Number 8400022, Minneapolis, Minnesota, United States|Investigational Site Number 8400007, Papillion, Nebraska, United States|Investigational Site Number 8400025, Edmond, Oklahoma, United States|Investigational Site Number 8400011, Medford, Oregon, United States|Investigational Site Number 8400024, Portland, Oregon, United States|Investigational Site Number 8400010, Dallas, Texas, United States|Investigational Site Number 8400023, Dallas, Texas, United States|Investigational Site Number 8400006, Plano, Texas, United States|Investigational Site Number 8400008, Murray, Utah, United States|Investigational Site Number 8400014, Milwaukee, Wisconsin, United States|Investigational Site Number 0320001, Buenos Aires, Argentina|Investigational Site Number 0320003, Caba, Argentina|Investigational Site Number 0320002, Caba, Argentina|Investigational Site Number 0320004, Caba, Argentina|Investigational Site Number 0320005, Mendoza, Argentina|Investigational Site Number 1520002, Quillota, Chile|Investigational Site Number 1520001, Santiago, Chile|Investigational Site Number 1520009, Santiago, Chile|Investigational Site Number 1520008, Santiago, Chile|Investigational Site Number 1520007, Santiago, Chile|Investigational Site Number 1520004, Santiago, Chile|Investigational Site Number 1520005, Talca, Chile|Investigational Site Number 1520003, Viña Del Mar, Chile|Investigational Site Number 4840005, Chihuahua, Mexico|Investigational Site Number 4840004, Durango, Mexico|Investigational Site Number 4840002, Guadalajara, Mexico|Investigational Site Number 4840006, Monterrey, Mexico|Investigational Site Number 4840001, Monterrey, Mexico|Investigational Site Number 4840003, Veracruz, Mexico|Investigational Site Number 6160001, Bialystok, Poland|Investigational Site Number 6160008, Bialystok, Poland|Investigational Site Number 6160005, Bydgoszcz, Poland|Investigational Site Number 6160007, Krakow, Poland|Investigational Site Number 6160002, Poznan, Poland|Investigational Site Number 6160006, Poznan, Poland|Investigational Site Number 6160003, Znin, Poland|Investigational Site Number 6430003, Moscow, Russian Federation|Investigational Site Number 6430001, Moscow, Russian Federation|Investigational Site Number 6430005, Moscow, Russian Federation|Investigational Site Number 6430008, Ryazan, Russian Federation|Investigational Site Number 6430010, Saint-Petersburg, Russian Federation|Investigational Site Number 6430006, Saint-Petersburg, Russian Federation|Investigational Site Number 6430007, St-Petersburg, Russian Federation|Investigational Site Number 6430009, Stavropol, Russian Federation|Investigational Site Number 6430004, Ulyanovsk, Russian Federation|Investigational Site Number 7920004, Ankara, Turkey|Investigational Site Number 7920003, Bursa, Turkey|Investigational Site Number 7920001, Istanbul, Turkey|Investigational Site Number 7920006, Izmir, Turkey|Investigational Site Number 7920007, Izmir, Turkey|Investigational Site Number 7920008, Kirikkale, Turkey|Investigational Site Number 7920002, Mersin, Turkey|Investigational Site Number 7920009, Rize, Turkey|Investigational Site Number 8040008, Chernivtsi, Ukraine|Investigational Site Number 8040012, Ivano-Frankivsk, Ukraine|Investigational Site Number 8040002, Kharkiv, Ukraine|Investigational Site Number 8040009, Kharkiv, Ukraine|Investigational Site Number 8040011, Kharkiv, Ukraine|Investigational Site Number 8040007, Kyiv, Ukraine|Investigational Site Number 8040001, Kyiv, Ukraine|Investigational Site Number 8040006, Odesa, Ukraine|Investigational Site Number 8040003, Ternopil, Ukraine|Investigational Site Number 8040005, Vinnytsya, Ukraine",,"https://ClinicalTrials.gov/show/NCT03387852"
58,"NCT03462017","Pharmacodynamic Study to Assess the Effects of Repeated Dosing of SAR247799 on Endothelial Function in Patients With Type 2 Diabetes Mellitus",,"Completed","No Results Available","Microvascular Coronary Artery Disease","Drug: SAR247799|Drug: Placebo|Drug: Sildenafil|Drug: Acetylcholine","Change in Flow Mediated Dilation (FMD)|Microvascular reactivity|Number of adverse events|Assessment of pharmacokinetic (PK) parameter: Cmax|Assessment of PK parameter: Ctrough|Assessment of PK parameter: tmax|Assessment of PK parameter: AUC0-24","Sanofi","All","18 Years to 64 Years   (Adult)","Phase 1","54","Industry","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","PDY15286|2017-002592-26|U1111-1197-8124","March 7, 2018","December 22, 2018","December 22, 2018","March 12, 2018",,"December 20, 2019","Investigational Site Number 2760002, Mainz, Germany|Investigational Site Number 2760001, Neuss, Germany",,"https://ClinicalTrials.gov/show/NCT03462017"
59,"NCT00914277","SAR407899 Single-dose in Treatment of Mild to Moderate Erectile Dysfunction","RHOKET","Completed","No Results Available","Erectile Dysfunction","Drug: SAR407899|Drug: Placebo|Drug: Sildenafil","Duration of penile rigidity during sexual stimulation|Time to onset of penile rigidity|Blood pressure","Sanofi","Male","18 Years to 60 Years   (Adult)","Phase 2","24","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ACT10775|EudraCT:2009-009936-56","May 2009","September 2009","October 2009","June 4, 2009",,"May 2, 2011","Sanofi-Aventis Administrative Office, Paris, France",,"https://ClinicalTrials.gov/show/NCT00914277"
60,"NCT02984683","Study Evaluating Efficacy and Safety of SAR566658 Treatment in Patients With CA6 Positive Metastatic Triple Negative Breast Cancer",,"Completed","No Results Available","Triple Negative Breast Cancer","Drug: SAR566658 (ACT14884)","Objective response rate (ORR)|Disease control rate|Duration of response - time|Progression free survival - time|Time to progression|Number of keratopathies|Incidence of positive patients for antidrug antibodies as a measure of SAR566658 immunogenicity","Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 2","23","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ACT14884|2016‐001962‐27|U1111-1182-7044","March 14, 2017","August 13, 2018","August 13, 2018","December 7, 2016",,"August 16, 2019","Investigational Site Number 8400002, El Paso, Texas, United States|Investigational Site Number 0560001, Leuven, Belgium|Investigational Site Number 2030002, Praha 2, Czechia|Investigational Site Number 3800003, Genova, Italy|Investigational Site Number 3800001, Milano, Italy|Investigational Site Number 3800004, Roma, Italy|Investigational Site Number 5280001, Maastricht, Netherlands|Investigational Site Number 5280002, Rotterdam, Netherlands|Investigational Site Number 7240002, Barcelona, Spain|Investigational Site Number 7240005, Lleida, Spain|Investigational Site Number 7240001, Madrid, Spain|Investigational Site Number 7240006, Madrid, Spain|Investigational Site Number 7240003, Sevilla, Spain|Investigational Site Number 7240004, Valencia, Spain",,"https://ClinicalTrials.gov/show/NCT02984683"
61,"NCT01505062","Study of SAR421869 in Patients With Retinitis Pigmentosa Associated With Usher Syndrome Type 1B",,"Terminated","No Results Available","Usher Syndrome|Retinitis Pigmentosa","Genetic: SAR421869","The incidence of adverse events|To determine delay in retinal degeneration following the SAR421869 injection","Sanofi","All","6 Years and older   (Child, Adult, Older Adult)","Phase 1|Phase 2","9","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TDU13600|US1/001/10","March 26, 2012","August 16, 2019","August 16, 2019","January 6, 2012",,"January 18, 2020","Investigational Site Number 840001, Portland, Oregon, United States|Investigational Site Number 250001, Paris, France",,"https://ClinicalTrials.gov/show/NCT01505062"
62,"NCT01013324","Study of XL147 (SAR245408) in Advanced or Recurrent Endometrial Carcinoma",,"Completed","No Results Available","Endometrial Cancer|Endometrial Neoplasms","Drug: XL147 (SAR245408)","Efficacy as defined by overall response rate and progression-free survival (PFS) at 6 months|Safety of XL147 in the EC population|Duration of response and PFS|Characterize pharmacokinetic and pharmacodynamic profiles of XL147","Sanofi","Female","18 Years and older   (Adult, Older Adult)","Phase 2","67","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ARD11436|XL147-201","January 2010","March 2013","March 2013","November 13, 2009",,"June 3, 2016","Investigational Site Number 1526, Newport Beach, California, United States|Investigational Site Number 1532, Orlando, Florida, United States|Investigational Site Number 1239, Augusta, Georgia, United States|Investigational Site Number 1133, Boston, Massachusetts, United States|Investigational Site Number 1325, Columbus, Ohio, United States|Investigational Site Number 1434, Oklahoma City, Oklahoma, United States|Investigational Site Number 1132, Abington, Pennsylvania, United States|Investigational Site Number 1134, Philadelphia, Pennsylvania, United States|Investigational Site Number 1142, Providence, Rhode Island, United States|Investigational Site Number 1527, Dallas, Texas, United States|Investigational Site Number 3212, Kortrijk, Belgium|Investigational Site Number 3211, Leuven, Belgium|Investigational Site Number 3218, Wilrijk, Belgium",,"https://ClinicalTrials.gov/show/NCT01013324"
63,"NCT02294474","Comparison of SAR342434 to Humalog as the Rapid Acting Insulin in Adult Patients With Type 2 Diabetes Mellitus Also Using Insulin Glargine","SORELLA2","Completed","Has Results","Type 2 Diabetes Mellitus","Drug: SAR342434|Drug: Humalog|Drug: insulin glargine HOE901","Change in HbA1c From Baseline to Week 26|Percentage of Participants With HbA1c <7.0% and <=6.5% at Week 26|Change in Fasting Plasma Glucose (FPG) From Baseline to Week 26|Change in Mean 24-Hour Plasma Glucose Concentration From Baseline to Week 26|Change in Post Prandial Glucose (PPG) Excursion From Baseline to Week 26|Percentage of Participants With Hypoglycemia (Any Hypoglycemia, Documented Symptomatic Hypoglycemia and Severe Hypoglycemia)|Percentage of Participants With Hypersensitivity Reactions and Injection Site Reactions|Percentage of Participants With Treatment-Emergent Anti-insulin Antibodies (AIAs)","Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 3","505","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EFC13403|2014-002844-42|U1111-1156-4296","January 2015","February 2016","February 2016","November 19, 2014","January 18, 2018","January 18, 2018","Investigational Site Number 840217, Foley, Alabama, United States|Investigational Site Number 840237, Muscle Shoals, Alabama, United States|Investigational Site Number 840245, Chandler, Arizona, United States|Investigational Site Number 840219, Phoenix, Arizona, United States|Investigational Site Number 840227, Phoenix, Arizona, United States|Investigational Site Number 840212, Little Rock, Arkansas, United States|Investigational Site Number 840241, El Cajon, California, United States|Investigational Site Number 840238, Fresno, California, United States|Investigational Site Number 840229, Greenbrae, California, United States|Investigational Site Number 840231, Huntington Beach, California, United States|Investigational Site Number 840247, Long Beach, California, United States|Investigational Site Number 840234, Los Angeles, California, United States|Investigational Site Number 840235, Northridge, California, United States|Investigational Site Number 840251, Palm Springs, California, United States|Investigational Site Number 840249, Santa Ana, California, United States|Investigational Site Number 840223, Temecula, California, United States|Investigational Site Number 840259, Tustin, California, United States|Investigational Site Number 840240, Walnut Creek, California, United States|Investigational Site Number 840214, Boynton Beach, Florida, United States|Investigational Site Number 840246, Miami, Florida, United States|Investigational Site Number 840226, New Port Richey, Florida, United States|Investigational Site Number 840205, Ocoee, Florida, United States|Investigational Site Number 840206, Palm Harbor, Florida, United States|Investigational Site Number 840242, Port Charlotte, Florida, United States|Investigational Site Number 840253, Lawrenceville, Georgia, United States|Investigational Site Number 840207, Stockbridge, Georgia, United States|Investigational Site Number 840248, Arlington Heights, Illinois, United States|Investigational Site Number 840204, Avon, Indiana, United States|Investigational Site Number 840257, Evansville, Indiana, United States|Investigational Site Number 840230, Des Moines, Iowa, United States|Investigational Site Number 840239, Rockville, Maryland, United States|Investigational Site Number 840236, Troy, Michigan, United States|Investigational Site Number 840216, Lincoln, Nebraska, United States|Investigational Site Number 840220, Las Vegas, Nevada, United States|Investigational Site Number 840233, Las Vegas, Nevada, United States|Investigational Site Number 840224, Linden, New Jersey, United States|Investigational Site Number 840232, Greensboro, North Carolina, United States|Investigational Site Number 840211, Morehead City, North Carolina, United States|Investigational Site Number 840228, Morganton, North Carolina, United States|Investigational Site Number 840225, Fargo, North Dakota, United States|Investigational Site Number 840221, Columbus, Ohio, United States|Investigational Site Number 840255, Dayton, Ohio, United States|Investigational Site Number 840250, Tipton, Pennsylvania, United States|Investigational Site Number 840243, Uniontown, Pennsylvania, United States|Investigational Site Number 840208, Chattanooga, Tennessee, United States|Investigational Site Number 840215, Jackson, Tennessee, United States|Investigational Site Number 840203, Austin, Texas, United States|Investigational Site Number 840258, Dallas, Texas, United States|Investigational Site Number 840201, Dallas, Texas, United States|Investigational Site Number 840222, Renton, Washington, United States|Investigational Site Number 840209, Milwaukee, Wisconsin, United States|Investigational Site Number 032201, Caba, Argentina|Investigational Site Number 032206, Capital Federal, Argentina|Investigational Site Number 032202, Capital Federal, Argentina|Investigational Site Number 032205, Ciudad Autonoma De Buenos Aire, Argentina|Investigational Site Number 032203, Salta, Argentina|Investigational Site Number 152202, Santiago, Chile|Investigational Site Number 152204, Santiago, Chile|Investigational Site Number 152201, Santiago, Chile|Investigational Site Number 170203, Armenia, Colombia|Investigational Site Number 276201, Berlin, Germany|Investigational Site Number 276204, Heidelberg, Germany|Investigational Site Number 276202, Neumünster, Germany|Investigational Site Number 276206, Potsdam, Germany|Investigational Site Number 276205, Stuttgart, Germany|Investigational Site Number 276203, Sulzbach-Rosenberg, Germany|Investigational Site Number 348205, Budapest, Hungary|Investigational Site Number 348202, Budapest, Hungary|Investigational Site Number 348204, Debrecen, Hungary|Investigational Site Number 348208, Komárom, Hungary|Investigational Site Number 348210, Nagykanizsa, Hungary|Investigational Site Number 348203, Szolnok, Hungary|Investigational Site Number 348209, Sátoraljaújhely, Hungary|Investigational Site Number 380203, Bologna, Italy|Investigational Site Number 380201, Milano, Italy|Investigational Site Number 380204, Roma, Italy|Investigational Site Number 380202, Sesto San Giovanni, Italy|Investigational Site Number 410202, Seoul, Korea, Republic of|Investigational Site Number 410204, Seoul, Korea, Republic of|Investigational Site Number 410205, Seoul, Korea, Republic of|Investigational Site Number 410201, Wonju, Korea, Republic of|Investigational Site Number 642210, Bacau, Romania|Investigational Site Number 642201, Bucuresti, Romania|Investigational Site Number 642202, Bucuresti, Romania|Investigational Site Number 642206, Cluj Napoca, Romania|Investigational Site Number 642204, Deva, Romania|Investigational Site Number 642205, Oradea, Romania|Investigational Site Number 642209, Sibiu, Romania|Investigational Site Number 642207, Targu Mures, Romania|Investigational Site Number 642208, Targu Mures, Romania|Investigational Site Number 642203, Timisoara, Romania|Investigational Site Number 643201, Saint-Petersburg, Russian Federation|Investigational Site Number 643205, Saratov, Russian Federation|Investigational Site Number 643203, St-Petersburg, Russian Federation|Investigational Site Number 643202, St-Petersburg, Russian Federation|Investigational Site Number 643204, St. Petersburg, Russian Federation|Investigational Site Number 724201, Barcelona, Spain|Investigational Site Number 724203, Málaga, Spain|Investigational Site Number 724202, Palma De Mallorca, Spain|Investigational Site Number 792201, Istanbul, Turkey|Investigational Site Number 792202, Istanbul, Turkey|Investigational Site Number 792204, Izmir, Turkey|Investigational Site Number 792203, Izmir, Turkey",,"https://ClinicalTrials.gov/show/NCT02294474"
64,"NCT03350191","A Clinical Study to Investigate if SAR425899 Binds to the Liver and Pancreas in Overweight to Obese Type 2 Diabetes Mellitus Patients",,"Completed","No Results Available","Type 2 Diabetes Mellitus","Drug: SAR425899|Drug: [68Ga] Ga-DO3A-VS-Cys40-Tuna-2 (glucagon receptor tracer)|Drug: [68Ga] Ga-DO3A-VS-Cys40-Exendin-4 (GLP-1 receptor tracer)","Glucagon receptor occupancy|GLP-1 receptor occupancy|Adverse events|Pharmacokinetics|Change in fasting plasma glucose (FPG)|Change in ketone bodies|Change lipid biomarkers|Change in volume of distribution (Vt) in the liver|Change in Vt in the pancreas|Average standard uptake values (SUVs) of PET tracers in the liver and pancreas","Sanofi|Antaros Medical AB","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1","13","Industry|Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","PDY15264|2017-001789-23","December 20, 2017","June 7, 2018","June 7, 2018","November 22, 2017",,"October 11, 2018","Investigational Site Number 7520001, Uppsala, Sweden",,"https://ClinicalTrials.gov/show/NCT03350191"
65,"NCT01861249","Long Term Safety And Tolerability Of SAR339658 In Patients With Ulcerative Colitis (UC)",,"Terminated","No Results Available","Ulcerative Colitis","Drug: SAR339658","Percentage of participants with Adverse Events|Percentage of participants with abnormal safety parameters (laboratory data and vital signs)|Proportion of participants with Clinical Remission by Mayo Score|Proportion of participants with Mucosal Healing|Change from baseline in the partial Mayo Score|Change from baseline in Inflammatory Bowel Disease Questionnaire (IBDQ)","Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 2","6","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LTS12593|2013-001012-30|U1111-1141-4634","July 2013","May 2014","April 2016","May 23, 2013",,"July 13, 2016","Investigational Site Number 840059, Mission Hills, California, United States|Investigational Site Number 840008, Miramar,, Florida, United States|Investigational Site Number 840048, Winter Park, Florida, United States|Investigational Site Number 840024, Mexico, Missouri, United States|Investigational Site Number 840088, San Antonio, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01861249"
66,"NCT02273180","Comparison of SAR342434 to Humalog as the Rapid Acting Insulin in Adult Patients With Type 1 Diabetes Mellitus Also Using Insulin Glargine","SORELLA1","Completed","Has Results","Type 1 Diabetes Mellitus","Drug: SAR342434|Drug: Humalog|Drug: Insulin glargine HOE901","Change in HbA1c From Baseline to Week 26|Percentage of Participants With HbA1c <7.0% at Week 26|Change in Fasting Plasma Glucose (FPG) From Baseline to Week 26|Change in Mean 24-Hour Plasma Glucose Concentration From Baseline to Week 26|Change in Post Prandial Plasma Glucose (PPG) Excursion From Baseline to Week 26|Number of Hypoglycemia Events (Any Hypoglycemia, Documented Symptomatic Hypoglycemia and Severe Hypoglycemia) Per Participant-Year|Percentage of Participants With Hypersensitivity Reactions and Injection Site Reactions|Percentage of Participants With Treatment Emergent Anti-insulin Antibodies (AIAs)","Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 3","507","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EFC12619|2013-002945-12|U1111-1131-5038","October 2014","December 2015","July 2016","October 23, 2014","January 18, 2018","January 18, 2018","Investigational Site Number 840049, Tucson, Arizona, United States|Investigational Site Number 840016, Bell Gardens, California, United States|Investigational Site Number 840048, Chula Vista, California, United States|Investigational Site Number 840046, Concord, California, United States|Investigational Site Number 840039, Fresno, California, United States|Investigational Site Number 840028, La Jolla, California, United States|Investigational Site Number 840022, Ventura, California, United States|Investigational Site Number 840003, Denver, Colorado, United States|Investigational Site Number 840037, Denver, Colorado, United States|Investigational Site Number 840005, Bradenton, Florida, United States|Investigational Site Number 840061, Miami Lakes, Florida, United States|Investigational Site Number 840057, Miami Lakes, Florida, United States|Investigational Site Number 840050, Miami, Florida, United States|Investigational Site Number 840042, Miami, Florida, United States|Investigational Site Number 840006, New Port Richey, Florida, United States|Investigational Site Number 840013, North Miami Beach, Florida, United States|Investigational Site Number 840031, Port Charlotte, Florida, United States|Investigational Site Number 840036, Atlanta, Georgia, United States|Investigational Site Number 840045, Roswell, Georgia, United States|Investigational Site Number 840020, Idaho Falls, Idaho, United States|Investigational Site Number 840019, Chicago, Illinois, United States|Investigational Site Number 840033, Chicago, Illinois, United States|Investigational Site Number 840012, McHenry, Illinois, United States|Investigational Site Number 840004, Des Moines, Iowa, United States|Investigational Site Number 840043, Marrero, Louisiana, United States|Investigational Site Number 840021, Metairie, Louisiana, United States|Investigational Site Number 840038, Baltimore, Maryland, United States|Investigational Site Number 840014, Rockville, Maryland, United States|Investigational Site Number 840060, Great Falls, Montana, United States|Investigational Site Number 840026, Omaha, Nebraska, United States|Investigational Site Number 840040, Omaha, Nebraska, United States|Investigational Site Number 840015, Albuquerque, New Mexico, United States|Investigational Site Number 840054, Albuquerque, New Mexico, United States|Investigational Site Number 840059, Mineola, New York, United States|Investigational Site Number 840030, Burlington, North Carolina, United States|Investigational Site Number 840051, Greenville, North Carolina, United States|Investigational Site Number 840062, Wilmington, North Carolina, United States|Investigational Site Number 840018, Gallipolis, Ohio, United States|Investigational Site Number 840007, Dakota Dunes, South Dakota, United States|Investigational Site Number 840027, Rapid City, South Dakota, United States|Investigational Site Number 840041, Dallas, Texas, United States|Investigational Site Number 840029, Dallas, Texas, United States|Investigational Site Number 840034, Dallas, Texas, United States|Investigational Site Number 840002, Houston, Texas, United States|Investigational Site Number 840011, Chesapeake, Virginia, United States|Investigational Site Number 840023, Tacoma, Washington, United States|Investigational Site Number 840009, Milwaukee, Wisconsin, United States|Investigational Site Number 250002, Corbeil Essonnes, France|Investigational Site Number 250005, Mantes La Jolie, France|Investigational Site Number 250003, Montpellier Cedex 5, France|Investigational Site Number 250001, Vandoeuvre Les Nancy, France|Investigational Site Number 276001, Berlin, Germany|Investigational Site Number 276004, Dortmund, Germany|Investigational Site Number 276006, Hannover, Germany|Investigational Site Number 276002, Heidelberg, Germany|Investigational Site Number 276003, Neumünster, Germany|Investigational Site Number 276008, Pirna, Germany|Investigational Site Number 276007, Potsdam, Germany|Investigational Site Number 276005, Sulzbach-Rosenberg, Germany|Investigational Site Number 348002, Budapest, Hungary|Investigational Site Number 348005, Budapest, Hungary|Investigational Site Number 348003, Budapest, Hungary|Investigational Site Number 348011, Budapest, Hungary|Investigational Site Number 348010, Budapest, Hungary|Investigational Site Number 348001, Budapest, Hungary|Investigational Site Number 348007, Debrecen, Hungary|Investigational Site Number 392006, Chuo-Ku, Japan|Investigational Site Number 392003, Higashiosaka-Shi, Japan|Investigational Site Number 392004, Izumisano-Shi, Japan|Investigational Site Number 392005, Kamakura-Shi, Japan|Investigational Site Number 392001, Shinjuku-Ku, Japan|Investigational Site Number 392002, Yamato-Shi, Japan|Investigational Site Number 616005, Krakow, Poland|Investigational Site Number 616001, Poznan, Poland|Investigational Site Number 616003, Szczecin, Poland|Investigational Site Number 616002, Warszawa, Poland|Investigational Site Number 616004, Zabrze, Poland|Investigational Site Number 643003, Moscow, Russian Federation|Investigational Site Number 643006, Samara, Russian Federation|Investigational Site Number 643002, Saratov, Russian Federation|Investigational Site Number 643004, St-Petersburg, Russian Federation|Investigational Site Number 643001, St-Petersburg, Russian Federation|Investigational Site Number 643005, St-Petersburg, Russian Federation|Investigational Site Number 643007, Tomsk, Russian Federation|Investigational Site Number 724002, A Coruña, Spain|Investigational Site Number 724001, Cáceres, Spain|Investigational Site Number 724004, Lérida, Spain|Investigational Site Number 724005, Málaga, Spain|Investigational Site Number 724003, Sabadell, Spain",,"https://ClinicalTrials.gov/show/NCT02273180"
67,"NCT01392924","Safety and Pharmacokinetics of SAR245408 Daily Oral in Patients With Solid Tumors",,"Completed","No Results Available","Neoplasm Malignant","Drug: SAR245408","Dose limiting toxicity in cycle 1|Number of treatment emergent adverse events|Number of serious adverse events|Number of abnormality of laboratory test as graded by National Cancer Institute-Common Toxicity Criteria|Pharmacokinetics (Cmax) of SAR245408|Pharmacokinetics (tmax) of SAR245408|Pharmacokinetics (AUC) of SAR245408|Pharmacokinetics (accumulation ratio) of SAR245408|Pharmacokinetics (Ctrough) of SAR245408|Objective tumor response as defined by RECIST (response evaluation criteria in solid tumors)","Sanofi","All","20 Years and older   (Adult, Older Adult)","Phase 1","10","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TED11883|U1111-1118-9727","August 2011","February 2012","November 2014","July 13, 2011",,"December 3, 2014","Investigational Site Number 392002, Kobe-Shi, Japan|Investigational Site Number 392001, Nagoya-Shi, Japan",,"https://ClinicalTrials.gov/show/NCT01392924"
68,"NCT01470456","Combination of SAR3419 and Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma",,"Completed","No Results Available","Diffuse Large B-Cell Lymphoma","Drug: SAR3419|Drug: rituximab","Number of participants achieving an Objective Response Rate|Number of participants with Adverse Events|Response Duration -Time|Progression Free Survival -Time|Overall survival -Time","Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 2","50","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TCD12333|2011-002865-39|U1111-1120-0315","November 2011","July 2013","September 2014","November 11, 2011",,"November 13, 2014","Investigational Site Number 040002, Graz, Austria|Investigational Site Number 250004, Creteil Cedex, France|Investigational Site Number 250009, Dijon, France|Investigational Site Number 250006, Lille Cedex, France|Investigational Site Number 250011, Marseille Cedex 9, France|Investigational Site Number 250010, Montpellier, France|Investigational Site Number 250008, Nantes Cedex 01, France|Investigational Site Number 250007, Paris Cedex 10, France|Investigational Site Number 250001, Pierre Benite Cedex, France|Investigational Site Number 250005, Rennes, France|Investigational Site Number 250003, Rouen Cedex, France|Investigational Site Number 250002, Villejuif Cedex, France|Investigational Site Number 578001, Oslo, Norway",,"https://ClinicalTrials.gov/show/NCT01470456"
69,"NCT01420783","Study With SAR302503 in Patients With Polycythemia Vera or Essential Thrombocythemia",,"Completed","No Results Available","Hematopoietic Neoplasm","Drug: SAR302503","Dose Ranging Phase: Proportion of PV patients with absence of phlebotomy and hematocrit below 45% and proportion of ET patients with a platelet count ≤ 400 x 10x9/L for a minimum of 3 months during the first 8 cycles of therapy.|PV Dose Expansion Phase: Proportion of PV patients with absence of phlebotomy eligibility beginning at Day 1 of Cycle 4 visit and continuing through Day 1 of Cycle 6 visit.|ET Dose Ranging Phase (only 600 mg dose group): Proportion of ET patients with a platelet count ≤400 x 10x9/L beginning at Day 1 of Cycle 4 visit and continuing through Day 1 of Cycle 6 visit.|Proportion of PV patients with absence of phlebotomy eligibility beginning at Day 1 of Cycle 4 visit through Cycle 8 (for PV dose expansion phase only).|Proportion of ET patients with platelet count ≤400 x 10x9/L beginning at Day 1 of Cycle 4 visit and continuing through Cycle 8.|Characterization of clinicohematologic response (CR, PR, and no Response) defined by European LeukemiaNet beginning at Day 1 of Cycle 6 visit through Cycle 8.|Percent change in spleen volume (per Magnetic Resonance Imaging (MRI)) at the end of Cycles 4 and 8 or end of treatment (EOT) relative to baseline.|Proportion of patients with a ≥ 35% reduction in spleen volume (per Magnetic Resonance Imaging (MRI)) at the end of Cycles 4 and 8 or end of treatment (EOT) relative to baseline.|Number of participants who have changes in histological, cytogenetic, and molecular responses in bone marrow.|Response (defined as either a 2-point improvement in or resolution of a symptom present at baseline) at the end of Cycles 1, 4, and 8 or end of treatment (EOT), as measured by the Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF).|Cumulative Distribution Function of responses between treatment groups at the end of Cycles 1, 4, and 8 or EOT on the MPN-SAF.|For each MPN-associated symptom present at baseline on the MPN-SAF, proportion of patients with resolution of that symptom at the end of Cycles 1, 4, and 8.|To measure generic health-related quality of life and utility values using the EQ-5D questionnaire after completion of 8 cycles of therapy.|Characterization of the safety profile of SAR302503, including the frequency, duration, and severity of adverse events graded using the National Cancer Institute (NCI) - CTCAE version 4.03, clinical laboratory parameters, ECG, and vital signs.","Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 2","81","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ARD12042|2011-001847-58|U1111-1121-4203","October 2011","November 2012","May 2014","August 22, 2011",,"March 17, 2016","Investigational Site Number 840008, Scottsdale, Arizona, United States|Investigational Site Number 840004, La Jolla, California, United States|Investigational Site Number 840005, Los Angeles, California, United States|Investigational Site Number 840011, Palo Alto, California, United States|Investigational Site Number 840010, Ann Arbor, Michigan, United States|Investigational Site Number 840007, Rochester, Minnesota, United States|Investigational Site Number 840003, St Louis, Missouri, United States|Investigational Site Number 840001, Houston, Texas, United States|Investigational Site Number 036001, Clayton, Australia|Investigational Site Number 036002, Kingswood, Australia|Investigational Site Number 036004, Kogarah, Australia|Investigational Site Number 036003, Randwick, Australia|Investigational Site Number 124002, Montreal, Canada|Investigational Site Number 124003, Toronto, Canada|Investigational Site Number 124001, Vancouver, Canada|Investigational Site Number 250004, Brest, France|Investigational Site Number 250003, Marseille, France|Investigational Site Number 250001, Paris Cedex 10, France|Investigational Site Number 276004, Frankfurt Am Main, Germany|Investigational Site Number 276003, Mannheim, Germany|Investigational Site Number 380003, Bologna, Italy|Investigational Site Number 380001, Firenze, Italy|Investigational Site Number 380004, Orbassano, Italy|Investigational Site Number 410001, Seongnam, Korea, Republic of|Investigational Site Number 410003, Seoul, Korea, Republic of|Investigational Site Number 410004, Seoul, Korea, Republic of|Investigational Site Number 410002, Seoul, Korea, Republic of|Investigational Site Number 724004, Badalona, Spain|Investigational Site Number 724001, Barcelona, Spain|Investigational Site Number 724003, Madrid, Spain|Investigational Site Number 724002, Valencia, Spain|Investigational Site Number 826001, Belfast, United Kingdom|Investigational Site Number 826006, Birmingham, United Kingdom|Investigational Site Number 826003, London, United Kingdom|Investigational Site Number 826004, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01420783"
70,"NCT04059484","Phase 2 Study of SAR439859 Versus Physician's Choice in Premenopausal and Postmenopausal Locally Advanced or Metastatic ER-positive Breast Cancer",,"Recruiting","No Results Available","Breast Cancer Metastatic","Drug: SAR439859|Drug: Endocrine monotherapy as per physician choice","Progression free survival (PFS)|Objective Response Rate (ORR)|Disease Control Rate (DCR)|Clinical Benefit Rate (CBR)|Duration of Response (DOR)|PFS according to (ESR1) mutation status|Overall Survival (OS)|Assessments of the Pharmacokinetic (PK) parameter of SAR439859: Plasma Concentrations|Patient Reported Outcome (PRO) - health-related quality of life and health status using the European Quality of Life-5 Dimensions (EQ-5D)|Patient Reported Outcome (PRO) - the European Organisation for Research and Treatment of Cancer core quality of life questionnaire (EORTC-QLQ-C30)|Patient Reported Outcome (PRO) - EORTC-QLQ breast cancer (EORTC-QLQ-BR23)|Overall safety profile - Treatment-Emergent Adverse events","Sanofi","Female","18 Years and older   (Adult, Older Adult)","Phase 2","282","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ACT16105|2018-004593-98|U1111-1217-2774","October 22, 2019","February 2021","August 2022","August 16, 2019",,"January 22, 2020","Investigational Site Number 8400008, Birmingham, Alabama, United States|Investigational Site Number 8400018, Bakersfield, California, United States|Investigational Site Number 8400012, Tinley Park, Illinois, United States|Investigational Site Number 8400031, Urbana, Illinois, United States|Investigational Site Number 8400015, Boston, Massachusetts, United States|Investigational Site Number 8400003, Billings, Montana, United States|Investigational Site Number 8400025, Hackensack, New Jersey, United States|Investigational Site Number 8400030, Pinehurst, North Carolina, United States|Investigational Site Number 8400006, Canton, Ohio, United States|Investigational Site Number 8400001, Philadelphia, Pennsylvania, United States|Investigational Site Number 8400023, Pittsburgh, Pennsylvania, United States|Investigational Site Number 8400022, Fort Worth, Texas, United States|Investigational Site Number 8400026, Burlington, Vermont, United States|Investigational Site Number 0320004, La Rioja, Argentina|Investigational Site Number 0320005, Rosario, Argentina|Investigational Site Number 0360001, Nedlands, Australia|Investigational Site Number 0360003, South Brisbane, Australia|Investigational Site Number 0360002, Woolloongabba, Australia|Investigational Site Number 0760001, Porto Alegre, Brazil|Investigational Site Number 1240004, Calgary, Canada|Investigational Site Number 2500006, Creteil Cedex, France|Investigational Site Number 2500007, Marseille, France|Investigational Site Number 2500005, Paris Cedex 10, France|Investigational Site Number 2500002, Saint-Herblain, France|Investigational Site Number 2500001, Villejuif Cedex, France|Investigational Site Number 3800002, Milano, Italy|Investigational Site Number 3800003, Prato, Italy|Investigational Site Number 3920001, Kashiwa-Shi, Japan|Investigational Site Number 4840002, Monterrey, Mexico|Investigational Site Number 4840006, Veracruz, Mexico|Investigational Site Number 8400028, Hato Rey, Puerto Rico|Investigational Site Number 6430001, Moscow, Russian Federation|Investigational Site Number 6430003, Moscow, Russian Federation|Investigational Site Number 6430002, Saint -Petersburg, Russian Federation|Investigational Site Number 6430004, Saint-Petersburg, Russian Federation|Investigational Site Number 1580003, Tainan, Taiwan|Investigational Site Number 7920004, Ankara, Turkey|Investigational Site Number 7920002, Edirne, Turkey|Investigational Site Number 7920001, Istanbul, Turkey|Investigational Site Number 7920003, Istanbul, Turkey",,"https://ClinicalTrials.gov/show/NCT04059484"
71,"NCT03637764","Safety, Preliminary Efficacy and PK of Isatuximab (SAR650984) Alone or in Combination With Atezolizumab in Patients With Advanced Malignancies",,"Recruiting","No Results Available","Neoplasm","Drug: Isatuximab SAR650984|Drug: Atezolizumab","Dose Limiting Toxicities (DLTs)|Adverse events (AEs)|Maximum tolerated dose (MTD)|Recommended Phase 2 dose (RP2D)|Response Rate|Progression free survival|Immunogenicity: isatuximab|Immunogenicity: atezolizumab|Tumor burden change|Disease control rate|Duration of response|Progress free survival|Pharmacokinetic (PK) parameters: Area under the curve (AUC0-T)|Assessment of PK parameter: Cmax|Assessment of PK parameter: tmax","Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","350","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ACT15377|2018-000390-67|U1111-1202-0839","August 6, 2018","April 2024","April 2024","August 20, 2018",,"November 19, 2019","Investigational Site Number 8400003, Los Angeles, California, United States|Investigational Site Number 8400004, Santa Monica, California, United States|Investigational Site Number 8400207, Boston, Massachusetts, United States|Investigational Site Number 8400007, Boston, Massachusetts, United States|Investigational Site Number 8400107, Boston, Massachusetts, United States|Investigational Site Number 8400001, Hackensack, New Jersey, United States|Investigational Site Number 8400006, Philadelphia, Pennsylvania, United States|Investigational Site Number 8400002, Houston, Texas, United States|Investigational Site Number 8400005, Seattle, Washington, United States|Investigational Site Number 0560001, Bruxelles, Belgium|Investigational Site Number 0560002, Gent, Belgium|Investigational Site Number 1240002, Edmonton, Canada|Investigational Site Number 1240001, Toronto, Canada|Investigational Site Number 2030001, Brno, Czechia|Investigational Site Number 2030003, Olomouc, Czechia|Investigational Site Number 2030002, Praha 2, Czechia|Investigational Site Number 2030004, Praha 8, Czechia|Investigational Site Number 2500003, Bordeaux Cedex, France|Investigational Site Number 2500005, Rennes Cedex, France|Investigational Site Number 2500001, Villejuif Cedex, France|Investigational Site Number 3000002, Patra, Greece|Investigational Site Number 3800007, Meldola, Italy|Investigational Site Number 3800009, Milano, Italy|Investigational Site Number 3800006, Napoli, Italy|Investigational Site Number 3800004, Padova, Italy|Investigational Site Number 3800002, Pavia, Italy|Investigational Site Number 3800005, Roma, Italy|Investigational Site Number 3800003, Rozzano, Italy|Investigational Site Number 5280001, Rotterdam, Netherlands|Investigational Site Number 7240001, Barcelona, Spain|Investigational Site Number 7240002, Barcelona, Spain|Investigational Site Number 7240006, Hospitalet De Llobregat, Spain|Investigational Site Number 7240009, Madrid, Spain|Investigational Site Number 7240003, Madrid, Spain|Investigational Site Number 7240007, Madrid, Spain|Investigational Site Number 7240004, Madrid, Spain|Investigational Site Number 7240008, Pamplona, Spain|Investigational Site Number 1580005, Kaohsiung, Taiwan|Investigational Site Number 1580002, Tainan, Taiwan|Investigational Site Number 1580001, Taipei 100, Taiwan|Investigational Site Number 1580003, Taipei, Taiwan|Investigational Site Number 1580006, Taipei, Taiwan|Investigational Site Number 1580004, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT03637764"
72,"NCT01657214","Phase I, Dose Escalation of SAR125844 in Asian Solid Tumor Patients","SARMETA","Completed","No Results Available","Neoplasm Malignant","Drug: SAR125844","- DOSE ESCALATION To determine the maximum tolerated dose (MTD) of SAR125844|- EXPANSION Cohort To evaluate the preliminary anti-tumoral effect of SAR125844|Number of patients with treatment emergent events|Assessment of PK parameter Cmax|Assessment of PK parameter AUCs|Assessment of PK parameter CL|Assessment of PD parameter ShedMET|Assessment of PD parameter HGF","Sanofi","All","20 Years and older   (Adult, Older Adult)","Phase 1","70","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TED12337|U1111-1126-7527","September 2012","January 2016","January 2016","August 6, 2012",,"February 17, 2016","Investigational Site Number 392001, Kashiwa-Shi, Japan|Investigational Site Number 392004, Suita-Shi, Japan|Investigational Site Number 392002, Sunto-Gun, Japan|Investigational Site Number 392003, Takatsuki-Shi, Japan|Investigational Site Number 410001, Seoul, Korea, Republic of|Investigational Site Number 410004, Seoul, Korea, Republic of|Investigational Site Number 410003, Seoul, Korea, Republic of|Investigational Site Number 410002, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01657214"
73,"NCT01659138","Efficacy and Safety of SAR339658 in Patients With Moderate to Severe Ulcerative Colitis","FUSCIA","Terminated","No Results Available","Ulcerative Colitis","Drug: SAR339658|Other: Placebo","Proportion of Participants with Clinical Response by Mayo Score|Proportion of Participants with Clinical Remission by Mayo Score|Proportion of Participants with Mucosal Healing|Change from Baseline in Inflammatory Bowel Disease Questionnaire (IBDQ)|Change from Baseline in Quality of Life (QoL) SF-36|Change from Baseline in the partial Mayo Score|Number of Participants with adverse events","Sanofi","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","28","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","ACT12688|2012-002013-19|U1111-1124-1076","August 2012","June 2014","April 2016","August 7, 2012",,"July 13, 2016","Investigational Site Number 840065, Sun City, Arizona, United States|Investigational Site Number 840059, Mission Hills, California, United States|Investigational Site Number 840074, San Diego, California, United States|Investigational Site Number 840061, Littleton, Colorado, United States|Investigational Site Number 840003, Miami, Florida, United States|Investigational Site Number 840008, Miramar,, Florida, United States|Investigational Site Number 840048, Winter Park,, Florida, United States|Investigational Site Number 840053, Savannah,, Georgia, United States|Investigational Site Number 840001, Chicago, Illinois, United States|Investigational Site Number 840005, Oak Lawn, Illinois, United States|Investigational Site Number 840078, Hammond, Louisiana, United States|Investigational Site Number 840070, Rochester Hills, Michigan, United States|Investigational Site Number 840060, Ocean Springs, Mississippi, United States|Investigational Site Number 840024, Mexico, Missouri, United States|Investigational Site Number 840051, Great Neck, New York, United States|Investigational Site Number 840071, Rochester, New York, United States|Investigational Site Number 840089, Winston Salem, North Carolina, United States|Investigational Site Number 840046, Cincinnati, Ohio, United States|Investigational Site Number 840045, Phoenixville, Pennsylvania, United States|Investigational Site Number 840019, Pasadena,, Texas, United States|Investigational Site Number 840088, San Antonio, Texas, United States|Investigational Site Number 840038, Sugar Land, Texas, United States|Investigational Site Number 840068, Charlottesville,, Virginia, United States|Investigational Site Number 840034, Seattle, Washington, United States|Investigational Site Number 840064, Wauwatosa, Wisconsin, United States|Investigational Site Number 040003, Innsbruck, Austria|Investigational Site Number 124002, Vancouver, Canada|Investigational Site Number 250003, Grenoble, France|Investigational Site Number 250006, Vandoeuvre Les Nancy, France|Investigational Site Number 276001, Berlin, Germany|Investigational Site Number 276007, Hamburg, Germany|Investigational Site Number 276005, Hamburg, Germany|Investigational Site Number 380003, Firenze, Italy|Investigational Site Number 380006, San Giovanni Rotondo, Italy|Investigational Site Number 616001, Gdynia, Poland|Investigational Site Number 616004, Lodz, Poland|Investigational Site Number 616005, Lodz, Poland|Investigational Site Number 616002, Lodz, Poland|Investigational Site Number 616007, Poznan, Poland|Investigational Site Number 616006, Sroda Wielkopolska, Poland|Investigational Site Number 616008, Warszawa, Poland",,"https://ClinicalTrials.gov/show/NCT01659138"
74,"NCT01736592","Phase I/II Follow-up Study of SAR422459 in Patients With Stargardt's Macular Degeneration",,"Active, not recruiting","No Results Available","Stargardt's Disease","Drug: SAR422459 administered in previous study TDU13583","The incidence of Adverse Events|Delay in retinal degeneration","Sanofi","All","6 Years and older   (Child, Adult, Older Adult)","Phase 1|Phase 2","46","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LTS13588|SG1/002/11","December 14, 2012","June 1, 2034","June 1, 2034","November 29, 2012",,"October 3, 2019","Investigational Site Number 840001, Portland, Oregon, United States|Investigational Site Number 250001, Paris, France",,"https://ClinicalTrials.gov/show/NCT01736592"
75,"NCT01367444","Phase I/II Study of SAR422459 in Patients With Stargardt's Macular Degeneration",,"Terminated","No Results Available","Stargardt's Disease","Drug: SAR422459","Number of patients with treatment emergent adverse events|Change from baseline in ocular safety assessments|Delay in retinal degeneration","Sanofi","All","6 Years and older   (Child, Adult, Older Adult)","Phase 1|Phase 2","27","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TDU13583|SG1/001/10","June 8, 2011","August 16, 2019","August 16, 2019","June 7, 2011",,"January 18, 2020","Investigational Site Number 840002, Miami, Florida, United States|Investigational Site Number 840005, Iowa City, Iowa, United States|Investigational Site Number 840001, Portland, Oregon, United States|Investigational Site Number 840004, Houston, Texas, United States|Investigational Site Number 250001, Paris, France",,"https://ClinicalTrials.gov/show/NCT01367444"
76,"NCT01651143","Proof of Biological Activity of SAR100842 in Systemic Sclerosis",,"Completed","No Results Available","Systemic Sclerosis","Drug: SAR100842|Drug: Placebo (for SAR100842)","Safety and tolerability during the 8 week treatment period (core part): Number of patients reporting adverse events|Change from baseline to Week 8 in biomarkers obtained from blood and skin|Change from baseline to Week 8 in Modified Rodnan Skin Score (mRSS)|Change from baseline to Week 8 in Scleroderma Health Assessment Questionnaire (SHAQ) score","Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 2","32","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ACT12339|2012-001369-34|U1111-1127-2854","January 2013","November 2013","April 2014","July 26, 2012",,"March 25, 2016","Investigational Site Number 840006, Scottsdale, Arizona, United States|Investigational Site Number 840003, Washington, District of Columbia, United States|Investigational Site Number 840004, Baltimore, Maryland, United States|Investigational Site Number 840001, Boston, Massachusetts, United States|Investigational Site Number 840002, Ann Arbor, Michigan, United States|Investigational Site Number 840007, New Brunswick, New Jersey, United States|Investigational Site Number 840008, Pittsburgh, Pennsylvania, United States|Investigational Site Number 250003, Lille, France|Investigational Site Number 250001, Paris Cedex 14, France|Investigational Site Number 380001, Milano, Italy|Investigational Site Number 756001, Zürich, Switzerland|Investigational Site Number 826001, London, United Kingdom|Investigational Site Number 826002, Salford, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01651143"
77,"NCT03319667","Clinical Benefit of SAR650984, Bortezomib, Lenalidomide and Dexamethasone Combination in NDMM Patients Not Eligible for Transplant","IMROZ","Active, not recruiting","No Results Available","Plasma Cell Myeloma","Drug: Isatuximab SAR650984|Drug: Bortezomib|Drug: Lenalidomide|Drug: Dexamethasone|Drug: Acetaminophen (paracetamol) or equivalent|Drug: Ranitidine or equivalent|Drug: Diphenhydramine or equivalent","Progression free survival (PFS)|Very good partial response (VGPR) or better rate|Minimal residual disease (MRD) negativity rate|Complete response rate (CR)|Overall response rate (ORR)|Time to progression (TTP)|Duration of response (DOR)|Time to first response (TT1R)|PFS on next line of therapy (PFS2)|PFS in MRD negative patients|Overall survival (OS)|Adverse Events|Assessment of PK parameter: Ctrough|Assessment of PK parameter: AUC|Assessment of PK parameter: CL|Immunogenicity|Patient reported outcome (PRO): QLQ-C30|PRO: QLQ-MY20|PRO: EQ-5D-5L","Sanofi","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 3","475","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","EFC12522|2017-002238-21|U1111-1194-2121","December 7, 2017","December 2022","January 2025","October 24, 2017",,"November 19, 2019","Investigational Site Number 8400006, Fort Myers, Florida, United States|Investigational Site Number 8400004, Saint Petersburg, Florida, United States|Investigational Site Number 8400007, Kansas City, Missouri, United States|Investigational Site Number 8400005, Nashville, Tennessee, United States|Investigational Site Number 8400001, Houston, Texas, United States|Investigational Site Number 8400009, Tyler, Texas, United States|Investigational Site Number 0360005, Clayton, Australia|Investigational Site Number 0360004, Heidelberg West, Australia|Investigational Site Number 0360003, Liverpool, Australia|Investigational Site Number 0360006, Nedlands, Australia|Investigational Site Number 0360007, South Brisbane, Australia|Investigational Site Number 0360001, Waratah, Australia|Investigational Site Number 0360008, West Perth, Australia|Investigational Site Number 0360002, Wollongong, Australia|Investigational Site Number 0560001, Liège, Belgium|Investigational Site Number 1560002, Beijing, China|Investigational Site Number 1560003, Beijing, China|Investigational Site Number 1560008, Changchun, China|Investigational Site Number 1560007, Fuzhou, China|Investigational Site Number 1560009, Guangzhou, China|Investigational Site Number 1560006, Guangzhou, China|Investigational Site Number 1560005, Hangzhou, China|Investigational Site Number 1560014, Hangzhou, China|Investigational Site Number 1560004, Nanjing, China|Investigational Site Number 1560013, Shanghai, China|Investigational Site Number 1560011, Shenyang, China|Investigational Site Number 1560001, Tianjin, China|Investigational Site Number 1560012, Wuhan, China|Investigational Site Number 2030002, Brno, Czechia|Investigational Site Number 2030007, Hradec Kralove, Czechia|Investigational Site Number 2030004, Olomouc, Czechia|Investigational Site Number 2030003, Ostrava - Poruba, Czechia|Investigational Site Number 2030006, Plzen, Czechia|Investigational Site Number 2030001, Praha 2, Czechia|Investigational Site Number 2080002, Aalborg, Denmark|Investigational Site Number 2080003, Aarhus N, Denmark|Investigational Site Number 2080004, Odense C, Denmark|Investigational Site Number 2500011, Bayonne, France|Investigational Site Number 2500007, Caen Cedex 9, France|Investigational Site Number 2500009, Dijon, France|Investigational Site Number 2500008, La Roche Sur Yon, France|Investigational Site Number 2500001, Lille, France|Investigational Site Number 2500003, Nantes, France|Investigational Site Number 2500012, Paris, France|Investigational Site Number 2500002, Pessac, France|Investigational Site Number 2500006, Pierre Benite Cedex, France|Investigational Site Number 2500005, Poitiers Cedex, France|Investigational Site Number 2500004, Toulouse Cedex 9, France|Investigational Site Number 2500010, Vandoeuvre-Les-Nancy Cedex, France|Investigational Site Number 2760003, Berlin, Germany|Investigational Site Number 2760004, Frankfurt Am Main, Germany|Investigational Site Number 2760001, Heidelberg, Germany|Investigational Site Number 2760005, Tübingen, Germany|Investigational Site Number 3000003, Athens, Greece|Investigational Site Number 3000001, Athens, Greece|Investigational Site Number 3000002, Thessaloniki, Greece|Investigational Site Number 3800005, Ancona, Italy|Investigational Site Number 3800003, Bergamo, Italy|Investigational Site Number 3800001, Bologna, Italy|Investigational Site Number 3800004, Brescia, Italy|Investigational Site Number 3800002, Torino, Italy|Investigational Site Number 3920004, Higashiibaraki-Gun, Japan|Investigational Site Number 3920008, Konan-Ku, Yokohama-Shi, Japan|Investigational Site Number 3920003, Kumamoto-Shi, Japan|Investigational Site Number 3920007, Nagoya-Shi, Japan|Investigational Site Number 3920005, Okayama-Shi, Japan|Investigational Site Number 3920009, Sendai-Shi, Japan|Investigational Site Number 3920001, Shibuya-Ku, Japan|Investigational Site Number 3920002, Shinjuku-Ku, Japan|Investigational Site Number 3920006, Sunto-Gun, Japan|Investigational Site Number 3920010, Yamagata-Shi, Japan|Investigational Site Number 4400002, Klaipeda, Lithuania|Investigational Site Number 4400001, Vilnius, Lithuania|Investigational Site Number 4840001, Monterrey, Mexico|Investigational Site Number 5540001, Auckland, New Zealand|Investigational Site Number 5540003, Hamilton, New Zealand|Investigational Site Number 5540002, Takapuna, New Zealand|Investigational Site Number 6160002, Gdansk, Poland|Investigational Site Number 6160003, Lodz, Poland|Investigational Site Number 6160004, Poznan, Poland|Investigational Site Number 6160001, Warszawa, Poland|Investigational Site Number 6200002, Braga, Portugal|Investigational Site Number 6200006, Coimbra, Portugal|Investigational Site Number 6200001, Lisboa, Portugal|Investigational Site Number 6200005, Porto, Portugal|Investigational Site Number 6200003, Porto, Portugal|Investigational Site Number 6430001, Moscow, Russian Federation|Investigational Site Number 6430002, Moscow, Russian Federation|Investigational Site Number 7240005, Barcelona, Spain|Investigational Site Number 7240004, Barcelona, Spain|Investigational Site Number 7240003, Madrid, Spain|Investigational Site Number 7240001, Murcia, Spain|Investigational Site Number 7520002, Lund, Sweden|Investigational Site Number 7520001, Stockholm, Sweden|Investigational Site Number 1580003, Changhua, Taiwan|Investigational Site Number 1580002, Taichung, Taiwan|Investigational Site Number 1580001, Taipei, Taiwan|Investigational Site Number 7920006, Adana, Turkey|Investigational Site Number 7920007, Ankara, Turkey|Investigational Site Number 7920001, Ankara, Turkey|Investigational Site Number 7920002, Istanbul, Turkey|Investigational Site Number 7920004, Izmir, Turkey|Investigational Site Number 7920003, Izmir, Turkey|Investigational Site Number 7920005, Kayseri, Turkey|Investigational Site Number 7920008, Samsun, Turkey",,"https://ClinicalTrials.gov/show/NCT03319667"
78,"NCT01763190","Open Label Pharmacokinetic Study of SAR302503 in Subjects With Renal Impairment",,"Completed","No Results Available","Renal Impairment","Drug: SAR302503","Pharmacokinetic parameter: Cmax, AUClast and AUC|Pharmacokinetic parameters : unbound AUC, unbound Cmax, CL/F, Vss/F , t1/2z, t1/2eff, Rac, pred|Safety parameters including Clinical tests|Safety parameters including laboratory tests|Safety parameters including ECG parameters|Number of subjects with adverse events (AEs)","Sanofi","All","18 Years to 79 Years   (Adult, Older Adult)","Phase 1","36","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","POP13449|U1111-1115-8416","November 2012","July 2013","July 2013","January 8, 2013",,"May 13, 2015","Investigational Site Number 840002, Orlando, Florida, United States|Investigational Site Number 840003, St. Paul, Minnesota, United States|Investigational Site Number 840001, Knoxville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT01763190"
79,"NCT00796731","SAR3419 Administered Weekly in Patients With Relapsed/Refractory CD19-positive B-cell Non-Hodgkin's Lymphoma",,"Completed","No Results Available","Lymphoma|Non-Hodgkin","Drug: SAR3419","Incidence of DLT(s) at each dose level|Cumulative DLT(s)|Incidence of Adverse Events and laboratory abnormalities|Tumor response (complete response, partial response) and duration of the response|Pharmacokinetics parameters","Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 1","77","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TED6829|EudraCT 2007-004868-41","October 2008","June 2012","June 2012","November 24, 2008",,"July 17, 2012","Sanofi-Aventis Investigational Site Number 250004, Creteil Cedex, France|Sanofi-Aventis Investigational Site Number 250006, Lille Cedex, France|Sanofi-Aventis Investigational Site Number 250001, Pierre Benite Cedex, France|Sanofi-Aventis Investigational Site Number 250005, Rennes, France|Sanofi-Aventis Investigational Site Number 250003, Rouen Cedex, France|Sanofi-Aventis Investigational Site Number 250002, Villejuif Cedex, France",,"https://ClinicalTrials.gov/show/NCT00796731"
80,"NCT01762462","Open Label Pharmacokinetic Study of SAR302503 in Subjects With Hepatic Impairment",,"Completed","No Results Available","Hepatic Impairment","Drug: SAR302503","Pharmacokinetic parameter: Cmax, AUClast and AUC|Pharmacokinetic parameters : unbound AUC, unbound Cmax, CL/F, Vss/F , t1/2z, t1/2eff, Rac, pred|Safety parameters including Clinical tests|Safety parameters including laboratory tests|Safety parameters including ECG parameters|Number of subjects with adverse events (AEs) - Time Frame:","Sanofi","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1","17","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","POP13450|U1111-1118-5554","December 2012","March 2013","March 2013","January 7, 2013",,"August 29, 2013","Investigational Site Number 840003, Miami, Florida, United States|Investigational Site Number 840002, Orlando, Florida, United States|Investigational Site Number 840001, Knoxville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT01762462"
81,"NCT01420770","Phase 2 Study of SAR302503 in Patients With Myelofibrosis",,"Completed","No Results Available","Hematopoietic Neoplasm","Drug: SAR302503","The percent change in spleen volume based on MRI at the end of Cycle 3 relative to baseline|The proportion of patients who achieve ≥35% reduction in spleen volume from baseline, to Cycle 6 end of cycle (EOC)|The percent change in spleen volume based on MRI at Cycle 6 EOC compared to baseline|Duration of maintenance of ≥35% reduction in spleen volume relative to baseline, as measured at Cycle 3 EOC, at Cycle 6 EOC, after a year, after 18 months and after two years and at end of treatment (EOT).|Characterization of the safety profile of SAR302503, including the frequency, duration, and severity of adverse events (AEs) 2 years|Area under the plasma concentration versus time curve (AUC) of SAR302503|Peak plasma concentration (CMax) of SAR302503|In patients with the JAK2V617F mutation, change in peripheral blood granulocyte JAK2V617F allele burden from baseline to Cycle 3 EOC, to Cycle 6 EOC and at the end of every third cycle thereafter until Cycle 12 EOC and EOT","Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 2","30","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ARD11936|U1111-1119-2965","August 2011","April 2014","April 2014","August 22, 2011",,"March 16, 2016","Investigational Site Number 840001, San Francisco, California, United States|Investigational Site Number 840003, Ann Arbor, Michigan, United States|Investigational Site Number 840006, Rochester, Minnesota, United States|Investigational Site Number 840007, Canton, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT01420770"
82,"NCT01403636","A Study of Investigational SAR245409 in Patients With Certain Lymphoma or Leukemia",,"Completed","No Results Available","Lymphoma","Drug: SAR245409","Objective response rate (ORR) as defined as the proportion of patients who experience complete response/remission (CR) or partial response/remission (PR)|Progression free survival (PFS) at 6 months","Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 2","167","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ARD12130|2011-001616-57|U1111-1118-6417","October 2011","September 2014","September 2014","July 27, 2011",,"March 17, 2016","Investigational Site Number 840012, Los Angeles, California, United States|Investigational Site Number 840104, Fort Meyers, Florida, United States|Investigational Site Number 840006, Augusta, Georgia, United States|Investigational Site Number 840011, Maywood, Illinois, United States|Investigational Site Number 840010, Kansas City, Kansas, United States|Investigational Site Number 840013, Lexington, Kentucky, United States|Investigational Site Number 840007, Paducah, Kentucky, United States|Investigational Site Number 840004, Boston, Massachusetts, United States|Investigational Site Number 840015, St Louis, Missouri, United States|Investigational Site Number 840014, Canton, Ohio, United States|Investigational Site Number 840001, Philadelphia, Pennsylvania, United States|Investigational Site Number 840002, Morgantown, West Virginia, United States|Investigational Site Number 036002, Clayton, Australia|Investigational Site Number 036001, Hobart, Australia|Investigational Site Number 036005, Kingswood, Australia|Investigational Site Number 036003, Perth, Australia|Investigational Site Number 056003, Bruxelles, Belgium|Investigational Site Number 056002, Gent, Belgium|Investigational Site Number 056001, Leuven, Belgium|Investigational Site Number 250002, Montpellier, France|Investigational Site Number 250001, Pierre Benite Cedex, France|Investigational Site Number 250004, Rennes, France|Investigational Site Number 250005, Rouen Cedex, France|Investigational Site Number 250003, Villejuif Cedex, France|Investigational Site Number 276003, Frankfurt Am Main, Germany|Investigational Site Number 276002, Jena, Germany|Investigational Site Number 276001, Ulm, Germany|Investigational Site Number 528001, Amsterdam, Netherlands|Investigational Site Number 528003, Groningen, Netherlands|Investigational Site Number 528002, Rotterdam, Netherlands",,"https://ClinicalTrials.gov/show/NCT01403636"
83,"NCT02435121","A Study Assessing Efficacy and Safety of SAR125844 in NSCLC Patients With MET Amplification",,"Completed","No Results Available","Neoplasm Malignant","Drug: SAR125844","Determination of the objective response rate of SAR125844 as per RECIST 1.1|Progression-free survival rate|Overall survival rate|Proportion of patients with adverse events|Assessment of pharmacokinetic parameters: maximum plasma concentration (Cmax)|Assessment of pharmacokinetic parameters: area under curve (AUC)|Assessment of pharmacokinetic parameters: total clearance (CL)|Assessment of pharmacokinetic parameters: half-life (t1/2)|Assessment of lung cancer symptoms by Core Quality of Life questionnaire (QLQ-C30) +LC13|Assessment of health-related quality of life by QLQ-C30/LC13|Assessment of treatment satisfaction by Cancer Therapy Satisfaction Questionnaire","Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 2","1","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ACT14205|2014-005696-93|U1111-1163-1136","November 2015","January 2016","January 2016","May 6, 2015",,"March 23, 2016","Investigational Site Number 056001, Edegem, Belgium",,"https://ClinicalTrials.gov/show/NCT02435121"
84,"NCT01943838","A Study of the Safety and Pharmacokinetics of SAR245408 Tablets in Patients With Solid Tumors or Lymphoma",,"Completed","No Results Available","Neoplasm Malignant","Drug: SAR245408","Dose Limiting Toxicities|Number of patients with treatment-emergent adverse events|Maximum SAR245408 plasma concentration|Area under the SAR245408 plasma concentration versus time curve","Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 1","18","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TED12863|2012-003368-39|U1111-1132-9056","October 2013","February 2015","February 2015","September 17, 2013",,"April 22, 2016","Investigational Site Number 056001, Leuven, Belgium",,"https://ClinicalTrials.gov/show/NCT01943838"
85,"NCT01213381","Safety and Pharmacokinetics of SAR240550 (BSI-201) Twice Weekly in Patients With Advanced Solid Tumors",,"Completed","No Results Available","Advance Solid Tumors","Drug: Iniparib (SAR240550 - BSI-201)|Drug: Gemcitabine|Drug: Carboplatin","Dose Limiting Toxicity in cycle 1|Efficacy assessment as tumor response defined by Response Evaluation Criteria in Solid Tumors (RECIST)|Safety based on clinical and laboratory tests and Adverse Events (AEs)|Pharmacokinetics of SAR240550|Pharmacodynamics of SAR240550|Pharmacogenomic analysis of glutathione S-transferase (GST) genotypes","Sanofi","All","20 Years and older   (Adult, Older Adult)","Phase 1","18","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TED11451|U1111-1117-3152","September 2010","February 2013","February 2013","October 4, 2010",,"May 24, 2013","Sanofi-Aventis Investigational Site Number 392001, Kobe-Shi, Japan|Sanofi-Aventis Investigational Site Number 392002, Matsuyama-Shi, Japan",,"https://ClinicalTrials.gov/show/NCT01213381"
86,"NCT01436565","A Study of Investigational SAR256212 in Combination With SAR245408 in Patients With Solid Tumor Cancers",,"Completed","No Results Available","Solid Tumor Cancers","Drug: MM-121 (SAR256212)|Drug: SAR245408","Maximum tolerated dose|Peak and trough levels of SAR256212 and SAR245408|Pharmacodynamic change in ErbB3 protein and mRNA levels as well as components of the PI3K pathway will be measured|Number of participants with adverse events|overall response rate|Number of patients who develop anti-MM-121 antibodies","Sanofi|Merrimack Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 1","26","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TCD11721|U1111-1121-4146","November 2011","May 2014","May 2014","September 19, 2011",,"June 13, 2014","Investigational Site Number 840001, Boston, Massachusetts, United States|Investigational Site Number 840101, Brookline, Massachusetts, United States|Investigational Site Number 840002, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT01436565"
87,"NCT02603510","Assessment of the Safety of SAR342434 and Humalog® When Administered as Continuous Subcutaneous Insulin Infusion",,"Completed","No Results Available","Type 1 Diabetes Mellitus","Drug: SAR342434|Drug: insulin lispro","Frequency of infusion set occlusions|Number of infusion set changes in each treatment period|Number of insulin pump alarms for infusion set occlusions|Number of adverse events","Sanofi","All","19 Years and older   (Adult, Older Adult)","Phase 1","27","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PDY13502|U1111-1170-3739","November 2015","April 2016","April 2016","November 11, 2015",,"May 19, 2016","Investigational Site Number 840002, Little Rock, Arkansas, United States|Investigational Site Number 840001, Denver, Colorado, United States",,"https://ClinicalTrials.gov/show/NCT02603510"
88,"NCT01785329","Pharmacokinetic of Alirocumab SAR236553 (REGN727) Administered Subcutaneously at 3 Different Injection Sites in Healthy Subjects",,"Completed","No Results Available","Hypercholesterolemia","Drug: alirocumab SAR236553 (REGN727)","Assessment of the serum concentrations of alirocumab SAR236553 (REGN727) after a single subcutaneous administration at 3 different injection sites in healthy subjects as a measure of the pharmacokinetics of this investigational medicinal product.|Assessment of the serum concentrations of low-density lipoprotein cholesterol after a single subcutaneous administration of alirocumab SAR236553 (REGN727) as a measure of the pharmacodynamic effect of this investigational medicinal product.|Assessment of the number of subjects with adverse events after a single subcutaneous administration of alirocumab SAR236553 (REGN727) as a measure of the safety/tolerability of this investigational medicinal product.|Assessment of the serum concentration of anti-drug antibodies after a single subcutaneous dose of alirocumab SAR236553 (REGN727) as a measure of the immunogenicity of this investigational medicinal product.","Sanofi|Regeneron Pharmaceuticals","All","18 Years to 45 Years   (Adult)","Phase 1","60","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","BDR13362|2012-005005-40|U1111-1134-2618","February 2013","July 2013","July 2013","February 7, 2013",,"August 19, 2013","Investigational Site Number 826001, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01785329"
89,"NCT03594955","First in Human Testing of Dose-escalation of SAR440234 in Patients With Acute Myeloid Leukemia, Acute Lymphoid Leukemia and Myelodysplastic Syndrome",,"Recruiting","No Results Available","Leukaemia","Drug: SAR440234","Incidence of Dose-limiting toxicities (DLTs)|Incidence of allergic reactions/hypersensitivity and CRS/acute infusion reactions|Overall response rate (ORR)|Duration of response (DOR)|Event-free survival|Adverse events|Preliminary Anti-leukemia Activity|Immunogenicity of SAR440234","Sanofi","All","16 Years and older   (Child, Adult, Older Adult)","Phase 1|Phase 2","77","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TED15138|2017-004148-39|U1111-1197-8041","October 24, 2018","September 2022","September 2022","July 20, 2018",,"January 27, 2020","Investigational Site Number 2500004, Marseille, France|Investigational Site Number 2500001, Paris Cedex 10, France|Investigational Site Number 2500003, Villejuif Cedex, France",,"https://ClinicalTrials.gov/show/NCT03594955"
90,"NCT03463135","A Study to Assess Primarily the Tolerability and Safety of SAR439794 After Repeated Sublingual Daily Administration in Peanut Allergic Adult and Adolescent Patients",,"Active, not recruiting","No Results Available","Food Allergy","Drug: Glucopyranosyl Lipid A (GLA)|Drug: Sublingual Immuno Therapy (SLIT) Peanut Extract (PE)|Drug: Placebo for GLA|Drug: Placebo for SLIT PE","Adverse events (AEs)|Assessment of pharmacodynamic (PD) parameter: Peanut-specific serum Immunoglobulin G (IgG) levels|Assessment of PD parameter: Peanut-specific serum IgG levels|Assessment of PD parameter: Peanut-specific serum Immunoglobulin E (IgE) levels|Assessment of PD parameter: Skin Prick Test|Maximum SLIT PE dose","Sanofi","All","12 Years to 55 Years   (Child, Adult)","Phase 1","44","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","TDR14287|U1111-1200-1824","May 7, 2018","May 8, 2019","March 2020","March 13, 2018",,"January 10, 2020","Investigational Site Number 8400004, Little Rock, Arkansas, United States|Investigational Site Number 8400019, Mission Viejo, California, United States|Investigational Site Number 8400008, San Diego, California, United States|Investigational Site Number 8400020, San Jose, California, United States|Investigational Site Number 8400006, Stanford, California, United States|Investigational Site Number 8400013, Denver, Colorado, United States|Investigational Site Number 8400014, Louisville, Kentucky, United States|Investigational Site Number 8400002, Baltimore, Maryland, United States|Investigational Site Number 8400001, Boston, Massachusetts, United States|Investigational Site Number 8400009, Minneapolis, Minnesota, United States|Investigational Site Number 8400016, Minneapolis, Minnesota, United States|Investigational Site Number 8400010, Charleston, North Carolina, United States|Investigational Site Number 8400011, Cincinnati, Ohio, United States|Investigational Site Number 8400012, Medford, Oregon, United States|Investigational Site Number 8400003, Seattle, Washington, United States|Investigational Site Number 8400017, Madison, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT03463135"
91,"NCT00739206","Study of SAR97276A in the Treatment of Uncomplicated and Severe Malaria in Adults and Children.",,"Terminated","No Results Available","Malaria","Drug: SAR97276A","Combination of fever clearance, general condition improvement at 48h parasite reduction at 72h and no need for rescue therapy at 72h|Parasite reduction|Safety assessment","Sanofi","All","6 Months to 65 Years   (Child, Adult, Older Adult)","Phase 2","113","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ACT10004","August 2008","June 2009","June 2009","August 21, 2008",,"June 16, 2010","Sanofi-Aventis Administrative Office, Porto Novo, Benin|Sanofi-Aventis Administrative Office, Ouagadougou, Burkina Faso|Sanofi-Aventis Administrative Office, Libreville, Gabon|Sanofi-Aventis Administrative Office, Dodoma, Tanzania",,"https://ClinicalTrials.gov/show/NCT00739206"
92,"NCT01585623","Drug Interaction Study of SAR302503 in Patients With Solid Tumor",,"Completed","No Results Available","Solid Tumor","Drug: SAR302503|Drug: omeprazol|Drug: metoprolol|Drug: midazolam","Omerprazole/metoprolol/midazolam - Pharmacokinetic parameter: AUC, AUClast|Omerprazole/metoprolol/midazolam - Pharmacokinetic parameter : Cmax, Tmax, and t1/2z|SAR302503 - Pharmacokinetic parameter : Cmax, Tmax, Ctrough and AUC0-24|Clinical and laboratory events graded by the NCI CTCAE (National Cancer Institute Common Terminology Criteria for Adverse Events) v4.03 (Segment 1 and 2)|Objective response ratio (Complete response (CR) and partial response (PR)) (Segment 2)","Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 1","16","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","INT12497|U1111-1125-8930","June 2012","March 2013","March 2013","April 26, 2012",,"March 22, 2013","Investigational Site Number 840004, Augusta, Georgia, United States|Investigational Site Number 840001, Detroit, Michigan, United States|Investigational Site Number 840002, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT01585623"
93,"NCT03202875","A Study to Compare Pharmacokinetics (PK) and Pharmacodynamics (PD) of SAR341402 to Insulin Aspart in Subjects With Type 1 Diabetes Mellitus",,"Completed","No Results Available","Type 1 Diabetes","Drug: SAR341402|Drug: Insulin Aspart","Assessment of PK parameters: maximum plasma concentration (Cmax)|Assessment of PK parameters: Area under the concentration versus time curve (AUC)|Assessment of PK parameter: AUC from dosing to last concentration (AUClast)|Assessment of PD parameters: Area under the body weight standardized glucose infusion rate (GIR)|Assessment of PK: Fractional area under the concentration versus time curve|Assessment of PK: Time to 20 % of INS-AUC|Assessment of PK: time to reach INS-Cmax (INS-tmax)|Assessment of PK: time to reach INS-t1/2z (INS-t1/2z)|Assessment of PD: Fractional area under the body weight standardized GIR versus time curve|Assessment of PD: Time to 20 % of total GIR-AUC0-12h|Assessment of PD: Maximum smoothed body weight standardized GIR (GIRmax)|Assessment of PD: Time to GIRmax (GIR-tmax)|Number of adverse events (AEs)","Sanofi","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","30","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","PDY12695|2012-002355-42|U1111-1127-2950","November 14, 2012","December 28, 2012","December 28, 2012","June 29, 2017",,"June 29, 2017","Investigational Site 276001, Neuss, Germany",,"https://ClinicalTrials.gov/show/NCT03202875"
94,"NCT01209793","Safety and Tolerability Study of REGN846 (SAR302352) in Healthy Volunteers",,"Completed","No Results Available","Healthy","Biological: REGN846","Incidence and severity of adverse events|PK profile|Immunogenicity","Regeneron Pharmaceuticals|Sanofi","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","40","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","R846-HV-1007","November 2010","September 2011","September 2011","September 27, 2010",,"June 1, 2012","Nucleus Network, Melbourne, Australia",,"https://ClinicalTrials.gov/show/NCT01209793"
95,"NCT00173563","Induction of Cytokines in Human Monocytes by SARS-CoV in Adults and Children",,"Unknown status","No Results Available","Healthy",,,"National Taiwan University Hospital|National Science Council, Taiwan","All","2 Years to 50 Years   (Child, Adult)",,"10","Other","Observational","Time Perspective: Prospective","9461700731|NSC92-2751-B-002-026-Y","January 2005",,"September 2005","September 15, 2005",,"December 3, 2007","National Taiwan University Hospital, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT00173563"
96,"NCT03916601","Comparison of Exposure and Activity of SAR341402 Mix 70/30 to NovoLog Mix 70/30, NovoMix 30 and SAR341402 Rapid-acting Solution in Patients With Type 1 Diabetes Mellitus",,"Completed","No Results Available","Type 1 Diabetes","Drug: SAR341402|Drug: Insulin Aspart","(Cohort 1) Assessment of PK parameter: Maximum insulin concentration (INS-Cmax)|(Cohort 1) Assessment of PK parameter: Area under the insulin concentration time curve (INS-AUClast)|(Cohort 2) Assessment of PK parameters: Area under the insulin concentration time curve from 0 to 4 hours post administration (INS-AUC0-4H)|(Cohort 2) Area under the insulin concentration time curve from 4 to 12 hours post administration (INS-AUC4-12H)|(Cohort 2) Assessment of PK parameter: Maximum insulin concentration (INS-Cmax)|Assessment of PK parameter: Area under the insulin concentration time curve from 0 to infinity (INS-AUC)|Assessment of PK parameter: Area under the insulin concentration time curve for fractional periods post administration (INS-AUC0-4H, INS-AUC0-24H, INS-AUC4-24H)|Assessment of PK parameter: Time to INS-Cmax|Assessment of PK parameter: Half-life (t1/2)|Assessment of PD parameter: GIR versus time curve from 0 to 24 hours post administration (GIR-AUC0-24H)|Assessment of PD parameter: Maximum smoothed body weight standardized glucose infusion rate (GIRmax)|Assessment of PD parameter: Time to GIRmax (GIR-tmax)|Assessment of PK parameter: Time to Cmax (INS-tmax)|Assessment of PD parameter: The area under the body weight standardized glucose infusion rate (GIR) versus time curve from 0 to 4 hours post administration (GIR-AUC0-4H)|Assessment of PD parameter: The area under the body weight standardized glucose infusion rate (GIR) versus time curve from 4 to 12 hours post administration (GIR-AUC4-12H)","Sanofi","All","18 Years to 64 Years   (Adult)","Phase 1","52","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","PDY15084|2017-002482-22|U1111-1197-7984","December 13, 2017","March 22, 2018","March 22, 2018","April 16, 2019",,"April 16, 2019","Investigational Site Number 2760001, Neuss, Germany",,"https://ClinicalTrials.gov/show/NCT03916601"
97,"NCT01596270","A Study of the Safety and Pharmacokinetics of SAR245409 Tablets in Patients With Solid Tumors or Lymphoma",,"Completed","No Results Available","Neoplasm Malignant","Drug: SAR245409","Dose Limiting Toxicities|Number of patients with treatment-emergent adverse events|Maximum SAR245409 plasma concentration|Area under the SAR245409 plasma concentration versus time curve|Ratio of maximum SAR245409 plasma concentration between fed and fasted dosing|Ratio of area under the SAR245409 plasma concentration versus time curve between fed and fasted dosing","Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 1","49","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)","TED12471|U1111-1123-1488","June 2012","October 2014","October 2014","May 10, 2012",,"October 27, 2014","Investigational Site Number 840001, Detroit, Michigan, United States|Investigational Site Number 840002, New Brunswick, New Jersey, United States|Investigational Site Number 840003, Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01596270"
98,"NCT03546907","Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of SAR440340 (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)",,"Active, not recruiting","No Results Available","Chronic Obstructive Pulmonary Disease","Drug: Any Inhaled Corticosteroids as prescribed by treating physician as standard of care|Drug: Any Long Acting Beta Agonist as prescribed by treating physician as standard of care|Drug: Any Long Acting Muscarinic Agonist as prescribed by treating physician as standard of care|Drug: Any short-acting β agonist as prescribed by treating physician as standard of care","Rate of moderate-to-severe acute Exacerbations in chronic obstructive pulmonary disease (AECOPD) patients|Change in pre-bronchodilator forced expiratory volume in 1 second (FEV1)|Time to first COPD Exacerbation|Adverse Events|Change in post-bronchodilator FEV1","Sanofi|Regeneron Pharmaceuticals","All","40 Years to 75 Years   (Adult, Older Adult)","Phase 2","343","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ACT15104|2017-003290-34|U1111-1194-2134","July 16, 2018","October 3, 2019","February 19, 2020","June 6, 2018",,"December 19, 2019","Investigational Site Number 8400002, Los Angeles, California, United States|Investigational Site Number 8400003, Riverside, California, United States|Investigational Site Number 8400006, Rolling Hills Estates, California, United States|Investigational Site Number 8400015, Westminster, California, United States|Investigational Site Number 8400013, Jacksonville, Florida, United States|Investigational Site Number 8400012, Columbia, Maryland, United States|Investigational Site Number 8400016, North Dartmouth, Massachusetts, United States|Investigational Site Number 8400020, South Dartmouth, Massachusetts, United States|Investigational Site Number 8400011, Minneapolis, Minnesota, United States|Investigational Site Number 8400005, Jamaica, New York, United States|Investigational Site Number 8400019, Chapel Hill, North Carolina, United States|Investigational Site Number 8400004, Raleigh, North Carolina, United States|Investigational Site Number 8400001, Medford, Oregon, United States|Investigational Site Number 8400009, Philadelphia, Pennsylvania, United States|Investigational Site Number 8400007, Plano, Texas, United States|Investigational Site Number 8400008, Greenfield, Wisconsin, United States|Investigational Site Number 0320001, Buenos Aires, Argentina|Investigational Site Number 0320005, Caba, Argentina|Investigational Site Number 0320002, Caba, Argentina|Investigational Site Number 0320004, Caba, Argentina|Investigational Site Number 0320006, Quilmes, Argentina|Investigational Site Number 0320003, Rosario, Argentina|Investigational Site Number 0360005, Bedford Park, Australia|Investigational Site Number 0360002, Chermside, Australia|Investigational Site Number 0360004, Clayton, Australia|Investigational Site Number 0360003, Frankston, Australia|Investigational Site Number 0360006, Kent Town, Australia|Investigational Site Number 0360001, Murdoch, Australia|Investigational Site Number 1240002, Burlington, Canada|Investigational Site Number 1240009, Hamilton, Canada|Investigational Site Number 1240003, Montreal, Canada|Investigational Site Number 1240001, Montreal, Canada|Investigational Site Number 1240005, Quebec, Canada|Investigational Site Number 1240006, St-Charles Borrommee, Canada|Investigational Site Number 1240008, Trois-Rivieres, Canada|Investigational Site Number 1240007, Vancouver, Canada|Investigational Site Number 1240004, Victoriaville, Canada|Investigational Site Number 1520002, Quillota, Chile|Investigational Site Number 1520001, Santiago, Chile|Investigational Site Number 1520007, Santiago, Chile|Investigational Site Number 1520004, Santiago, Chile|Investigational Site Number 1520003, Talcahuano, Chile|Investigational Site Number 1520005, Talca, Chile|Investigational Site Number 2760006, Berlin, Germany|Investigational Site Number 2760001, Großhansdorf, Germany|Investigational Site Number 2760002, Hamburg, Germany|Investigational Site Number 2760007, Koblenz, Germany|Investigational Site Number 2760004, München, Germany|Investigational Site Number 2760005, Rüdersdorf Bei Berlin, Germany|Investigational Site Number 6160001, Bialystok, Poland|Investigational Site Number 6160008, Bialystok, Poland|Investigational Site Number 6160005, Bydgoszcz, Poland|Investigational Site Number 6160009, Grudziadz, Poland|Investigational Site Number 6160007, Krakow, Poland|Investigational Site Number 6160002, Poznan, Poland|Investigational Site Number 6160006, Poznan, Poland|Investigational Site Number 6160010, Rzeszow, Poland|Investigational Site Number 6160003, Znin, Poland|Investigational Site Number 6430003, Moscow, Russian Federation|Investigational Site Number 6430001, Moscow, Russian Federation|Investigational Site Number 6430005, Moscow, Russian Federation|Investigational Site Number 6430002, Moscow, Russian Federation|Investigational Site Number 6430010, Saint-Petersburg, Russian Federation|Investigational Site Number 6430006, Saint-Petersburg, Russian Federation|Investigational Site Number 6430007, St-Petersburg, Russian Federation|Investigational Site Number 6430009, Stavropol, Russian Federation|Investigational Site Number 6430004, Ulyanovsk, Russian Federation|Investigational Site Number 7920004, Ankara, Turkey|Investigational Site Number 7920001, Istanbul, Turkey|Investigational Site Number 7920006, Izmir, Turkey|Investigational Site Number 7920007, Izmir, Turkey|Investigational Site Number 7920008, Kirikkale, Turkey|Investigational Site Number 7920002, Mersin, Turkey|Investigational Site Number 8040008, Chernivtsi, Ukraine|Investigational Site Number 8040012, Ivano-Frankivsk, Ukraine|Investigational Site Number 8040004, Ivano-Frankivsk, Ukraine|Investigational Site Number 8040002, Kharkiv, Ukraine|Investigational Site Number 8040011, Kharkiv, Ukraine|Investigational Site Number 8040007, Kyiv, Ukraine|Investigational Site Number 8040001, Kyiv, Ukraine|Investigational Site Number 8040006, Odesa, Ukraine|Investigational Site Number 8040003, Ternopil, Ukraine|Investigational Site Number 8040005, Vinnytsya, Ukraine",,"https://ClinicalTrials.gov/show/NCT03546907"
99,"NCT01391533","Study of SAR125844 Single Agent Administered as Slow Intravenous Infusion in Adult Patients With Advanced Malignant Solid Tumors","SARMET","Completed","No Results Available","Malignant Solid Tumors","Drug: SAR125844","Dose Escalation To determine the maximum tolerated dose (MTD) of SAR125844|Expansion Cohorts To evaluate the preliminary anti-tumoral effect of SAR125844|Number of patients with treatment emergent events|Assessment of PK parameter Cmax|Assessment of PK parameter AUCs|Assessment of PK parameter CL|Assessment of PD parameter ShedMET|Assessment of PD parameter HGF","Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 1","72","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)","TED11449|2010-021398-36|U1111-1117-9878","July 2011","April 2016","April 2016","July 12, 2011",,"April 13, 2016","Investigational Site Number 840001, Boston, Massachusetts, United States|Investigational Site Number 250002, Dijon, France|Investigational Site Number 250001, Villejuif, France|Investigational Site Number 380004, Bologna, Italy|Investigational Site Number 380002, Milano, Italy|Investigational Site Number 380001, Milano, Italy|Investigational Site Number 724001, Barcelona, Spain|Investigational Site Number 724003, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT01391533"
100,"NCT01753739","Bepotastine Besilate Nasal Sprays in the Treatment of Seasonal Allergic Rhinitis (SAR)",,"Completed","No Results Available","Seasonal Allergic Rhinitis","Drug: Bepotastine besilate|Drug: Placebo","Nasal Symptoms Score|Nasal Symptom Score by day|Nasal and Ocular Symptom Score|50% reduction in Nasal Symptom Score","Bausch & Lomb Incorporated","All","12 Years and older   (Child, Adult, Older Adult)","Phase 2","613","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","823","January 2013","February 2013","May 2013","December 20, 2012",,"August 1, 2014","Bausch & Lomb Incorporated, Irvine, California, United States",,"https://ClinicalTrials.gov/show/NCT01753739"
101,"NCT03284957","Phase 1 / 2 Study of SAR439859 Single Agent and in Combination With Palbociclib in Postmenopausal Women With Estrogen Receptor Positive Advanced Breast Cancer",,"Recruiting","No Results Available","Breast Cancer","Drug: SAR439859|Drug: palbociclib|Drug: midazolam","Part A : To determine the RD of SAR439859|Part C : To determine the RD of SAR439859 in combination with palbociclib|Part B : to evaluate the ORR of SAR439859|Part D: Adverse Events|Part E: AUClast and AUC of midazolam|Part A, B, C, E: Adverse Events|ORR|Time to First Response (TTR)|Clinical Benefit Rate (CBR)|Duration of response|tlag of SAR439859 after single dose (Part A, B, C, D)|tmax of SAR439859 after single dose (Part A, B, C, D)|Cmax of SAR439859 after single dose (Part A, B, C, D)|AUC0-24 of SAR439859 after single dose (Part A, B, C, D)|tmax of SAR439859 after repeated dose administration (Part A, B, C, D)|Cmax of SAR439859 after repeated dose administration (Part A, B, C, D)|AUC0-24 of SAR439859 after repeated dose administration (Part A, B,C, D)|Ctrough of SAR439859 during repeated dose administration (Part A, B, C, D)|tmax of palbociclib after single dose (Part C, D)|Cmax of palbociclib after single dose (Part C, D)|AUC0-24 of palbociclib after single dose (Part C, D)|tmax of palbociclib after repeated dose administration (Part C, D)|Cmax of palbociclib after repeated dose administration (Part C, D)|AUC0-24 of palbociclib after repeated dose administration (Part C, D)|Urine excretion of SAR439859 (Part B)|Cytochrome P450 3A (CYP3A) enzyme induction and inhibition (Part B)|CYP3A enzyme induction and inhibition (Part A, E)|ER occupancy at 18FES-PET imaging (Part A)|Non-progression rate at 6 months|Observation of tumor changes by FES PET and FDG PET scans","Sanofi","Female","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","259","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TED14856|2017-000690-36|U1111-1189-4896","September 20, 2017","July 2021","July 2021","September 15, 2017",,"January 13, 2020","Investigational Site Number 8400005, Denver, Colorado, United States|Investigational Site Number 8400002, Boston, Massachusetts, United States|Investigational Site Number 8400102, Boston, Massachusetts, United States|Investigational Site Number 8400003, New York, New York, United States|Investigational Site Number 8400008, Pittsburgh, Pennsylvania, United States|Investigational Site Number 8400009, Charleston, South Carolina, United States|Investigational Site Number 8400004, Dallas, Texas, United States|Investigational Site Number 8400007, Round Rock, Texas, United States|Investigational Site Number 8400001, Seattle, Washington, United States|Investigational Site Number 0560001, Leuven, Belgium|Investigational Site Number 0560002, Wilrijk, Belgium|Investigational Site Number 1240004, Edmonton, Canada|Investigational Site Number 1240005, Montreal, Canada|Investigational Site Number 1240002, Toronto, Canada|Investigational Site Number 1240003, Vancouver, Canada|Investigational Site Number 2030002, Brno, Czechia|Investigational Site Number 2030004, Hradec Kralove, Czechia|Investigational Site Number 2030001, Praha 2, Czechia|Investigational Site Number 2030003, Praha 4, Czechia|Investigational Site Number 2500002, Bordeaux Cedex, France|Investigational Site Number 2500005, Lille, France|Investigational Site Number 2500003, Lyon, France|Investigational Site Number 2500001, Saint-Herblain, France|Investigational Site Number 2500004, Villejuif Cedex, France|Investigational Site Number 3800001, Milano, Italy|Investigational Site Number 3800003, Milano, Italy|Investigational Site Number 3800004, Napoli, Italy|Investigational Site Number 3800002, Negrar, Italy|Investigational Site Number 6160004, Gdynia, Poland|Investigational Site Number 6160001, Warsaw, Poland|Investigational Site Number 6200001, Lisboa, Portugal|Investigational Site Number 6200002, Lisboa, Portugal|Investigational Site Number 6200003, Porto, Portugal|Investigational Site Number 7240007, Madrid, Spain|Investigational Site Number 7240001, Madrid, Spain|Investigational Site Number 7240002, Madrid, Spain|Investigational Site Number 8260002, Cardiff, United Kingdom|Investigational Site Number 8260001, Glasgow, United Kingdom|Investigational Site Number 8260003, Oxford, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03284957"
102,"NCT03236311","A Dose Titration Study to Assess the Effects of SAR407899 in Patients With MVA and/or Persistent Stable Angina Despite Angiographically Successful PCI",,"Terminated","Has Results","Microvascular Coronary Artery Disease","Drug: SAR407899|Drug: Placebo|Drug: Adenosine|Drug: Regadenoson|Drug: 13N-ammonia|Drug: 82Rubidium","Change From Baseline in Uncorrected Global Coronary Flow Reserve (CFR) at Week 4|Change From Baseline in Angina-induced Physical Limitation Assessed Using Seattle Angina Questionnaire Physical Limitation Scale (SAQ-PL) at Week 4|Pharmacokinetic Parameter: SAR407899 Plasma Concentration","Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 2","10","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ACT14656|2016-000629-38|U1111-1182-1709","October 12, 2017","July 23, 2018","July 23, 2018","August 1, 2017","July 11, 2019","July 11, 2019","Investigational Site Number 8400003, Los Angeles, California, United States|Investigational Site Number 8400001, Jacksonville, Florida, United States|Investigational Site Number 8400013, Wellington, Florida, United States|Investigational Site Number 8400008, Baltimore, Maryland, United States|Investigational Site Number 8400006, Boston, Massachusetts, United States|Investigational Site Number 8400010, Philadelphia, Pennsylvania, United States|Investigational Site Number 2080001, København Nv, Denmark|Investigational Site Number 4100002, Seoul, Korea, Republic of|Investigational Site Number 5280001, Nijmegen, Netherlands|Investigational Site Number 7520001, Lund, Sweden","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/11/NCT03236311/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/11/NCT03236311/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03236311"
103,"NCT01644474","Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Ezetimibe in Patients With Hypercholesterolemia","ODYSSEY MONO","Completed","Has Results","Hypercholesterolemia","Drug: Alirocumab|Drug: Ezetimibe|Drug: Placebo (for Alirocumab)|Drug: Placebo (for Ezetimibe)","Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent-to-Treat (ITT) Analysis|Percent Change From Baseline in Calculated LDL-C at Week 12 - ITT Analysis|Percent Change From Baseline in Apolipoprotein B (Apo B) at Week 24 - ITT Analysis|Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 24 - ITT Analysis|Percent Change From Baseline in Total Cholesterol (Total-C) at Week 24 - ITT Analysis|Percent Change From Baseline in Apo B at Week 12 - ITT Analysis|Percent Change From Baseline in Non-HDL-C at Week 12 - ITT Analysis|Percent Change From Baseline in Total-C at Week 12 - ITT Analysis|Percentage of Participants Achieving Calculated LDL-C <100 mg/dL (2.59 mmol/L) at Week 24 - ITT Analysis|Percentage of Participants Achieving Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - ITT Analysis|Percent Change From Baseline in Lipoprotein (a) at Week 24 - ITT Analysis|Percent Change From Baseline in HDL-C at Week 24 - ITT Analysis|Percent Change From Baseline in HDL-C at Week 12 - ITT Analysis|Percent Change From Baseline in Lipoprotein (a) at Week 12 - ITT Analysis|Percent Change From Baseline in Fasting Triglycerides at Week 24 - ITT Analysis|Percent Change From Baseline in Fasting Triglycerides at Week 12 - ITT Analysis|Percent Change From Baseline in Apolipoprotein A-1 (Apo A-1) at Week 24 - ITT Analysis|Percent Change From Baseline in Apo A-1 at Week 12 - ITT Analysis","Sanofi|Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 3","103","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","EFC11716|U1111-1124-1167|2011-001424-38","July 2012","July 2013","July 2013","July 19, 2012","November 6, 2015","November 6, 2015","Investigational Site Number 840603, Overland Park, Kansas, United States|Investigational Site Number 840601, Cincinnati, Ohio, United States|Investigational Site Number 840602, Richmond, Virginia, United States|Investigational Site Number 056601, Antwerpen, Belgium|Investigational Site Number 246601, Helsinki, Finland|Investigational Site Number 528602, Groningen, Netherlands|Investigational Site Number 528601, Rotterdam, Netherlands|Investigational Site Number 528603, Velp, Netherlands",,"https://ClinicalTrials.gov/show/NCT01644474"
104,"NCT02489344","Evaluation of the Long-term Safety, Pharmacodynamics, and Exploratory Efficacy of GZ/SAR402671 in Treatment-Naïve Adult Male Patients With Fabry Disease",,"Completed","Has Results","Fabry Disease","Drug: GZ/SAR402671","Number of Participants With Treatment Emergent Adverse Events (TEAEs)|Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Hematological Parameters|Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Electrolytes|Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Liver Function Parameters|Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Metabolic Parameters|Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Renal Function Parameters|Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Urinalysis|Number of Participants With Potentially Clinically Significant Vital Signs Abnormalities|Number of Participants With Potentially Clinically Significant Electrocardiogram (ECG) Abnormalities|Change From Baseline in Plasma Globotriaosylceramide (GL-3) Concentration at Weeks 26, 52, 104, and 156|Change From Baseline in Plasma Lyso Globotriaosylceramide (Lyso GL-3) Concentration at Weeks 26, 52, 104, and 156|Change From Baseline in Plasma Glucosylceramide (GL-1) Concentration At Weeks 26, 52, 104, and 156|Change From Baseline in Plasma Monosialodihexosylganglioside (GM3) Concentration At Weeks 26, 52, 104, and 156|Change From Baseline in Urine GL-3 Concentration At Weeks 26, 52, 104, and 156|Change From Baseline in High Sensitivity Cardiac Troponin T At Weeks 26, 52, 104, and 156|Change From Baseline in Podocyturia Counts (Per Milligram of Creatinine) At Weeks 12, 26, and 156|Summary of Shifts From Baseline in Skin GL-3 Score in Superficial Capillary Endothelial Cells Over Time: Number of Participants in Categories of Shift in GL-3 Score|Summary of Shifts From Baseline in Skin GL-3 Score in Deep Vessels Endothelial Cells Over Time: Number of Participants in Categories of Shift in GL-3 Score|Summary of Shifts From Baseline in Skin GL-3 Score in Deep Vessels Smooth Muscle Cells Over Time: Number of Participants in Categories of Shift in GL-3 Score|Summary of Shifts From Baseline in Skin GL-3 Score in Perineurium Cells Over Time: Number of Participants in Categories of Shift in GL-3 Score|Change From Baseline in Mental Component Summary and Physical Component Summary of the Short Form-36 (SF-36) Health Survey at Weeks 26, 52, 104 and 156|Gastrointestinal (GI) Symptoms: Number of Participants With Abdominal Pain at Baseline and Weeks 2, 4, 8, 12, 18, 26, 52, 104, and 156|Gastrointestinal Symptoms: Abdominal Pain Severity Score at Baseline and Weeks 2, 4, 8, 12, 18, 26, 52, 104, and 156|Gastrointestinal Symptoms: Number of Days With Abdominal Pain Score at Baseline and Weeks 2, 4, 8, 12, 18, 26, 52, 104, and 156|Gastrointestinal Symptoms: Number of Participants With Abdominal Distension at Baseline and Weeks 2, 4, 8, 12, 18, 26, 52, 104, and 156|Gastrointestinal Symptoms: Abdominal Distension Severity Score at Baseline and Weeks 2, 4, 8, 12, 18, 26, and 156|Gastrointestinal Symptoms: Number of Participants in Categories of Response Regarding Eating Less Due to Abdominal Pain/Bloating at Baseline and Weeks 2, 4, 8, 12, 18, 26, 52, 104, and 156|Gastrointestinal Symptoms: Satisfaction Over Bowel Habits at Baseline and Weeks 2, 4, 8, 12, 18, 26, 52, 104, and 156|Gastrointestinal Symptoms: Frequency of Bowel Movements - Most Number of Times Bowel Movement Per Day at Baseline and Weeks 2, 4, 8, 12, 18, 26, 52, 104, and 156|Gastrointestinal Symptoms: Frequency of Bowel Movements - Least Number of Times Bowel Movement Per Day at Baseline and Weeks 2, 4, 8, 12, 18, 26, 52, 104, and 156|Gastrointestinal Symptoms: Influence of GI Symptoms of Fabry Disease on Life at Baseline and Weeks 2, 4, 8, 12, 18, 26, 52, 104, and 156|Gastrointestinal Symptoms: Number of Participants With Stool Consistency Assessment by Bristol Stool Scale Scoring at Baseline and Weeks 26, 52, 104, and 156|Change From Baseline in Beck Depression Inventory (BDI) Total Score at Weeks 26, 104, and 156|Change From Baseline in Albumin/Creatinine Ratio (ACR) and Protein/Creatinine Ratio (PCR) at Weeks 26, 52, 104, and 156|Number of Participants in Categories of Echocardiogram (ECHO) Results at Baseline and at Weeks 26, 52, 104, and 156|Number of Participants in Categories of Brain Magnetic Resonance Imaging (MRI) Results at Baseline and Weeks 26, and 156|Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Weeks 26, 52, 104, and 156","Genzyme, a Sanofi Company|Sanofi","Male","18 Years and older   (Adult, Older Adult)","Phase 2","8","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LTS14116|2014-004995-49|U1111-1165-9049","July 7, 2015","November 20, 2018","November 20, 2018","July 3, 2015","December 9, 2019","December 9, 2019","Investigational Site Number 840002, Atlanta, Georgia, United States|Investigational Site Number 840003, Cincinnati, Ohio, United States|Investigational Site Number 840001, Fairfax, Virginia, United States|Investigational Site Number 250001, Garches, France|Investigational Site Number 616001, Warszawa, Poland|Investigational Site Number 643002, Moscow, Russian Federation|Investigational Site Number 826002, Cambridge, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/44/NCT02489344/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/44/NCT02489344/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02489344"
105,"NCT02321709","Multiple Ascending Dose Study To Assess The Safety Profile Of SAR113244 Versus Placebo In Lupus Male And Female Patients",,"Completed","No Results Available","Systemic Lupus Erythematosus","Drug: SAR113244|Drug: placebo","Number of participants with adverse events and treatment-emergent adverse events|Change in physical examination, body weight, vital signs and laboratory parameters|Safety and tolerability (erythema, swelling, degree of itching, and present pain intensity at injection site by measuring diameter and qualitative assessment)|Assessment of pharmacokinetic parameter - maximum concentration (Cmax)|Assessment of pharmacokinetic parameter - time of maximum concentration (Tmax)|Assessment of pharmacokinetic parameter - area under curve 0-4 weeks (AUC0-4w)|Assessment of pharmacokinetic parameter - time of the last point with quantifiable concentration (tlast) and terminal elimination half-life (t1/2z)|Assessment of pharmacokinetic parameter - lowest concentration of drug before the next dose (Ctrough)|Assessment of pharmacokinetic parameter - apparent total body clearance (CLss/F)|Assessment of pharmacokinetic parameter - absorption-dependent apparent volume of distribution at steady state (Vss/F)|Number of participants with anti-SAR113244 antibody titers|Pharmacodynamic parameter changes|Pharmacodynamic parameters: peripheral blood B and T cells subsets","Sanofi","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1","21","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","TDR11407|2014-001690-13|U1111-1154-6184","November 2014","March 2016","March 2016","December 22, 2014",,"May 2, 2016","Investigational Site Number 276001, Berlin, Germany",,"https://ClinicalTrials.gov/show/NCT02321709"
106,"NCT01001923","Single Injection of REGN475/SAR164877 in the Treatment of Chronic Pancreatitis Pain",,"Terminated","No Results Available","Abdominal Pain Upper","Drug: REGN475/SAR164877|Drug: Placebo (for REGN475/SAR164877)","Mean change from baseline in pain intensity as assessed by Pain Intensity Numeric Rating Scale (PI-NRS)|Mean change from baseline in pain intensity as assessed by PI-NRS|Percentage of pain-free days (score ""0"" pain on PI-NRS)|Percentage of days with rescue analgesia use|Change from baseline in Short Form-12 Item Quality of Life Questionnaire [SF-12] score|Patient Global Impression of Change [PGIC] score|Percentage of participants with at least 30% and 50% reduction from baseline in pain intensity|Pharmacokinetic: REGN475/SAR164877 serum concentration","Regeneron Pharmaceuticals","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","15","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","ACT11286","December 2009","January 2011","January 2011","October 27, 2009",,"May 27, 2013","Sanofi-Aventis Investigational Site Number 840024, Arcadia, California, United States|Sanofi-Aventis Investigational Site Number 840011, Bell Gardens, California, United States|Sanofi-Aventis Investigational Site Number 840003, Monterey, California, United States|Sanofi-Aventis Investigational Site Number 840048, San Diego, California, United States|Sanofi-Aventis Investigational Site Number 840034, Stanford, California, United States|Sanofi-Aventis Investigational Site Number 840031, Miami, Florida, United States|Sanofi-Aventis Investigational Site Number 840029, St. Petersburg, Florida, United States|Sanofi-Aventis Investigational Site Number 840017, Marietta, Georgia, United States|Sanofi-Aventis Investigational Site Number 840013, Worcester, Massachusetts, United States|Sanofi-Aventis Investigational Site Number 840030, Lebanon, New Hampshire, United States|Sanofi-Aventis Investigational Site Number 840023, New York, New York, United States|Sanofi-Aventis Investigational Site Number 840052, Winston Salem, North Carolina, United States|Sanofi-Aventis Investigational Site Number 840005, Cleveland, Ohio, United States|Sanofi-Aventis Investigational Site Number 840043, Dallas, Texas, United States|Sanofi-Aventis Investigational Site Number 840053, Desoto, Texas, United States|Sanofi-Aventis Investigational Site Number 840050, Southlake, Texas, United States|Sanofi-Aventis Investigational Site Number 840040, East Sandy, Utah, United States",,"https://ClinicalTrials.gov/show/NCT01001923"
107,"NCT00692640","Safety Study of XL147 (SAR245408) in Combination With Erlotinib in Adults With Solid Tumors",,"Completed","No Results Available","Cancer|Non-small Cell Lung Cancer","Drug: XL147 (SAR245408)|Drug: Erlotinib","Safety, tolerability, and maximum tolerated dose of XL147 administered in combination with erlotinib|To evaluate plasma pharmacokinetics of XL147 and erlotinib when administered in combination|To evaluate preliminary efficacy of XL147 in combination with erlotinib in adults with refractory solid tumors","Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 1","35","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TED11434|XL147-002","May 2008","November 2011","November 2011","June 6, 2008",,"March 23, 2012","Investigational Site Number 1214, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT00692640"
108,"NCT02331810","Pharmacodynamics Assessment Study After Single Subcutaneous Dose Of SAR113244 Versus Placebo In Lupus Male And Female Patients",,"Withdrawn","No Results Available","Systemic Lupus Erythematosus","Drug: SAR113244|Drug: placebo","Percentage decrease in B cell subsets (expressed as percentages of total B-cells) from baseline|Assessment of pharmacokinetic parameter - maximum concentration (Cmax)|Assessment of pharmacokinetic parameter - time of maximum concentration (Tmax)|Assessment of pharmacokinetic parameter - area under curve from zero to infinity (AUCinf)|Assessment of pharmacokinetic parameter - time of the last point with quantifiable concentration (tlast) and terminal elimination half-life (t1/2z)|Assessment of pharmacokinetic parameter-apparent oral clearance (CL/F)|Assessment of pharmacokinetic parameter- absorption-dependent apparent volume of distribution at steady state (Vss/F)|Number of participants with anti-SAR113244 antibody titers|Number of participants with adverse events and treatment-emergent adverse events, including those that deviated from baseline values of hematology, biochemistry, coagulation and urine|Number of participants with injection site reactions|Number of participants with abnormalities and changes in laboratory parameters|Assessment of pharmacodynamics - clinical and/or lupus-related scores|Assessment of pharmacodynamics - blood/urine parameters|Pharmacodynamic parameters: peripheral blood B and T cells subsets","Sanofi","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1","0","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","PDY14076|2014-001690-13|U1111-1154-6184","April 2016","May 2017","May 2017","January 6, 2015",,"June 3, 2016",,,"https://ClinicalTrials.gov/show/NCT02331810"
109,"NCT02273258","A Study to Compare Pharmacokinetics and Pharmacodynamics of SAR342434 to Insulin Lispro in Subjects With Type 1 Diabetes",,"Completed","No Results Available","Type 1 Diabetes","Drug: SAR342434|Drug: Insulin Lispro","Maximum plasma concentration (Cmax) of SAR342434, US-approved Humalog and EU-approved Humalog|Area under the concentration versus time curve (AUC) of SAR342434, US-approved Humalog and EU-approved Humalog|Area under the body weight standardized glucose infusion rate (GIR) versus time curve from 0 to 12 hours post administration (GIR-AUC0-12)|The fractional area under the concentration versus time curve from 0 or y to x hours post administration (INS-AUC0 or Y to X)|Time to 20% of AUC (t20%-AUC)|NS-tmax, INS-t1/2z|The fractional area under the body weight standardized GIR versus time curve from 0 or y to x hours post administration (GIR-AUC0 or Y to X)|Time to 20% of total GIR-AUC0-12h (t20%-GIR-AUC0-12h)|Maximum smoothed body weight standardized GIR (GIRmax)|Time to GIRmax (GIR-tmax)|Duration of blood glucose control (time to elevation of smoothed blood glucose profile above clamp level and to elevation above different pre-specified blood glucose levels)|Number of patients with AEs, SAEs, laboratory, vital signs and electrocardiographic abnormalities , injections site reaction assessment (ISR), and if any, hypoglycemia","Sanofi","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","30","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","PDY12704|2012-004453-86|U1111-1134-4816","March 2013","July 2013","July 2013","October 23, 2014",,"October 23, 2014","Sanofi Administrative Office, Frankfurt, Germany",,"https://ClinicalTrials.gov/show/NCT02273258"
110,"NCT03871348","A First-in-Human Dose Escalation and Expansion Study to Evaluate Intratumoral Administration of SAR441000 as Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors",,"Recruiting","No Results Available","Metastatic Neoplasm","Drug: SAR441000|Drug: Cemiplimab REGN2810","For dose escalation: Incidence of Dose Limiting Toxicities (DLTs) (Monotherapy)|For dose escalation: Incidence of Dose Limiting Toxicities (DLTs) (Combination therapy)|For dose escalation: Maximum tolerated dose (MTD) of SAR441000 (Monotherapy)|For dose escalation: Maximum tolerated dose (MTD) of SAR441000 (Combination therapy)|Adverse Events|For Expansion: Objective Response Rate (ORR)|Assessment of Pharmacokinetic (PK) parameter for SAR441000 (Cmax) (Monotherapy)|Assessment of Pharmacokinetic (PK) parameter for SAR441000 (Cmax) (Combination therapy)|Assessment of PK parameter for SAR441000 (AUC) (Monotherapy)|Assessment of PK parameter for SAR441000 (AUC) (Combination therapy)|Assessment of PK parameter (Ctrough) for SAR441000|Assessment of PK parameter for cemiplimab (Cmax)|Assessment of PK parameter of cemiplimab (AUC)|Assessment of PK parameter for cemiplimab (Ctrough)|Immunogenicity of SAR441000 and cemiplimab|DCR|DoR|Progression Free Survival (PFS)|Incidence of Treatment Emergent Adverse Events (TEAE) during dose expansion phase|Recommended dose of SAR441000 for expansion phase (Monotherapy)|Recommended dose of SAR441000 for expansion phase (Combination therapy)|For Dose Escalation: Objective Response Rate (ORR)","Sanofi|Biontech RNA Pharmaceuticals GmbH","All","18 Years and older   (Adult, Older Adult)","Phase 1","264","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TED15297|2017-004766-94|U1111-1205-1176","January 3, 2019","August 2021","December 2021","March 12, 2019",,"January 27, 2020","Investigational Site Number 8400002, Houston, Texas, United States|Investigational Site Number 0560001, Bruxelles, Belgium|Investigational Site Number 0560002, Leuven, Belgium|Investigational Site Number 2500001, Villejuif Cedex, France|Investigational Site Number 2760002, Frankfurt Am Main, Germany|Investigational Site Number 2760001, Mainz, Germany|Investigational Site Number 2760003, Mannheim, Germany",,"https://ClinicalTrials.gov/show/NCT03871348"
111,"NCT01118728","Extension Study for Long Term Evaluation of SAR153191 (REGN88) in Patients With Ankylosing Spondylitis","SUSTAIN","Terminated","Has Results","Ankylosing Spondylitis","Drug: Sarilumab","Percentage of Participants Experiencing Any Treatment-emergent Adverse Event (TEAE), Serious Adverse Event (SAE) and Treatment Discontinuation|Percentage of Participants Who Achieved 20% Response in Ankylosing Spondylitis (AS) Working Group Criteria for Response (ASAS20)","Sanofi|Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 2","223","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LTS11298|2010-019263-11","June 2010","December 2011","December 2011","May 7, 2010","June 21, 2017","June 21, 2017","Sanofi-Aventis Administrative Office, Bridgewater, New Jersey, United States|Sanofi-Aventis Administrative Office, Macquarie Park, New South Wales, Australia|Sanofi-Aventis Administrative Office, Wien, Austria|Sanofi-Aventis Administrative Office, Diegem, Belgium|Sanofi-Aventis Administrative Office, Laval, Canada|Sanofi-Aventis Administrative Office, Praha, Czechia|Sanofi-Aventis Administrative Office, Paris, France|Sanofi-Aventis Administrative Office, Budapest, Hungary|Sanofi-Aventis Administrative Office, Vilnius, Lithuania|Sanofi-Aventis Administrative Office, Gouda, Netherlands|Sanofi-Aventis Administrative Office, Warszawa, Poland|Sanofi-Aventis Administrative Office, Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT01118728"
112,"NCT01001715","Single Injection of REGN475/SAR164877 in Treatment of Vertebral Fracture Pain",,"Terminated","No Results Available","Back Pain","Drug: REGN475/SAR164877|Drug: Placebo (for REGN475/SAR164877)","Mean change from baseline in pain intensity as assessed by Pain Intensity Numeric Rating Scale [PI-NRS]|Mean change from baseline in pain intensity as assessed by PI-NRS|Percentage of pain-free days (score ""0"" pain on PI-NRS)|Percentage of days with rescue analgesia use|Change from baseline in Quality of Life Questionnaire of the European Foundation for Osteoporosis [QUALEFFO] score|Change from baseline in Short Form-12 Item Quality of Life Questionnaire [SF-12] score|Patient Global Impression of Change [PGIC] score|Percentage of participants with at least 30% and 50% reduction from baseline in pain intensity|Pharmacokinetic: REGN475/SAR164877 serum concentration","Regeneron Pharmaceuticals","All","40 Years to 80 Years   (Adult, Older Adult)","Phase 2","41","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","ACT11308","November 2009","January 2011","January 2011","October 27, 2009",,"May 27, 2013","Sanofi-Aventis Investigational Site Number 840005, Beverly Hills, California, United States|Sanofi-Aventis Investigational Site Number 840001, Fresno, California, United States|Sanofi-Aventis Investigational Site Number 840017, Sacramento, California, United States|Sanofi-Aventis Investigational Site Number 840028, San Diego, California, United States|Sanofi-Aventis Investigational Site Number 840008, Stockton, California, United States|Sanofi-Aventis Investigational Site Number 840013, Boynton Beach, Florida, United States|Sanofi-Aventis Investigational Site Number 840047, Clearwater, Florida, United States|Sanofi-Aventis Investigational Site Number 840034, Atlanta, Georgia, United States|Sanofi-Aventis Investigational Site Number 840026, New York, New York, United States|Sanofi-Aventis Investigational Site Number 840044, Fort Worth, Texas, United States|Sanofi-Aventis Investigational Site Number 840023, Southlake, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01001715"
113,"NCT01217814","Effect of SAR153191 (REGN88) With Methotrexate in Patients With Active Rheumatoid Arthritis Who Failed TNF-α Blockers",,"Terminated","Has Results","Rheumatoid Arthritis","Drug: Sarilumab|Drug: Placebo|Drug: Golimumab|Drug: methotrexate (MTX)|Drug: Folic/folinic acid","Percentage of Participants Who Achieved at Least 20% Improvement in American College of Rheumatology (ACR20) Core Set Disease Activity Index at Week 12|Percentage of Participants Who Achieved at Least 50% Improvement in American College of Rheumatology (ACR50) Core Set Disease Activity Index at Week 12|Percentage of Participants Who Achieved at Least 70% Improvement in American College of Rheumatology Core (ACR70) Set Disease Activity Index at Week 12|Disease Activity Score for 28 Joints (DAS28) at Week 12|European League Against Rheumatism (EULAR) Response at Week 12|Percentage of Participants Achieving DAS28 Remission Score < 2.6 at Week 12|Pharmacokinetic (PK) Parameter: Serum Concentration of Functional and Bound Sarilumab","Sanofi|Regeneron Pharmaceuticals","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","16","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","ACT11575|2010-021020-94|U1111-1115-3763","November 2010","September 2011","September 2011","October 8, 2010","September 1, 2017","September 1, 2017","Investigational Site Number 840026, Freehold, New Jersey, United States|Investigational Site Number 840043, New York, New York, United States|Investigational Site Number 840025, Jackson, Tennessee, United States|Investigational Site Number 840038, Austin, Texas, United States|Investigational Site Number 170004, Barranquilla, Colombia|Investigational Site Number 170005, Barranquilla, Colombia|Investigational Site Number 170007, Bucaramanga, Colombia|Investigational Site Number 203002, Uherske Hradiste, Czechia|Investigational Site Number 380002, Firenze, Italy|Investigational Site Number 380005, Genova, Italy|Investigational Site Number 484008, Durango, Mexico|Investigational Site Number 484002, Guadalajara, Mexico|Investigational Site Number 724004, Oviedo, Spain|Investigational Site Number 724002, Valencia, Spain",,"https://ClinicalTrials.gov/show/NCT01217814"
114,"NCT01437787","Phase III Study of SAR302503 in Intermediate-2 and High Risk Patients With Myelofibrosis","JAKARTA","Completed","No Results Available","Hematopoietic Neoplasm","Drug: SAR302503|Drug: Placebo","Response Rate (RR), defined as the proportion of patients who have a ≥35% reduction in volume of spleen size at the end of Cycle 6, and confirmed 4 weeks thereafter|Symptom Response Rate (SRR): Proportion of patients with ≥50% reduction from baseline to the end of Cycle 6 in the total symptom score.|OS (overall survival) of either 400 mg/day or 500 mg/day of IMP as compared to placebo.|PFS (progression free survival) of either 400 mg/day or 500 mg/day of IMP as compared to placebo.|Proportion of patients who have ≥25% reduction in volume of spleen size at end of Cycle 6, and confirmed 4 weeks thereafter.|Duration of spleen response, measured by MRI (or CT scan in patients with contraindications for MRI.|Clinical and laboratory events graded by the NCI CTCAE v4.03.","Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 3","289","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","EFC12153|2011-001897-25|U1111-1121-7170","December 2011","June 2014","June 2014","September 21, 2011",,"January 8, 2016","Investigational Site Number 840014, Scottsdale, Arizona, United States|Investigational Site Number 840001, La Jolla, California, United States|Investigational Site Number 840012, La Jolla, California, United States|Investigational Site Number 840006, Los Angeles, California, United States|Investigational Site Number 840013, Baton Rouge, Louisiana, United States|Investigational Site Number 840008, Rochester, Minnesota, United States|Investigational Site Number 840009, Newark, New Jersey, United States|Investigational Site Number 840002, Canton, Ohio, United States|Investigational Site Number 840004, Houston, Texas, United States|Investigational Site Number 036001, Box Hill, Australia|Investigational Site Number 036005, Herston, Australia|Investigational Site Number 036003, Randwick, Australia|Investigational Site Number 036004, Tweed Heads, Australia|Investigational Site Number 036002, Wodonga, Australia|Investigational Site Number 040001, Wien, Austria|Investigational Site Number 056003, Antwerpen, Belgium|Investigational Site Number 056001, Leuven, Belgium|Investigational Site Number 076002, Jau, Brazil|Investigational Site Number 076004, Porto Alegre, Brazil|Investigational Site Number 076001, Rio De Janeiro, Brazil|Investigational Site Number 124001, Montreal, Canada|Investigational Site Number 124003, Montreal, Canada|Investigational Site Number 124002, Saint John, Canada|Investigational Site Number 250006, Marseille, France|Investigational Site Number 250005, Nantes Cedex 01, France|Investigational Site Number 250004, Nimes, France|Investigational Site Number 250002, Pierre Benite Cedex, France|Investigational Site Number 250007, Poitiers, France|Investigational Site Number 250003, Toulouse, France|Investigational Site Number 250001, Villejuif Cedex, France|Investigational Site Number 276006, Aachen, Germany|Investigational Site Number 276007, Bonn, Germany|Investigational Site Number 276008, Dresden, Germany|Investigational Site Number 276001, Mannheim, Germany|Investigational Site Number 348002, Budapest, Hungary|Investigational Site Number 348001, Debrecen, Hungary|Investigational Site Number 348007, Györ, Hungary|Investigational Site Number 348006, Kecskemét, Hungary|Investigational Site Number 348003, Miskolc, Hungary|Investigational Site Number 372002, Dublin, Ireland|Investigational Site Number 372001, Galway, Ireland|Investigational Site Number 376003, Haifa, Israel|Investigational Site Number 376002, Tel Hashomer, Israel|Investigational Site Number 380002, Bergamo, Italy|Investigational Site Number 380007, Bologna, Italy|Investigational Site Number 380004, Firenze, Italy|Investigational Site Number 380001, Pavia, Italy|Investigational Site Number 380006, Pavia, Italy|Investigational Site Number 380003, Varese, Italy|Investigational Site Number 410002, Bundang-Gu, Korea, Republic of|Investigational Site Number 410004, Seoul, Korea, Republic of|Investigational Site Number 410003, Seoul, Korea, Republic of|Investigational Site Number 410001, Seoul, Korea, Republic of|Investigational Site Number 410005, Seoul, Korea, Republic of|Investigational Site Number 410006, Seoul, Korea, Republic of|Investigational Site Number 410007, Seoul, Korea, Republic of|Investigational Site Number 440001, Kaunas, Lithuania|Investigational Site Number 440002, Klaipeda, Lithuania|Investigational Site Number 484001, Queretaro, Mexico|Investigational Site Number 616005, Brzozow, Poland|Investigational Site Number 616002, Gdansk, Poland|Investigational Site Number 616006, Lodz, Poland|Investigational Site Number 616010, Warszawa, Poland|Investigational Site Number 616003, Wroclaw, Poland|Investigational Site Number 620005, Coimbra, Portugal|Investigational Site Number 620004, Lisboa, Portugal|Investigational Site Number 620001, Lisboa, Portugal|Investigational Site Number 620003, Porto, Portugal|Investigational Site Number 642003, Brasov, Romania|Investigational Site Number 642004, Bucharest, Romania|Investigational Site Number 642002, Bucuresti, Romania|Investigational Site Number 642006, Bucuresti, Romania|Investigational Site Number 642001, Timisoara, Romania|Investigational Site Number 643009, Moscow, Russian Federation|Investigational Site Number 643001, Moscow, Russian Federation|Investigational Site Number 643010, Nizhny Novgorod, Russian Federation|Investigational Site Number 643008, Petrozavodsk, Russian Federation|Investigational Site Number 643004, St-Petersburg, Russian Federation|Investigational Site Number 643005, St.-Petersburg, Russian Federation|Investigational Site Number 643007, Volgograd, Russian Federation|Investigational Site Number 702002, Singapore, Singapore|Investigational Site Number 702001, Singapore, Singapore|Investigational Site Number 710003, Johannesburg, South Africa|Investigational Site Number 710002, Parktown, South Africa|Investigational Site Number 724001, Barcelona, Spain|Investigational Site Number 724002, Madrid, Spain|Investigational Site Number 752001, Stockholm, Sweden|Investigational Site Number 752002, Uddevalla, Sweden|Investigational Site Number 158002, Changhua, Taiwan|Investigational Site Number 158003, Kaohsiung, Taiwan|Investigational Site Number 158001, Taipei, Taiwan|Investigational Site Number 826006, Belfast, United Kingdom|Investigational Site Number 826003, Birmingham, United Kingdom|Investigational Site Number 826002, Glasgow, United Kingdom|Investigational Site Number 826004, Leeds, United Kingdom|Investigational Site Number 826001, London, United Kingdom|Investigational Site Number 826005, London, United Kingdom|Investigational Site Number 826007, Manchester, United Kingdom|Investigational Site Number 826008, Newcastle Upon Tyne, United Kingdom|Investigational Site Number 826009, Oxford, United Kingdom|Investigational Site Number 826010, Southampton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01437787"
115,"NCT01537653","Safety, Tolerability and Pharmacokinetics of SAR231893 (REGN668) in Healthy Japanese Adult Male Subjects",,"Completed","No Results Available","Healthy","Drug: SAR231893 (REGN668)|Drug: placebo","Number of subjects with standard safety assessments (adverse events, physical examinations, 12 lead ECGs, vital signs and laboratory tests)|Pharmacokinetics: Serum concentrations of SAR231893 (REGN668) over time|Pharmacodynamics: Serum total Immunoglobulin E (IgE) and Thymus and activation regulated chemokine (TARC) over time","Sanofi|Regeneron Pharmaceuticals","Male","20 Years to 45 Years   (Adult)","Phase 1","32","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","TDU12265|U1111-1127-2719","March 2012","October 2012","October 2012","February 23, 2012",,"December 6, 2013","Investigational Site Number 392001, Toshima-Ku, Japan",,"https://ClinicalTrials.gov/show/NCT01537653"
116,"NCT01463397","Efficacy and Safety of SAR292833 Administration for 4 Weeks in Patients With Chronic Peripheral Neuropathic Pain","Alchemilla","Completed","No Results Available","Neuropathic Pain","Drug: SAR292833|Drug: placebo","Change from baseline in the average daily pain intensity as measured by the 11-point NRS;|Percentage of patients with reduction in pain intensity of at least 30% and 50% at endpoint compared to baseline derived from the primary efficacy endpoint;|Change in Neuropathic Pain Symptom Inventory (NPSI) after 4 weeks treatment compared to baseline|Change in intensity of the mechanical allodynia after 4 weeks treatment compared to baseline using visual analog scale (VAS)|Amount of and time to first rescue medication intake during the treatment period.|Change in Daily Sleep Interference Score (DSIS), clinical global impression of change (PGIC and CGIC).","Sanofi","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 2","191","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","ACT11917|2011-001876-21|U1111-1120-0404","March 2012","May 2013","May 2013","November 1, 2011",,"February 26, 2016","Investigational Site Number 840014, Tucson, Arizona, United States|Investigational Site Number 840007, Garden Grove, California, United States|Investigational Site Number 840020, Newport Beach, California, United States|Investigational Site Number 840038, Santa Ana, California, United States|Investigational Site Number 840002, Tustin, California, United States|Investigational Site Number 840046, Coral Gables, Florida, United States|Investigational Site Number 840013, Ocala, Florida, United States|Investigational Site Number 840034, Palm Beach Gardens, Florida, United States|Investigational Site Number 840019, Evansville, Indiana, United States|Investigational Site Number 840012, Indianapolis, Indiana, United States|Investigational Site Number 840042, Framingham, Massachusetts, United States|Investigational Site Number 840004, Springfield, Massachusetts, United States|Investigational Site Number 840035, St. Louis, Missouri, United States|Investigational Site Number 840010, Las Vegas, Nevada, United States|Investigational Site Number 840037, Albuquerque, New Mexico, United States|Investigational Site Number 840040, Hartsdale, New York, United States|Investigational Site Number 840001, New York, New York, United States|Investigational Site Number 840033, Rochester, New York, United States|Investigational Site Number 840015, Raleigh, North Carolina, United States|Investigational Site Number 840022, Winston Salem, North Carolina, United States|Investigational Site Number 840017, Toledo, Ohio, United States|Investigational Site Number 840044, Altoona, Pennsylvania, United States|Investigational Site Number 840018, Johnstown, Pennsylvania, United States|Investigational Site Number 840045, Tullahoma, Tennessee, United States|Investigational Site Number 840006, Austin, Texas, United States|Investigational Site Number 840043, Dallas, Texas, United States|Investigational Site Number 840032, Dallas, Texas, United States|Investigational Site Number 840016, Seattle, Washington, United States|Investigational Site Number 203002, Olomouc, Czech Republic|Investigational Site Number 203005, Praha 10, Czech Republic|Investigational Site Number 203006, Praha 10, Czech Republic|Investigational Site Number 348001, Budapest, Hungary|Investigational Site Number 348005, Budapest, Hungary|Investigational Site Number 348007, Budapest, Hungary|Investigational Site Number 348002, Budapest, Hungary|Investigational Site Number 348006, Debrecen, Hungary|Investigational Site Number 348003, Zalaegerszeg, Hungary|Investigational Site Number 616001, Bydgoszcz, Poland|Investigational Site Number 616002, Lublin, Poland|Investigational Site Number 616007, Sandomierz, Poland|Investigational Site Number 616004, Wloclawek, Poland|Investigational Site Number 643006, Kazan, Russian Federation|Investigational Site Number 643007, Kazan, Russian Federation|Investigational Site Number 643008, Moscow, Russian Federation|Investigational Site Number 643010, Moscow, Russian Federation|Investigational Site Number 643009, Moscow, Russian Federation|Investigational Site Number 643001, Moscow, Russian Federation|Investigational Site Number 643011, Moscow, Russian Federation|Investigational Site Number 643004, Nizhny Novgorod, Russian Federation|Investigational Site Number 643012, Novosibirsk, Russian Federation|Investigational Site Number 643013, St-Petersburg, Russian Federation|Investigational Site Number 643003, St-Petersburg, Russian Federation|Investigational Site Number 643014, St-Petersburg, Russian Federation|Investigational Site Number 643005, Yaroslavl, Russian Federation|Investigational Site Number 703004, Banska Bystrica, Slovakia|Investigational Site Number 703001, Dubnica Nad Vahom, Slovakia|Investigational Site Number 703003, Krompachy, Slovakia|Investigational Site Number 804002, Kiev, Ukraine|Investigational Site Number 804005, Kiev, Ukraine|Investigational Site Number 804004, Kyiv, Ukraine|Investigational Site Number 804003, Kyiv, Ukraine",,"https://ClinicalTrials.gov/show/NCT01463397"
117,"NCT02906020","A Global Study to Assess the Drug Dynamics, Efficacy, and Safety of GZ/SAR402671 in Parkinson's Disease Patients Carrying a Glucocerebrosidase (GBA) Gene Mutation","MOVES-PD","Active, not recruiting","No Results Available","Parkinson's Disease","Drug: GZ/SAR402671|Drug: Placebo","Change from baseline in Movement Disorder Society Unified Parkinson's Disease Rating Scale Part II and III score|Change from baseline in Parkinson's Disease Cognitive Rating Scale|Change from baseline in Movement Disorder Society Unified Parkinson's Disease Rating Scale Part I, II, and III score|Change from baseline in Hoehn and Yahr score","Genzyme, a Sanofi Company|Sanofi","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","270","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ACT14820|2016-000657-12|U1111-1180-6918","December 15, 2016","December 2020","February 2023","September 19, 2016",,"January 10, 2020","Investigational Site Number 8400017, Scottsdale, Arizona, United States|Investigational Site Number 8400011, Scottsdale, Arizona, United States|Investigational Site Number 8400004, La Jolla, California, United States|Investigational Site Number 8400019, Palo Alto, California, United States|Investigational Site Number 8400013, Sunnyvale, California, United States|Investigational Site Number 8400015, New Haven, Connecticut, United States|Investigational Site Number 8400008, Boca Raton, Florida, United States|Investigational Site Number 8400016, Chicago, Illinois, United States|Investigational Site Number 8400005, Chicago, Illinois, United States|Investigational Site Number 8400014, Boston, Massachusetts, United States|Investigational Site Number 8400018, New York, New York, United States|Investigational Site Number 8400010, New York, New York, United States|Investigational Site Number 8400001, New York, New York, United States|Investigational Site Number 8400021, Portland, Oregon, United States|Investigational Site Number 8400020, Portland, Oregon, United States|Investigational Site Number 8400009, Portland, Oregon, United States|Investigational Site Number 8400002, Philadelphia, Pennsylvania, United States|Investigational Site Number 8400006, Fairfax, Virginia, United States|Investigational Site Number 8400012, Kirkland, Washington, United States|Investigational Site Number 0400001, Innsbruck, Austria|Investigational Site Number 1240001, Montreal, Canada|Investigational Site Number 1240002, Ottawa, Canada|Investigational Site Number 1240003, Vancouver, Canada|Investigational Site Number 2500001, Paris Cedex 13, France|Investigational Site Number 2760002, Kiel, Germany|Investigational Site Number 2760003, München, Germany|Investigational Site Number 2760001, Tübingen, Germany|Investigational Site Number 3000004, Athens, Greece|Investigational Site Number 3000002, Larissa, Greece|Investigational Site Number 3760002, Haifa, Israel|Investigational Site Number 3760003, Petah-Tikva, Israel|Investigational Site Number 3760001, Tel Aviv, Israel|Investigational Site Number 3760004, Tel Hashomer, Israel|Investigational Site Number 3800001, Catanzaro, Italy|Investigational Site Number 3800004, Milano, Italy|Investigational Site Number 3800003, Pavia, Italy|Investigational Site Number 3800006, Rozzano, Italy|Investigational Site Number 3800002, Salerno, Italy|Investigational Site Number 3920001, Bunkyo-Ku, Japan|Investigational Site Number 3920003, Kodaira-Shi, Japan|Investigational Site Number 3920002, Kyoto-Shi, Japan|Investigational Site Number 3920005, Nagoya-Shi, Japan|Investigational Site Number 3920004, Osaka-Shi, Japan|Investigational Site Number 5780001, Trondheim, Norway|Investigational Site Number 6200002, Coimbra, Portugal|Investigational Site Number 6200003, Torres Vedras, Portugal|Investigational Site Number 7020001, Singapore, Singapore|Investigational Site Number 7020002, Singapore, Singapore|Investigational Site Number 7240002, Barcelona, Spain|Investigational Site Number 7240001, Sevilla, Spain|Investigational Site Number 7520001, Stockholm, Sweden|Investigational Site Number 1580001, Taoyuan County, Taiwan|Investigational Site Number 8260001, London, United Kingdom|Investigational Site Number 8260002, Oxford, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02906020"
118,"NCT02155881","Efficacy and Safety of Ciclesonide Nasal Spray in Participants With Seasonal Allergic Rhinitis (SAR) in Russia",,"Completed","Has Results","Seasonal Allergic Rhinitis","Drug: Ciclesonide|Drug: Ciclesonide Placebo","Change From Baseline Over 2 Weeks in Participant-Reported Morning and Evening Reflective Total Nasal Symptom Scores (TNSS)|Change From Baseline Over 2 Weeks in Participant-Reported Morning and Evening Instantaneous Total Nasal Symptom Scores|Change From Baseline Over 2 Weeks in Participant-Reported Morning and Evening Reflective Total Ocular Symptom Scores (TOSS)|Change From Baseline Over 2 Weeks in Participant-Reported Morning and Evening Instantaneous Total Ocular Symptom Scores|Change From Baseline Over 2 Weeks in Participant-Reported Individual Morning and Evening Reflective Total Nasal Symptom Score|Change From Baseline Over 2 Weeks in Participant-Reported Individual Morning and Evening Reflective Total Ocular Symptom Score|Change From Baseline Over 2 Weeks in Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) Total Score|Change From Baseline Over 2 Weeks in Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) Individual Domain Score","AstraZeneca","All","18 Years and older   (Adult, Older Adult)","Phase 3","80","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CIC-RR-001|U1111-1152-9472","August 2014","October 2014","November 2014","June 4, 2014","October 6, 2016","February 2, 2017","Kazan, Russian Federation|Krasnodar, Russian Federation|Moscow, Russian Federation|Saratov, Russian Federation|Stavropol, Russian Federation",,"https://ClinicalTrials.gov/show/NCT02155881"
119,"NCT01537640","Comparison of the Pharmacokinetics and Safety of Two SAR231893 (REGN668) Drug Products in Healthy Subjects",,"Completed","No Results Available","Healthy","Biological: SAR231893 (REGN668) DP1|Biological: SAR231893 (REGN668) DP2","Assessment of serum concentrations of SAR231893 (REGN668)|Pain evaluation at injection site using Visual Analog Scale (VAS)|Erythema at injection site by measuring diameter|Edema at injection site by measuring diameter|Number of participants experiencing adverse events","Sanofi|Regeneron Pharmaceuticals","All","18 Years to 45 Years   (Adult)","Phase 1","30","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","PKM12350|U1111-1119-3152","February 2012","July 2012","July 2012","February 23, 2012",,"December 6, 2013","Investigational Site Number 840001, Daytona Beach, Florida, United States",,"https://ClinicalTrials.gov/show/NCT01537640"
120,"NCT02631551","Efficacy and Safety of Fixed Dose Combination GSP 301 Nasal Spray (NS) in the Treatment of Seasonal Allergic Rhinitis (SAR)","GSP 301-301","Completed","Has Results","Seasonal Allergic Rhinitis","Drug: GSP 301 NS|Drug: Olopatadine HCl NS|Drug: Mometasone furoate NS|Drug: GSP 301 Placebo NS","Change in Average AM and PM Subject-reported 12-hour Reflective Total Nasal Symptoms Score (rTNSS) From Baseline to End of Treatment.","Glenmark Specialty S.A.","All","12 Years and older   (Child, Adult, Older Adult)","Phase 3","1180","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","GPL/CT/2014/016/III","March 2016","July 2016","July 2016","December 16, 2015","August 15, 2018","September 25, 2018","Investigational Site 20, Mission Viejo, California, United States|Investigational Site 31, San Diego, California, United States|Investigational Site 29, San Jose, California, United States|Investigational Site 25, Centennial, Colorado, United States|Investigational Site 22, Colorado Springs, Colorado, United States|Investigational Site 10, Jupiter, Florida, United States|Investigational Site 30, Miami, Florida, United States|Investigational Site 37, Marietta, Georgia, United States|Investigational Site 15, Stockbridge, Georgia, United States|Investigational Site 23, Stockbridge, Georgia, United States|Investigational Site 11, Louisville, Kentucky, United States|Investigational Site 14, Baltimore, Maryland, United States|Investigational Site 33, Wheaton, Maryland, United States|Investigational Site 26, Ypsilanti, Michigan, United States|Investigational Site 19, Minneapolis, Minnesota, United States|Investigational Site 21, Saint Louis, Missouri, United States|Investigational Site 16, Bellevue, Nebraska, United States|Investigational Site 12, Skillman, New Jersey, United States|Investigational Site 36, Rochester, New York, United States|Investigational Site 18, Raleigh, North Carolina, United States|Investigational Site 27, Cincinnati, Ohio, United States|Investigational Site 34, Middleburg Heights, Ohio, United States|Investigational Site 32, Medford, Oregon, United States|Investigational Site 35, Portland, Oregon, United States|Investigational Site 13, Orangeburg, South Carolina, United States|Investigational Site 17, Spartanburg, South Carolina, United States|Investigational Site 3, Austin, Texas, United States|Investigational Site 5, Austin, Texas, United States|Investigational Site 8, Austin, Texas, United States|Investigational Site 1, Kerrville, Texas, United States|Investigational Site 7, New Braunfels, Texas, United States|Investigational Site 2, San Antonio, Texas, United States|Investigational Site 4, San Antonio, Texas, United States|Investigational Site 6, San Antonio, Texas, United States|Investigational Site 9, San Antonio, Texas, United States|Investigational Site 28, Waco, Texas, United States|Investigational Site 24, Draper, Utah, United States",,"https://ClinicalTrials.gov/show/NCT02631551"
121,"NCT01670734","Pharmacokinetic and Tolerability of Alirocumab SAR236553 (REGN727) in Patients With Hepatic Impairment and in Healthy Subjects",,"Completed","No Results Available","Hypercholesterolemia","Drug: alirocumab SAR236553 (REGN727)","Pharmacokinetics: Assessment of serum concentrations of alirocumab SAR236553 (REGN727)|Assessment of PK parameter - terminal elimination half-life (t1/2z) [|Assessment of PK parameter - apparent total body clearance (CL/F)|Assessment of PK parameter - Distribution volume at the steady-state (Vss/F)|Assessment of PK parameter - time to maximum concentration (tmax)|Assessment of PK parameter - Mean Residence Time (MRT [area])|Pharmacodynamics: Change in LDL-C from baseline|Number of participants with Adverse Events","Sanofi|Regeneron Pharmaceuticals","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1","25","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","POP12671|2012-002292-33|U1111-1129-0248","September 2012","May 2013","May 2013","August 22, 2012",,"June 28, 2013","Investigational Site Number 250001, Rennes, France|Investigational Site Number 498001, Chisinau, Moldova, Republic of",,"https://ClinicalTrials.gov/show/NCT01670734"
122,"NCT00724334","A Long-Term Study of the Effects of Orally Administered SAR302503 in Patients With Myelofibrosis",,"Completed","No Results Available","Myelofibrosis","Drug: SAR302503 (TG101348)","Safety (i.e. adverse events, effects on laboratory parameters, vital signs and ECGs) and tolerability|Clinical activity and pharmacodynamics","Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","42","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TED12015|MF-TG101348-002","July 2008","May 2014","May 2014","July 29, 2008",,"March 17, 2016","Investigational Site Number 840103, La Jolla, California, United States|Investigational Site Number 840102, Stanford, California, United States|Investigational Site Number 840105, Boston, Massachusetts, United States|Investigational Site Number 840106, Ann Arbor, Michigan, United States|Investigational Site Number 840104, Rochester, Minnesota, United States|Investigational Site Number 840101, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00724334"
123,"NCT02228460","Evaluate the Safety, Pharmacodynamics, Pharmacokinetics, and Exploratory Efficacy of GZ/SAR402671 in Treatment-naïve Adult Male Patients With Fabry Disease",,"Completed","Has Results","Fabry Disease","Drug: GZ/SAR402671","Change From Baseline at Week 26 in Skin Globotriaosylceramide (GL-3) Score in Superficial Skin Capillary Endothelium: Number of Participants in Categories of Shift in GL-3 Score From Baseline to Week 26|Mean Change From Baseline at Week 26 in Skin GL-3 Score in Superficial Skin Capillary Endothelium|Change From Baseline in Plasma GL-3 Concentration at Week 26|Change From Baseline in Plasma Lyso Globotriaosylceramide (Lyso-GL-3) Concentration at Week 26|Change From Baseline in Plasma Glucosylceramide (GL-1) Concentration at Week 26|Change From Baseline at Week 26 in Skin GL-3 Score in Deep Vessels Endothelial Cells: Number of Participants in Categories of Shift in GL-3 Score From Baseline to Week 26|Change From Baseline at Week 26 in Skin GL-3 Score in Deep Vessels Smooth Muscle Cells: Number of Participants in Categories of Shift in GL-3 Score From Baseline to Week 26|Change From Baseline at Week 26 in Skin GL-3 Score in Perineurium Cells: Number of Participants in Categories of Shift in GL-3 Score From Baseline to Week 26|Change From Baseline in Urine Globotriaosylceramide (GL-3) Concentration at Week 26|Number of Participants With Treatment Emergent Adverse Events (TEAEs)|Pharmacokinetics (PK): Maximum Plasma Drug Concentration (Cmax) of GZ/SAR402671|PK: Plasma Trough Concentration (Ctrough) of GZ/SAR402671|PK: Time to Reach Maximum Plasma Drug Concentration (Tmax) of GZ/SAR402671|PK: Area Under Plasma Concentration Versus Time Curve From 0 to 24 Hours (AUC0-24) of GZ/SAR402671|PK: Terminal Half-life (t1/2z) of GZ/SAR402671|PK: Apparent Total Body Clearance of GZ/SAR402671 at Steady State (CLss/F)|PK: Apparent Volume of Distribution of GZ/SAR402671 (Vss/F) at Steady State|PK: Cumulated Amount of GZ/SAR402671 Excreted in Urine From 0 to 24 Hours (Ae0-24)|PK: Percentage of Dose of GZ/SAR402671 Excreted in Urine From 0 to 24 Hours (fe0-24)|PK: Renal Clearance (CLR) of GZ/SAR402671 From 0 to 24 Hours","Genzyme, a Sanofi Company|Sanofi","Male","18 Years to 49 Years   (Adult)","Phase 2","11","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ACT13739|2013-005324-41|U1111-1152-1456","November 2014","September 2016","September 2016","August 29, 2014","December 17, 2019","December 17, 2019","Investigational Site Number 840002, Atlanta, Georgia, United States|Investigational Site Number 840003, Cincinnati, Ohio, United States|Investigational Site Number 840001, Fairfax, Virginia, United States|Investigational Site Number 250001, Garches, France|Investigational Site Number 616001, Warszawa, Poland|Investigational Site Number 643002, Moscow, Russian Federation|Investigational Site Number 826003, Birmingham, United Kingdom|Investigational Site Number 826002, Cambridge, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02228460"
124,"NCT01529853","To Evaluate the Effect of Different Doses of SAR156597 Given to Patients With Idiopathic Pulmonary Fibrosis (IPF)",,"Completed","No Results Available","Idiopathic Pulmonary Fibrosis","Drug: SAR156597|Drug: Placebo (for SAR156597)","Safety/tolerability: Number of participants with Adverse events|Pharmacodynamic: Change in forced (expiratory) vital capacity (FVC)|Pharmacodynamic: Change in carbon monoxide diffusing lung capacity (DLco)|Pharmacodynamic: Change in Saint George Respiratory Questionnaire (SGRQ)|Pharmacodynamic: Change in plasma levels of biomarkers|Pharmacokinetic: SAR156597 plasma concentration","Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","24","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","TDR11326|2011-005481-37|U1111-1124-1425","January 2012","October 2013","October 2013","February 9, 2012",,"February 15, 2016","Investigational Site Number 840008, Sacramento, California, United States|Investigational Site Number 840009, Jacksonville, Florida, United States|Investigational Site Number 840011, Jacksonville, Florida, United States|Investigational Site Number 840006, Chicago, Illinois, United States|Investigational Site Number 840004, Joliet, Illinois, United States|Investigational Site Number 840005, Maywood, Illinois, United States|Investigational Site Number 840002, Wichita, Kansas, United States|Investigational Site Number 840003, Minneapolis, Minnesota, United States|Investigational Site Number 840013, New York, New York, United States|Investigational Site Number 840014, Cincinnati, Ohio, United States|Investigational Site Number 840010, Charleston, South Carolina, United States|Investigational Site Number 124003, Edmonton, Canada|Investigational Site Number 124001, Hamilton, Canada|Investigational Site Number 124002, Vancouver, Canada|Investigational Site Number 152003, Santiago, Chile|Investigational Site Number 152001, Santiago, Chile|Investigational Site Number 152002, Santiago, Chile|Investigational Site Number 484003, Mexico City, Mexico|Investigational Site Number 484002, Monterrey, Mexico|Investigational Site Number 724001, Barcelona, Spain|Investigational Site Number 724002, Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT01529853"
125,"NCT01024608","Study in Adult and Adolescent Subjects With Seasonal Allergic Rhinitis (SAR)",,"Completed","Has Results","Seasonal Allergic Rhinitis|Hay Fever","Drug: Beclomethasone dipropionate|Drug: Placebo Nasal Aerosol","Change From Baseline in Average Subject-Reported AM and PM Reflective Total Nasal Symptom Score (rTNSS) Over the Two-week Treatment Period|Change From Baseline in Average Subject-Reported AM and PM Instantaneous Total Nasal Symptom Score (iTNSS) Over the Two-week Treatment Period|Change From Baseline at Week 2 in Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) in Participants With Impaired Quality of Life at Baseline|Change From Baseline in AM and PM Subject-reported Reflective Ocular Symptom Score Over the 2-week Treatment Period","Teva Branded Pharmaceutical Products, R&D Inc.|Teva Pharmaceutical Industries","All","12 Years and older   (Child, Adult, Older Adult)","Phase 3","340","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","BDP-AR-301","December 2009","February 2010","February 2010","December 3, 2009","May 23, 2012","May 23, 2012","Teva Clinical Trial Site, Austin, Texas, United States|Teva Clinical Trial Site, New Braunfels, Texas, United States|Teva Clinical Trial Site, San Antonio, Texas, United States|Teva Clinical Trial Site, Waco, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01024608"
126,"NCT01156870","First in Man Study of SAR566658 Administered in Patients With CA6-Positive and Refractory Solid Tumor",,"Completed","No Results Available","Neoplasm Malignant","Drug: SAR566658","Dose Escalation to determine the maximum tolerated dose (MTD) of SAR566658|Extension Cohorts to evaluate the preliminary anti-tumoral effect of SAR566658|To assess the effect of SAR566658 at the recommended dose on CYP3A enzyme activity using midazolam as probe|Overall safety profile based on adverse events reporting, laboratory tests, vital signs and specific pulmonary and ocular tests, according to the NCI-CTC AE v4.03|Pharmacokinetic (PK) parameters|Immunogenicity evaluation (anti-drug antibodies)|Antitumoral response|To assess the effect of SAR566658 at recommended dose on CYP3A enzyme activity using midazolam|To assess safety in the alternative schedules of SAR566658 administration","Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 1","114","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TED10499|U1111-1116-4129","September 8, 2010","April 7, 2017","April 7, 2017","July 5, 2010",,"May 10, 2017","Investigational Site Number 840002, Cincinnati, Ohio, United States|Investigational Site Number 840001, San Antonio, Texas, United States|Investigational Site Number 250001, Toulouse Cedex, France|Investigational Site Number 724002, Madrid, Spain|Investigational Site Number 724001, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT01156870"
127,"NCT01587040","Open Label Treatment Extension Study With SAR245408 or SAR245409 as a Monotherapy or as a Combination Regimen",,"Completed","Has Results","Neoplasm Malignant","Drug: SAR245408|Drug: SAR245409","Number of Participants With Treatment Emergent Adverse Events (TEAEs)|Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Hematological Parameters|Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Biochemical Parameters","Sanofi","All","Child, Adult, Older Adult","Phase 1|Phase 2","61","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TED12414|2011-006140-78|U1111-1124-1403","July 20, 2012","May 23, 2018","May 23, 2018","April 27, 2012","June 11, 2019","June 11, 2019","Investigational Site Number 840010, Birmingham, Alabama, United States|Investigational Site Number 840009, Los Angeles, California, United States|Investigational Site Number 840008, Los Angeles, California, United States|Investigational Site Number 840022, Denver, Colorado, United States|Investigational Site Number 840104, Fort Myers, Florida, United States|Investigational Site Number 840006, Augusta, Georgia, United States|Investigational Site Number 840004, Boston, Massachusetts, United States|Investigational Site Number 840021, Saint Louis, Missouri, United States|Investigational Site Number 840002, New Brunswick, New Jersey, United States|Investigational Site Number 840020, Canton, Ohio, United States|Investigational Site Number 840015, Columbus, Ohio, United States|Investigational Site Number 840017, Philadelphia, Pennsylvania, United States|Investigational Site Number 840007, Nashville, Tennessee, United States|Investigational Site Number 840003, Dallas, Texas, United States|Investigational Site Number 840005, San Antonio, Texas, United States|Investigational Site Number 840018, Morgantown, West Virginia, United States|Investigational Site Number 056001, Leuven, Belgium|Investigational Site Number 250004, Montpellier, France|Investigational Site Number 250003, Pierre Benite Cedex, France|Investigational Site Number 250005, Rouen Cedex, France|Investigational Site Number 724001, Barcelona, Spain","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/40/NCT01587040/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/40/NCT01587040/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT01587040"
128,"NCT01723735","Effect of Alirocumab (SAR236553/REGN727) Administered on Top of Ezetimibe or Fenofibrate on Lipid Profiles in Healthy Subjects",,"Completed","No Results Available","Hypercholesterolemia","Drug: Alirocumab|Drug: Ezetimibe|Drug: Ezetimibe Placebo|Drug: Fenofibrate","Assessment of the effect of alirocumab on LDL-C|Assessment of the pharmacodynamic profile of alirocumab|Pharmacokinetics: Assessment of serum concentrations of alirocumab|Pharmacokinetics: Assessment of serum concentrations of proprotein convertase subtilisin kexin type 9 (PCSK9)","Sanofi|Regeneron Pharmaceuticals","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","79","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","PKD12910|U1111-1131-3203|2012-003049-13","November 2012","July 2013","July 2013","November 8, 2012",,"September 28, 2016","Investigational Site Number 250001, Rennes, France|Investigational Site Number 250002, Rueil Malmaison, France",,"https://ClinicalTrials.gov/show/NCT01723735"
129,"NCT01511549","Safety, Tolerability and Pharmacokinetics of SAR113945 in Japanese Patients With Knee Osteoarthritis",,"Completed","No Results Available","Knee Osteoarthritis","Drug: placebo|Drug: SAR113945","Number of patients with safety assessments (adverse events, vital signs, 12 lead ECGs and laboratory tests)|Examination of skin/soft tissue of injected knee, and knee joint|Pharmacokinetic parameter (AUC)|Pharmacokinetic parameter (Cmax)|Pharmacokinetic parameter (tmax)|Pharmacokinetic parameter (t1/2)|Pharmacodynamic parameter (WOMAC index)|Pharmacodynamic parameter (biomarkers relating to osteoarthritis)","Sanofi","All","40 Years and older   (Adult, Older Adult)","Phase 1","24","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","TDU11333|U1111-1121-4499","January 2012","September 2012","September 2012","January 18, 2012",,"October 1, 2012","Investigational Site Number 392001, Osaka-Shi, Japan",,"https://ClinicalTrials.gov/show/NCT01511549"
130,"NCT01421498","Safety and Efficacy Study of SAR 1118 to Treat Dry Eye Conducted in a Controlled Adverse Environment (CAE) (OPUS-1)","OPUS-1","Completed","Has Results","Keratoconjunctivitis Sicca|Dry Eye Disease","Drug: Lifitegrast|Drug: Placebo","Ocular Sign: Change From Baseline in Inferior Corneal Fluorescein Staining to Day 84|Ocular Symptom: Change From Baseline in Visual-Related Subscale of the Symptom Functional Scale Score to Day 84","Shire","All","18 Years and older   (Adult, Older Adult)","Phase 3","588","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","1118-KCS-200","August 29, 2011","April 28, 2012","April 28, 2012","August 22, 2011","February 24, 2017","December 19, 2018","OPUS-1 Investigational Site, Waterbury, Connecticut, United States|OPUS-1 Investigational Site, Louisville, Kentucky, United States|OPUS-1 Investigational Site, Augusta, Maine, United States|OPUS-1 Investigational Site, Lewiston, Maine, United States|OPUS-1 Investigational Site, Andover, Massachusetts, United States|OPUS-1 Investigational Site, Lancaster, Massachusetts, United States|OPUS-1 Investigational Site, Quincy, Massachusetts, United States|OPUS-1 Investigational Site, Wakefield, Massachusetts, United States|OPUS-1 Investigational Site, Winchester, Massachusetts, United States|OPUS-1 Investigational Site, Derry, New Hampshire, United States|OPUS-1 Investigational Site, Manchester, New Hampshire, United States|OPUS-1 Investigational Site, Memphis, Tennessee, United States|OPUS-1 Investigational Site, Norfolk, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT01421498"
131,"NCT01445938","Anti-parasitic Activity and Safety Assessment of SAR97276A in Children With Uncomplicated Malaria",,"Terminated","No Results Available","Malaria","Drug: SAR97276A|Drug: arthemeter + lumefantrine (ACTs)","Parasite Reduction Ratio (PRR)|Evolution of mean Parasitaemia over time (nb/µL)|Evolution of mean Gametocytes count over time (nb/µL)|Fever Clearance (time to reach Temperature < 38°C)|General conditions improvement: mean total symptom score over time|SAR97276 pharmacokinetic profile in plasma and blood","Sanofi","All","2 Years to 17 Years   (Child)","Phase 2","20","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PDY11737|2010-021398-36|U1111-1118-0694","October 2011","January 2012","January 2012","October 4, 2011",,"December 13, 2012","Investigational Site Number 204001, Cotonou, Benin|Investigational Site Number 854001, Ouagadougou, Burkina Faso|Investigational Site Number 266001, Libreville, Gabon|Investigational Site Number 404001, Kisumu, Kenya",,"https://ClinicalTrials.gov/show/NCT01445938"
132,"NCT01061723","Dose Ranging Study to Evaluate the Efficacy and Safety of SAR153191 (REGN88) in Patients With Ankylosing Spondylitis","ALIGN","Completed","Has Results","Ankylosing Spondylitis","Drug: Sarilumab|Drug: Placebo","Percentage of Participants Who Achieved 20% Response According to the Assessment in Ankylosing Spondylitis (AS) Working Group Criteria for Response (ASAS20) at Week 12|Percentage of Participants Who Achieved 40% Response According to the Assessment in AS Working Group Criteria for Response (ASAS40) at Week 12|Percentage of Participants Who Achieved Partial Remission According to the Assessment in AS Working Group Criteria for Response (ASAS) at Week 12|Change From Baseline in Ankylosing Spondylitis Disease Activity Score (ASDAS) at Week 12|Change From Baseline in BASDAI Score at Week 12|Change From Baseline in Range of Motion Assessed by the Bath AS Metrology Index (BASMI) at Week 12|Change From Baseline in Magnetic Resonance Imaging (MRI) Score of the Spine Assessed by the Berlin Modification of the AS Spine MRI-active (ASspiMRI-a) Score at Week 12|Percentage of Participants Who Achieved ASAS 5/6 Improvement Criteria at Week 12|Change From Baseline in Chest Expansion at Week 12|Change From Baseline in Swollen Joint Index at Week 12|Change From Baseline in Hs-CRP at Week 12|Change From Baseline in ASAS Individual Components at Week 12","Sanofi|Regeneron Pharmaceuticals","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","301","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","DRI11073|2009-016068-35","February 2010","June 2011","June 2011","February 3, 2010","August 8, 2017","August 8, 2017","Investigational Site Number 840006, Birmingham, Alabama, United States|Investigational Site Number 840033, Anaheim, California, United States|Investigational Site Number 840027, Los Angeles, California, United States|Investigational Site Number 840007, San Diego, California, United States|Investigational Site Number 840013, San Francisco, California, United States|Investigational Site Number 840017, Upland, California, United States|Investigational Site Number 840009, Boca Raton, Florida, United States|Investigational Site Number 840001, Naples, Florida, United States|Investigational Site Number 840032, Orlando, Florida, United States|Investigational Site Number 840015, Boise, Idaho, United States|Investigational Site Number 840021, Rock Island, Illinois, United States|Investigational Site Number 840018, Kansas City, Kansas, United States|Investigational Site Number 840003, Wheaton, Maryland, United States|Investigational Site Number 840029, Worcester, Massachusetts, United States|Investigational Site Number 840008, Lansing, Michigan, United States|Investigational Site Number 840002, Saint Louis, Missouri, United States|Investigational Site Number 840028, Freehold, New Jersey, United States|Investigational Site Number 840016, Albany, New York, United States|Investigational Site Number 840036, Syracuse, New York, United States|Investigational Site Number 840010, Toledo, Ohio, United States|Investigational Site Number 840005, Oklahoma City, Oklahoma, United States|Investigational Site Number 840023, Bethlehem, Pennsylvania, United States|Investigational Site Number 840014, Duncansville, Pennsylvania, United States|Investigational Site Number 840004, Dallas, Texas, United States|Investigational Site Number 840030, Houston, Texas, United States|Investigational Site Number 840034, Chesapeake, Virginia, United States|Investigational Site Number 036001, East Malvern, Australia|Investigational Site Number 036003, Hobart, Australia|Investigational Site Number 036004, Shenton Park, Australia|Investigational Site Number 036002, Woolloongabba, Australia|Investigational Site Number 040001, Graz, Austria|Investigational Site Number 040002, Wien, Austria|Investigational Site Number 056003, Brussels, Belgium|Investigational Site Number 056005, Genk, Belgium|Investigational Site Number 056001, Gent, Belgium|Investigational Site Number 056002, Leuven, Belgium|Investigational Site Number 056004, Liège, Belgium|Investigational Site Number 124007, London, Canada|Investigational Site Number 124004, Montreal, Canada|Investigational Site Number 124008, Newmarket, Canada|Investigational Site Number 124003, Pointe-Claire, Canada|Investigational Site Number 124001, Quebec, Canada|Investigational Site Number 124006, Saskatoon, Canada|Investigational Site Number 124005, Toronto, Canada|Investigational Site Number 124009, Trois-Rivières, Canada|Investigational Site Number 124002, Vancouver, Canada|Investigational Site Number 124010, Vancouver, Canada|Investigational Site Number 203003, Brno, Czechia|Investigational Site Number 203005, Hlucin, Czechia|Investigational Site Number 203002, Hradec Kralove, Czechia|Investigational Site Number 203001, Praha 2, Czechia|Investigational Site Number 203004, Uherske Hradiste, Czechia|Investigational Site Number 250001, Besancon, France|Investigational Site Number 250005, Bordeaux, France|Investigational Site Number 250002, Creteil Cedex, France|Investigational Site Number 250003, Paris, France|Investigational Site Number 276002, Berlin, Germany|Investigational Site Number 276004, Erlangen, Germany|Investigational Site Number 276003, Frankfurt Am Main, Germany|Investigational Site Number 276005, Hamburg, Germany|Investigational Site Number 276001, Herne, Germany|Investigational Site Number 348001, Budapest, Hungary|Investigational Site Number 348003, Debrecen, Hungary|Investigational Site Number 348005, Sátoraljaújhely, Hungary|Investigational Site Number 348004, Veszprém, Hungary|Investigational Site Number 440001, Kaunas, Lithuania|Investigational Site Number 440002, Vilnius, Lithuania|Investigational Site Number 528001, Amsterdam, Netherlands|Investigational Site Number 528002, Nijmegen, Netherlands|Investigational Site Number 616002, Bialystok, Poland|Investigational Site Number 616001, Krakow, Poland|Investigational Site Number 616004, Lublin, Poland|Investigational Site Number 616005, Torun, Poland|Investigational Site Number 616003, Warszawa, Poland|Investigational Site Number 724005, Barcelona, Spain|Investigational Site Number 724004, La Coruña, Spain|Investigational Site Number 724002, Madrid, Spain|Investigational Site Number 724001, Sevilla, Spain|Investigational Site Number 792002, Ankara, Turkey|Investigational Site Number 792001, Izmir, Turkey",,"https://ClinicalTrials.gov/show/NCT01061723"
133,"NCT03414736","A Study on Safety and Tolerability of SAR425899 in Overweight to Obese Subjects and Type 2 Diabetes Mellitus Patients Not Requiring Anti-Diabetic Pharmacotherapy With an Optional 6-month Safety Extension Period",,"Completed","No Results Available","Type 2 Diabetes Mellitus","Drug: SAR425899","Frequency of gastrointestinal (GI) adverse events (AEs)|Frequency of GI AEs|Change in body weight|Change in fasting plasma glucose (FPG)|Change in hemoglobin A1c (HbA1c)|Adverse events (AEs)","Sanofi","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1","60","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TDR15516|U1111-1205-1368","January 19, 2018","October 5, 2018","October 5, 2018","January 30, 2018",,"November 26, 2018","Investigational Site Number 8400002, Saint Paul, Minnesota, United States|Investigational Site Number 8400003, Knoxville, Tennessee, United States|Investigational Site Number 8400001, Austin, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03414736"
134,"NCT01448317","Ascending Dose Study of the Safety and Tolerability of Alirocumab (SAR236553/REGN727) in Japanese Healthy Volunteers",,"Completed","No Results Available","Hypercholesterolemia","Drug: Alirocumab (Solution)|Drug: Alirocumab (Lyophilized formulation)|Drug: Placebo (Solution)|Drug: Placebo (Lyophilized formulation)","Number of participants with Adverse Events|Change in serum Low-Density Lipoprotein Cholesterol (LDL-C) from baseline to each visit.|Change in ApolipoproteinB, ApolipoproteinA1 and Lipoprotein(a) from baseline to each visit.|Change in Total Cholesterol (T-C), High-Density Lipoprotein Cholesterol (HDL-C), Very Low-Density Lipoprotein Cholesterol (VLDL-C) and Triglycerides (TG) from baseline to each visit.","Sanofi|Regeneron Pharmaceuticals","Male","20 Years to 65 Years   (Adult, Older Adult)","Phase 1","32","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","TDU12190|U1111-1118-1213","May 2011","January 2012","January 2012","October 7, 2011",,"September 28, 2016","Sanofi-Aventis Administrative Office, Tokyo, Japan",,"https://ClinicalTrials.gov/show/NCT01448317"
135,"NCT03192345","A First-in-human Study of the Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of SAR439459 Monotherapy and Combination of SAR439459 and Cemiplimab in Patients With Advanced Solid Tumors",,"Recruiting","No Results Available","Malignant Solid Tumor","Biological: SAR439459|Drug: Cemiplimab REGN2810","Incidence of Dose Limiting Toxicities (DLTs)|Objective Response Rate (ORR) for Part 2B|Overall safety profile|Progression free survival (PFS)|Time to progression (TTP)|Objective Response Rate (ORR) Part 2A|Duration of response Part 2B (urothelial cancer cohort only)|Immunogenicity evaluation|Cmax for SAR439459 and for cemiplimab|AUC for SAR439459|AUC0-tau for SAR439459 and for cemiplimab|t1/2z for SAR439459|CL for SAR439459|Vss for SAR439459","Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 1","225","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TCD14678|2018-001113-32","June 9, 2017","November 2021","August 2022","June 20, 2017",,"January 18, 2020","Investigational Site Number 8400007, Duarte, California, United States|Investigational Site Number 8400004, Fairway, Kansas, United States|Investigational Site Number 8400001, Boston, Massachusetts, United States|Investigational Site Number 8400101, Boston, Massachusetts, United States|Investigational Site Number 8400008, Durham, North Carolina, United States|Investigational Site Number 8400006, Nashville, Tennessee, United States|Investigational Site Number 8400003, Dallas, Texas, United States|Investigational Site Number 0360002, Heidelberg West, Australia|Investigational Site Number 0560001, Leuven, Belgium|Investigational Site Number 1240003, Calgary, Canada|Investigational Site Number 1240002, Montreal, Canada|Investigational Site Number 1240001, Toronto, Canada|Investigational Site Number 2330001, Tallinn, Estonia|Investigational Site Number 2500002, Marseille Cedex 5, France|Investigational Site Number 2500003, Nantes, France|Investigational Site Number 2500004, Paris Cedex 10, France|Investigational Site Number 2500001, Villejuif Cedex, France|Investigational Site Number 5280001, Rotterdam, Netherlands|Investigational Site Number 5280002, Utrecht, Netherlands",,"https://ClinicalTrials.gov/show/NCT03192345"
136,"NCT02531152","28-Day Repeated Topical Study to Evaluate the Safety and Activity of 5 Escalating Dose Levels of SAR366234 and One Dose of Latanoprost in Patients With Open Angle Glaucoma or Ocular Hypertension",,"Completed","No Results Available","Open Angle Glaucoma -Ocular Hypertension","Drug: Latanoprost|Drug: SAR366234","Number of adverse events (including local tolerance and ophthalmological examinations)|Assessment of IOP using Goldman applanation tonometry","Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 1","54","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","TDR13459|U1111-1153-3544","September 2015","April 2016","April 2016","August 24, 2015",,"April 27, 2016","Investigational Site Number 840001, Inglewood, California, United States|Investigational Site Number 840003, Cape Coral, Florida, United States|Investigational Site Number 840005, Roswell, Georgia, United States|Investigational Site Number 840004, St Joseph, Michigan, United States|Investigational Site Number 840002, Memphis, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT02531152"
137,"NCT01045304","Study of SAR240550 (BSI-201) in Combination With Gemcitabine/Carboplatin, in Patients With Metastatic Triple Negative Breast Cancer",,"Completed","No Results Available","Breast Cancer, Metastatic","Drug: Iniparib|Drug: Gemcitabine|Drug: Carboplatin","Overall response rate (ORR)|Clinical benefit rate (CBR)|Progression-free survival|Overall survival","Sanofi","Female","18 Years and older   (Adult, Older Adult)","Phase 2","163","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TCD11418|2009-016091-80","February 2010","March 2011","November 2012","January 11, 2010",,"January 14, 2014","Sanofi-Aventis Investigational Site Number 036002, Parkville, Australia|Sanofi-Aventis Investigational Site Number 036001, Perth, Australia|Sanofi-Aventis Investigational Site Number 036003, Westmead, Australia|Sanofi-Aventis Investigational Site Number 056001, Bruxelles, Belgium|Sanofi-Aventis Investigational Site Number 056002, Leuven, Belgium|Sanofi-Aventis Investigational Site Number 250005, Besancon Cedex, France|Sanofi-Aventis Investigational Site Number 250003, Bordeaux, France|Sanofi-Aventis Investigational Site Number 250002, Dijon, France|Sanofi-Aventis Investigational Site Number 250006, Paris Cedex 05, France|Sanofi-Aventis Investigational Site Number 250004, Paris, France|Sanofi-Aventis Investigational Site Number 250001, Toulouse, France|Sanofi-Aventis Investigational Site Number 380004, Genova, Italy|Sanofi-Aventis Investigational Site Number 380001, Milano, Italy|Sanofi-Aventis Investigational Site Number 380002, Modena, Italy|Sanofi-Aventis Investigational Site Number 380003, Udine, Italy|Sanofi-Aventis Investigational Site Number 528001, Rotterdam, Netherlands|Sanofi-Aventis Investigational Site Number 724002, Barcelona, Spain|Sanofi-Aventis Investigational Site Number 724004, Madrid, Spain|Sanofi-Aventis Investigational Site Number 724001, Málaga, Spain|Sanofi-Aventis Investigational Site Number 724003, Valencia, Spain",,"https://ClinicalTrials.gov/show/NCT01045304"
138,"NCT02625636","A Study to Evaluate Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Doses of SAR438544 in Comparison to Placebo and Glucagon in Healthy Subjects and Type 1 Diabetes Mellitus Patients",,"Completed","No Results Available","Type 1 Diabetes Mellitus","Drug: SAR438544|Drug: placebo|Drug: r-glucagon","Number of patients with adverse events|Assessment of PD parameter: continuous monitoring of blood glucose levels over a period of 6 hours post-dose|Assessment of PD parameter: area under plasma concentration of the BG-time curve between investigational medicinal product (IMP) dosing and time t (BG-AUC0-t)|Assessment of PD parameter: BG-maximum concentration (BG-Cmax)|Assessment of PD parameter: BG-time to Cmax (BG-tmax)|Assessment of PK parameter (recombinant glucagon and SAR438544): Cmax|Assessment of PK parameter (recombinant glucagon and SAR438544): tmax|Assessment of PK parameter (recombinant glucagon and SAR438544): tlast|Assessment of PK parameter (recombinant glucagon and SAR438544): terminal half life|Assessment of PK parameter (recombinant glucagon and SAR438544): area under curve from zero time until the last measurable concentration (AUClast)|Assessment of PK parameter (recombinant glucagon and SAR438544): AUC|Assessment of PK parameter (recombinant glucagon and SAR438544): partial AUCs (AUC0-t)","Sanofi","All","18 Years to 60 Years   (Adult)","Phase 1","20","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","TDU14518|U1111-1172-1152","December 2015","February 2016","February 2016","December 9, 2015",,"August 23, 2016","Investigational Site Number 840001, Chula Vista, California, United States",,"https://ClinicalTrials.gov/show/NCT02625636"
139,"NCT00099463","Phase I Study of a Vaccine for Severe Acute Respiratory Syndrome (SARS)",,"Completed","No Results Available","Healthy","Procedure: Blood Test|Procedure: Urine Test|Procedure: Physical Exam|Drug: Vaccine|Drug: VRC-SRSDNA015-00-VP",,"National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC)","All","18 Years to 50 Years   (Adult)","Phase 1","10","NIH","Interventional","Primary Purpose: Treatment","050056|05-I-0056","December 9, 2004",,"August 22, 2007","December 15, 2004",,"July 2, 2017","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00099463"
140,"NCT01389700","Pharmacokinetics, Pharmacodynamics and Safety Evaluation of SAR279356 in Intensive Care Unit Mechanically Ventilated Patients",,"Terminated","No Results Available","Infection Prophylaxis","Drug: SAR279356|Drug: placebo","Pharmacokinetics parameters of SAR279356 : Ceoi, AUClast and CL|Opsonophagocytic assay (OPA)|Opsonophagocytic killing assay (OPK)|Dosage of human anti-human antibodies (HAHA)|Occurrence of infections","Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 2","7","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","PKD11791|U1111-1118-6717","October 2011","December 2012","December 2012","July 8, 2011",,"December 12, 2014","Investigational Site Number 840010, Los Angeles, California, United States|Investigational Site Number 840020, Stanford, California, United States|Investigational Site Number 840006, Jacksonville, Florida, United States|Investigational Site Number 840001, Pikeville, Kentucky, United States|Investigational Site Number 840009, Butte, Montana, United States|Investigational Site Number 840003, Camden, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT01389700"
141,"NCT00756847","Safety Study of XL147 (SAR245408), in Combination With Paclitaxel and Carboplatin in Adults With Solid Tumors",,"Completed","No Results Available","Cancer|Non-Small Cell Lung Cancer|Endometrial Carcinoma|Ovarian Carcinoma","Drug: XL147 (SAR245408),|Drug: paclitaxel|Drug: carboplatin","To evaluate the safety, tolerability, and MTD of XL147 administered in combination with paclitaxel (at doses up to 175 mg/m2) and carboplatin in subjects with advanced solid tumors|To evaluate the safety, tolerability, and MTD of XL147 administered in combination with paclitaxel (at doses up to 225 mg/m2) and carboplatin in subjects with NSCLC|To investigate the relationship between selected biomarkers and efficacy and safety outcomes|To assess plasma pharmacokinetics (PK) of XL147, paclitaxel, and carboplatin when used in combination|To evaluate preliminary antitumor activity of XL147 in combination with carboplatin and paclitaxel","Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 1","52","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TED11435|XL147-003","September 2008","May 2012","October 2012","September 22, 2008",,"April 10, 2013","Investigational Site Number, St. Louis, Missouri, United States|Investigational Site Number, Oklahoma City, Oklahoma, United States|Investigational Site Number, Houston, Texas, United States|Investigational Site Number, Madison, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT00756847"
142,"NCT01053728","Study of How Single Rising Doses of SAR161271 Are Absorbed and Act in Patients With Type 1 Diabetes Mellitus (T1DM)",,"Completed","No Results Available","Type 1 Diabetes Mellitus","Drug: SAR161271|Drug: Insulin glargine HOE901","- Safety in terms of adverse and serious adverse events, vital signs, ECG, safety laboratory for each cohort|- Pharmacodynamics (Glucose infusion rate) time-action profile|- Pharmacokinetic parameters|- anti-insulin antibody production","Sanofi","Male","18 Years to 60 Years   (Adult)","Phase 1|Phase 2","46","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","TDU10987|TDU10948","February 2010","May 2010","November 2010","January 21, 2010",,"July 26, 2011","Sanofi-Aventis Administrative Office, Berlin, Germany",,"https://ClinicalTrials.gov/show/NCT01053728"
143,"NCT01082068","Study of XL147 (SAR245408) or XL765 (SAR245409) in Combination With Letrozole in Subjects With Breast Cancer",,"Completed","No Results Available","Breast Cancer","Drug: XL147 (SAR245408)|Drug: XL765 (SAR245409)|Drug: letrozole (Femara)","Safety and tolerability of XL147 and letrozole and XL765 and letrozole|In Phase 1, to determine the maximum tolerated dose of XL147 in combination with letrozole and of XL765 in combination with letrozole|In Phase 2, to evaluate progression-free survival at 3 months|In Phase 2, to assess other clinical benefit and efficacy parameters|Pharmacokinetics and pharmacodynamics of XL147, XL765 and letrozole","Sanofi","Female","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","72","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ARD11437|XL147-202","June 2010","April 2013","April 2013","March 8, 2010",,"June 3, 2016","Investigational Site Number 1537, Los Angeles, California, United States|Investigational Site Number 1601, Denver, Colorado, United States|Investigational Site Number 1238, Fort Meyers, Florida, United States|Investigational Site Number 1441, Chicago, Illinois, United States|Investigational Site Number 1138, Boston, Massachusetts, United States|Investigational Site Number 1331, Ann Arbor, Michigan, United States|Investigational Site Number 1330, Detroit, Michigan, United States|Investigational Site Number 5201, Columbia, Missouri, United States|Investigational Site Number 1252, Durham, North Carolina, United States|Investigational Site Number 1214, Nashville, Tennessee, United States|Investigational Site Number 5246, El Paso, Texas, United States|Investigational Site Number 3321, Nantes Saint Herblain, France|Investigational Site Number 3324, Paris Cedex 05, France|Investigational Site Number 3415, Barcelona, Spain|Investigational Site Number 3419, Barcelona, Spain|Investigational Site Number 3413, Madrid, Spain|Investigational Site Number 3420, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT01082068"
144,"NCT01673737","A Phase I/Ib Trial for the Evaluation of SAR260301 in Monotherapy or in Combination With Vemurafenib in Patients With Various Advanced Cancer",,"Completed","No Results Available","Neoplasm Malignant","Drug: SAR260301|Drug: Vemurafenib","Maximal tolerated dose (MTD) of SAR260301 in monotherapy (Study Part A)|Maximal tolerated dose (MTD) of SAR260301 in combination with vemurafenib (Study Part B)|Number of patients with treatment emergent events|Assessment of PK parameters for SAR260301 and vemurafenib, including tmax, Cmax, AUC, Rac (Day 28/Day1), half-life, CL, Ctrough|Assessment of PK parameters for SAR260301 including tmax, Cmax, AUC fasting and fed (food effect)(Only part A)|Assessment of urine excretion of SAR2690301 (Part A)|Assessment of potential for CYP induction (4beta-hydroxycholesterol)(Part A)|Assessment of PK parameter Rac (Day 28/Day 1) on AUC and Cmax|Assessment of PD parameter Serine/threonine protein kinase Akt (AKT) phosphorylation in blood platelets|Assessment of PD parameter AKT phosphorylation in tumor (expansion phase only)|Assessment of preliminary antitumor activity as documented by tumor response (defined by RECIST1.1 criteria for solid tumors, international working group (IWG) and revised response for lymphomas, and tumor markers when relevant)","Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 1","75","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TCD12739|U1111-1129-2696","August 2012","February 2015","February 2015","August 28, 2012",,"April 10, 2015","Investigational Site Number 840001, Boston, Massachusetts, United States|Investigational Site Number 840101, Boston, Massachusetts, United States|Investigational Site Number 840002, Houston, Texas, United States|Investigational Site Number 124001, Toronto, Canada",,"https://ClinicalTrials.gov/show/NCT01673737"
145,"NCT01523171","Phase II, Open Label, Single Arm Study of SAR302503 In Myelofibrosis Patients Previously Treated With Ruxolitinib","JAKARTA2","Completed","No Results Available","Hematopoietic Neoplasm","Drug: SAR302503","Response Rate (RR), defined as the proportion of subjects who have a ≥35% reduction from baseline in volume of spleen at the end of Cycle 6 as measured by Magnetic Resonance Imaging (MRI) (or CT scan in subjects with contraindications for MRI)|Symptom Response Rate (SRR): Proportion of subjects with a ≥50% reduction from baseline to the end of Cycle 6 in the total symptom score using the modified MFSAF|Duration of spleen response, measured by MRI (or CT scan in subjects with contraindications for MRI)|Proportion of subjects with a ≥50% reduction in length of spleen by palpation from baseline at the end of Cycle 6|Response Rate at the end of Cycle 3, defined as the proportion of subjects who have a ≥35% reduction from baseline in volume of spleen at the end of Cycle 3 as measured by MRI (or CT scan in subjects with contraindications for MRI)|Percent change of spleen volume at the end of Cycles 3 and 6 from baseline as measured by MRI (or CT scan in subjects with contraindications for MRI)|Safety, as assessed by clinical, laboratory, ECG, and vital sign events; graded by the NCI CTCAE v4.03|Plasma concentrations of SAR302503|The effect of SAR302503 on the JAK2V617F allele burden","Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 2","97","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ARD12181|2011-005226-21|U1111-1124-0967","April 2012","April 2014","April 2014","February 1, 2012",,"March 17, 2016","Investigational Site Number 840007, Phoenix, Arizona, United States|Investigational Site Number 840003, San Francisco, California, United States|Investigational Site Number 840004, San Francisco, California, United States|Investigational Site Number 840005, Atlanta, Georgia, United States|Investigational Site Number 840014, Chicago, Illinois, United States|Investigational Site Number 840001, Kansas City, Kansas, United States|Investigational Site Number 840017, Baltimore, Maryland, United States|Investigational Site Number 840013, Baltimore, Maryland, United States|Investigational Site Number 840010, Ann Arbor, Michigan, United States|Investigational Site Number 840009, New York, New York, United States|Investigational Site Number 840018, New York, New York, United States|Investigational Site Number 840022, Cleveland, Ohio, United States|Investigational Site Number 840019, Middletown, Ohio, United States|Investigational Site Number 840024, Charleston, South Carolina, United States|Investigational Site Number 840002, Houston, Texas, United States|Investigational Site Number 840015, Salt Lake City, Utah, United States|Investigational Site Number 040002, Salzburg, Austria|Investigational Site Number 040001, Wien, Austria|Investigational Site Number 056002, Antwerpen, Belgium|Investigational Site Number 056003, Leuven, Belgium|Investigational Site Number 124001, Toronto, Canada|Investigational Site Number 250001, Marseille, France|Investigational Site Number 250003, Nimes Cedex 9, France|Investigational Site Number 250002, Paris Cedex 10, France|Investigational Site Number 250006, Paris Cedex 12, France|Investigational Site Number 250004, Toulouse, France|Investigational Site Number 276003, Frankfurt Am Main, Germany|Investigational Site Number 276007, Leipzig, Germany|Investigational Site Number 276006, Magdeburg, Germany|Investigational Site Number 276001, Mannheim, Germany|Investigational Site Number 276005, Ulm, Germany|Investigational Site Number 380004, Firenze, Italy|Investigational Site Number 380001, Milano, Italy|Investigational Site Number 380002, Roma, Italy|Investigational Site Number 380003, Varese, Italy|Investigational Site Number 528002, Amsterdam, Netherlands|Investigational Site Number 528003, Maastricht, Netherlands|Investigational Site Number 528001, Nijmegen, Netherlands|Investigational Site Number 724001, Barcelona, Spain|Investigational Site Number 724003, Majadahonda, Spain|Investigational Site Number 724002, Salamanca, Spain|Investigational Site Number 826001, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01523171"
146,"NCT00704080","A Study of XL765 (SAR245409) in Combination With Temozolomide With and Without Radiation in Adults With Malignant Gliomas",,"Completed","No Results Available","Mixed Gliomas|Malignant Gliomas|Glioblastoma Multiforme","Drug: XL765 (SAR245409)|Drug: Temozolomide","Safety, tolerability, and maximum tolerated dose of XL765 administered in combination with temozolomide in subjects with anaplastic gliomas or glioblastoma currently stable on a maintenance temozolomide dose|To evaluate plasma pharmacokinetics and pharmacodynamic effects of XL765 and temozolomide when administered in combination|To evaluate preliminary efficacy of XL765 in combination with temozolomide in adults with anaplastic gliomas or glioblastoma","Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 1","54","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TED11441|XL765-002","August 2008","February 2012","February 2013","June 24, 2008",,"April 10, 2013","Investigational Site Number, Birmingham, Alabama, United States|Investigational Site Number, Los Angeles, California, United States|Investigational Site Number, Boston, Massachusetts, United States|Investigational Site Number, New York, New York, United States|Investigational Site Number, Rochester, New York, United States|Investigational Site Number, Cleveland, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT00704080"
147,"NCT01443650","Injection Site Tolerability, Safety, Pharmacokinetics, Pharmacodynamics in Different Single-Dose Treatments of Alirocumab SAR236553 (REGN727) in Healthy Subjects",,"Completed","No Results Available","Hypercholesterolemia","Drug: alirocumab SAR236553 (REGN727)","Pain using Present Pain Intensity (PPI) verbal questionnaire and Visual Analog Scale (VAS)|Erythema at injection site by measuring diameter and qualitative assessment|Edema at injection site by measuring diameter and qualitative assessment|Assessment of PK parameter - time to maximum concentration (tmax)|Pharmacodynamics: Change in LDL-C from baseline|Number of participants with Adverse Events|Assessment of PK parameter - maximum concentration (Cmax)|Assessment of PK parameter - area under curve (AUC)|Assessment of PK parameter - area under curve versus time curve (AUC0-D29)|Assessment of PK parameter - plasma concentration on Day 29 (C D29)|Assessment of PK parameter - terminal elimination half-life (t1/2z)","Sanofi|Regeneron Pharmaceuticals","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","36","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","PKD12275|U1111-1120-0670","July 2011","November 2011","November 2011","September 30, 2011",,"June 28, 2013","Sanofi-Aventis Administrative Office, Bridgewater, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT01443650"
148,"NCT01061736","Evaluation of Sarilumab (SAR153191/REGN88) on Top of Methotrexate in Rheumatoid Arthritis Patients","RA-MOBILITY","Completed","Has Results","Rheumatoid Arthritis","Drug: Sarilumab|Drug: Placebo (for sarilumab)|Drug: Methotrexate|Drug: Folic Acid","Part A: Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Week 12|Part B: Percentage of Participants Achieving ACR20 Response at Week 24|Part B: Change From Baseline in Health Assessment Question Disability Index (HAQ-DI) at Week 16|Part B: Change From Baseline in Van Der Heijde Modified Total Sharp Score (mTSS) at Week 52|Part B: Percentage of Participants Achieving a Major Clinical Response at Week 52","Sanofi|Regeneron Pharmaceuticals","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2|Phase 3","1675","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","EFC11072|2009-016266-90","March 2010","October 2013","October 2013","February 3, 2010","June 28, 2017","June 28, 2017","Investigational Site Number 840070, Anniston, Alabama, United States|Investigational Site Number 840004, Birmingham, Alabama, United States|Investigational Site Number 840072, Gilbert, Arizona, United States|Investigational Site Number 840029, Beverly Hills, California, United States|Investigational Site Number 840007, Palm Desert, California, United States|Investigational Site Number 840008, San Francisco, California, United States|Investigational Site Number 840021, Santa Maria, California, United States|Investigational Site Number 840049, Upland, California, United States|Investigational Site Number 840050, Dunedin, Florida, United States|Investigational Site Number 840041, Jacksonville, Florida, United States|Investigational Site Number 840067, Jupiter, Florida, United States|Investigational Site Number 840048, Miami, Florida, United States|Investigational Site Number 840006, Orlando, Florida, United States|Investigational Site Number 840063, Palm Harbor, Florida, United States|Investigational Site Number 840060, Sarasota, Florida, United States|Investigational Site Number 840003, Atlanta, Georgia, United States|Investigational Site Number 840028, Decatur, Georgia, United States|Investigational Site Number 840027, Marietta, Georgia, United States|Investigational Site Number 840018, Idaho Falls, Idaho, United States|Investigational Site Number 840046, Chicago, Illinois, United States|Investigational Site Number 840015, Lexington, Kentucky, United States|Investigational Site Number 840073, Cumberland, Maryland, United States|Investigational Site Number 840055, Frederick, Maryland, United States|Investigational Site Number 840013, Wheaton, Maryland, United States|Investigational Site Number 840066, Saint Louis, Missouri, United States|Investigational Site Number 840071, Omaha, Nebraska, United States|Investigational Site Number 840056, New York, New York, United States|Investigational Site Number 840068, Hickory, North Carolina, United States|Investigational Site Number 840044, Toledo, Ohio, United States|Investigational Site Number 840002, Oklahoma City, Oklahoma, United States|Investigational Site Number 840011, Tulsa, Oklahoma, United States|Investigational Site Number 840065, Tulsa, Oklahoma, United States|Investigational Site Number 840010, Bethlehem, Pennsylvania, United States|Investigational Site Number 840009, Duncansville, Pennsylvania, United States|Investigational Site Number 840062, Reading, Pennsylvania, United States|Investigational Site Number 840058, Columbia, South Carolina, United States|Investigational Site Number 840016, North Charleston, South Carolina, United States|Investigational Site Number 840025, Jackson, Tennessee, United States|Investigational Site Number 840001, Dallas, Texas, United States|Investigational Site Number 840022, Dallas, Texas, United States|Investigational Site Number 840012, Dallas, Texas, United States|Investigational Site Number 840020, Houston, Texas, United States|Investigational Site Number 840069, Lubbock, Texas, United States|Investigational Site Number 840074, Mesquite, Texas, United States|Investigational Site Number 840061, Tacoma, Washington, United States|Investigational Site Number 032005, Buenos Aires, Argentina|Investigational Site Number 032007, Buenos Aires, Argentina|Investigational Site Number 032008, Buenos Aires, Argentina|Investigational Site Number 032006, Caba, Argentina|Investigational Site Number 032002, Cordoba, Argentina|Investigational Site Number 032003, Córdoba, Argentina|Investigational Site Number 032012, Mar Del Plata, Argentina|Investigational Site Number 032011, Quilmes, Argentina|Investigational Site Number 032010, Ramos Mejia, Argentina|Investigational Site Number 032001, Rosario, Argentina|Investigational Site Number 032004, Tucuman, Argentina|Investigational Site Number 032009, Zarate, Argentina|Investigational Site Number 036003, Camperdown, Australia|Investigational Site Number 036005, Clayton, Australia|Investigational Site Number 036002, East Malvern, Australia|Investigational Site Number 036012, Fitzroy, Australia|Investigational Site Number 036010, Garran, Australia|Investigational Site Number 036004, Heidelberg West, Australia|Investigational Site Number 036009, Herston, Australia|Investigational Site Number 036001, Maroochydore, Australia|Investigational Site Number 036006, St Leonards, Australia|Investigational Site Number 036011, Sydney, Australia|Investigational Site Number 036014, Victoria Park, Australia|Investigational Site Number 036007, Woodville, Australia|Investigational Site Number 040001, Graz, Austria|Investigational Site Number 040002, Wien, Austria|Investigational Site Number 112002, Minsk, Belarus|Investigational Site Number 112001, Minsk, Belarus|Investigational Site Number 056003, Genk, Belgium|Investigational Site Number 056001, Liège, Belgium|Investigational Site Number 076008, Campinas, Brazil|Investigational Site Number 076012, Campinas, Brazil|Investigational Site Number 076001, Curitiba, Brazil|Investigational Site Number 076006, Goiania, Brazil|Investigational Site Number 076010, Juiz De Fora, Brazil|Investigational Site Number 076004, Porto Alegre, Brazil|Investigational Site Number 076005, Rio De Janeiro, Brazil|Investigational Site Number 076011, Salvador, Brazil|Investigational Site Number 076002, Sao Paulo, Brazil|Investigational Site Number 076003, Sao Paulo, Brazil|Investigational Site Number 076013, Vitoria, Brazil|Investigational Site Number 124004, Burlington, Canada|Investigational Site Number 124003, Mississauga, Canada|Investigational Site Number 124008, Newmarket, Canada|Investigational Site Number 124002, St. Catharines, Canada|Investigational Site Number 124005, Toronto, Canada|Investigational Site Number 124001, Toronto, Canada|Investigational Site Number 124012, Winnipeg, Canada|Investigational Site Number 152005, Osorno, Chile|Investigational Site Number 152010, Puerto Montt, Chile|Investigational Site Number 152012, Santiago, Chile|Investigational Site Number 152001, Santiago, Chile|Investigational Site Number 152002, Santiago, Chile|Investigational Site Number 152008, Santiago, Chile|Investigational Site Number 152009, Santiago, Chile|Investigational Site Number 152011, Santiago, Chile|Investigational Site Number 152013, Santiago, Chile|Investigational Site Number 152014, Talca, Chile|Investigational Site Number 152004, Valdivia, Chile|Investigational Site Number 152006, Vina Del Mar, Chile|Investigational Site Number 152007, Viña Del Mar, Chile|Investigational Site Number 170004, Barranquilla, Colombia|Investigational Site Number 170001, Bogota, Colombia|Investigational Site Number 170008, Bogota, Colombia|Investigational Site Number 170003, Bogotá, Colombia|Investigational Site Number 170006, Bogotá, Colombia|Investigational Site Number 170007, Bucaramanga, Colombia|Investigational Site Number 170009, Bucaramanga, Colombia|Investigational Site Number 170002, Medellin, Colombia|Investigational Site Number 203005, Brno, Czechia|Investigational Site Number 203004, Hlucin, Czechia|Investigational Site Number 203001, Praha 2, Czechia|Investigational Site Number 203002, Uherske Hradiste, Czechia|Investigational Site Number 818001, Cairo, Egypt|Investigational Site Number 818002, Cairo, Egypt|Investigational Site Number 233001, Tallinn, Estonia|Investigational Site Number 233002, Tallinn, Estonia|Investigational Site Number 246001, Helsinki, Finland|Investigational Site Number 246002, Hyvinkää, Finland|Investigational Site Number 246003, Pori, Finland|Investigational Site Number 276007, Berlin, Germany|Investigational Site Number 276008, Berlin, Germany|Investigational Site Number 276004, Erlangen, Germany|Investigational Site Number 276003, Frankfurt Am Main, Germany|Investigational Site Number 276015, Halle/Saale, Germany|Investigational Site Number 276005, Hamburg, Germany|Investigational Site Number 276013, Hamburg, Germany|Investigational Site Number 276012, Heidelberg, Germany|Investigational Site Number 276001, Herne, Germany|Investigational Site Number 276006, Hildesheim, Germany|Investigational Site Number 300001, Athens, Greece|Investigational Site Number 300002, Heraklion, Greece|Investigational Site Number 300003, Thessaloniki, Greece|Investigational Site Number 348006, Budapest, Hungary|Investigational Site Number 348014, Budapest, Hungary|Investigational Site Number 348003, Debrecen, Hungary|Investigational Site Number 348010, Debrecen, Hungary|Investigational Site Number 348011, Eger, Hungary|Investigational Site Number 348013, Gy?r, Hungary|Investigational Site Number 348015, Szombathely, Hungary|Investigational Site Number 348005, Sátoraljaújhely, Hungary|Investigational Site Number 348004, Veszprém, Hungary|Investigational Site Number 356015, Ahmedabad, India|Investigational Site Number 356007, Bangalore, India|Investigational Site Number 356003, Chennai, India|Investigational Site Number 356012, Hyderabad, India|Investigational Site Number 356005, Hyderabad, India|Investigational Site Number 356011, Lucknow, India|Investigational Site Number 356013, Lucknow, India|Investigational Site Number 356001, Maharashtra, India|Investigational Site Number 356010, Mumbai, India|Investigational Site Number 356004, Mumbai, India|Investigational Site Number 356002, New Delhi, India|Investigational Site Number 356008, New Delhi, India|Investigational Site Number 410014, Anyang, Korea, Republic of|Investigational Site Number 410006, Busan, Korea, Republic of|Investigational Site Number 410004, Daegu, Korea, Republic of|Investigational Site Number 410013, Daegu, Korea, Republic of|Investigational Site Number 410005, Daejeon, Korea, Republic of|Investigational Site Number 410010, Gwangju, Korea, Republic of|Investigational Site Number 410009, Incheon, Korea, Republic of|Investigational Site Number 410001, Incheon, Korea, Republic of|Investigational Site Number 410011, Jeonju, Korea, Republic of|Investigational Site Number 410007, Seoul, Korea, Republic of|Investigational Site Number 410012, Seoul, Korea, Republic of|Investigational Site Number 410003, Seoul, Korea, Republic of|Investigational Site Number 410002, Seoul, Korea, Republic of|Investigational Site Number 410008, Suwon, Korea, Republic of|Investigational Site Number 440001, Kaunas, Lithuania|Investigational Site Number 440002, Vilnius, Lithuania|Investigational Site Number 458001, Ipoh, Malaysia|Investigational Site Number 458002, Kuching, Malaysia|Investigational Site Number 458003, Putrajaya, Malaysia|Investigational Site Number 484008, Durango, Mexico|Investigational Site Number 484002, Guadalajara, Mexico|Investigational Site Number 484004, Merida, Mexico|Investigational Site Number 484009, Merida, Mexico|Investigational Site Number 484007, Metepec, Mexico|Investigational Site Number 484003, Mexico City, Mexico|Investigational Site Number 484001, Mexico, D.F., Mexico|Investigational Site Number 484005, Monterrey, Mexico|Investigational Site Number 528002, Heerlen, Netherlands|Investigational Site Number 554004, Christchurch, New Zealand|Investigational Site Number 554002, Rotorua, New Zealand|Investigational Site Number 554003, Tauranga, New Zealand|Investigational Site Number 554001, Timaru, New Zealand|Investigational Site Number 578004, Kristiansand, Norway|Investigational Site Number 578006, Tønsberg, Norway|Investigational Site Number 608003, Cebu City, Philippines|Investigational Site Number 608001, Manila, Philippines|Investigational Site Number 608002, Manila, Philippines|Investigational Site Number 616002, Bialystok, Poland|Investigational Site Number 616003, Bialystok, Poland|Investigational Site Number 616001, Krakow, Poland|Investigational Site Number 616005, Lublin, Poland|Investigational Site Number 616006, Torun, Poland|Investigational Site Number 616004, Warszawa, Poland|Investigational Site Number 616012, Wroclaw, Poland|Investigational Site Number 620003, Aveiro, Portugal|Investigational Site Number 620001, Lisboa, Portugal|Investigational Site Number 620002, Lisboa, Portugal|Investigational Site Number 642006, Braila, Romania|Investigational Site Number 642004, Bucharest, Romania|Investigational Site Number 642010, Bucharest, Romania|Investigational Site Number 642001, Bucuresti, Romania|Investigational Site Number 642002, Bucuresti, Romania|Investigational Site Number 642003, Bucuresti, Romania|Investigational Site Number 642005, Galati, Romania|Investigational Site Number 642008, Ploiesti, Romania|Investigational Site Number 643017, Kemerovo, Russian Federation|Investigational Site Number 643006, Kemerovo, Russian Federation|Investigational Site Number 643004, Moscow, Russian Federation|Investigational Site Number 643020, Moscow, Russian Federation|Investigational Site Number 643001, Moscow, Russian Federation|Investigational Site Number 643002, Moscow, Russian Federation|Investigational Site Number 643012, Moscow, Russian Federation|Investigational Site Number 643009, Novosibirsk, Russian Federation|Investigational Site Number 643016, Ryazan, Russian Federation|Investigational Site Number 643014, Saint-Petersburg, Russian Federation|Investigational Site Number 643010, Samara, Russian Federation|Investigational Site Number 643011, Saratov, Russian Federation|Investigational Site Number 643007, St-Petersburg, Russian Federation|Investigational Site Number 643008, St-Petersburg, Russian Federation|Investigational Site Number 643013, Ufa, Russian Federation|Investigational Site Number 710011, Cape Town, South Africa|Investigational Site Number 710007, Cape Town, South Africa|Investigational Site Number 710009, Cape Town, South Africa|Investigational Site Number 710003, Durban, South Africa|Investigational Site Number 710002, Durban, South Africa|Investigational Site Number 710001, Johannesburg, South Africa|Investigational Site Number 710004, Kempton Park, South Africa|Investigational Site Number 710005, Pretoria, South Africa|Investigational Site Number 710006, Pretoria, South Africa|Investigational Site Number 710008, Pretoria, South Africa|Investigational Site Number 710010, Stellenbosch, South Africa|Investigational Site Number 724010, Barcelona, Spain|Investigational Site Number 724009, La Coruña, Spain|Investigational Site Number 724011, Sabadell, Spain|Investigational Site Number 724012, Santiago De Compostela, Spain|Investigational Site Number 724007, Sevilla, Spain|Investigational Site Number 158002, Linkou, Taiwan|Investigational Site Number 158001, Taipei, Taiwan|Investigational Site Number 764001, Bangkok, Thailand|Investigational Site Number 764003, Bangkok, Thailand|Investigational Site Number 792003, Adana, Turkey|Investigational Site Number 792002, Ankara, Turkey|Investigational Site Number 792005, Ankara, Turkey|Investigational Site Number 792004, Antalya, Turkey|Investigational Site Number 792001, Izmir, Turkey|Investigational Site Number 804003, Dnipropetrovsk, Ukraine|Investigational Site Number 804002, Donetsk, Ukraine|Investigational Site Number 804010, Kharkov, Ukraine|Investigational Site Number 804008, Kyiv, Ukraine|Investigational Site Number 804004, Kyiv, Ukraine|Investigational Site Number 804005, Lviv, Ukraine|Investigational Site Number 804006, Simferopol, Ukraine|Investigational Site Number 804009, Zaporizhzhia, Ukraine",,"https://ClinicalTrials.gov/show/NCT01061736"
149,"NCT01204125","Two Regimens of SAR240550/Weekly Paclitaxel and Paclitaxel Alone as Neoadjuvant Therapy in Triple Negative Breast Cancer Patients","SOLTI NEOPARP","Completed","No Results Available","Breast Cancer Female","Drug: paclitaxel|Drug: Iniparib (SAR2405550 -BSI-201)","Pathological Complete Response (pCR) rate defined as the complete absence of invasive carcinoma on histological examination of the breast at the time of definitive surgery and confirmed by blinded centralized review|Pathological Complete Response (pCR) rate in the breast and axilla|Objective Response Rate(ORR) defined in the Response Evaluation Criteria in Solid Tumors (RECIST 1.1) as complete response rate + partial response rate|Breast conservation rate|Disease Free Survival rate (DFS)|Overall Survival (OS)|Safety parameters (number of patients AE, SAE or AEPM)|Molecular-biological testing","Sanofi|SOLTI Breast Cancer Research Group","Female","18 Years and older   (Adult, Older Adult)","Phase 2","141","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TCD11419|2010-018960-17","September 2010","October 2012","February 2017","September 17, 2010",,"March 22, 2017","Investigational Site Number 250001, Besancon Cedex, France|Investigational Site Number 250004, Bordeaux, France|Investigational Site Number 250006, Bron Cedex, France|Investigational Site Number 250003, Paris Cedex 10, France|Investigational Site Number 250002, Toulouse, France|Investigational Site Number 250005, Villejuif, France|Investigational Site Number 276003, Erlangen, Germany|Investigational Site Number 276004, Hamburg, Germany|Investigational Site Number 276002, Köln, Germany|Investigational Site Number 276001, Mönchengladbach, Germany|Investigational Site Number 724001, Barcelona, Spain|Investigational Site Number 724009, Cáceres, Spain|Investigational Site Number 724013, Córdoba, Spain|Investigational Site Number 724006, Islas Baleares, Spain|Investigational Site Number 724012, Jaén, Spain|Investigational Site Number 724002, Lérida, Spain|Investigational Site Number 724005, Madrid, Spain|Investigational Site Number 724016, Madrid, Spain|Investigational Site Number 724007, Reus, Spain|Investigational Site Number 724018, Santiago De Compostela, Spain|Investigational Site Number 724017, Sevilla, Spain|Investigational Site Number 724010, Sevilla, Spain|Investigational Site Number 724003, Torrevieja, Spain|Investigational Site Number 724011, Valencia, Spain|Investigational Site Number 724015, Valencia, Spain",,"https://ClinicalTrials.gov/show/NCT01204125"
150,"NCT01410513","Study Combining SAR245409 With Rituximab or Bendamustine Plus Rituximab in Patients With Indolent Lymphoma, Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia",,"Completed","No Results Available","Indolent Non-Hodgkin Lymphoma|Mantle Cell Lymphoma|Chronic Lymphocytic Leukemia","Drug: SAR245409","Identification Of Dose-Limiting Toxicity (DLT) and Maximum Tolerated Dose (MTD)|Number of subjects with treatment emergent adverse events|Pharmacokinetics (Cmax) of SAR245409|Pharmacokinetics (tmax) of SAR245409|Pharmacokinetics (AUC0-12h) of SAR245409|Pharmacokinetics (Ctrough) of SAR245409|Pharmacokinetics (AUC) of bendamustine|Pharmacokinetics (AUClast) of bendamustine|Pharmacokinetics (Ceoi) of bendamustine|Pharmacokinetics (tmax) of bendamustine|Pharmacokinetics (Cl) of bendamustine|Pharmacokinetics (Vss) of bendamustine|Pharmacokinetics (AUC0-7h) of rituximab|Pharmacokinetics (Ceoi) of rituximab|Pharmacokinetics (tmax) of rituximab|Efficacy as determined by objective response rate (ORR)","Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 1","37","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TCD12012|U1111-1119-2906","December 2011","May 2014","May 2014","August 5, 2011",,"April 1, 2016","Investigational Site Number 840004, Aurora, Colorado, United States|Investigational Site Number 840006, Augusta, Georgia, United States|Investigational Site Number 840002, Charleston, South Carolina, United States",,"https://ClinicalTrials.gov/show/NCT01410513"
151,"NCT01709513","Study of Alirocumab (REGN727/SAR236553) in Patients With Primary Hypercholesterolemia and Moderate, High, or Very High Cardiovascular (CV) Risk, Who Are Intolerant to Statins (ODYSSEY ALTERNATIVE)",,"Completed","Has Results","Hypercholesterolemia","Drug: Atorvastatin|Drug: Ezetimibe|Drug: Alirocumab|Drug: Placebo","Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent--To-Treat (ITT) Analysis|Percent Change From Baseline in Calculated LDL-C at Week 24 - On--Treatment Analysis|Percent Change From Baseline in Calculated LDL--C at Week 12 -- ITT Analysis|Percent Change From Baseline in Calculated LDL-C at Week 12 - On--Treatment Analysis|Percent Change From Baseline in Apolipoprotein (Apo) B at Week 24 -- ITT Analysis|Percent Change From Baseline in Apo B at Week 24 -- On--Treatment Analysis|Percent Change From Baseline in Non--High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 24 -- ITT Analysis|Percent Change From Baseline in Non--HDL-C at Week 24 -- On--Treatment Analysis|Percent Change From Baseline in Total Cholesterol (Total--C) at Week 24 - ITT Analysis|Percent Change From Baseline in Apo B at Week 12 -- ITT Analysis|Percent Change From Baseline in Non-HDL-C at Week 12 - ITT Analysis|Percent Change From Baseline in Total-C at Week 12 - ITT Analysis|Percentage of Very High CV Risk Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) or Moderate or High CV Risk Participants Reaching Calculated LDL-C <100 mg/dL (2.59 mmol/L) at Week 24 - ITT Analysis|Percentage of Very High CV Risk Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) or Moderate or High CV Risk Participants Reaching Calculated LDL-C <100 mg/dL (2.59 mmol/L) at Week 24 - On-Treatment Analysis|Percentage of Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - ITT Analysis|Percentage of Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - On-Treatment Analysis|Percent Change From Baseline in Lipoprotein(a) at Week 24 - ITT Analysis|Percent Change From Baseline in HDL-C at Week 24 - ITT Analysis|Percent Change From Baseline in Fasting Triglycerides at Week 24 - ITT Analysis|Percent Change From Baseline in Apo A-1 at Week 24 - ITT Analysis|Percent Change From Baseline in Lipoprotein(a) at Week 12 -- ITT Analysis|Percent Change in HDL-C From Baseline to Week 12 -- ITT Analysis|Percent Change in Fasting Triglycerides From Baseline to Week 12 -- ITT Analysis|Percent Change From Baseline in Apo A--1 at Week 12 -- ITT Analysis","Regeneron Pharmaceuticals|Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 3","314","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","R727-CL-1119","September 2012","May 2014","May 2017","October 18, 2012","August 28, 2015","August 28, 2017","Anaheim, California, United States|Beverly Hills, California, United States|Mission Viejo, California, United States|Newport Beach, California, United States|Northridge, California, United States|Thousand Oaks, California, United States|Hartford, Connecticut, United States|Boynton Beach, Florida, United States|Jacksonville, Florida, United States|Lakeland, Florida, United States|Pembroke Pines, Florida, United States|Sarasota, Florida, United States|Tampa, Florida, United States|Trinity, Florida, United States|Addison, Illinois, United States|Chicago, Illinois, United States|Indianapolis, Indiana, United States|Kansas City, Kansas, United States|Auburn, Maine, United States|Boston, Massachusetts, United States|Minneapolis, Minnesota, United States|Rochester, Minnesota, United States|Saint Louis, Missouri, United States|Clifton, New Jersey, United States|New York, New York, United States|Poughkeepsie, New York, United States|Durham, North Carolina, United States|Cincinnati, Ohio, United States|Marion, Ohio, United States|Danville, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Port Matilda, Pennsylvania, United States|Scranton, Pennsylvania, United States|Wilkes-Barre, Pennsylvania, United States|Summerville, South Carolina, United States|Kingsport, Tennessee, United States|Nashville, Tennessee, United States|Dallas, Texas, United States|Fort Worth, Texas, United States|Salt Lake City, Utah, United States|Richmond, Virginia, United States|Feldkirch, Austria|Graz, Austria|Innsbruck, Austria|Chicoutimi, Quebec, Canada|Montreal (2 locations), Quebec, Canada|Sainte-Foy, Quebec, Canada|Bron, France|Dijon, France|Lille, France|Paris, France|Saint-Herblain, France|Venissieux, France|Holon, Israel|Jerusalem, Israel|Ofakim, Israel|Safed, Israel|Tel-Hashomer, Israel|Cinisello Balsamo, Italy|Napoli, Italy|Palermo, Italy|Roma, Italy|Oslo (2 locations), Norway|Burton-on-Trent, United Kingdom|Chesterfield, United Kingdom|Isle of White, United Kingdom|Londonderry/N. Ireland, United Kingdom|Peterborough, United Kingdom|Salford, United Kingdom|Stevenage, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01709513"
152,"NCT01485302","Single and Repeated Dosing Study to Assess the Safety and the Concentration-time Profile of SAR228810 in Alzheimer's Patients",,"Completed","No Results Available","Alzheimer's Disease","Drug: SAR228810","number of patients with adverse events|AUC|Cmax|t1/2z|brain magnetic resonance imaging|hematology, biochemistry, coagulation|vital signs, ECG","Sanofi","All","50 Years to 85 Years   (Adult, Older Adult)","Phase 1","48","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","TDR12399|2011-002910-35|U1111-1120-0550","January 2012","February 2015","February 2015","December 5, 2011",,"March 25, 2015","Investigational Site Number 100001, Sofia, Bulgaria|Investigational Site Number 250001, Pierre Bénite, France|Investigational Site Number 250002, Toulouse Cedex 3, France|Investigational Site Number 528001, Leiden, Netherlands|Investigational Site Number 710001, Bloemfontein, South Africa|Investigational Site Number 752003, Malmö, Sweden|Investigational Site Number 752002, Mölndal, Sweden|Investigational Site Number 752001, Stockholm, Sweden",,"https://ClinicalTrials.gov/show/NCT01485302"
153,"NCT00070707","Nasonex Compared With Placebo in Participants With Seasonal Allergic Rhinitis (SAR) and Concomitant Asthma (P03280)",,"Completed","Has Results","Rhinitis, Allergic, Seasonal|Asthma","Drug: Mometasone|Drug: Placebo|Drug: Albuterol/Salbutamol","Change From Baseline in Morning (AM) and Evening (PM) Total Asthma Symptom Severity (TASS)|Change From Baseline in AM and PM Cough Symptom Score|Change From Baseline in AM and PM Wheeze Symptom Score|Change From Baseline in AM and PM Difficulty Breathing Symptom Score|Change From Baseline in AM and PM Chest Tightness Symptom Score|Change From Baseline in Pulmonary Auscultation/Wheezing Assessment|Change From Baseline in AM and PM Total Nasal Symptom Severity (TNSS)|Change From Baseline in AM and PM Rhinorrhea Symptom Score|Change From Baseline in AM and PM Nasal Itching Symptom Score|Change From Baseline in AM and PM Nasal Sneezing Symptom Score|Change From Baseline in AM and PM Nasal Congestion Symptom Score|Change From Baseline in AM and PM Peak Expiratory Flow Rate (PEFR)|Change From Baseline in Forced Expiratory Volume in One Second (FEV1)|Change From Baseline in Forced Vital Capacity (FVC)|Change From Baseline in Forced Expiratory Flow (FEF) Between 25% and 75% of the Vital Capacity (FEF25%-75%)|Change From Baseline in the Weekly Average Number of Puffs of Albuterol/Salbutamol Used|Change From Baseline in Weekly Average Nighttime Awakenings Due to Asthma|Change From Baseline in Weekly Average Interference With Sleep|Change From Baseline in Weekly Average Interference With Daily Activities|Therapeutic Response to Asthma Symptoms|Therapeutic Response to SAR Nasal Symptoms","Merck Sharp & Dohme Corp.|Integrated Therapeutics Group","All","15 Years to 75 Years   (Child, Adult, Older Adult)","Phase 4","188","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","P03280|MK-0887-064","April 3, 2003","November 26, 2003","November 26, 2003","October 10, 2003","July 18, 2019","July 18, 2019",,,"https://ClinicalTrials.gov/show/NCT00070707"
154,"NCT00882687","Efficacy Study to Evaluate the Effectiveness of 3 Concentrations of SAR 1118 in Allergic Conjunctivitis",,"Completed","Has Results","Allergic Conjunctivitis","Drug: Lifitegrast|Other: Placebo","Ocular Itching at Day 7 (7 Minutes Post Conjunctival Allergen Challenge [CAC 6])|Ocular Itching at Day 14 (7 Minutes Post CAC 9)|Conjunctival Redness at Day 7 (20 Minutes Post CAC 6)|Conjunctival Redness at Day 14 (20 Minutes Post CAC 9)|Ocular Itching at Day 6 (CAC 4), 5 (CAC 7)|Conjunctival Redness at Day 6 (CAC 4), 5 (CAC 7)","Shire","All","18 Years and older   (Adult, Older Adult)","Phase 2","60","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","1118-ACJ-100","April 2009","May 2009","May 2009","April 16, 2009","February 24, 2017","February 24, 2017","Ora, Andover, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT00882687"
155,"NCT01644188","Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Ezetimibe on Top of Statin in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY COMBO II)",,"Completed","Has Results","Hypercholesterolemia","Drug: Alirocumab|Drug: Placebo (for alirocumab)|Drug: Ezetimibe|Drug: Placebo (for ezetimibe)|Drug: Lipid Modifying Therapy (LMT)","Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent-to-treat (ITT) Analysis|Percent Change From Baseline in Calculated LDL--C at Week 24 - On--Treatment Analysis|Percent Change From Baseline in Calculated LDL-C at Week 12 - ITT Analysis|Percent Change From Baseline in Calculated LDL-C at Week 12 - On-Treatment Analysis|Percent Change From Baseline in Apolipoprotein B (Apo-B) at Week 24 - ITT Analysis|Percent Change From Baseline in Apo B at Week 24 - On-Treatment Analysis|Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 24 - ITT Analysis|Percent Change From Baseline in Non-HDL-C at Week 24 - On-Treatment Analysis|Percent Change From Baseline in Total Cholesterol (Total-C) at Week 24 - ITT Analysis|Percent Change From Baseline in Apo-B at Week 12 - ITT Analysis|Percent Change From Baseline in Non-HDL-C at Week 12 - ITT Analysis|Percent Change From Baseline in Total-C at Week 12 - ITT Analysis|Percent Change From Baseline in Calculated LDL-C at Week 52 - ITT Analysis|Percentage of Participants Achieving Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - ITT Analysis|Percentage of Participants Achieving Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - On-Treatment Analysis|Percent Change From Baseline in Lipoprotein(a) at Week 24 - ITT Analysis|Percent Change From Baseline in HDL-C at Week 24 - ITT Analysis|Percent Change From Baseline in Fasting Triglycerides at Week 24 - ITT Analysis|Percent Change From Baseline in Apolipoprotein A-1 (Apo A-1) at Week 24 - ITT Analysis|Percent Change From Baseline in Lipoprotein(a) at Week 12 - ITT Analysis|Percent Change From Baseline in HDL-C at Week 12 - ITT Analysis|Percent Change From Baseline in Fasting Triglycerides at Week 12 - ITT Analysis|Percent Change From Baseline in Apo A-1 at Week 12 - ITT Analysis","Sanofi|Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 3","720","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","EFC11569|U1111-1121-4315|2011-004130-34","August 2012","May 2014","July 2015","July 18, 2012","November 6, 2015","August 4, 2016","Investigational Site Number 840980, Birmingham, Alabama, United States|Investigational Site Number 840918, Phoenix, Arizona, United States|Investigational Site Number 840925, Tucson, Arizona, United States|Investigational Site Number 840959, Anaheim, California, United States|Investigational Site Number 840301, Beverly Hills, California, United States|Investigational Site Number 840933, Chino, California, United States|Investigational Site Number 840991, Lincoln, California, United States|Investigational Site Number 840979, Los Angeles, California, United States|Investigational Site Number 840952, Palm Springs, California, United States|Investigational Site Number 840930, Thousand Oaks, California, United States|Investigational Site Number 840921, Vista, California, United States|Investigational Site Number 840962, Boynton Beach, Florida, United States|Investigational Site Number 840987, Bradenton, Florida, United States|Investigational Site Number 840302, Clearwater, Florida, United States|Investigational Site Number 840935, Jacksonville, Florida, United States|Investigational Site Number 840903, Miami, Florida, United States|Investigational Site Number 840920, Miami, Florida, United States|Investigational Site Number 840943, Ocala, Florida, United States|Investigational Site Number 840981, Oveido, Florida, United States|Investigational Site Number 840961, Port Orange, Florida, United States|Investigational Site Number 840303, Sarasota, Florida, United States|Investigational Site Number 840986, St. Petersburg, Florida, United States|Investigational Site Number 840988, St. Petersburg, Florida, United States|Investigational Site Number 840995, Meridian, Idaho, United States|Investigational Site Number 840902, Evansville, Indiana, United States|Investigational Site Number 840960, Topeka, Kansas, United States|Investigational Site Number 840940, Oxon Hill, Maryland, United States|Investigational Site Number 840966, Fall River, Massachusetts, United States|Investigational Site Number 840917, Kansas City, Missouri, United States|Investigational Site Number 840998, St. Louis, Missouri, United States|Investigational Site Number 840946, Butte, Montana, United States|Investigational Site Number 840914, Lincoln, Nebraska, United States|Investigational Site Number 840949, Albuquerque, New Mexico, United States|Investigational Site Number 840974, New Windsor, New York, United States|Investigational Site Number 840955, Greenville, North Carolina, United States|Investigational Site Number 840938, Lexington, North Carolina, United States|Investigational Site Number 840976, Smithfield, North Carolina, United States|Investigational Site Number 840985, Winston-Salem, North Carolina, United States|Investigational Site Number 840963, Cincinnati, Ohio, United States|Investigational Site Number 840970, Lyndhust, Ohio, United States|Investigational Site Number 840906, Marion, Ohio, United States|Investigational Site Number 840997, Marion, Ohio, United States|Investigational Site Number 840964, Perrysburg, Ohio, United States|Investigational Site Number 840913, Charleston, South Carolina, United States|Investigational Site Number 840912, Greer, South Carolina, United States|Investigational Site Number 840992, Summerville, South Carolina, United States|Investigational Site Number 840932, Bristol, Tennessee, United States|Investigational Site Number 840944, Nashville, Tennessee, United States|Investigational Site Number 840994, Fort Worth, Texas, United States|Investigational Site Number 840973, Houston, Texas, United States|Investigational Site Number 840939, Houston, Texas, United States|Investigational Site Number 840945, Sugar Land, Texas, United States|Investigational Site Number 840971, Tomball, Texas, United States|Investigational Site Number 840982, Orem, Utah, United States|Investigational Site Number 840931, Norfolk, Virginia, United States|Investigational Site Number 840984, Richmond, Virginia, United States|Investigational Site Number 840928, Renton, Washington, United States|Investigational Site Number 840990, Spokane, Washington, United States|Investigational Site Number 124902, Brampton, Canada|Investigational Site Number 124914, Mirabel, Canada|Investigational Site Number 124903, Montreal, Canada|Investigational Site Number 124918, Toronto, Canada|Investigational Site Number 208913, Esbjerg, Denmark|Investigational Site Number 208914, Glostrup, Denmark|Investigational Site Number 208905, Hellerup, Denmark|Investigational Site Number 208911, Herlev, Denmark|Investigational Site Number 208907, Hvidovre, Denmark|Investigational Site Number 208901, København S, Denmark|Investigational Site Number 208906, Køge, Denmark|Investigational Site Number 208908, Roskilde, Denmark|Investigational Site Number 208903, Silkeborg, Denmark|Investigational Site Number 250906, Dijon, France|Investigational Site Number 250907, Montpellier Cedex 5, France|Investigational Site Number 250903, Nantes, France|Investigational Site Number 250905, Nimes, France|Investigational Site Number 348908, Budapest, Hungary|Investigational Site Number 348901, Budapest, Hungary|Investigational Site Number 348903, Budapest, Hungary|Investigational Site Number 348905, Debrecen, Hungary|Investigational Site Number 348906, Szekesfehervar, Hungary|Investigational Site Number 376908, Holon, Israel|Investigational Site Number 376903, Kfar Saba, Israel|Investigational Site Number 376906, Ofakim, Israel|Investigational Site Number 376902, Petach Tikva, Israel|Investigational Site Number 376904, Rehovot, Israel|Investigational Site Number 376907, Safed, Israel|Investigational Site Number 376901, Tel Aviv, Israel|Investigational Site Number 410908, Anyang-Si, Korea, Republic of|Investigational Site Number 410920, Busan, Korea, Republic of|Investigational Site Number 410926, Daegu, Korea, Republic of|Investigational Site Number 410923, Gwangju, Korea, Republic of|Investigational Site Number 410909, Seoul, Korea, Republic of|Investigational Site Number 410922, Seoul, Korea, Republic of|Investigational Site Number 410921, Seoul, Korea, Republic of|Investigational Site Number 410905, Seoul, Korea, Republic of|Investigational Site Number 410901, Seoul, Korea, Republic of|Investigational Site Number 410914, Seoul, Korea, Republic of|Investigational Site Number 410924, Seoul, Korea, Republic of|Investigational Site Number 410915, Suwon, Korea, Republic of|Investigational Site Number 410913, Uijeongbu, Korea, Republic of|Investigational Site Number 410927, Wonju, Korea, Republic of|Investigational Site Number 643906, Barnaul, Russian Federation|Investigational Site Number 643903, Kemerovo, Russian Federation|Investigational Site Number 643927, Moscow, Russian Federation|Investigational Site Number 643928, Moscow, Russian Federation|Investigational Site Number 643931, Moscow, Russian Federation|Investigational Site Number 643924, Moscow, Russian Federation|Investigational Site Number 643932, Moscow, Russian Federation|Investigational Site Number 643908, Moscow, Russian Federation|Investigational Site Number 643904, Moscow, Russian Federation|Investigational Site Number 643911, Orenburg, Russian Federation|Investigational Site Number 643921, Ryazan, Russian Federation|Investigational Site Number 643925, Saint-Petersburg, Russian Federation|Investigational Site Number 643922, Saint-Petersburg, Russian Federation|Investigational Site Number 643929, Saratov, Russian Federation|Investigational Site Number 643914, St-Petersburg, Russian Federation|Investigational Site Number 710917, Alberton, South Africa|Investigational Site Number 710909, Bloemfontein, South Africa|Investigational Site Number 710914, Bloemfontein, South Africa|Investigational Site Number 710905, Cape Town, South Africa|Investigational Site Number 710904, Cape Town, South Africa|Investigational Site Number 710918, Middelburg, South Africa|Investigational Site Number 710913, Pretoria, South Africa|Investigational Site Number 710915, Somerset West, South Africa|Investigational Site Number 804905, Kiev, Ukraine|Investigational Site Number 804902, Uzhhorod, Ukraine",,"https://ClinicalTrials.gov/show/NCT01644188"
156,"NCT01812707","Efficacy and Safety Evaluation of Alirocumab (SAR236553/REGN727) in Patients With Primary Hypercholesterolemia on Stable Atorvastatin Therapy in Japan",,"Completed","Has Results","Hypercholesterolemia","Drug: Alirocumab|Drug: Placebo (for alirocumab)|Drug: Atorvastatin","Percent Change From Baseline in Calculated LDL-C at Week 12 - On-Treatment Analysis|Absolute Change From Baseline in Calculated LDL-C (mmol/L) at Week 12 - On-Treatment Analysis|Absolute Change From Baseline in Calculated LDL-C (mg/dL) at Week 12 - On-Treatment Analysis|Percentage of Participants Achieving Calculated LDL-C <100 mg/dL (2.59 mmol/L) and < 70 mg/dL (1.81 mmol/L) at Week 12 - On-Treatment Analysis|Percent Change From Baseline in Total Cholesterol, High-Density Lipoprotein Cholesterol (HDL-C), Non-HDL-C, and Apolipoprotein B (Apo-B) at Week 12 - On-Treatment Analysis|Percent Change From Baseline in Fasting Triglycerides and Lipoprotein (a) at Week 12 - On-Treatment Analysis|Absolute Change From Baseline in Apolipoprotein B/Apolipoprotein A-1 (ApoB/ApoA-1) Ratio at Week 12 - On-Treatment Analysis","Sanofi|Regeneron Pharmaceuticals","All","20 Years to 75 Years   (Adult, Older Adult)","Phase 2","100","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","DFI12361|U1111-1134-4749","March 2013","January 2014","January 2014","March 18, 2013","September 24, 2015","October 4, 2016","Investigational Site Number 392002, Koganei-Shi, Japan|Investigational Site Number 392001, Shinjuku-Ku, Japan|Investigational Site Number 392003, Suita-Shi, Japan|Investigational Site Number 392004, Suita-Shi, Japan",,"https://ClinicalTrials.gov/show/NCT01812707"
157,"NCT00783146","Efficacy and Safety of Desloratadine vs. Fexofenadine 180 mg. vs. Placebo for Treating Seasonal Allergic Rhinitis (SAR) (Study P04054)",,"Completed","No Results Available","Seasonal Allergic Rhinitis","Drug: desloratadine|Drug: fexofenadine|Drug: placebo","Compare the efficacy of the study treatments with respect to the change from Baseline in the mean AM self-rated instantaneous total symptom score (TSS) (not including nasal congestion) averaged over the 15 days of treatment|Change from Baseline in the mean AM/PM self-rated 12-hour reflective TSS (not including nasal congestion) averaged over the 15 days of treatment.|Change from Baseline in the mean AM self-rated instantaneous individual symptom scores, including nasal congestion, averaged over the 15 days of treatment.|Change from Baseline in the mean AM/PM self-rated 12-hour reflective individual symptom scores, including nasal congestion, averaged over the 15 days of treatment.|Joint physician-patient evaluation of response to therapy.","Merck Sharp & Dohme Corp.","All","12 Years and older   (Child, Adult, Older Adult)","Phase 4","728","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","P04054","August 1, 2004","October 1, 2004","October 1, 2004","October 31, 2008",,"May 11, 2017",,,"https://ClinicalTrials.gov/show/NCT00783146"
158,"NCT01113333","Safety, Tolerability and Pharmacokinetics of SAR113945 Following Intra-articular Administration in Patients With Knee Osteoarthritis",,"Completed","No Results Available","Osteoarthritis","Drug: placebo|Drug: SAR113945","Standard safety investigations (Physical examinations, 12 lead ECGs, vital signs (Blood pressure, heart rate, body temperature) and laboratory tests (hematology/coagulation, biochemistry, quantitative urinalysis))|Examination of skin/soft tissue of injected knee|Examination of knee joint of injected knee|Pharmacokinetic parameters for SAR113945 and potential metabolites(s) from plasma concentration (i.e. AUC, Cmax, tmax, t1/2)|Pharmacodynamic parameters (WOMAC Index, biomarkers relating to inflammation and cartilage/bone turnover)","Sanofi","All","40 Years and older   (Adult, Older Adult)","Phase 1","40","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","TDU10820|2009-017502-36|U1111-1116-5630","April 2010","February 2011","February 2011","April 29, 2010",,"March 23, 2011","Sanofi-Aventis Investigational Site Number 276001, Berlin, Germany",,"https://ClinicalTrials.gov/show/NCT01113333"
159,"NCT00854360","Study to Assess the Efficacy and Safety of BDP HFA Nasal Aerosol in Patients 12 Years and Older With SAR",,"Completed","Has Results","Seasonal Allergic Rhinitis|Hayfever","Drug: Beclomethasone dipropionate HFA Nasal Aerosol|Drug: Placebo","Change From Baseline in Average AM and PM Reflective Total Nasal Symptom Score (rTNSS) Over the Two-week Treatment Period|Change From Baseline in Average AM and PM Instantaneous Total Nasal Symptom Score (iTNSS) Over the Two Week Treatment Period|Change From Baseline in Morning Instantaneous Total Nasal Symptom Score (iTNSS) Over the Two-week Treatment Period|Change From Baseline in Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ)|Change From Baseline in Morning 24-hour Reflective Ocular Symptom Score Over the Two-week Treatment Period|Change From Baseline in Morning 24-hour Reflective Non-nasal Symptom Score Over the Two-week Treatment Period","Teva Branded Pharmaceutical Products, R&D Inc.|Teva Pharmaceutical Industries","All","12 Years and older   (Child, Adult, Older Adult)","Phase 2","487","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","BDP-AR-201","March 2009","May 2009","May 2009","March 3, 2009","May 22, 2012","May 22, 2012","Teva Global Respiratory Research Study Site, Mission Viejo, California, United States|Teva Global Respiratory Research Study Site, San Diego, California, United States|Teva Global Respiratory Research Study Site, San Diego, California, United States|Teva Global Respiratory Research Study Site, Colorado Springs, Colorado, United States|Teva Global Respiratory Research Study Site, Denver, Colorado, United States|Teva Global Respiratory Research Study Site, Gainesville, Georgia, United States|Teva Global Respiratory Research Study Site, Savannah, Georgia, United States|Teva Global Respiratory Research Study Site, Indianapolis, Indiana, United States|Teva Global Respiratory Research Study Site, Overland Park, Kansas, United States|Teva Global Respiratory Research Study Site, Bethesda, Maryland, United States|Teva Global Respiratory Research Study Site, St. Louis, Missouri, United States|Teva Global Respiratory Research Study Site, Brick, New Jersey, United States|Teva Global Respiratory Research Study Site, Raleigh, North Carolina, United States|Teva Global Respiratory Research Study Site, Medford, Oregon, United States|Teva Global Respiratory Research Study Site, Portland, Oregon, United States|Teva Global Respiratory Research Study Site, Blue Bell, Pennsylvania, United States|Teva Global Respiratory Research Study Site, Pittsburgh, Pennsylvania, United States|Teva Global Respiratory Research Study Site, Upland, Pennsylvania, United States|Teva Global Respiratory Research Study Site, Charleston, South Carolina, United States|Teva Global Respiratory Research Study Site, Austin, Texas, United States|Teva Global Respiratory Research Study Site, Dallas, Texas, United States|Teva Global Respiratory Research Study Site, New Braunfels, Texas, United States|Teva Global Respiratory Research Study Site, San Antonio, Texas, United States|Teva Global Respiratory Research Study Site, Draper, Utah, United States|Teva Global Respiratory Research Study Site, Burke, Virginia, United States|Teva Global Respiratory Research Study Site, Richmond, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT00854360"
160,"NCT01266525","Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil",,"Completed","No Results Available","Dementia Alzheimer's Type","Drug: SAR110894|Drug: placebo (for SAR110894)|Drug: Donepezil","Change from baseline to Week 24 in the standard 11-item total score from the 13-item Alzheimer's Disease Assessment Scale - Cognitive subscale (ADAS-Cog).|Change from baseline in the Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL) global score|Change from baseline in each of the two remaining items of the ADAS-Cog (namely ""delayed word recall"" and ""concentration/distractibility"")|Change from baseline in each of the five factors from the Cognitive Drug Research System (CDR-S) computerized assessment|Change from baseline in the Mini Mental State Examination (MMSE) total score","Sanofi","All","55 Years and older   (Adult, Older Adult)","Phase 2","291","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","DRI10734|2010-022596-64|U1111-1115-7535","February 2011","January 2013","January 2013","December 24, 2010",,"March 14, 2016","Investigational Site Number 840041, Gilbert, Arizona, United States|Investigational Site Number 840032, Phoenix, Arizona, United States|Investigational Site Number 840024, Costa Mesa, California, United States|Investigational Site Number 840013, Fresno, California, United States|Investigational Site Number 840030, La Jolla, California, United States|Investigational Site Number 840001, Redlands, California, United States|Investigational Site Number 840002, Santa Ana, California, United States|Investigational Site Number 840026, Sherman Oaks, California, United States|Investigational Site Number 840034, Darien, Connecticut, United States|Investigational Site Number 840003, Delray Beach, Florida, United States|Investigational Site Number 840015, Hialeah, Florida, United States|Investigational Site Number 840004, Jacksonville, Florida, United States|Investigational Site Number 840006, Miami, Florida, United States|Investigational Site Number 840012, Orlando, Florida, United States|Investigational Site Number 840011, Tampa, Florida, United States|Investigational Site Number 840005, W Palm Beach, Florida, United States|Investigational Site Number 840008, Baton Rouge, Louisiana, United States|Investigational Site Number 840025, Quincy, Massachusetts, United States|Investigational Site Number 840009, Hattiesburg, Mississippi, United States|Investigational Site Number 840040, Eatontown, New Jersey, United States|Investigational Site Number 840018, Cedarhurst, New York, United States|Investigational Site Number 840039, Charlotte, North Carolina, United States|Investigational Site Number 840037, Tulsa, Oklahoma, United States|Investigational Site Number 840014, Franklin, Tennessee, United States|Investigational Site Number 840038, Austin, Texas, United States|Investigational Site Number 840021, Bennington, Vermont, United States|Investigational Site Number 840031, Williamsburg, Virginia, United States|Investigational Site Number 036002, Adelaide, Australia|Investigational Site Number 036007, Chermside, Australia|Investigational Site Number 036008, Heidelberg West, Australia|Investigational Site Number 036006, Herston, Australia|Investigational Site Number 036001, Nedlands, Australia|Investigational Site Number 036004, Randwick, Australia|Investigational Site Number 036009, Toowoomba, Australia|Investigational Site Number 036005, Waratah, Australia|Investigational Site Number 036003, Woodville, Australia|Investigational Site Number 124010, Calgary, Canada|Investigational Site Number 124015, Gatineau, Canada|Investigational Site Number 124009, Greenfield Park, Canada|Investigational Site Number 124014, Halifax, Canada|Investigational Site Number 124001, London, Canada|Investigational Site Number 124011, Montreal, Canada|Investigational Site Number 124008, Ottawa, Canada|Investigational Site Number 124013, Regina, Canada|Investigational Site Number 124003, Sherbrooke, Canada|Investigational Site Number 124006, St. John, Canada|Investigational Site Number 124002, Toronto, Canada|Investigational Site Number 124004, Toronto, Canada|Investigational Site Number 250004, Bordeaux, France|Investigational Site Number 250001, Lille Cedex, France|Investigational Site Number 250009, Limoges, France|Investigational Site Number 250007, Marseille, France|Investigational Site Number 250003, Nantes, France|Investigational Site Number 250005, Nice, France|Investigational Site Number 250006, Paris, France|Investigational Site Number 250008, Strasbourg Cedex, France|Investigational Site Number 250002, Toulouse Cedex 3, France|Investigational Site Number 276011, Berlin, Germany|Investigational Site Number 276012, Dresden, Germany|Investigational Site Number 276007, München, Germany|Investigational Site Number 276008, München, Germany|Investigational Site Number 276001, Schwerin, Germany|Investigational Site Number 276009, Würzburg, Germany|Investigational Site Number 380006, Ancona, Italy|Investigational Site Number 380004, Castellanza, Italy|Investigational Site Number 380005, Cefalù, Italy|Investigational Site Number 380002, Milano, Italy|Investigational Site Number 380001, Milano, Italy|Investigational Site Number 380003, Milano, Italy|Investigational Site Number 616004, Bydgoszcz, Poland|Investigational Site Number 616003, Gdansk, Poland|Investigational Site Number 616001, Gdynia, Poland|Investigational Site Number 616002, Poznan, Poland|Investigational Site Number 616006, Szczecin, Poland|Investigational Site Number 616005, Warszawa, Poland|Investigational Site Number 620002, Amadora, Portugal|Investigational Site Number 620001, Lisboa, Portugal|Investigational Site Number 724002, Algorta, Spain|Investigational Site Number 724001, Barcelona, Spain|Investigational Site Number 724008, Madrid, Spain|Investigational Site Number 724007, Sevilla, Spain|Investigational Site Number 724003, Terrassa, Spain",,"https://ClinicalTrials.gov/show/NCT01266525"
161,"NCT01709500","Study of Alirocumab (REGN727/SAR236553) in Patients With heFH (Heterozygous Familial Hypercholesterolemia) Who Are Not Adequately Controlled With Their LMT (Lipid-Modifying Therapy)","ODYSSEY FH II","Completed","Has Results","Heterozygous Familial Hypercholesterolemia","Drug: LMT (atorvastatin, simvastatin, or rosuvastatin)|Drug: alirocumab|Drug: Placebo","Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent--to--Treat (ITT) Analysis|Percent Change From Baseline in Calculated LDL-C at Week 24 - On-Treatment Analysis|Percent Change From Baseline in Calculated LDL-C at Week 12 - ITT Analysis|Percent Change From Baseline in Calculated LDL-C at Week 12 - On- Treatment Analysis|Percent Change From Baseline in Apolipoprotein (Apo) B at Week 24 - ITT Analysis|Percent Change From Baseline in Apo B at Week 24 - On-Treatment Analysis|Percent Change From Baseline in Non-High -Density Lipoprotein Cholesterol (Non-HDL-C) at Week 24 - ITT Analysis|Percent Change From Baseline in Non-HDL-C at Week 24 - On-Treatment Analysis|Percent Change From Baseline in Total Cholesterol (Total-C) at Week 24 - ITT Analysis|Percent Change From Baseline in Apo B at Week 12 - ITT Analysis|Percent Change From Baseline in Non-HDL-C at Week 12 - ITT Analysis|Percent Change From Baseline in Total-C at Week 12 - ITT Analysis|Percent Change From Baseline in Calculated LDL-C at Week 52 - ITT Analysis|Percentage of Very High CV Risk Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) or High CV Risk Participants Reaching Calculated LDL-C <100 mg/dL (2.59 mmol/L) at Week 24 - ITT Analysis|Percentage of Very High CV Risk Participants Reaching Calculated LDL--C <70 mg/dL (1.81 mmol/L) or High CV Risk Participants Reaching Calculated LDL--C <100 mg/dL (2.59 mmol/L) at Week 24 - On-Treatment Analysis|Percentage of Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - ITT Analysis|Percentage of Participants Reaching Calculated LDL--C <70 mg/dL (1.81 mmol/L) at Week 52 - On-Treatment Analysis|Percent Change From Baseline in Lipoprotein (a) at Week 24 - ITT Analysis|Percent Change From Baseline in HDL-C at Week 24 - ITT Analysis|Percent Change From Baseline in Fasting Triglycerides at Week 24 - ITT Analysis|Percent Change From Baseline in Apo A-1 at Week 24 - ITT Analysis|Percent Change From Baseline in Lipoprotein (a) at Week 12 - ITT Analysis|Percent Change From Baseline in HDL-C at Week 12 - ITT Analysis|Percent Change From Baseline in Fasting Triglycerides at Week 12 - ITT Analysis|Percent Change From Baseline in Apo A-1 at Week 12 - ITT Analysis","Regeneron Pharmaceuticals|Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 3","249","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","R727-CL-1112","December 2012","May 2014","January 2015","October 18, 2012","October 28, 2015","October 28, 2015","Hradec Kralove, Czech Republic|Praha 2, Czech Republic|Praha 5, Czech Republic|Praha 8, Czech Republic|Trutnov, Czech Republic|Vyskov, Czech Republic|Alkmaar, Netherlands|Amsterdam, Netherlands|Apeldoorn, Netherlands|Enschede, Netherlands|Goes, Netherlands|Groningen, Netherlands|Hoogeveen, Netherlands|Hoorn, Netherlands|Rotterdam, Netherlands|Sittard- Geleen, Netherlands|Utrecht (2 locations), Netherlands|Venlo, Netherlands|Waalwijk, Netherlands|Oslo, Norway|Cardiff, United Kingdom|London, United Kingdom|Manchester, United Kingdom|Middlesex, United Kingdom|Newcastle upon Tyne, United Kingdom|West Bromwich, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01709500"
162,"NCT00783211","Efficacy and Safety of Desloratadine vs. Fexofenadine 180 mg. vs. Placebo for Treating Seasonal Allergic Rhinitis (SAR)(Study P04053)(COMPLETED)",,"Completed","No Results Available","Seasonal Allergic Rhinitis","Drug: desloratadine|Drug: fexofenadine|Drug: placebo","Compare the efficacy of the study treatments with respect to the change from Baseline in the mean AM self-rated instantaneous total symptom score (TSS) (not including nasal congestion) averaged over the 15 days of treatment|Change from Baseline in the mean AM/PM self-rated 12-hour reflective TSS (not including nasal congestion) averaged over the 15 days of treatment.|Change from Baseline in the mean AM self-rated instantaneous individual symptom scores, including nasal congestion, averaged over the 15 days of treatment.|Change from Baseline in the mean AM/PM self-rated 12-hour reflective individual symptom scores, including nasal congestion, averaged over the 15 days of treatment.|Joint physician-patient evaluation of response to therapy.","Merck Sharp & Dohme Corp.","All","12 Years and older   (Child, Adult, Older Adult)","Phase 4","722","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","P04053","August 1, 2004","October 1, 2004","October 1, 2004","October 31, 2008",,"May 11, 2017",,,"https://ClinicalTrials.gov/show/NCT00783211"
163,"NCT01598415","Safety of Single Doses of SAR113945 and Efficacy and Safety of a New Formulation Given Into the Knee in Osteoarthritis Patients / Part II",,"Completed","No Results Available","Knee Osteoarthritis","Drug: SAR113945|Drug: placebo","Womac Pain Score (5 items)|Womac Total Score (24 items)|Womac Stiffness (2 items)|Womac Physical Function (17 items)|synovial fluid levels|Number of patients reporting Adverse Events of special interest: tolerability at the site of injection and in the knee + other events reported by the patient","Sanofi","All","40 Years and older   (Adult, Older Adult)","Phase 2","130","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","ACT12505|2011-003232-31|U1111-1124-5323|TDU11685/ACT12505","April 2012","February 2013","February 2013","May 15, 2012",,"October 17, 2014","Investigational Site Number 276001, Berlin, Germany|Investigational Site Number 276002, München, Germany",,"https://ClinicalTrials.gov/show/NCT01598415"
164,"NCT00423995","Effect of Loratadine/Montelukast Combination on Congestion in SAR Patients Exposed to Pollen in an EEU (Study P04822)",,"Completed","No Results Available","Seasonal Allergic Rhinitis","Drug: Loratadine/montelukast combination",,"Merck Sharp & Dohme Corp.","All","18 Years and older   (Adult, Older Adult)","Phase 3","379","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","P04822","November 1, 2006","March 1, 2007","March 10, 2007","January 18, 2007",,"March 24, 2017",,,"https://ClinicalTrials.gov/show/NCT00423995"
165,"NCT01644175","Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia (ODYSSEY COMBO I)",,"Completed","Has Results","Hypercholesterolemia","Drug: Placebo (for alirocumab)|Drug: Alirocumab|Drug: Lipid-Modifying Therapy (LMT)","Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent-to-Treat (ITT) Analysis|Percent Change From Baseline in Calculated LDL-C at Week 24 - On-Treatment Analysis|Percent Change From Baseline in Calculated LDL-C at Week 12 - ITT Analysis|Percent Change From Baseline in Calculated LDL-C at Week 12 - On-Treatment Analysis|Percent Change From Baseline in Apolipoprotein (Apo) B at Week 24 - ITT Analysis|Percent Change From Baseline in Apo B at Week 24 - On-treatment Analysis|Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 24 - ITT Analysis|Percent Change From Baseline in Non-HDL-C at Week 24 - On-treatment Analysis|Percent Change From Baseline in Total Cholesterol (Total-C) at Week 24 - ITT Analysis|Percent Change From Baseline in Apo B at Week 12 - ITT Analysis|Percent Change From Baseline in Non-HDL-C at Week 12 - ITT Analysis|Percent Change From Baseline in Total-C at Week 12 - ITT Analysis|Percent Change From Baseline in Calculated LDL-C at Week 52 - ITT Analysis|Percentage of Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - ITT Analysis|Percentage of Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - On-treatment Analysis|Percent Change From Baseline in Lipoprotein(a) at Week 24 - ITT Analysis|Percent Change From Baseline in HDL-C at Week 24 - ITT Analysis|Percent Change From Baseline in Fasting Triglycerides at Week 24 - ITT Analysis|Percent Change From Baseline in Apolipoprotein A-1 at Week 24 - ITT Analysis|Percent Change From Baseline in Lipoprotein(a) at Week 12- ITT Analysis|Percent Change From Baseline in HDL-C at Week 12 - ITT Analysis|Percent Change From Baseline in Fasting Triglycerides at Week 12 - ITT Analysis|Percent Change From Baseline in Apo A-1 at Week 12 - ITT Analysis","Sanofi|Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 3","316","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","EFC11568|U1111-1121-4356","July 2012","April 2014","April 2014","July 18, 2012","November 6, 2015","November 6, 2015","Investigational Site Number 840857, Birmingham, Alabama, United States|Investigational Site Number 840891, Mobile, Alabama, United States|Investigational Site Number 840876, Montgomery, Alabama, United States|Investigational Site Number 840865, Glendale, Arizona, United States|Investigational Site Number 840826, Jonesboro, Arkansas, United States|Investigational Site Number 840870, Burbank, California, United States|Investigational Site Number 840851, Los Angeles, California, United States|Investigational Site Number 840845, Los Gatos, California, United States|Investigational Site Number 840844, Sacramento, California, United States|Investigational Site Number 840801, San Jose, California, United States|Investigational Site Number 840886, Tarzana, California, United States|Investigational Site Number 840862, Torrance, California, United States|Investigational Site Number 840893, Vista, California, United States|Investigational Site Number 840867, Boca Raton, Florida, United States|Investigational Site Number 840884, Boynton Beach, Florida, United States|Investigational Site Number 840836, Clearwater, Florida, United States|Investigational Site Number 840866, Coral Gables, Florida, United States|Investigational Site Number 840895, Ft. Lauderdale, Florida, United States|Investigational Site Number 840820, Hialeah, Florida, United States|Investigational Site Number 840805, Miami, Florida, United States|Investigational Site Number 840811, Oviedo, Florida, United States|Investigational Site Number 840881, Port Orange, Florida, United States|Investigational Site Number 840816, West Palm Beach, Florida, United States|Investigational Site Number 840850, Columbus, Georgia, United States|Investigational Site Number 840840, Eagle, Idaho, United States|Investigational Site Number 840842, Chicago, Illinois, United States|Investigational Site Number 840898, Evanston, Illinois, United States|Investigational Site Number 840847, Morton, Illinois, United States|Investigational Site Number 840896, Indianapolis, Indiana, United States|Investigational Site Number 840894, Michigan City, Indiana, United States|Investigational Site Number 840838, Mishawaka, Indiana, United States|Investigational Site Number 840823, Paducah, Kentucky, United States|Investigational Site Number 840858, Eunice, Louisiana, United States|Investigational Site Number 840802, New Orleans, Louisiana, United States|Investigational Site Number 840855, Salisbury, Massachusetts, United States|Investigational Site Number 840890, Battle Creek, Michigan, United States|Investigational Site Number 840832, Southfield, Michigan, United States|Investigational Site Number 840839, Edina, Minnesota, United States|Investigational Site Number 840888, Minneapolis, Minnesota, United States|Investigational Site Number 840837, Port Gibson, Mississippi, United States|Investigational Site Number 840814, Jefferson City, Missouri, United States|Investigational Site Number 840833, Sparks, Nevada, United States|Investigational Site Number 840817, Newington, New Hampshire, United States|Investigational Site Number 840853, New Windsor, New York, United States|Investigational Site Number 840822, Rochester, New York, United States|Investigational Site Number 840824, Cary, North Carolina, United States|Investigational Site Number 840880, Smithfield, North Carolina, United States|Investigational Site Number 840502, Winston-Salem, North Carolina, United States|Investigational Site Number 840852, Winston-Salem, North Carolina, United States|Investigational Site Number 840846, Cincinnati, Ohio, United States|Investigational Site Number 840899, Cincinnati, Ohio, United States|Investigational Site Number 840831, Columbus, Ohio, United States|Investigational Site Number 840860, Kettering, Ohio, United States|Investigational Site Number 840809, Willoughby Hills, Ohio, United States|Investigational Site Number 840818, Norman, Oklahoma, United States|Investigational Site Number 840812, Eugene, Oregon, United States|Investigational Site Number 840803, Downington, Pennsylvania, United States|Investigational Site Number 840869, Philadelphia, Pennsylvania, United States|Investigational Site Number 840825, Pittsburgh, Pennsylvania, United States|Investigational Site Number 840872, Anderson, South Carolina, United States|Investigational Site Number 840885, Charleston, South Carolina, United States|Investigational Site Number 840813, Greer, South Carolina, United States|Investigational Site Number 840827, Mt. Pleasant, South Carolina, United States|Investigational Site Number 840868, Corpus Christi, Texas, United States|Investigational Site Number 840877, Houston, Texas, United States|Investigational Site Number 840841, Houston, Texas, United States|Investigational Site Number 840830, San Antonio, Texas, United States|Investigational Site Number 840854, San Antonio, Texas, United States|Investigational Site Number 840883, San Antonio, Texas, United States|Investigational Site Number 840889, Tomball, Texas, United States|Investigational Site Number 840878, Bountiful, Utah, United States|Investigational Site Number 840819, Orem, Utah, United States|Investigational Site Number 840863, Salt Lake City, Utah, United States|Investigational Site Number 840804, Manassas, Virginia, United States|Investigational Site Number 840882, Norfolk, Virginia, United States|Investigational Site Number 840810, Weber City, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT01644175"
166,"NCT01617655","Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia (ODYSSEY HIGH FH)",,"Completed","Has Results","Hypercholesterolaemia","Drug: Alirocumab|Drug: Placebo (for alirocumab)|Drug: Lipid Modifying Therapy (LMT)","Percent Change From Baseline in Calculated LDL-C at Week 24 - ITT Analysis|Percent Change From Baseline in Calculated LDL-C at Week 24 - On-Treatment Analysis|Percent Change From Baseline in Calculated LDL-C at Week 12 - ITT Analysis|Percent Change From Baseline in Calculated LDL-C at Week 12 - On-Treatment Analysis|Percent Change From Baseline in Apolipoprotein B (Apo B) at Week 24 - ITT Analysis|Percent Change From Baseline in Apo B at Week 24 - On-Treatment Analysis|Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 24 - ITT Analysis|Percent Change From Baseline in Non-HDL-C at Week 24 - On-Treatment Analysis|Percent Change From Baseline in Total Cholesterol (Total-C) at Week 24 - ITT Analysis|Percent Change From Baseline in Apo B at Week 12 - ITT Analysis|Percent Change From Baseline in Non-HDL-C at Week 12 - ITT Analysis|Percent Change From Baseline in Total-C at Week 12 - ITT Analysis|Percent Change From Baseline in Calculated LDL-C at Week 52 - ITT Analysis|Percentage of Very High Cardiovascular (CV) Risk Participants Achieving Calculated LDL-C < 70 mg/dL (<1.81 mmol/L) or High CV Risk Participants Achieving Calculated LDL-C < 100 mg/dL (<2.59 mmol/L) at Week 24 - ITT Analysis|Percentage of Very High CV Risk Participants Achieving Calculated LDL-C < 70 mg/dL (<1.81 mmol/L) or High CV Risk Participants Achieving Calculated LDL-C < 100 mg/dL (<2.59 mmol/L) at Week 24 - On-Treatment Analysis|Percent Change From Baseline in Lipoprotein (a) at Week 24 - ITT Analysis|Percent Change From Baseline in HDL-C at Week 24 - ITT Analysis|Percent Change From Baseline in Fasting Triglycerides at Week 24 - ITT Analysis|Percent Change From Baseline in Apolipoprotein A-1 (Apo A-1) at Week 24 - ITT Analysis|Percent Change From Baseline in Lipoprotein (a) at Week 12 - ITT Analysis|Percent Change From Baseline in HDL-C at Week 12 - ITT Analysis|Percent Change From Baseline in Fasting Triglycerides at Week 12 - ITT Analysis|Percent Change From Baseline in Apo A-1 at Week 12 - ITT Analysis|Percentage of Participants Achieving Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - ITT Analysis|Percentage of Participants Achieving Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - On-Treatment Analysis","Sanofi|Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 3","107","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","EFC12732|U1111-1128-5459|2012-001096-37","June 2012","May 2014","January 2015","June 12, 2012","November 6, 2015","October 4, 2016","Investigational Site Number 840742, Bell Gardens, California, United States|Investigational Site Number 840703, Newport Beach, California, United States|Investigational Site Number 840712, Newport Beach, California, United States|Investigational Site Number 840743, Northridge, California, United States|Investigational Site Number 840734, Washington, District of Columbia, United States|Investigational Site Number 840738, Miami, Florida, United States|Investigational Site Number 840710, Ponte Vedra, Florida, United States|Investigational Site Number 840701, New York, New York, United States|Investigational Site Number 840702, Durham, North Carolina, United States|Investigational Site Number 840714, Cincinnati, Ohio, United States|Investigational Site Number 840705, Philadelphia, Pennsylvania, United States|Investigational Site Number 840709, Philadelphia, Pennsylvania, United States|Investigational Site Number 840713, Philadelphia, Pennsylvania, United States|Investigational Site Number 840736, Dallas, Texas, United States|Investigational Site Number 124704, Quebec, Canada|Investigational Site Number 124703, Sherbrooke, Canada|Investigational Site Number 528713, Amsterdam, Netherlands|Investigational Site Number 528701, Amsterdam, Netherlands|Investigational Site Number 528704, Groningen, Netherlands|Investigational Site Number 528716, Leiden, Netherlands|Investigational Site Number 528709, Utrecht, Netherlands|Investigational Site Number 643706, Arkhangelsk, Russian Federation|Investigational Site Number 643705, Kazan, Russian Federation|Investigational Site Number 643703, Moscow, Russian Federation|Investigational Site Number 643711, Moscow, Russian Federation|Investigational Site Number 643708, Moscow, Russian Federation|Investigational Site Number 643702, Saint Petersburg, Russian Federation|Investigational Site Number 643710, St-Petersburg, Russian Federation|Investigational Site Number 643709, St-Petersburg, Russian Federation|Investigational Site Number 643707, Yaroslavl, Russian Federation|Investigational Site Number 710701, Bloemfontein, South Africa|Investigational Site Number 710704, Bloemfontein, South Africa|Investigational Site Number 710706, Cap Town, South Africa|Investigational Site Number 710702, Parktown, South Africa|Investigational Site Number 710703, Somerset West, South Africa",,"https://ClinicalTrials.gov/show/NCT01617655"
167,"NCT01463488","Safety of Single Doses of SAR113945 and Efficacy and Safety of a New Formulation Given Into the Knee in Osteoarthritis Patients / Part I",,"Completed","No Results Available","Knee Osteoarthritis","Drug: SAR113945|Drug: placebo","Pain, Stiffness and Physical Function sub-scales from the WOMAC Index|Number of patients reporting Adverse Events of special interest: tolerability at the site of injection and in the knee + other events reported by the patient|Pharmacokinetics (Cmax)|Pharmacokinetics (AUC)|Pharmacokinetics (t1/2)|synovial fluid levels","Sanofi","All","40 Years and older   (Adult, Older Adult)","Phase 1","24","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","TDU11685|2011-003232-31|U1111-1121-3831|TDU11685/ACT12505","November 2011","August 2012","August 2012","November 2, 2011",,"August 23, 2012","Investigational Site Number 276001, Berlin, Germany",,"https://ClinicalTrials.gov/show/NCT01463488"
168,"NCT00612820","A Phase II Study Evaluating Intranasal GSK256066 and Fluticasone Propionate in Subjects With Seasonal Allergic Rhinitis (SAR)",,"Completed","No Results Available","Rhinitis, Allergic, Seasonal","Drug: GSK256066|Drug: fluticasone propionate","Investigate effect of repeat intranasal doses of fluticasone propionate alone vs. GSK256066 + fluticasone propionate on nasal symptoms of allergic rhinitis provoked by spending 4 hours in the Vienna Challenge Chamber after morning dosing on Day 2.|•Nasal symptoms|Eye and global symptoms, nasal obstruction and secretions|Weighted mean TNSS (sneeze, itch, rhinorrhoea and obstruction)|Weighted mean eye symptom score (watery eyes, itchy eyes, red eyes)|Weighted mean global symptom score (sneeze, itch, rhinorrhoea, obstruction, cough, itchy throat, itchy ears, watery eyes, itchy eyes and red eyes)|Weighted mean nasal airflow resistance (measured using active anterior rhinomanometry) and secretion weight (measured by weighing tissues)|Weighted mean components of TNSS (sneeze, itch, rhinorrhoea and obstruction)|FEV1, ECGs, Vitals, AEs, and laboratory safety parameters.|Effect of GSK256066 on ribonucleic acid (RNA) levels indicative of PDE4 inhibition in nasal scrape samples and on protein biomarkers of PDE4 inhibition in lavage samples|Effect of fluticasone propionate on RNA levels indicative of glucocorticoid-provoked gene expression in nasal scrape samples and on glucocorticoid receptor (GR) translocation in lavage samples","GlaxoSmithKline","All","18 Years to 50 Years   (Adult)","Phase 2","55","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double|Primary Purpose: Treatment","IPR110723","January 2008","May 2008","May 2008","February 12, 2008",,"November 3, 2016","GSK Investigational Site, Vienna, Austria",,"https://ClinicalTrials.gov/show/NCT00612820"
169,"NCT01507831","Long-term Safety and Tolerability of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY Long Term)",,"Completed","Has Results","Hypercholesterolemia","Drug: Placebo (for alirocumab)|Drug: Alirocumab|Drug: Lipid-Modifying Therapy (LMT)","Percentage of Participants Who Experienced Adverse Events (AEs)|Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent-to-Treat (ITT) Analysis|Percent Change From Baseline in Calculated LDL-C at Week 24 - On-Treatment Analysis|Percent Change From Baseline in Calculated LDL-C at Week 12 - ITT Analysis|Percent Change From Baseline in Calculated LDL-C at Week 12 - On-treatment Analysis|Percent Change From Baseline in Measured LDL-C at Week 24 - ITT Analysis|Percent Change From Baseline in Apolipoprotein (Apo) B at Week 24 - ITT Analysis|Percent Change From Baseline in Apo B at Week 24 - On-Treatment Analysis|Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 24 - ITT Analysis|Percent Change From Baseline in Non-HDL-C at Week 24 - On-Treatment Analysis|Percent Change From Baseline in Total Cholesterol (Total-C) at Week 24 - ITT Analysis|Percent Change From Baseline in Apo B at Week 12 - ITT Analysis|Percent Change From Baseline in Non-HDL-C at Week 12 - ITT Analysis|Percent Change From Baseline in Total-C at Week 12 - ITT Analysis|Percentage of Very High Cardiovascular (CV) Risk Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) or High CV Risk Participants Reaching Calculated LDL-C <100 mg/dL (2.59 mmol/L) at Week 24 - ITT Analysis|Percentage of Very High CV Risk Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) or High CV Risk Participants Reaching Calculated LDL-C <100 mg/dL (2.59 mmol/L) at Week 24 - On-Treatment Analysis|Percentage of Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - ITT Analysis|Percentage of Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - On-Treatment Analysis|Percent Change From Baseline in Lipoprotein (a) at Week 24 - ITT Analysis|Percent Change From Baseline in HDL-C at Week 24 - ITT Analysis|Percent Change From Baseline in Fasting Triglycerides at Week 24 - ITT Analysis|Percent Change From Baseline in Apo A1 at Week 24 - ITT Analysis|Percent Change From Baseline in Lipoprotein (a) at Week 12 - ITT Analysis|Percent Change From Baseline in HDL-C at Week 12 - ITT Analysis|Percent Change From Baseline in Fasting Triglycerides at Week 12 - ITT Analysis|Percent Change From Baseline in Apo A1 at Week 12 - ITT Analysis","Sanofi|Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 3","2341","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","LTS11717|2011-002806-59|U1111-1121-3928","January 2012","November 2014","November 2014","January 11, 2012","December 22, 2015","December 22, 2015","Investigational Site Number 840159, Huntsville, Alabama, United States|Investigational Site Number 840028, Gilbert, Arizona, United States|Investigational Site Number 840035, Sierra Vista, Arizona, United States|Investigational Site Number 840052, Tempe, Arizona, United States|Investigational Site Number 840065, Tempe, Arizona, United States|Investigational Site Number 840079, Tempe, Arizona, United States|Investigational Site Number 840094, Tempe, Arizona, United States|Investigational Site Number 840103, Tucson, Arizona, United States|Investigational Site Number 840209, Beverly Hills, California, United States|Investigational Site Number 840194, Beverly Hills, California, United States|Investigational Site Number 840207, Fresno, California, United States|Investigational Site Number 840101, Lincoln, California, United States|Investigational Site Number 840076, Long Beach, California, United States|Investigational Site Number 840214, Pasadena, California, United States|Investigational Site Number 840045, Sacramento, California, United States|Investigational Site Number 840163, Santa Rosa, California, United States|Investigational Site Number 840086, Colorado Springs, Colorado, United States|Investigational Site Number 840077, Golden, Colorado, United States|Investigational Site Number 840224, Bridgeport, Connecticut, United States|Investigational Site Number 840134, Guilford, Connecticut, United States|Investigational Site Number 840246, Hartford, Connecticut, United States|Investigational Site Number 840055, Stamford, Connecticut, United States|Investigational Site Number 840091, Stamford, Connecticut, United States|Investigational Site Number 840150, Atlantis, Florida, United States|Investigational Site Number 840020, Bradenton, Florida, United States|Investigational Site Number 840041, Brandon, Florida, United States|Investigational Site Number 840184, Clearwater, Florida, United States|Investigational Site Number 840242, Clearwater, Florida, United States|Investigational Site Number 840039, Clearwater, Florida, United States|Investigational Site Number 840182, Crystal River, Florida, United States|Investigational Site Number 840002, Daytona Beach, Florida, United States|Investigational Site Number 840166, Daytona Beach, Florida, United States|Investigational Site Number 840167, Fleming Island, Florida, United States|Investigational Site Number 840018, Fort Lauderdale, Florida, United States|Investigational Site Number 840090, Ft. Lauderdale, Florida, United States|Investigational Site Number 840153, Jacksonville, Florida, United States|Investigational Site Number 840181, Jacksonville, Florida, United States|Investigational Site Number 840152, Jacksonville, Florida, United States|Investigational Site Number 840154, Lake Mary, Florida, United States|Investigational Site Number 840059, Largo, Florida, United States|Investigational Site Number 840221, Miami, Florida, United States|Investigational Site Number 840021, New Port Richey, Florida, United States|Investigational Site Number 840122, New Smyrna Beach, Florida, United States|Investigational Site Number 840151, Ocala, Florida, United States|Investigational Site Number 840108, Ormond Beach, Florida, United States|Investigational Site Number 840067, Palm Harbor, Florida, United States|Investigational Site Number 840006, Pembroke Pines, Florida, United States|Investigational Site Number 840168, Ponte Vedra, Florida, United States|Investigational Site Number 840164, Sarasota, Florida, United States|Investigational Site Number 840175, Sarasota, Florida, United States|Investigational Site Number 840001, St. Petersburg, Florida, United States|Investigational Site Number 840003, St. Petersburg, Florida, United States|Investigational Site Number 840036, West Palm Beach, Florida, United States|Investigational Site Number 840117, Cumming, Georgia, United States|Investigational Site Number 840110, Roswell, Georgia, United States|Investigational Site Number 840026, Savannah, Georgia, United States|Investigational Site Number 840075, Meridian, Idaho, United States|Investigational Site Number 840027, Evansville, Indiana, United States|Investigational Site Number 840093, Indianapolis, Indiana, United States|Investigational Site Number 840222, Iowa City, Iowa, United States|Investigational Site Number 840165, West Des Moines, Iowa, United States|Investigational Site Number 840200, Kansas City, Kansas, United States|Investigational Site Number 840040, Wichita, Kansas, United States|Investigational Site Number 840061, Wichita, Kansas, United States|Investigational Site Number 840032, Wichita, Kansas, United States|Investigational Site Number 840084, Wichita, Kansas, United States|Investigational Site Number 840244, Biddeford, Maine, United States|Investigational Site Number 840158, Framingham, Maine, United States|Investigational Site Number 840193, Novi, Michigan, United States|Investigational Site Number 840162, Saginaw, Michigan, United States|Investigational Site Number 840033, Saint Louis, Missouri, United States|Investigational Site Number 840113, St. Louis, Missouri, United States|Investigational Site Number 840095, Henderson, Nevada, United States|Investigational Site Number 840096, Henderson, Nevada, United States|Investigational Site Number 840022, Edison, New Jersey, United States|Investigational Site Number 840011, Hillsborough, New Jersey, United States|Investigational Site Number 840049, Trenton, New Jersey, United States|Investigational Site Number 840097, Bronxville, New York, United States|Investigational Site Number 840129, Brooklyn, New York, United States|Investigational Site Number 840160, Poughkeepsie, New York, United States|Investigational Site Number 840217, Asheville, North Carolina, United States|Investigational Site Number 840023, Charlotte, North Carolina, United States|Investigational Site Number 840083, Greensboro, North Carolina, United States|Investigational Site Number 840104, Raleigh, North Carolina, United States|Investigational Site Number 840068, Cincinnati, Ohio, United States|Investigational Site Number 840007, Dayton, Ohio, United States|Investigational Site Number 840013, Marion, Ohio, United States|Investigational Site Number 840161, Mentor, Ohio, United States|Investigational Site Number 840005, Tulsa, Oklahoma, United States|Investigational Site Number 840170, Beaver, Pennsylvania, United States|Investigational Site Number 840180, Camp Hill, Pennsylvania, United States|Investigational Site Number 840004, Duncansville, Pennsylvania, United States|Investigational Site Number 840046, Jersey Shore, Pennsylvania, United States|Investigational Site Number 840155, Phoenixville, Pennsylvania, United States|Investigational Site Number 840177, Scranton, Pennsylvania, United States|Investigational Site Number 840202, Wyomissing, Pennsylvania, United States|Investigational Site Number 840073, Charleston, South Carolina, United States|Investigational Site Number 840087, Greenville, South Carolina, United States|Investigational Site Number 840074, Simpsonville, South Carolina, United States|Investigational Site Number 840105, Varnville, South Carolina, United States|Investigational Site Number 840190, Knoxville, Tennessee, United States|Investigational Site Number 840092, Dallas, Texas, United States|Investigational Site Number 840212, Dallas, Texas, United States|Investigational Site Number 840058, Fort Worth, Texas, United States|Investigational Site Number 840149, Fort Worth, Texas, United States|Investigational Site Number 840070, Fort Worth, Texas, United States|Investigational Site Number 840038, Houston, Texas, United States|Investigational Site Number 840047, Houston, Texas, United States|Investigational Site Number 840053, Plano, Texas, United States|Investigational Site Number 840072, Sugar Land, Texas, United States|Investigational Site Number 840241, Tyler, Texas, United States|Investigational Site Number 840031, Salt Lake City, Utah, United States|Investigational Site Number 840204, Chesapeake, Virginia, United States|Investigational Site Number 840120, Spokane, Washington, United States|Investigational Site Number 840111, Milwaukee, Wisconsin, United States|Investigational Site Number 032006, Buenos Aires, Argentina|Investigational Site Number 032010, Caba, Argentina|Investigational Site Number 032008, Capital Federal, Argentina|Investigational Site Number 032001, Coronel Suarez, Argentina|Investigational Site Number 032004, Resistencia, Argentina|Investigational Site Number 032007, Zarate, Argentina|Investigational Site Number 056005, Antwerpen, Belgium|Investigational Site Number 056004, Genk, Belgium|Investigational Site Number 056001, Natoye, Belgium|Investigational Site Number 056002, Wetteren, Belgium|Investigational Site Number 100008, Pleven, Bulgaria|Investigational Site Number 100014, Plovdiv, Bulgaria|Investigational Site Number 100005, Sofia, Bulgaria|Investigational Site Number 100012, Sofia, Bulgaria|Investigational Site Number 100015, Sofia, Bulgaria|Investigational Site Number 100009, Sofia, Bulgaria|Investigational Site Number 100001, Sofia, Bulgaria|Investigational Site Number 100013, Stara Zagora, Bulgaria|Investigational Site Number 100007, Varna, Bulgaria|Investigational Site Number 124013, Cambridge, Canada|Investigational Site Number 124027, Coquitlam, Canada|Investigational Site Number 124001, Hawkesbury, Canada|Investigational Site Number 124002, London, Canada|Investigational Site Number 124009, Mirabel, Canada|Investigational Site Number 124018, Montreal, Canada|Investigational Site Number 124007, Ottawa, Canada|Investigational Site Number 124011, Quebec, Canada|Investigational Site Number 124005, Saint John'S, Canada|Investigational Site Number 124008, Sarnia, Canada|Investigational Site Number 124022, Terrebonne, Canada|Investigational Site Number 124003, Vancouver, Canada|Investigational Site Number 124006, Victoria, Canada|Investigational Site Number 124015, Woodstock, Canada|Investigational Site Number 152007, Osorno, Chile|Investigational Site Number 152008, Santiago, Chile|Investigational Site Number 152006, Santiago, Chile|Investigational Site Number 152004, Temuco, Chile|Investigational Site Number 170004, Barranquilla, Colombia|Investigational Site Number 170005, Barranquilla, Colombia|Investigational Site Number 170008, Barranquilla, Colombia|Investigational Site Number 170001, Manizales, Colombia|Investigational Site Number 170003, Medellin, Colombia|Investigational Site Number 203004, Praha 2, Czech Republic|Investigational Site Number 203007, Praha 5, Czech Republic|Investigational Site Number 203006, Praha 5, Czech Republic|Investigational Site Number 208005, Aarhus, Denmark|Investigational Site Number 208004, Hellerup, Denmark|Investigational Site Number 208003, Slagelse, Denmark|Investigational Site Number 208001, Svendborg, Denmark|Investigational Site Number 208002, Viborg, Denmark|Investigational Site Number 246002, Joensuu, Finland|Investigational Site Number 246001, Kokkola, Finland|Investigational Site Number 246003, Kuopio, Finland|Investigational Site Number 246004, Vantaa, Finland|Investigational Site Number 250007, Bandol, France|Investigational Site Number 250003, Broglie, France|Investigational Site Number 250014, Bron Cedex, France|Investigational Site Number 250004, Dijon, France|Investigational Site Number 250006, Lille Cedex, France|Investigational Site Number 250009, Nantes, France|Investigational Site Number 250001, Nantes, France|Investigational Site Number 250002, Paris Cedex 13, France|Investigational Site Number 250010, Pessac, France|Investigational Site Number 250012, Rennes, France|Investigational Site Number 250005, Vieux Conde, France|Investigational Site Number 250008, Vihiers, France|Investigational Site Number 276001, Bad Wörishofen, Germany|Investigational Site Number 276007, Berlin, Germany|Investigational Site Number 276005, Berlin, Germany|Investigational Site Number 276014, Berlin, Germany|Investigational Site Number 276008, Bochum, Germany|Investigational Site Number 276009, Dresden, Germany|Investigational Site Number 276004, Essen, Germany|Investigational Site Number 276010, Frankfurt A.M., Germany|Investigational Site Number 276011, Görlitz, Germany|Investigational Site Number 276019, Hannover, Germany|Investigational Site Number 276013, Leipzig, Germany|Investigational Site Number 276012, Magdeburg, Germany|Investigational Site Number 276003, Magdeburg, Germany|Investigational Site Number 276006, Schwerin, Germany|Investigational Site Number 276015, Witten, Germany|Investigational Site Number 348003, Baja, Hungary|Investigational Site Number 348007, Budapest, Hungary|Investigational Site Number 348009, Budapest, Hungary|Investigational Site Number 348008, Budapest, Hungary|Investigational Site Number 348013, Budapest, Hungary|Investigational Site Number 348004, Debrecen, Hungary|Investigational Site Number 348002, Nagykanizsa, Hungary|Investigational Site Number 348006, Nyiregyhaza, Hungary|Investigational Site Number 348001, Sopron, Hungary|Investigational Site Number 348011, Urhida, Hungary|Investigational Site Number 376002, Afula, Israel|Investigational Site Number 376003, Holon, Israel|Investigational Site Number 376005, Holon, Israel|Investigational Site Number 376004, Nazareth, Israel|Investigational Site Number 380006, Chieti, Italy|Investigational Site Number 380002, Cinisello Balsamo, Italy|Investigational Site Number 380009, Milano, Italy|Investigational Site Number 380007, Napoli, Italy|Investigational Site Number 380001, Palermo, Italy|Investigational Site Number 380005, Pozzilli, Italy|Investigational Site Number 380008, Vittorio Veneto, Italy|Investigational Site Number 380010, Zingonia-Osio Sotto, Italy|Investigational Site Number 484010, Df, Mexico|Investigational Site Number 484004, Mexico, Mexico|Investigational Site Number 484008, Not Provided, Mexico|Investigational Site Number 484001, San Luis Potosi, Mexico|Investigational Site Number 484002, Tijuana, Mexico|Investigational Site Number 484009, Torreon, Mexico|Investigational Site Number 484003, Xalapa, Mexico|Investigational Site Number 528013, Amsterdam, Netherlands|Investigational Site Number 528001, Amsterdam, Netherlands|Investigational Site Number 528004, Breda, Netherlands|Investigational Site Number 528005, Eindhoven, Netherlands|Investigational Site Number 528007, Groningen, Netherlands|Investigational Site Number 528011, Hoogeveen, Netherlands|Investigational Site Number 528002, Hoorn, Netherlands|Investigational Site Number 528008, Leiderdorp, Netherlands|Investigational Site Number 528009, Rotterdam, Netherlands|Investigational Site Number 528006, Velp, Netherlands|Investigational Site Number 528012, Venlo, Netherlands|Investigational Site Number 528010, Zoetermeer, Netherlands|Investigational Site Number 578005, Elverum, Norway|Investigational Site Number 578001, Hamar, Norway|Investigational Site Number 578002, Oslo, Norway|Investigational Site Number 578004, Skedsmokorset, Norway|Investigational Site Number 578003, Stavanger, Norway|Investigational Site Number 616008, Gdynia, Poland|Investigational Site Number 616003, Gdynia, Poland|Investigational Site Number 616001, Gniewkowo, Poland|Investigational Site Number 616010, Katowice, Poland|Investigational Site Number 616018, Krakow, Poland|Investigational Site Number 616004, Piotrkow Trybunalski, Poland|Investigational Site Number 616013, Pulawy, Poland|Investigational Site Number 616009, Warszawa, Poland|Investigational Site Number 616007, Wroclaw, Poland|Investigational Site Number 620006, Funchal / Madeira, Portugal|Investigational Site Number 620002, Lisboa, Portugal|Investigational Site Number 620001, Lisboa, Portugal|Investigational Site Number 620005, Porto, Portugal|Investigational Site Number 642005, Baia Mare, Romania|Investigational Site Number 642002, Brasov, Romania|Investigational Site Number 642004, Targu Mures, Romania|Investigational Site Number 642001, Timisoara, Romania|Investigational Site Number 643005, Barnaul, Russian Federation|Investigational Site Number 643012, Moscow, Russian Federation|Investigational Site Number 643008, Moscow, Russian Federation|Investigational Site Number 643014, Perm, Russian Federation|Investigational Site Number 643006, St Petersburg, Russian Federation|Investigational Site Number 643009, St.Petersburg, Russian Federation|Investigational Site Number 643004, Yaroslavl, Russian Federation|Investigational Site Number 710010, Centurion, South Africa|Investigational Site Number 710008, Meyerspark, South Africa|Investigational Site Number 710011, Middelburg, South Africa|Investigational Site Number 710006, Parktown, South Africa|Investigational Site Number 710004, Pretoria, South Africa|Investigational Site Number 710001, Pretoria, South Africa|Investigational Site Number 710002, Pretoria, South Africa|Investigational Site Number 710009, Roodepoort, South Africa|Investigational Site Number 710003, Somerset West, South Africa|Investigational Site Number 710005, Witbank, South Africa|Investigational Site Number 710007, Worcester, South Africa|Investigational Site Number 724006, Córdoba, Spain|Investigational Site Number 724003, Granada, Spain|Investigational Site Number 724002, Madrid, Spain|Investigational Site Number 724007, Málaga, Spain|Investigational Site Number 724008, Quart De Poblet, Spain|Investigational Site Number 724005, Reus, Spain|Investigational Site Number 724001, Sabadell, Spain|Investigational Site Number 724004, Sevilla, Spain|Investigational Site Number 752002, Rättvik, Sweden|Investigational Site Number 752006, Stockholm, Sweden|Investigational Site Number 752003, Stockholm, Sweden|Investigational Site Number 752004, Stockholm, Sweden|Investigational Site Number 752001, Örebro, Sweden|Investigational Site Number 804012, Chernivtsi, Ukraine|Investigational Site Number 804003, Dnipropetrovsk, Ukraine|Investigational Site Number 804002, Donetsk, Ukraine|Investigational Site Number 804014, Kharkiv, Ukraine|Investigational Site Number 804016, Kiev, Ukraine|Investigational Site Number 804011, Kyiv, Ukraine|Investigational Site Number 804010, Kyiv, Ukraine|Investigational Site Number 804001, Kyiv, Ukraine|Investigational Site Number 804008, Kyiv, Ukraine|Investigational Site Number 804013, Kyiv, Ukraine|Investigational Site Number 804005, Zhytomyr, Ukraine|Investigational Site Number 826004, Addlestone, United Kingdom|Investigational Site Number 826009, Birmingham, United Kingdom|Investigational Site Number 826016, Birmingham, United Kingdom|Investigational Site Number 826021, Blackpool, United Kingdom|Investigational Site Number 826023, Cambridge, United Kingdom|Investigational Site Number 826012, Cardiff, United Kingdom|Investigational Site Number 826024, Chichester, United Kingdom|Investigational Site Number 826006, Chorley, United Kingdom|Investigational Site Number 826010, Glasgow, United Kingdom|Investigational Site Number 826003, Irvine, United Kingdom|Investigational Site Number 826008, Liverpool, United Kingdom|Investigational Site Number 826005, Liverpool, United Kingdom|Investigational Site Number 826025, Manchester, United Kingdom|Investigational Site Number 826007, Manchester, United Kingdom|Investigational Site Number 826001, Middlesex, United Kingdom|Investigational Site Number 826019, Penzance, United Kingdom|Investigational Site Number 826011, Reading, United Kingdom|Investigational Site Number 826013, Romford, United Kingdom|Investigational Site Number 826014, Soham, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01507831"
170,"NCT01082549","Trial of Gemcitabine/Carboplatin With or Without Iniparib (SAR240550) (a PARP1 Inhibitor) in Subjects With Previously Untreated Stage IV Squamous Non-Small-Cell Lung Cancer (NSCLC)","ECLIPSE","Completed","No Results Available","Squamous Cell Lung Cancer","Drug: gemcitabine/carboplatin|Drug: gemcitabine/carboplatin plus Iniparib","overall survival|progression free survival","Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 3","780","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EFC11553|20090321","March 2010","April 2013","April 2013","March 8, 2010",,"March 17, 2016","Investigational Site Number 840306, Birmingham, Alabama, United States|Investigational Site Number 840207, Huntsville, Alabama, United States|Investigational Site Number 840351, Muscle Shoals, Alabama, United States|Investigational Site Number 840338, Anaheim, California, United States|Investigational Site Number 840353, Burbank, California, United States|Investigational Site Number 840341, Concord, California, United States|Investigational Site Number 840317, Duarte, California, United States|Investigational Site Number 840339, La Verne, California, United States|Investigational Site Number 840309, Loma Linda, California, United States|Investigational Site Number 840307, Los Angeles, California, United States|Investigational Site Number 840327, Maywood, California, United States|Investigational Site Number 840303, San Diego, California, United States|Investigational Site Number 840321, Santa Rosa, California, United States|Investigational Site Number 840326, Stockton, California, United States|Investigational Site Number 840310, Vallejo, California, United States|Investigational Site Number 840336, Denver, Colorado, United States|Investigational Site Number 840346, Norwich, Connecticut, United States|Investigational Site Number 840315, Newark, Delaware, United States|Investigational Site Number 840216, Ft. Lauderdale, Florida, United States|Investigational Site Number 840215, Jacksonville, Florida, United States|Investigational Site Number 840217, Lakeland, Florida, United States|Investigational Site Number 840205, Orlando, Florida, United States|Investigational Site Number 840104, Sarasota, Florida, United States|Investigational Site Number 840343, Athens, Georgia, United States|Investigational Site Number 840213, Augusta, Georgia, United States|Investigational Site Number 840347, Augusta, Georgia, United States|Investigational Site Number 840201, Gainesville, Georgia, United States|Investigational Site Number 840301, Lawrenceville, Georgia, United States|Investigational Site Number 840305, Marietta, Georgia, United States|Investigational Site Number 840314, Tucker, Georgia, United States|Investigational Site Number 840313, Chicago, Illinois, United States|Investigational Site Number 840218, Evansville, Indiana, United States|Investigational Site Number 840319, Indianapolis, Indiana, United States|Investigational Site Number 840329, South Bend, Indiana, United States|Investigational Site Number 840316, Wichita, Kansas, United States|Investigational Site Number 840320, Louisville, Kentucky, United States|Investigational Site Number 840308, Scarborough, Maine, United States|Investigational Site Number 840202, Bethesda, Maryland, United States|Investigational Site Number 840345, Salisbury, Maryland, United States|Investigational Site Number 840337, Royal Oak, Michigan, United States|Investigational Site Number 840328, St. Louis Park, Minnesota, United States|Investigational Site Number 840210, Bridgeton, Missouri, United States|Investigational Site Number 840212, Omaha, Nebraska, United States|Investigational Site Number 840318, Las Vegas, Nevada, United States|Investigational Site Number 840204, Morristown, New Jersey, United States|Investigational Site Number 840350, Chapel Hill, North Carolina, United States|Investigational Site Number 840330, Durham, North Carolina, United States|Investigational Site Number 840105, Cincinnati, Ohio, United States|Investigational Site Number 840302, Cleveland, Ohio, United States|Investigational Site Number 840348, Cleveland, Ohio, United States|Investigational Site Number 840335, Columbus, Ohio, United States|Investigational Site Number 840311, Bend, Oregon, United States|Investigational Site Number 840211, West Reading, Pennsylvania, United States|Investigational Site Number 840352, Charleston, South Carolina, United States|Investigational Site Number 840106, Columbia, South Carolina, United States|Investigational Site Number 840220, Spartanburg, South Carolina, United States|Investigational Site Number 840103, Chattanooga, Tennessee, United States|Investigational Site Number 840208, Chattanooga, Tennessee, United States|Investigational Site Number 840203, Collierville, Tennessee, United States|Investigational Site Number 840101, Nashville, Tennessee, United States|Investigational Site Number 840323, Fort Worth, Texas, United States|Investigational Site Number 840219, Newport News, Virginia, United States|Investigational Site Number 840102, Richmond, Virginia, United States|Investigational Site Number 840312, Seattle, Washington, United States|Investigational Site Number 840344, Tacoma, Washington, United States|Investigational Site Number 840322, Morgantown, West Virginia, United States|Investigational Site Number 840331, Wauwatosa, Wisconsin, United States|Investigational Site Number 056004, Brugge, Belgium|Investigational Site Number 056003, Brussel, Belgium|Investigational Site Number 056001, Liège, Belgium|Investigational Site Number 124003, Edmonton, Canada|Investigational Site Number 124006, Greenfield Park, Canada|Investigational Site Number 124005, London, Canada|Investigational Site Number 124007, Oshawa, Canada|Investigational Site Number 124004, Quebec, Canada|Investigational Site Number 124001, Toronto, Canada|Investigational Site Number 250007, Brest, France|Investigational Site Number 250002, Dijon, France|Investigational Site Number 250009, Limoges Cedex, France|Investigational Site Number 250003, Marseille, France|Investigational Site Number 250004, Paris Cedex 13, France|Investigational Site Number 250010, Pierre Benite Cedex, France|Investigational Site Number 250008, Poitiers, France|Investigational Site Number 250001, Saint-Herblain Cedex, France|Investigational Site Number 250006, Strasbourg, France|Investigational Site Number 250005, Tours Cedex 1, France|Investigational Site Number 276002, Amberg, Germany|Investigational Site Number 276004, Berlin, Germany|Investigational Site Number 276007, Frankfurt Am Main, Germany|Investigational Site Number 276008, Großhansdorf, Germany|Investigational Site Number 276010, Halle/Saale, Germany|Investigational Site Number 276012, Heidelberg, Germany|Investigational Site Number 276009, Immenhausen, Germany|Investigational Site Number 276001, Löwenstein, Germany|Investigational Site Number 276006, München, Germany|Investigational Site Number 276003, Oldenburg, Germany|Investigational Site Number 348005, Budapest, Hungary|Investigational Site Number 348003, Budapest, Hungary|Investigational Site Number 348001, Mátraháza, Hungary|Investigational Site Number 348004, Nyíregyháza, Hungary|Investigational Site Number 376002, Kfar Saba, Israel|Investigational Site Number 376005, Petah-Tikva, Israel|Investigational Site Number 376003, Tel Hashomer, Israel|Investigational Site Number 376001, Tzrifin, Israel|Investigational Site Number 380006, Genova, Italy|Investigational Site Number 380001, Novara, Italy|Investigational Site Number 380008, Orbassano, Italy|Investigational Site Number 380002, Perugia, Italy|Investigational Site Number 380003, Roma, Italy|Investigational Site Number 380007, Roma, Italy|Investigational Site Number 442001, Luxembourg, Luxembourg|Investigational Site Number 528005, Breda, Netherlands|Investigational Site Number 528004, Eindhoven, Netherlands|Investigational Site Number 528001, Groningen, Netherlands|Investigational Site Number 528006, Maastricht, Netherlands|Investigational Site Number 528003, Zwolle, Netherlands|Investigational Site Number 616006, Bialystok, Poland|Investigational Site Number 616001, Krakow, Poland|Investigational Site Number 616007, Lubin, Poland|Investigational Site Number 616004, Olsztyn, Poland|Investigational Site Number 616008, Torun, Poland|Investigational Site Number 616002, Warszawa, Poland|Investigational Site Number 616005, Wroclaw, Poland|Investigational Site Number 642002, Alba Iulia, Romania|Investigational Site Number 642006, Bucuresti, Romania|Investigational Site Number 642001, Cluj Napoca, Romania|Investigational Site Number 642004, Craiova, Romania|Investigational Site Number 642005, Hunedoara, Romania|Investigational Site Number 724009, Badalona, Spain|Investigational Site Number 724003, Barcelona, Spain|Investigational Site Number 724004, La Coruña, Spain|Investigational Site Number 724005, Madrid, Spain|Investigational Site Number 724006, Madrid, Spain|Investigational Site Number 724002, Málaga, Spain|Investigational Site Number 724001, Palma De Mallorca, Spain|Investigational Site Number 724008, Sevilla, Spain|Investigational Site Number 724010, Valencia, Spain|Investigational Site Number 724007, Zaragoza, Spain|Investigational Site Number 826002, Glasgow, United Kingdom|Investigational Site Number 826005, Leeds, United Kingdom|Investigational Site Number 826001, Manchester, United Kingdom|Investigational Site Number 826006, Wolverhampton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01082549"
171,"NCT01342601","Safety and Efficacy of Ectoin Allergy Nasal Spray and Ectoin Allergy Eye Drops in the Treatment of Seasonal Allergic Rhinitis (SAR) in Children and Adolescents",,"Completed","No Results Available","Seasonal Allergic Rhinitis|Seasonal Allergic Conjunctivitis","Device: ect4allergy Nasal Spray (ANS01) and Eye Drops (AAT01)|Device: Placebo products","clinically relevant changes in vital signs|Incidence of adverse events|Overall assessment by the patient (Rhinoconjunctivitis Quality of Life Questionnaire (PRQLQ for children aged 5-12 years or AdolRQLQ for adolescents aged 13-17 years)|Change score in TNSS at visit V3 compared to baseline (V2) separately for a.m. and p.m. measurement|Change score in TOSS at visit V3 compared to baseline (V2) separately for a.m. and p.m. measurement|Change score in non-nasal score at visit V3 compared to baseline (V2) separately for a.m. and p.m. measurement|clinical relevant changes in physical examination parameters|Severity of Adverse events|Use of rescue medication|TNSS, separately for a.m. and p.m. measurement over time|TOSS over time (V2, V3), separately for a.m. and p.m. measurement over time|Non-nasal score over time (V2, V3), separately for a.m. and p.m. measurement over time|Symptom scores separately for a.m. and p.m. measurement over time","Bitop AG","All","5 Years to 17 Years   (Child)","Not Applicable","72","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","PPL-041","April 2011","September 2011","September 2011","April 27, 2011",,"October 13, 2011","Kinderarzt Bleckmann, Baunatal-Großenritte, Germany|Dr. med. Martina Weh, Berlin, Germany|Experimentelle Pneumologie RUB, Bochum, Germany|Kinderarztpraxis Bramsche, Bramsche, Germany|Dr. med. Friedrich Kaiser, Hamburg, Germany|Dr. Marlies Bölich, Jena, Germany|Dr. Ralph Maier, Tuttlingen, Germany|Dr.med. Dieter Schlegel und Lilli Hegai, Welzheim, Germany",,"https://ClinicalTrials.gov/show/NCT01342601"
172,"NCT01288443","Efficacy and Safety Evaluation of Alirocumab (SAR236553/REGN727) in Patients With Primary Hypercholesterolemia on Stable Atorvastatin Therapy",,"Completed","Has Results","Hypercholesterolemia","Drug: Alirocumab|Drug: Placebo (for alirocumab)|Drug: Atorvastatin","Percent Change From Baseline in Calculated LDL-C at Week 12 - On-Treatment Analysis|Absolute Change From Baseline in Calculated LDL-C (mmol/L) at Week 12 - On-Treatment Analysis|Absolute Change From Baseline in Calculated LDL-C (mg/dL) at Week 12 - On-Treatment Analysis|Percentage of Participants Achieving Calculated LDL-C <100 mg/dL (2.59 mmol/L) and <70 mg/dL (1.81 mmol/L) at Week 12 - On-Treatment Analysis|Percent Change From Baseline in Total Cholesterol, High-density Lipoprotein Cholesterol (HDL-C), Non-HDL-C and Apolipoprotein B (Apo-B) at Week 12 - On-Treatment Analysis|Percent Change From Baseline in Fasting Triglycerides and Lipoprotein(a) at Week 12 - On-Treatment Analysis|Absolute Change in the Ratio Apolipoprotein B/Apolipoprotein A-1 (ApoB/ApoA-1) From Baseline to Week 12 - On-Treatment Analysis","Sanofi|Regeneron Pharmaceuticals","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","183","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","DFI11565|U1111-1116-5252","January 2011","December 2011","December 2011","February 2, 2011","September 24, 2015","September 24, 2015","Investigational Site Number 840525, Tempe, Arizona, United States|Investigational Site Number 840516, Los Angeles, California, United States|Investigational Site Number 840528, Mission Viejo, California, United States|Investigational Site Number 840509, Newport Beach, California, United States|Investigational Site Number 840523, Palm Springs, California, United States|Investigational Site Number 840534, Westlake Village, California, United States|Investigational Site Number 840530, Colorado Springs, Colorado, United States|Investigational Site Number 840504, Aventura, Florida, United States|Investigational Site Number 840519, Aventura, Florida, United States|Investigational Site Number 840514, Jacksonville, Florida, United States|Investigational Site Number 840539, Jupiter, Florida, United States|Investigational Site Number 840502, Miami, Florida, United States|Investigational Site Number 840520, Pembroke Pines, Florida, United States|Investigational Site Number 840524, Ponte Vedra, Florida, United States|Investigational Site Number 840536, Port Orange, Florida, United States|Investigational Site Number 840507, St. Petersburg, Florida, United States|Investigational Site Number 840527, Chicago, Illinois, United States|Investigational Site Number 840506, Evansville, Indiana, United States|Investigational Site Number 840529, Indianapolis, Indiana, United States|Investigational Site Number 840515, Wichita, Kansas, United States|Investigational Site Number 840532, Madisonville, Kentucky, United States|Investigational Site Number 840535, Auburn, Maine, United States|Investigational Site Number 840503, Brockton, Massachusetts, United States|Investigational Site Number 840512, Las Vegas, Nevada, United States|Investigational Site Number 840505, Edison, New Jersey, United States|Investigational Site Number 840538, Rochester, New York, United States|Investigational Site Number 840508, Raleigh, North Carolina, United States|Investigational Site Number 840522, Statesville, North Carolina, United States|Investigational Site Number 840511, Cincinnati, Ohio, United States|Investigational Site Number 840526, Cincinnati, Ohio, United States|Investigational Site Number 840510, Lyndhurst, Ohio, United States|Investigational Site Number 840533, Tulsa, Oklahoma, United States|Investigational Site Number 840537, Eugene, Oregon, United States|Investigational Site Number 840521, Bristol, Tennessee, United States|Investigational Site Number 840531, Bountiful, Utah, United States|Investigational Site Number 840517, Norfolk, Virginia, United States|Investigational Site Number 840518, Richmond, Virginia, United States|Investigational Site Number 840513, Olympia, Washington, United States",,"https://ClinicalTrials.gov/show/NCT01288443"
173,"NCT00981240","Dose Escalation, Safety and Pharmacokinetic Study of SAR103168 in Patients Refractory/ Relapsed Acute Leukemias or High-risk Myelodysplastic Syndromes",,"Completed","No Results Available","Acute Myelogenous Leukemia","Drug: SAR103168","Incidence of DLTs during the initial 4-week period of treatment|Pharmacokinetic parameters of SAR103168|Global safety profile of SAR103168 based on treatment emergent adverse events (TEAEs), serious adverse events (SAEs), deaths, laboratory abnormalities|Preliminary evidence of anti-leukemia activity|Pharmacokinetic parameters of midazolam in the absence and the presence of SAR103168.","Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 1","30","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TED10416","September 2009","January 2012","February 2012","September 22, 2009",,"March 27, 2012","Sanofi-Aventis Investigational Site Number 840003, Atlanta, Georgia, United States|Sanofi-Aventis Investigational Site Number 840002, New York, New York, United States|Sanofi-Aventis Investigational Site Number 840001, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00981240"
174,"NCT01623115","Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy","ODYSSEY FH I","Completed","Has Results","Hypercholesterolemia","Drug: Alirocumab|Drug: Placebo (for alirocumab)|Drug: Lipid Modifying Therapy (LMT)","Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent-to-Treat (ITT) Analysis|Percent Change From Baseline in Calculated LDL-C at Week 24 - On-Treatment Analysis|Percent Change From Baseline in Calculated LDL-C at Week 12 - ITT Analysis|Percent Change From Baseline in Calculated LDL-C at Week 12 - On-Treatment Analysis|Percent Change From Baseline in Apolipoprotein B (Apo B) at Week 24 - ITT Analysis|Percent Change From Baseline in Apo B at Week 24 - On-Treatment Analysis|Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 24 - ITT Analysis|Percent Change From Baseline in Non-HDL-C at Week 24 - On-Treatment Analysis|Percent Change From Baseline in Total Cholesterol (Total-C) at Week 24 - ITT Analysis|Percent Change From Baseline in Apo B at Week 12 - ITT Analysis|Percent Change From Baseline in Non-HDL-C at Week 12 - ITT Analysis|Percent Change From Baseline in Total-C at Week 12 - ITT Analysis|Percent Change From Baseline in Calculated LDL-C at Week 52 - ITT Analysis|Percentage of Very High Cardiovascular (CV) Risk Participants Achieving Calculated LDL-C < 70 mg/dL (<1.81 mmol/L) or High CV Risk Participants Achieving Calculated LDL-C < 100 mg/dL (<2.59 mmol/L) at Week 24 - ITT Analysis|Percentage of Very High CV Risk Participants Achieving Calculated LDL-C < 70 mg/dL (<1.81 mmol/L) or High CV Risk Participants Achieving Calculated LDL-C < 100 mg/dL (<2.59 mmol/L) at Week 24 - On- Treatment Analysis|Percentage of Participants Achieving Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - ITT Analysis|Percentage of Participants Achieving Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - On-Treatment Analysis|Percent Change From Baseline in Lipoprotein (a) at Week 24 - ITT Analysis|Percent Change From Baseline in HDL-C at Week 24 - ITT Analysis|Percent Change From Baseline in Fasting Triglycerides at Week 24 - ITT Analysis|Percent Change From Baseline in Apolipoprotein A-1 (Apo A-1) at Week 24 - ITT Analysis|Percent Change From Baseline in Lipoprotein (a) at Week 12 - ITT Analysis|Percent Change From Baseline in HDL-C at Week 12 - ITT Analysis|Percent Change From Baseline in Fasting Triglycerides at Week 12 - ITT Analysis|Percent Change From Baseline in Apo A-1 at Week 12 - ITT Analysis","Sanofi|Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 3","486","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","EFC12492|U1111-1121-4275|2011-005109-56","July 2012","April 2014","December 2014","June 19, 2012","November 4, 2015","February 8, 2016","Investigational Site Number 840417, Bell Gardens, California, United States|Investigational Site Number 840429, Long Beach, California, United States|Investigational Site Number 840419, Los Angeles, California, United States|Investigational Site Number 840421, Mission Viejo, California, United States|Investigational Site Number 840412, Newport Beach, California, United States|Investigational Site Number 840428, Newport Beach, California, United States|Investigational Site Number 840461, Northridge, California, United States|Investigational Site Number 840452, Washington, District of Columbia, United States|Investigational Site Number 840456, Miami, Florida, United States|Investigational Site Number 840418, Ponte Vedra, Florida, United States|Investigational Site Number 840455, Evanston, Illinois, United States|Investigational Site Number 840415, Kansas City, Kansas, United States|Investigational Site Number 840425, Auburn, Maine, United States|Investigational Site Number 840411, Boston, Massachusetts, United States|Investigational Site Number 840409, St Louis, Missouri, United States|Investigational Site Number 840407, Morristown, New Jersey, United States|Investigational Site Number 840408, New York, New York, United States|Investigational Site Number 840401, Charlotte, North Carolina, United States|Investigational Site Number 840410, Durham, North Carolina, United States|Investigational Site Number 840430, Cincinnati, Ohio, United States|Investigational Site Number 840424, Portland, Oregon, United States|Investigational Site Number 840404, Philadelphia, Pennsylvania, United States|Investigational Site Number 840426, Philadelphia, Pennsylvania, United States|Investigational Site Number 840406, Nashville, Tennessee, United States|Investigational Site Number 840460, Dallas, Texas, United States|Investigational Site Number 840422, Bountiful, Utah, United States|Investigational Site Number 040403, Graz, Austria|Investigational Site Number 040402, Wien, Austria|Investigational Site Number 040405, Wien, Austria|Investigational Site Number 124404, Chicoutimi, Canada|Investigational Site Number 124401, Montreal, Canada|Investigational Site Number 124403, Quebec, Canada|Investigational Site Number 124406, Sherbrooke, Canada|Investigational Site Number 124407, Toronto, Canada|Investigational Site Number 203401, Praha, Czech Republic|Investigational Site Number 203403, Praha, Czech Republic|Investigational Site Number 203405, Uherske Hradiste, Czech Republic|Investigational Site Number 203402, Zlin, Czech Republic|Investigational Site Number 208401, Copenhagen, Denmark|Investigational Site Number 208403, Esbjerg, Denmark|Investigational Site Number 250403, Dijon, France|Investigational Site Number 250401, Paris Cedex 13, France|Investigational Site Number 250402, Saint Herblain, France|Investigational Site Number 376402, Holon, Israel|Investigational Site Number 376405, Jerusalem, Israel|Investigational Site Number 376404, Safed, Israel|Investigational Site Number 376401, Tel Hashomer, Israel|Investigational Site Number 528406, Amsterdam, Netherlands|Investigational Site Number 528410, Amsterdam, Netherlands|Investigational Site Number 528408, Den Helder, Netherlands|Investigational Site Number 528402, Groningen, Netherlands|Investigational Site Number 528411, Leiden, Netherlands|Investigational Site Number 528416, Maastricht, Netherlands|Investigational Site Number 528409, Nieuwegein, Netherlands|Investigational Site Number 528412, Sliedrecht, Netherlands|Investigational Site Number 578401, Bodø, Norway|Investigational Site Number 643402, Arkhangelsk, Russian Federation|Investigational Site Number 643407, Kazan, Russian Federation|Investigational Site Number 643409, Moscow, Russian Federation|Investigational Site Number 643413, Moscow, Russian Federation|Investigational Site Number 643401, Moscow, Russian Federation|Investigational Site Number 643412, Novisibirsk, Russian Federation|Investigational Site Number 643408, St-Petersburg, Russian Federation|Investigational Site Number 643406, St-Petersburg, Russian Federation|Investigational Site Number 643404, St-Petersburg, Russian Federation|Investigational Site Number 643410, Yaroslavl, Russian Federation|Investigational Site Number 710401, Bloemfontein, South Africa|Investigational Site Number 710405, Bloemfontein, South Africa|Investigational Site Number 710406, Cap Town, South Africa|Investigational Site Number 710402, Cape Town, South Africa|Investigational Site Number 710407, Parktown, South Africa|Investigational Site Number 710403, Parow, South Africa|Investigational Site Number 710408, Pretoria, South Africa|Investigational Site Number 710404, Rondebosch, South Africa|Investigational Site Number 710409, Somerset West, South Africa|Investigational Site Number 724403, A Coruna, Spain|Investigational Site Number 724408, Barcelona, Spain|Investigational Site Number 724406, Córdoba, Spain|Investigational Site Number 724407, Hospitalet De Llobregat, Spain|Investigational Site Number 724409, Madrid, Spain|Investigational Site Number 724401, Madrid, Spain|Investigational Site Number 724405, Madrid, Spain|Investigational Site Number 724404, Reus, Spain|Investigational Site Number 724402, Zaragoza, Spain|Investigational Site Number 752404, Goteborg, Sweden|Investigational Site Number 752401, Stockholm, Sweden|Investigational Site Number 826402, London, United Kingdom|Investigational Site Number 826403, London, United Kingdom|Investigational Site Number 826408, London, United Kingdom|Investigational Site Number 826409, London, United Kingdom|Investigational Site Number 826405, Manchester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01623115"
175,"NCT01042925","Study of XL147 (SAR245408) in Combination With Trastuzumab or Paclitaxel and Trastuzumab in Subjects With Metastatic Breast Cancer Who Have Progressed on a Previous Trastuzumab-based Regimen",,"Completed","No Results Available","Breast Cancer|Breast Neoplasms","Drug: XL147 (SAR245408)|Biological: trastuzumab|Drug: paclitaxel","Safety and tolerability of XL147 in combination with trastuzumab and in combination with trastuzumab and paclitaxel|In Phase 1, the maximum tolerated dose (MTD) of XL147 when administered in combination with trastuzumab and in combination with trastuzumab and paclitaxel|In Phase 2, objective tumor response|Duration of response and progression-free survival (Phase 2)|Pharmacokinetics and pharmacodynamics of XL147 and trastuzumab when given in combination, and of XL147, trastuzumab, and paclitaxel when given in combination","Sanofi","Female","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","42","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ARD11439|XL147-203","February 2010","December 2012","December 2012","January 6, 2010",,"June 3, 2016","Investigational Site Number 1537, Los Angeles, California, United States|Investigational Site Number 1238, Fort Meyers, Florida, United States|Investigational Site Number 1138, Boston, Massachusetts, United States|Investigational Site Number 1330, Detroit, Michigan, United States|Investigational Site Number 1151, Bronx, New York, United States|Investigational Site Number 1150, New York, New York, United States|Investigational Site Number 1214, Nashville, Tennessee, United States|Investigational Site Number 1246, Nashville, Tennessee, United States|Investigational Site Number 3413, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT01042925"
176,"NCT00549185","Multi-dose-escalation Safety and Pharmacokinetic Study of SAR3419 as Single Agent in Relapsed/Refractory B-cell Non Hodgkin's Lymphoma",,"Completed","No Results Available","Lymphoma|Non-Hodgkin","Drug: SAR3419","Incidence of Dose Limiting Toxicity(ies) at each tested dose level|Tumor response (complete response, partial response, stable disease) according to Cheson criteria and duration of response|Incidence of Adverse Events","Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 1","39","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TED6828","October 2007","January 2012","January 2012","October 25, 2007",,"February 14, 2012","Sanofi-Aventis Administrative Office, Bridgewater, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT00549185"
177,"NCT01288469","Efficacy and Safety Evaluation of Alirocumab (SAR236553/REGN727) When Co-administered With High Dose of Atorvastatin in Patients With Primary Hypercholesterolemia",,"Completed","Has Results","Hypercholesterolemia","Drug: Alirocumab|Drug: Placebo (for alirocumab)|Drug: Atorvastatin|Drug: Placebo (for atorvastatin)","Percent Change From Baseline in Calculated LDL-C at Week 8 - On-treatment Analysis|Absolute Change From Baseline in Calculated LDL-C (mmol/L) at Week 8 - On-treatment Analysis|Absolute Change From Baseline in Calculated LDL-C (mg/dL) at Week 8 - On-treatment Analysis|Percentage of Participants Achieving Calculated LDL-C <100 mg/dL (2.59 mmol/L) and < 70 mg/dL (1.81 mmol/L) at Week 8 - On-treatment Analysis|Percent Change From Baseline in Total Cholesterol, Fasting Triglycerides, Non-high-Density Lipoprotein Cholesterol (Non-HDL-C), Apolipoprotein B (Apo-B) and Lipoprotein(a) at Week 8 - On-treatment Analysis|Percent Change From Baseline in High-Density Lipoprotein Cholesterol (HDL-C) at Week 8 - On-treatment Analysis|Absolute Change in the Ratio Apolipoprotein B/Apolipoprotein A-1 (ApoB/ApoA-1) From Baseline to Week 8 - On-treatment Analysis","Sanofi|Regeneron Pharmaceuticals","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","92","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","DFI11566|U1111-1117-9994","January 2011","September 2011","September 2011","February 2, 2011","September 24, 2015","September 24, 2015","Investigational Site Number 840616, Mesa, Arizona, United States|Investigational Site Number 840601, Tucson, Arizona, United States|Investigational Site Number 840610, Los Angeles, California, United States|Investigational Site Number 840608, Newport Beach, California, United States|Investigational Site Number 840603, Doral, Florida, United States|Investigational Site Number 840611, Jacksonville, Florida, United States|Investigational Site Number 840618, Jupiter, Florida, United States|Investigational Site Number 840612, Miami, Florida, United States|Investigational Site Number 840614, Miami, Florida, United States|Investigational Site Number 840607, St. Petersburg, Florida, United States|Investigational Site Number 840605, Chicago, Illinois, United States|Investigational Site Number 840619, Chicago, Illinois, United States|Investigational Site Number 840604, Edison, New Jersey, United States|Investigational Site Number 840606, Rochester, New York, United States|Investigational Site Number 840615, Cincinnati, Ohio, United States|Investigational Site Number 840617, Cincinnati, Ohio, United States|Investigational Site Number 840602, Eugene, Oregon, United States|Investigational Site Number 840621, Richmond, Virginia, United States|Investigational Site Number 840609, Olympia, Washington, United States|Investigational Site Number 840613, Oregon, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT01288469"
178,"NCT00926185","A Study Evaluating the Efficacy of SAR 1118 (0.1%, 1.0%, 5.0%) Ophthalmic Solution in Subjects With Dry Eye Conducted in a Controlled Adverse Environment (CAE)",,"Completed","Has Results","Dry Eye","Drug: Lifitegrast|Drug: Placebo","Inferior Corneal Fluorescein Staining Score in Pre-Controlled Adverse Environment at Day 84|Inferior Corneal Staining Score Change From Baseline (CFB) to Day 84","Shire","All","18 Years and older   (Adult, Older Adult)","Phase 2","230","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","1118-KCS-100","June 2009","February 2010","February 2010","June 23, 2009","March 6, 2017","March 6, 2017","The Eye Care Group, Waterbury, Connecticut, United States|Central Maine Eye Care, Lewiston, Maine, United States|Ora, Inc. (two locations), Andover, Massachusetts, United States|Mundorf Eye Center, Charlotte, North Carolina, United States|Total Eye Care, P.A., Memphis, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT00926185"
179,"NCT00276016","The Effects of Phenylephrine Compared With Those of Placebo and Pseudoephedrine on Nasal Congestion in Subjects With Seasonal Allergic Rhinitis (SAR)(P04579)",,"Completed","Has Results","Rhinitis, Allergic, Seasonal","Drug: phenylephrine|Drug: pseudoephedrine|Drug: placebo","The Average Change From Baseline to Endpoint (6 Hours Post-dosing) in Nasal Congestion for Phenylephrine Compared With Placebo|The Average Change From Baseline to Endpoint (6 Hours Post-dosing) in Nasal Congestion for Pseudoephedrine and Placebo.","Merck Sharp & Dohme Corp.","All","18 Years to 55 Years   (Adult)","Phase 3","39","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","P04579","January 2006","February 2006","February 2006","January 12, 2006","July 29, 2010","September 28, 2015",,,"https://ClinicalTrials.gov/show/NCT00276016"
180,"NCT01010971","Clinical Trial to Assess the Efficacy and Safety of Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol for the Treatment of Seasonal Allergic Rhinitis (SAR) to Mountain Cedar in Subjects 12 Years and Older",,"Completed","Has Results","Seasonal Allergic Rhinitis","Drug: Ciclesonide HFA 160 μg|Drug: Ciclesonide HFA 80 μg|Drug: Placebo","Change From Baseline in Daily Subject-reported AM and PM Reflective TNSS Averaged Over the Two-week Treatment Period.|Change From Baseline in Daily Subject-reported AM and PM Instantaneous TNSS Averaged Over the 2-week Treatment Period.|Change From Baseline in Daily Subject-reported AM and PM Reflective TOSS Averaged Over the 2-week Treatment Period in Subjects With Baseline TOSS ≥5.0|Change From Baseline in the RQLQ(S) Overall Score at the End of the 2-week Treatment Period in Impaired Subjects With Baseline RQLQ(S) Score of ≥3.0|Change From Baseline in Daily Subject-reported AM Reflective TNSS Averaged Over the 2-week Treatment Period.|Change From Baseline in Daily Subject-reported PM Reflective TNSS Averaged Over the 2 Week Treatment Period.|Change From Baseline in Daily Subject-reported AM Instantaneous TNSS Averaged Over the 2-week Treatment Period.|Change From Baseline in Daily Subject-reported PM Instantaneous TNSS Averaged Over the 2-week Treatment Period.|Change From Baseline in Daily Subject-reported AM Reflective TOSS Averaged Over the 2-week Treatment Period in Subjects With Baseline TOSS ≥5.0|Change From Baseline in Daily Subject-reported PM Reflective TOSS Averaged Over the 2-week Treatment Period in Subjects With Baseline TOSS ≥5.0|Change From Baseline in Daily Subject-reported AM Instantaneous TOSS Averaged Over the 2-week Treatment Period in Subjects With Baseline TOSS ≥5.0.|Change From Baseline in Daily Subject-reported PM Instantaneous TOSS Averaged Over the 2-week Treatment Period in Subjects With Baseline TOSS ≥5.0.|Change From Baseline in Daily Subject-reported AM and PM Instantaneous TOSS Averaged Over the 2-week Treatment Period in Subjects With Baseline TOSS ≥5.0.|Change From Baseline in Daily Subject-reported Individual AM Instantaneous NSS Averaged Over the 2-week Treatment Period|Change From Baseline in Daily Subject-reported Individual PM Instantaneous NSS Averaged Over the 2-week Treatment Period|Change From Baseline in Daily Subject-reported Individual AM and PM Instantaneous NSS Averaged Over the 2-week Treatment Period|Change From Baseline in Daily Subject-reported Individual AM Reflective Nasal Symptom Scores (NSS) Averaged Over the 2-week Treatment Period.|Change From Baseline in Daily Subject-reported Individual PM Reflective NSS Averaged Over the 2-week Treatment Period.|Change From Baseline in Daily Subject-reported Individual AM and PM Reflective NSS Averaged Over the 2-week Treatment Period.|Change From Baseline in Daily Subject-reported Individual AM Instantaneous OSS in Subjects With Baseline TOSS≥5.0|Change From Baseline in Daily Subject-reported Individual PM Instantaneous OSS in Subjects With Baseline TOSS≥5.0|Change From Baseline in Daily Subject-reported Individual AM and PM Instantaneous OSS in Subjects With Baseline TOSS≥5.0|Change From Baseline in Daily Subject-reported Individual AM Reflective OSS in Subjects With Baseline TOSS ≥5.0|Change From Baseline in Daily Subject-reported Individual PM Reflective OSS in Subjects With Baseline TOSS ≥5.0|Change From Baseline in Daily Subject-reported Individual AM and PM Reflective OSS in Subjects With Baseline TOSS ≥5.0|Change From Baseline in the RQLQ(S) Domains at the End of the 2-week Treatment Period in Impaired Subjects With Baseline RQLQ(S) Score of ≥3.0|Time to Maximal Effect Over the 2-week of Double-blind Treatment Period.","Sunovion","All","12 Years and older   (Child, Adult, Older Adult)","Phase 3","671","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","060-634","December 2009","February 2010","February 2010","November 10, 2009","June 8, 2012","June 13, 2012","Allergy and Asthma Associates, Austin, Texas, United States|Sinus Clinical Research LLC, Austin, Texas, United States|Central Texas Health Research Corporation, New Braunfels, Texas, United States|Biogenics Research Institute, San Antonio, Texas, United States|Southwest Allergy and Asthma Research Center, Pa, San Antonio, Texas, United States|Sylvana Research, San Antonio, Texas, United States|San Antonio, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01010971"
181,"NCT00295022","Compare the Efficacy of Levocetirizine and Montelukast to Placebo in Reducing Seasonal Allergic Rhinitis (SAR) Symptoms in Ragweed Sensitive Subjects",,"Completed","Has Results","Rhinitis, Allergic, Seasonal","Drug: Placebo|Drug: Montelukast|Drug: Levocetirizine","Change From Baseline in the Major Symptom Complex (MSC) Score Over Period I|Change From Baseline in the MSC Score Over Period II|Change From Baseline in the MSC Score Over Period III|Change From Baseline in the MSC Score Over the Total Treatment Period (Period I + Period II + Period III)|Change From Baseline in the Total Symptom Complex (TSC) Score Over Period I|Change From Baseline in the Total Symptom Complex (TSC) Score Over Period II|Change From Baseline in the Total Symptom Complex (TSC) Score Over Period III|Change From Baseline in the Total Symptom Complex (TSC) Score Over the Total Treatment Period (Period I + Period II + Period III)|Change From Baseline in the TSC Score + Nasal Congestion Score Over Period I|Change From Baseline in the TSC Score + Nasal Congestion Score Over Period II|Change From Baseline in the TSC Score + Nasal Congestion Score Over Period III|Change From Baseline in the TSC Score + Nasal Congestion Score Over the Total Treatment Period (Period I + Period II + Period III)|Change From Baseline in the Individual Symptom Scores Over Period I|Change From Baseline in the Individual Symptom Scores Over Period II|Change From Baseline in the Individual Symptom Scores Over Period III|Change From Baseline in the Individual Symptom Scores Over the Total Treatment Period (Period I + Period II + Period III)|Time to First Feeling of Improvement During Period I|Onset of Action During Period I|Intensity of Action From Baseline in the MSC Score Over Period I|Intensity of Action From Baseline in the MSC Score Over Period II|Intensity of Action From Baseline in the MSC Score Over Period III|Variability of Action From Baseline in the MSC Score Over Period I|Variability of Action From Baseline in the MSC Score Over Period II|Variability of Action From Baseline in the MSC Score Over Period III|Global Satisfaction of the Subjects at the End of Period III|Percentage of Subjects, at the End of Period III Who Are Willing to Take the Same Medication During the Next Pollen Season","UCB S.A. - Pharma Sector|UCB Pharma","All","18 Years and older   (Adult, Older Adult)","Phase 4","418","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","A00414","July 29, 2006","October 1, 2006","October 1, 2006","February 22, 2006","July 23, 2018","September 11, 2018","Kingston, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT00295022"
182,"NCT00291642","A Study to Compare the Efficacy of Levocetirizine to Placebo in Reducing Symptoms of Seasonal Allergic Rhinitis (SAR) in Sensitive Subjects Exposed to Ragweed Pollen",,"Completed","Has Results","Rhinitis|Allergic|Seasonal","Drug: Placebo drops|Drug: Placebo tablets matching to levocetirizine|Drug: Placebo tablets matching to cetirizine|Drug: Levocetirizine drops|Drug: Levocetirizine tablets|Drug: Cetirizine drops|Drug: Cetirizine tablets","Change From Baseline in the Major Symptom Complex (MSC) Score Over Period I|Change From Baseline in the MSC Score Over Period II|Change From Baseline in the MSC Score Over the Total Treatment Period (Period I + Period II)|Change From Baseline in the Total Symptom Complex (TSC) Score Over Period I|Change From Baseline in the Total Symptom Complex (TSC) Score Over Period II|Change From Baseline in the Total Symptom Complex (TSC) Score Over the Total Treatment Period (Period I + Period II)|Change From Baseline in the Individual Symptom Scores Over Period I|Change From Baseline in the Individual Symptom Scores Over Period II|Change From Baseline in the Individual Symptom Scores Over the Total Treatment Period (Period I + Period II)","UCB Pharma","All","16 Years and older   (Child, Adult, Older Adult)","Phase 2","551","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","A00412","January 1, 2006","April 1, 2006","April 1, 2006","February 14, 2006","July 20, 2018","September 11, 2018","Kingston, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT00291642"
183,"NCT00315523","Compare the Efficacy of Levocetirizine to Montelukast in Reducing Symptoms of SAR in Sensitive Subjects Exposed to Ragweed Pollen",,"Completed","No Results Available","Rhinitis, Allergic, Seasonal","Drug: Levocetirizine","Compare efficacy of Levocetirizine 5 mg to montelukast 10 mg as measured by the mean change from baseline of major symptoms related to SAR in ragweed sensitive subjects.|Reduction in other SAR symptoms at different time points; Safety .","UCB Pharma","All","18 Years and older   (Adult, Older Adult)","Phase 3","403","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","A00415","July 2006","October 2006","October 2006","April 18, 2006",,"December 16, 2013","Mississauga, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT00315523"
184,"NCT00491504","This Study Contains an Active Drug Treatment Group With Mometasone Furoate Nasal Spray and a Placebo (Dummy) Treatment Group for Seasonal Allergic Rhinitis (SAR). (Study P05073)(COMPLETED)",,"Completed","Has Results","Seasonal Allergic Rhinitis","Drug: Mometasone Furoate Nasal Spray|Other: Placebo","Changes in the Total Nasal Symptom Severity Score (TNSS) at 6 Hours After Dosage Administration on Day 1","Merck Sharp & Dohme Corp.","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","310","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","P05073","February 2007","July 2007","July 2007","June 26, 2007","April 5, 2010","March 13, 2015",,,"https://ClinicalTrials.gov/show/NCT00491504"
185,"NCT03444506","Efficacy and Safety of Fixed Dose Combination (FDC) of Olopatadine Hydrochloride and Mometasone Furoate Nasal Spray (Molo; Also Referred as GSP 301) in the Treatment of Seasonal Allergic Rhinitis (SAR)","GSP 301- PoC","Completed","No Results Available","Seasonal Allergic Rhinitis","Drug: Molo 1 (also referred as GSP 301-2 NS)|Drug: Molo 2 (also referred as GSP 301-1 NS)|Drug: Placebo nasal spray|Drug: DYMISTA nasal spray|Drug: PATANASE nasal spray","Change in mean post-treatment instantaneous Total Nasal Symptoms Score (iTNSS) for Molo 1 and Molo 2 compared with placebo from baseline to end of treatment|Change in mean post-treatment iTNSS for Molo 1 and Molo 2 compared with reference products Dymista and Patanase|Change in mean post-treatment iTNSS for reference products Dymista and Patanase compared with placebo|Onset of action assessed by comparing change in iTNSS after the first dose|Change from baseline in post-treatment instantaneous Total Symptoms Score (iTSS) (Molo 1 and Molo 2 versus Active Comparator)|Change from baseline in individual instantaneous Nasal Symptoms Scores (iNSS) (Molo 1 and Molo 2 versus Active Comparator)|Change from baseline in instantaneous Total Ocular Symptom Score (iTOSS) (Molo 1 and Molo 2 versus Active Comparator)|Change in mean post-treatment Environmental Exposure Chamber - Rhinoconjunctivitis Quality-of-Life Questionnaire (EEC-QoLQ) scores|Responses to a reflective Global Assessment of Tolerability and Acceptance Questionnaire (GATAQ)","Glenmark Pharmaceuticals Ltd. India","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","180","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","GPL/CT/2013/001/II","January 27, 2014","February 28, 2014","February 28, 2014","February 23, 2018",,"June 20, 2018","Glenmark Investigational Site 1, Mississauga, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT03444506"
186,"NCT04244591","Glucocorticoid Therapy for Novel CoronavirusCritically Ill Patients With Severe Acute Respiratory Failure","Steroids-SARI","Not yet recruiting","No Results Available","Coronavirus Infections|Respiratory Infection Virus","Drug: methylprednisolone therapy|Other: Standard care","Lower Murray lung injury score|The difference of PaO2/FiO2 between two groups|Lower Sequential Organ Failure Assessment (SOFA) score|Mechanical ventilation support|Clearance of noval coronavirus|All-cause mortality","Peking Union Medical College Hospital|Zhongda Hospital|Zhongnan Hospital|Renmin Hospital of Wuhan University","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Glucocorticoid nCoV","January 26, 2020","April 25, 2020","December 25, 2020","January 28, 2020",,"January 28, 2020","Medical ICU,Peking Union Medical College Hospital, Beijing, Beijing, China",,"https://ClinicalTrials.gov/show/NCT04244591"
187,"NCT03465085","Streptokinase Versus Unfractionated Heparin Nebulization in Severe ARDS",,"Completed","No Results Available","Acute Respiratory Distress Syndrome|Severe Acute Respiratory Syndrome","Drug: Unfractionated heparin|Drug: Streptokinase","Change in PaO2/FiO2 ratio|Change in the plateau pressure|Change in the pulmonary compliance|ICU survival rate|ICU length of stay|Tracheostomy rate","Beni-Suef University","All","21 Years to 60 Years   (Adult)","Phase 3","60","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","Heparin-Streptokinase-ARDS","February 18, 2016","January 30, 2018","January 30, 2018","March 14, 2018",,"March 14, 2018",,,"https://ClinicalTrials.gov/show/NCT03465085"
188,"NCT00790023","Clinical Trial to Assess the Efficacy and Safety of Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol for the Treatment of Seasonal Allergic Rhinitis",,"Completed","Has Results","Seasonal Allergic Rhinitis","Drug: 80 mcg Ciclesonide|Drug: 160 mcg Ciclesonide|Drug: Placebo","Change From Baseline in Daily Subject-reported AM and PM Reflective Total Nasal Symptom Score (rTNSS) Averaged Over the Two-week Treatment Period.|Change From Baseline in Daily Subject-reported AM and PM iTNSS Averaged Over the Two-week Treatment Period.|Change From Baseline in Daily Subject-reported AM and PM rTOSS Averaged Over the Two-week Treatment Period in Participants With a Baseline rTOSS >= 5.0|Change From Baseline in Daily Subject-reported AM rTNSS Averaged Over the Two Week Treatment Period|Change From Baseline in Daily Subject-reported PM rTNSS Averaged Over the Two Week Treatment Period|Change From Baseline in Daily Subject-reported AM iTNSS Averaged Over the Two Week Treatment Period|Change From Baseline in Daily Subject-reported PM iTNSS Averaged Over the Two Week Treatment Period|Change From Baseline in Daily Subject-reported AM rTOSS Averaged Over the Two Week Treatment Period in Subjects With Baseline rTOSS ≥5.0|Change From Baseline in Daily Subject-reported PM rTOSS Averaged Over the Two Week Treatment Period in Subjects With Baseline rTOSS ≥5.0|Change From Baseline in Daily Subject-reported AM iTOSS Averaged Over the Two Week Treatment Period in Subjects With Baseline iTOSS ≥5.0|Change From Baseline in Daily Subject-reported PM iTOSS Averaged Over the Two Week Treatment Period in Subjects With Baseline iTOSS ≥5.0|Change From Baseline in Daily Subject Reported AM and PM iTOSS Averaged Over the Two Week Treatment Period in Subjects With Baseline iTOSS ≥5.0|Change From Baseline in Daily Subject-reported AM rNSS Averaged Over the Two Week Treatment Period|Change From Baseline in Daily Subject-reported PM rNSS Averaged Over the Two Week Treatment Period|Change From Baseline in Daily Subject-reported AM and PM rNSS Averaged Over the Two Week Treatment Period|Change From Baseline in Daily Subject-reported AM iNSS Averaged Over the Two Week Treatment Period|Change From Baseline in Daily Subject-reported PM iNSS Averaged Over the Two Week Treatment Period|Change From Baseline in Daily Subject-reported AM and PM iNSS Averaged Over the Two Week Treatment Period|Change From Baseline in Daily Subject-reported AM rOSS Averaged Over the Two Week Treatment Period in Subjects With Baseline rTOSS ≥5.0|Change From Baseline in Daily Subject-reported PM rOSS Averaged Over the Two Week Treatment Period in Subjects With Baseline rTOSS ≥5.0|Change From Baseline in Daily Subject-reported and AM and PM rOSS Averaged Over the Two Week Treatment Period in Subjects With Baseline rTOSS ≥5.0|Change From Baseline in Daily Subject-reported AM iOSS Averaged Over the Two Week Treatment Period in Subjects With Baseline iTOSS ≥5.0|Change From Baseline in Daily Subject-reported PM iOSS Averaged Over the Two Week Treatment Period in Subjects With Baseline iTOSS ≥5.0|Change From Baseline in Daily Subject-reported AM and PM iOSS Averaged Over the Two Week Treatment Period in Subjects With Baseline iTOSS ≥5.0|Change From Baseline in Overall Score of the Rhinoconjunctivitis Quality of Life Questionnaire With Standard Activities (RQLQ(S)) in Participants With a Baseline Overall Score >= 3.0|Onset of Improvement in Instantaneous Total Nasal Symptoms Scores (iTNSS)|Onset of Improvement in Instantaneous Total Ocular Symptoms Scores (iTOSS) in Subjects With Baseline iTOSS ≥5.0|Time to Maximal Effect as Measured by Change From Baseline in the Average AM and PM Reflective Total Nasal Symptoms Scores (rTNSS)","Sunovion","All","12 Years and older   (Child, Adult, Older Adult)","Phase 3","707","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","060-622","November 2008","February 2009","February 2009","November 13, 2008","June 8, 2012","April 8, 2016","Austin, Texas, United States|Kerrville, Texas, United States|New Braunfels, Texas, United States|San Antonio, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00790023"
189,"NCT01056185","Respiratory Virus Hospitalization Study (FLU 003 Plus)",,"Recruiting","No Results Available","Influenza|Novel Respiratory Virus-1 Middle Eastern Respiratory Syndrome Coronavirus (MERS-CoV)|Novel Respiratory Virus-2 Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV)",,"Death|Recovery from influenza illness (including days lost from normal activities) duration of hospitalization, days in intensive care, days of mechanical ventilation, days of dialysis, pregnancy outcome","University of Minnesota|National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health (NIH)","All","18 Years and older   (Adult, Older Adult)",,"1000","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","0603M83587 FLU 003","August 2009","December 2020","December 2020","January 26, 2010",,"November 19, 2019","UCSD Antiviral Research Center, San Diego, California, United States|George Washington Medical Faculty Associates, Washington, District of Columbia, United States|Washington DC VA Medical Center, Washington, District of Columbia, United States|University of Illinois at Chicago, Chicago, Illinois, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Baystate Infectious Diseases Clinical Research, Springfield, Massachusetts, United States|Henry Ford Health System, Detroit, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|Cooper University Hospital, Camden, New Jersey, United States|New Jersey Medical School Adult Clinical Research Center, Newark, New Jersey, United States|Montefiore Medical Center, Bronx, New York, United States|Cornell CRS, New York, New York, United States|Duke University, Durham, North Carolina, United States|The Ohio State University Medical Center, Columbus, Ohio, United States|Miami Valley Hospital, Dayton, Ohio, United States|University of Tennessee College of Medicine, Chattanooga, Tennessee, United States|Virginia Commonwealth University, Richmond, Virginia, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Hospital Nacional Profesor Alejandro Posadas, El Palomar, Buenos Aires, Argentina|Instituto Medico Platense, La Plata, Buenos Aires, Argentina|Hospital Universitario Austral, Pilar, Buenos Aires, Argentina|Hospital Profesor Bernardo Houssay, Vicente Lopez, Buenos Aires, Argentina|Sanatorio Britanico, Rosario, Santa Fe, Argentina|CEMIC, Buenos Aires, Argentina|Hospital General de Agudos JM Ramos Mejia, Buenos Aires, Argentina|Hospital Interzonal General de Agudos Dr. Diego Paroissien, Buenos Aires, Argentina|Hospital Italiano de Buenos Aires, Buenos Aires, Argentina|Hospital Privado Centro Medico de Cordoba, Cordoba, Argentina|Hospital Rawson, Cordoba, Argentina|St. Vincent's Hospital, Darlinghurst, New South Wales, Australia|Westmead Hospital, Westmead, New South Wales, Australia|The Alfred Hospital, Melbourne, Victoria, Australia|Centre Hospitalier Universitaire St. Pierre (C.H.U. St. Pierre), Brussels, Belgium|Clinica Alemana, Santiago, Chile|Fundacion Arriaran, Santiago, Chile|Arhus Universitetshospital, Skejby, Aarhus, Denmark|CHIP, Copenhagen, Denmark|Hvidovre University Hospital, Department of Infectious Diseases, Hvidovre, Denmark|Odense University Hospital, Odense, Denmark|Medizinische Universitatsklinik - Bonn, Immunologische Ambulanz CRS, Bonn, Germany|Klinik I fur Innere Medizin der Universitat zu Koln, Studienburo fur Infektiologie u. HIV, Cologne, Germany|Johann Wolfgang Goethe - University Hospital, Infektionsambulanz CRS, Frankfurt, Germany|1st Dept of Critical Care Medicine and Pulmonary Services, Evangelismos Hospital, Athens, Greece|1st Respiratory Medicine Dept, Athens Hosp for Diseases of the Chest ""Sotiria Hospital"", Athens, Greece|Evangelismos General Hospital, Athens, Greece|Hippokration University General Hospital of Athens, Athens, Greece|Hospital Nacional Arzobispo Loayza, Lima, Peru|Hospital Nacional Guillermo Almenara Irigoyen, Lima, Peru|Hospital Clinico San Carlos, Madrid, Spain|Hospital La Paz, Madrid, Spain|Hospital Universitario Gregorio Mara�on, Madrid, Spain|Hospital Universitario Infanta Leonor, Madrid, Spain|Hospital Txagorritxu, Vitoria-Gasteiz, Spain|Chulalongkorn University Hospital, Bangkok, Thailand|Khon Kaen University, Srinagarind Hospital, Khon Kaen, Thailand|Bamrasnaradura Institute, Nonthaburi, Thailand|Heatherwood and Wexham Park Hospitals NHS Foundation Trust, Slough, Berkshire, United Kingdom|Brighton and Sussex University Hospitals NHS Trust, Brighton, East Sussex, United Kingdom|Churchill Hospital, Headington, Oxford, United Kingdom|Sheffield Teaching Hospital NHS Foundation Trust, Sheffield, South Yorkshire, United Kingdom|Bradford Teaching Hospitals NHS Foundation Trust, Bradford, West Yorkshire, United Kingdom|St James's University Hospital, Leeds, West Yorkshire, United Kingdom|Newcastle General Hospital, Newcastle upon Tyne, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01056185"
190,"NCT01171664","Clinical Trial of STAHIST in Seasonal Allergic Rhinitis (SAR) Subjects","STA-2","Completed","No Results Available","Seasonal Allergic Rhinitis","Drug: Placebo|Drug: STAHIST","Total Symptom Scores(TSS)reported and compared between the two study arms|Adverse events--report and assess","Magna Pharmaceuticals, Inc.","All","18 Years to 60 Years   (Adult)","Phase 2","100","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","105781-2","September 2010","October 2010","January 2011","July 28, 2010",,"March 26, 2014","The South Bend Clinic, South Bend, Indiana, United States|Family Allergy & Asthma Research Institute, Louisville, Kentucky, United States",,"https://ClinicalTrials.gov/show/NCT01171664"
191,"NCT01058733","Semi-automatic Response System(SARS)in Type 2 Diabetes","SARS","Completed","No Results Available","Diabetes Mellitus","Other: Internet","physicians' labour time and frequency of contact with the online communication system required for reviewing the patients' information and sending recommendations","The Catholic University of Korea","All","20 Years to 70 Years   (Adult, Older Adult)","Not Applicable","79","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SARS-Project","October 2006","May 2007","May 2007","January 29, 2010",,"January 29, 2010","Seoul St. Mary's Hospital, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01058733"
192,"NCT00160537","POPULAR (Preference Of Patient Using Levocetirizine in Allergic Rhinitis)",,"Completed","No Results Available","Seasonal Allergic Rhinitis","Drug: Levocetirizine","Subjects' satisfaction / dissatisfaction after the first week of treatment.|allergic rhinitis symptoms scores over the first week of treatment , subject's satisfaction / dissatisfaction of their choice of treatment after the first week of treatment, time to first feeling of (sufficient) symptom improvement during the first we","UCB Pharma","All","18 Years and older   (Adult, Older Adult)","Phase 4","200","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double","A00391|EudraCT 2004-002971-18|POPULAR","May 2005","July 2005","July 2005","September 12, 2005",,"December 16, 2013",,,"https://ClinicalTrials.gov/show/NCT00160537"
193,"NCT00574210","PK/PD and Steady State Efficacy Study of Bilastine Compared With Placebo Given Orally in the Treatment of the Symptoms of SAR in an EEC Model (5-arm)",,"Completed","No Results Available","Seasonal Allergic Rhinitis|Hay Fever|Rhinoconjunctivitis","Drug: Bilastine|Drug: Placebo","Total Nasal Symptom Scores (TNSS)|Total Symptom Scores (TSS), Total Non-Nasal Symptom Scores (TNNSS), Total Ocular Symptoms Scores (TOSS), Area Under the Curve (AUC) of TNSS, TSS, TOSS, TNNSS, Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ - EEC)","Faes Farma, S.A.|Allied Research International","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","502","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","BILA 2507/EEC|P2FZ07001","October 2007","February 2008","February 2008","December 17, 2007",,"February 15, 2019","Allied Research International - Cetero Research, Mississauga, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT00574210"
194,"NCT04033367","SAR231893-LPS15497- ""Dupilumab Effect on Sleep in AD Patients""",,"Recruiting","No Results Available","Atopic Dermatitis","Drug: DUPILUMAB|Drug: PLACEBO","Percentage change from baseline to Week 12 in sleep quality numerical rating scale (NRS)|Change from baseline to Week 12 in sleep efficiency based on actigraphy data|Change from baseline to Week 12 in total sleep time based on actigraphy data|Change from baseline to Week 12 in wake after sleep onset based on actigraph data|Change from baseline to Week 12 in sleep latency based on actigraph data|Percent change from baseline to Week 12 in pruritus|Change from baseline to Week 12 in SCORing Atopic Dermatitis (SCORAD) total score|Change from baseline to Week 12 in SCORAD sleep Visual Analog Scale (VAS) subscore|Change from baseline to Week 12 in Patient Oriented Eczema Measure (POEM) total score|EASI50 (50% reduction in Eczema Area and Severity Index score) at Week 12|EASI75 (75% reduction in Eczema Area and Severity Index score) at Week12|Change from baseline to Week 12 in Dermatology Life Quality Index (DLQI) total score|Change from baseline to Week 12 in Patient-Reported Outcomes Measurement Information System (PROMIS) Sleep Related Impairment Short-Form 8a (SF8a) Total Score|Adverse events","Sanofi|Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 4","201","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","LPS15497|2018-004705-26|U1111-1223-4147","August 22, 2019","June 2021","June 2021","July 26, 2019",,"January 10, 2020","Investigational Site Number 8400002, Redwood City, California, United States|Investigational Site Number 8400001, Rolling Hills Estates, California, United States|Investigational Site Number 8400005, Denver, Colorado, United States|Investigational Site Number 8400003, Sarasota, Florida, United States|Investigational Site Number 8400007, Medford, Oregon, United States|Investigational Site Number 3760003, Jerusalem, Israel|Investigational Site Number 3760001, Rehovot, Israel",,"https://ClinicalTrials.gov/show/NCT04033367"
195,"NCT00659841","To Assess the Safety and Efficacy of Ciclesonide, Applied as a Nasal Spray in the Treatment of Seasonal Allergic Rhinitis (BY9010/M1-401)",,"Completed","No Results Available","Rhinitis, Allergic, Seasonal|Hay Fever","Drug: Ciclesonide|Drug: Placebo","Average of AM and PM patient-reported reflective Total Nasal Symptom Score (TNSS) over the first two weeks of treatment|Instantaneous patient-reported TNSS over the first two weeks of treatment|Physician Assessment of Overall Nasal Signs and Symptoms Severity (PANS) at Endpoint|Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) at Endpoint","AstraZeneca","All","12 Years and older   (Child, Adult, Older Adult)","Phase 3","302","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","BY9010/M1-401","December 2003","December 2004","February 2005","April 16, 2008",,"December 2, 2016","Altana/Nycomed, Austin, Texas, United States|Altana/Nycomed, Austin, Texas, United States|Altana/Nycomed, Kerrville, Texas, United States|Altana/Nycomed, New Braunfels, Texas, United States|Altana/Nycomed, San Antonio, Texas, United States|Altana/Nycomed, San Antonio, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00659841"
196,"NCT00659503","Study Using the Environmental Exposure Unit (EEU) to Assess the Onset of Action of Ciclesonide, Applied as a Nasal Spray in the Treatment of Seasonal Allergic Rhinitis (BY9010/M1-407)",,"Completed","No Results Available","Rhinitis, Allergic, Seasonal|Hay Fever","Drug: Ciclesonide|Drug: Placebo","Time to onset of action, measured by a difference from placebo in the change from baseline in patient- assessed instantaneous TNSS following treatment|Changes in TNSS from baseline at each time point|Changes in individual nasal symptom score from baseline at each time point|Proportion of patients exhibiting good/excellent response at each time point defined as all components of the patient-assessed TNSS scored as mild or less in severity.|Spontaneous and elicited adverse events (AEs)|Physical exam (including nasal exam)|Vital signs","AstraZeneca","All","18 Years and older   (Adult, Older Adult)","Phase 3","420","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","BY9010/M1-407","February 2005","April 2005","November 2005","April 16, 2008",,"December 2, 2016","Altana/Nycomed, Kingston, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT00659503"
197,"NCT00659594","Study Using the Environmental Exposure Chamber (EEC) to Assess the Onset of Action of Ciclesonide, Applied as a Nasal Spray in Treatment of Seasonal Allergic Rhinitis (BY9010/M1-406)",,"Completed","No Results Available","Rhinitis, Allergic, Seasonal|Hay Fever","Drug: Ciclesonide|Drug: Placebo","Time to onset of action, measured by a difference from placebo in the change from baseline in patient -assessed instantaneous TNSS following treatment|Changes in TNSS from baseline at each time point|Changes in individual nasal symptom score from baseline at each time point|Proportion of patients exhibiting good/excellent response at each time point defined as all components of the patient-assessed TNSS scored as mild or less in severity|Spontaneous and elicited adverse events (AEs)|Physical exam (including nasal exam)|Vital signs","AstraZeneca","All","18 Years and older   (Adult, Older Adult)","Phase 3","500","Industry","Interventional","Allocation: Randomized|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","BY9010/M1-406","November 2004","February 2005","September 2005","April 16, 2008",,"December 2, 2016","Altana/Nycomed, Mississauga, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT00659594"
198,"NCT00384475","A Study of Ciclesonide Nasal Spray in Patients 18 Years and Older With Seasonal Allergic Rhinitis (BY9010/M1-413)",,"Completed","No Results Available","Rhinitis, Allergic, Seasonal|Hay Fever","Drug: Ciclesonide Nasal Spray","Onset of action, measured by change from baseline in Total Nasal Symptom Score.|changes in symptoms, safety.","AstraZeneca","All","18 Years and older   (Adult, Older Adult)","Phase 3","500","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","BY9010/M1-413","October 2006","January 2007","January 2007","October 6, 2006",,"November 30, 2016","Altana Pharma/Nycomed, Ontario, Mississauga, Canada",,"https://ClinicalTrials.gov/show/NCT00384475"
199,"NCT04077892","Compare the Effect of INS Alone and Added LTRA in Treatment of SAR",,"Completed","No Results Available","Allergic Rhinitis","Drug: budesonide","The change of subjective AR symptoms|The change of objective examination: nasal patency|The change of Fractional Exhaled NO","Beijing Tongren Hospital","All","18 Years to 47 Years   (Adult)","Early Phase 1","46","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","TR-INS&LTRA-AR","June 1, 2016","September 30, 2016","September 30, 2016","September 4, 2019",,"September 4, 2019","Beijing Tongren Hospital, Beijing, Beijing, China",,"https://ClinicalTrials.gov/show/NCT04077892"
200,"NCT01271972","Study of Nesvacumab (REGN910/ SAR307746)",,"Completed","No Results Available","Solid Tumors","Drug: nesvacumab (REGN910/ SAR307746)","Determine the maximum tolerable dose or recommended phase 2 dose of nesvacumab (REGN910/ SAR307746) in patients with advanced solid malignancies|PK/PD profile|Immunogenicity|Anti-tumor activity|Correlative biomarkers","Regeneron Pharmaceuticals|Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 1","53","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","R910-ST-1010","January 2011","September 2014","May 2015","January 7, 2011",,"June 16, 2015","San Francisco, California, United States|San Antonio, Texas, United States|Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT01271972"
201,"NCT01910220","Study to Assess the Safety and Bioeffect of REGN1033 (SAR391786)",,"Completed","No Results Available","Healthy Volunteers","Drug: REGN1033 (SAR391786)|Other: placebo","Percent change in total lean mass|Number of TEAEs|Appendicular lean mass by DXA","Regeneron Pharmaceuticals|Sanofi","All","60 Years and older   (Adult, Older Adult)","Phase 1","125","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","R1033-HV-1223","August 2013","June 2014","October 2014","July 29, 2013",,"November 10, 2014","Gainesville, Florida, United States|Orlando, Florida, United States|Boston, Massachusetts, United States|St. Louis, Missouri, United States|Athens, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT01910220"
202,"NCT01963598","Study of the Safety and Efficacy of REGN1033 (SAR391786) in Patients With Sarcopenia",,"Completed","No Results Available","Sarcopenia","Drug: REGN1033 (SAR391786)|Drug: placebo","Percent change in total lean body mass|TEAEs|Change in appendicular lean mass|Change in maximal leg press strength (1-RM)|Change in maximal chest press strength (1-RM)|Change in 4M gait speed|Change in SPPB subscores|Change in distance walked in the 6MWT|Change in regional and total fat mass by DEXA|Change in hand grip strength by handheld dynamometer|Change in unloaded and loaded stair climb power","Regeneron Pharmaceuticals|Sanofi","All","70 Years and older   (Older Adult)","Phase 2","253","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","R1033-SRC-1239","November 2013","January 2015","February 2015","October 16, 2013",,"March 28, 2016","Anniston, Alabama, United States|Phoenix, Arizona, United States|El Cajon, California, United States|Garden Grove, California, United States|Laguna Hills, California, United States|San Francisco, California, United States|Walnut Creek, California, United States|Aurora, Colorado, United States|Gainesville, Florida, United States|Jacksonville, Florida, United States|Jupiter, Florida, United States|Orlando, Florida, United States|South Miami, Florida, United States|Chicago, Illinois, United States|Baton Rouge, Louisiana, United States|College Park, Maryland, United States|Elkridge, Maryland, United States|Boston, Massachusetts, United States|Edina, Minnesota, United States|Omaha, Nebraska, United States|Albuquerque, New Mexico, United States|High Point, North Carolina, United States|Winston-Salem, North Carolina, United States|Athens, Ohio, United States|Columbus, Ohio, United States|Duncansville, Pennsylvania, United States|Spartanburg, South Carolina, United States|Dallas, Texas, United States|Plano, Texas, United States|San Antonio, Texas, United States|Salt Lake City, Utah, United States|West Jordan, Utah, United States|Richmond, Virginia, United States|Limoges, France|Montpellier Cedex 5, France|Saint-Etienne Cedex 2, France|Toulouse, France|Amsterdam, Netherlands|Leeuwarden, Netherlands|Noord-Brabant, Netherlands|Albacete, Spain|L'Hospitalet de Llobregat, Spain|Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT01963598"
203,"NCT02121080","Study of the Safety and Tolerability of REGN2222(SAR438584) in Healthy Adult Volunteers",,"Completed","No Results Available","Healthy Volunteers","Drug: REGN2222(SAR438584)|Drug: placebo","The incidence and severity of treatment-emergent adverse events (TEAEs) in participants treated with REGN2222 or placebo.|Serum concentration|Presence or absence of antibodies","Regeneron Pharmaceuticals","All","18 Years to 60 Years   (Adult)","Phase 1","132","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","R2222-HV-1326","May 2014","February 2015","February 2015","April 23, 2014",,"March 11, 2015","Daytona Beach, Florida, United States|Evansville, Indiana, United States|Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02121080"
204,"NCT02057250","To Evaluate Sarilumab - SAR153191 (REGN88) - Auto-injector Device In Patients With Rheumatoid Arthritis","SARIL-RA-EASY","Completed","Has Results","RA","Drug: Sarilumab|Device: Auto-Injector Device (AID)|Device: Pre-filled Syringe (PFS)|Drug: Methotrexate|Drug: Sulfasalazine|Drug: Leflunomide|Drug: Hydroxychloroquine","Number of Validated AID Associated Product Technical Failures (PTFs)|Area Under the Serum Concentration Versus Time Curve Calculated Using the Trapezoidal Method During a Dose Interval (AUC[0-tau]) for Sarilumab","Sanofi|Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 3","217","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MSC12665|2012-004339-21|U1111-1130-9931","March 2014","February 2015","March 2016","February 7, 2014","June 20, 2017","June 20, 2017","Investigational Site Number 840152, Huntsville, Alabama, United States|Investigational Site Number 840221, Peoria, Arizona, United States|Investigational Site Number 840226, Roseville, California, United States|Investigational Site Number 840223, Boulder, Colorado, United States|Investigational Site Number 840229, Miami, Florida, United States|Investigational Site Number 840236, Orlando, Florida, United States|Investigational Site Number 840155, Palm Harbor, Florida, United States|Investigational Site Number 840220, South Miami, Florida, United States|Investigational Site Number 840202, Hagerstown, Maryland, United States|Investigational Site Number 840232, Flint, Michigan, United States|Investigational Site Number 840233, Kalamazoo, Michigan, United States|Investigational Site Number 840037, Tupelo, Mississippi, United States|Investigational Site Number 840112, Lincoln, Nebraska, United States|Investigational Site Number 840039, Albany, New York, United States|Investigational Site Number 840224, Cincinnati, Ohio, United States|Investigational Site Number 840002, Oklahoma City, Oklahoma, United States|Investigational Site Number 840065, Tulsa, Oklahoma, United States|Investigational Site Number 840009, Duncansville, Pennsylvania, United States|Investigational Site Number 840062, Reading, Pennsylvania, United States|Investigational Site Number 840016, North Charleston, South Carolina, United States|Investigational Site Number 840025, Jackson, Tennessee, United States|Investigational Site Number 840038, Austin, Texas, United States|Investigational Site Number 840230, Carrollton, Texas, United States|Investigational Site Number 840001, Dallas, Texas, United States|Investigational Site Number 840020, Houston, Texas, United States|Investigational Site Number 840239, Houston, Texas, United States|Investigational Site Number 840241, Houston, Texas, United States|Investigational Site Number 840242, Houston, Texas, United States|Investigational Site Number 840069, Lubbock, Texas, United States|Investigational Site Number 840074, Mesquite, Texas, United States|Investigational Site Number 840237, Plano, Texas, United States|Investigational Site Number 152005, Osorno, Chile|Investigational Site Number 152050, Santiago, Chile|Investigational Site Number 152014, Talca, Chile|Investigational Site Number 152007, Viña Del Mar, Chile|Investigational Site Number 484002, Guadalajara, Mexico|Investigational Site Number 484004, Merida, Mexico|Investigational Site Number 484005, Monterrey, Mexico|Investigational Site Number 616002, Bialystok, Poland|Investigational Site Number 616005, Lublin, Poland|Investigational Site Number 616004, Warszawa, Poland|Investigational Site Number 616017, Warszawa, Poland|Investigational Site Number 616012, Wroclaw, Poland|Investigational Site Number 643006, Kemerovo, Russian Federation|Investigational Site Number 643020, Moscow, Russian Federation|Investigational Site Number 643001, Moscow, Russian Federation|Investigational Site Number 643008, Saint-Petersburg, Russian Federation|Investigational Site Number 710050, Bellville, South Africa|Investigational Site Number 710011, Cape Town, South Africa|Investigational Site Number 710007, Cape Town, South Africa|Investigational Site Number 710003, Durban, South Africa|Investigational Site Number 710001, Johannesburg, South Africa|Investigational Site Number 710051, Port Elizabeth, South Africa",,"https://ClinicalTrials.gov/show/NCT02057250"
205,"NCT02210780","Study of Dupilumab (REGN668/ SAR231893) and Immune Responses in Adults With Atopic Dermatitis (AD)",,"Completed","No Results Available","Atopic Dermatitis","Drug: Dupilumab|Drug: placebo","Proportion of participants with a positive response to administered vaccine|Proportion of patients with a positive response at week 16|Menomune response|Proportion of patients who achieve IGA (0-1)|Proportion of patients achieving at least 50% reduction in EASI scores|Proportion of patients achieving at least 75% reduction in EASI scores|Change from baseline in maximum itch intensity (NRS)|Change from baseline in BSA|Change from baseline in the erythema of GISS|Change from baseline in the infiltration of GISS|Change from baseline in the infiltration/ papulation of GISS|Change from baseline in the excoriations of GISS|Change from baseline in the lichenification of GISS|Change from baseline to week 16 in POEM|TEAEs|Study drug discontinuation due to a TEAE|Incidence of skin-infections","Regeneron Pharmaceuticals|Sanofi","All","18 Years to 64 Years   (Adult)","Phase 2","194","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","R668-AD-1314","August 2014","August 2015","September 2015","August 7, 2014",,"February 8, 2017","Birmingham, Alabama, United States|Fort Smith, Arkansas, United States|Long Beach, California, United States|Los Angeles, California, United States|Mission Viejo, California, United States|Rolling Hills Estates, California, United States|San Diego (3 locations), California, United States|Santa Monica, California, United States|Denver, Colorado, United States|Jacksonville, Florida, United States|Miami (2 locations), Florida, United States|Tampa (2 locations), Florida, United States|Macon, Georgia, United States|Chicago, Illinois, United States|Maywood, Illinois, United States|West Dundee, Illinois, United States|Indianapolis, Indiana, United States|Plainfield, Indiana, United States|Overland Park, Kansas, United States|Boston, Massachusetts, United States|Ann Arbor, Michigan, United States|Troy, Michigan, United States|St. Louis, Missouri, United States|Hackensack, New Jersey, United States|Albuquerque (2 locations), New Mexico, United States|Buffalo, New York, United States|Forest Hills, New York, United States|New York, New York, United States|Cleveland, Ohio, United States|Norman, Oklahoma, United States|Tulsa, Oklahoma, United States|Medford, Oregon, United States|Portland (2 locations), Oregon, United States|Pittsburgh, Pennsylvania, United States|Charleston, South Carolina, United States|Greer, South Carolina, United States|Arlington, Texas, United States|Austin, Texas, United States|Houston, Texas, United States|Webster, Texas, United States|Richmond, Virginia, United States|Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT02210780"
206,"NCT01720576","Study to Assess the Safety and Tolerability of Multiple Ascending Doses of REGN1033 (SAR391786)",,"Completed","No Results Available","Healthy Volunteers","Drug: REGN1033 (SAR391786)|Drug: Placebo","Number of TEAEs|Serum concentration of REGN1033 (SAR391786)|immunogenicity","Regeneron Pharmaceuticals|Sanofi","All","60 Years and older   (Adult, Older Adult)","Phase 1","60","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","R1033-HV-1204","October 2012","June 2013","June 2013","November 2, 2012",,"September 12, 2013","Daytona Beach, Florida, United States|Evansville, Indiana, United States",,"https://ClinicalTrials.gov/show/NCT01720576"
207,"NCT01507402","A Study to Assess the Safety and Tolerability of Single Ascending Doses of REGN1033(SAR391786)",,"Completed","No Results Available","Healthy Volunteers","Drug: REGN1033(SAR391786)|Drug: Placebo","Number of TEAEs|Serum concentration|Immunogenicity","Regeneron Pharmaceuticals|Sanofi","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 1","76","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","R1033-HV-1107","January 2012","November 2012","November 2012","January 10, 2012",,"November 14, 2012","Honolulu, Hawaii, United States|Evansville, Indiana, United States",,"https://ClinicalTrials.gov/show/NCT01507402"
208,"NCT01055899","Safety Study of a Single Dose of REGN88(SAR153191)in Patients With Rheumatoid Arthritis",,"Completed","No Results Available","Rheumatoid Arthritis","Biological: REGN88","To assess the safety and tolerability of a single dose of subcutaneously administered REGN88 in subjects with rheumatoid arthritis who are receiving concomitant treatment with methotrexate|To assess the PK profile of a single subcutaneous (SC) dose of REGN88, and the immunogenicity of a single SC dose of REGN88","Regeneron Pharmaceuticals|Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 1","15","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","6R88-RA-0801","July 2008","March 2009","March 2009","January 26, 2010",,"September 30, 2013","Duncansville, Pennsylvania, United States|Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01055899"
209,"NCT01161082","Ascending Multi-dose Study of REGN727(SAR236553) With and Without Concomitant Atorvastatin",,"Completed","No Results Available","Hypercholesterolemia","Drug: REGN727(SAR236553)","The primary endpoint in the study is to assess the incidence and severity of treatment-emergent adverse events in hyperlipidemic patients treated with REGN727 or placebo receiving stable doses of atorvastatin.|To assess the pharmacodynamic effect of REGN727 added to atorvastatin on lipids|To assess the pharmacodynamic effect of monotherapy REGN727 in hyperlipidemic patients|To assess the pharmacokinetics of REGN727 in hyperlipidemic patients with or without atorvastatin","Regeneron Pharmaceuticals|Sanofi","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","72","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","R727-CL-1001","June 2010","May 2011","May 2011","July 13, 2010",,"January 27, 2015","Site 1, Cincinnati, Ohio, United States|Site 2, Knoxville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT01161082"
210,"NCT01915823","Safety and Efficacy Trial of Dymista Nasal Spray in Children Ages 4 to 11 With Seasonal Allergic Rhinitis (SAR)",,"Completed","Has Results","Seasonal Allergic Rhinitis","Drug: azelastine hydrochloride and fluticasone propionate|Drug: Dymista vehicle","Primary Efficacy|Safety","Meda Pharmaceuticals","All","4 Years to 11 Years   (Child)","Phase 3","348","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","MP 4008","July 2013","February 2014",,"August 5, 2013","June 29, 2015","June 29, 2015","Clinical Research Center of Alabama,LLC, Birmingham, Alabama, United States|Little Rock Allergy and Asthma Clinical research Center, Little Rock, Alaska, United States|Clinical Research Atlanta, Atlanta, Georgia, United States|Aeroallergy Research Laboratories of Savannah, Savannah, Georgia, United States|Atlanta Allergy and Asthma Clinic, Stockbridge, Georgia, United States|Sneeze, Wheeze and Itch Associates, Normal, Illinois, United States|Clinical Research Institute of Indiana, Indianapolis, Indiana, United States|Family Allergy and Asthma Reserach, Louisville, Kentucky, United States|Institute for Asthma and Allergy PC, Wheaton, Maryland, United States|Respiratory Medicine Research Institute of Michigan, Ypsilanti, Michigan, United States|Clinical Research Institute, Plymouth, Minnesota, United States|The Clinical Research Center, St. Louis, Missouri, United States|Clinical Research of the Ozarks,Inc, Warrensburg, Missouri, United States|Allergy and Asthma Research NJ inc, Mount Laurel, New Jersey, United States|Atlantic Research Center, Ocean, New Jersey, United States|Princeton Center for Clinical Research, Skillman, New Jersey, United States|North Carolina Clinical Research, Raleigh, North Carolina, United States|Bernstein Clinical Research Center, Cincinnati, Ohio, United States|Allergy, Asthma & Clinical Research Center, Oklahoma City, Oklahoma, United States|Oklahoma Institute of Allergy and Asthma, Oklahoma City, Oklahoma, United States|Allergy and Asthma Specialist PC, Blue Bell, Pennsylvania, United States|Asthma and Allergy Research Associate, Upland, Pennsylvania, United States|National Allergy, Asthma and Urticaria of Charleston, Charleston, South Carolina, United States|Allergy and Asthma Consultants, LLP, Charleston, South Carolina, United States|Isis Clinical Research, LLC, Ausitn, Texas, United States|Sirius Clinical Research, Austin, Texas, United States|Central Texas Health Research, New Braunfels, Texas, United States|Sylvana Research Associates, San Antonio, Texas, United States|Live Oak Allergy and Asthma Clinic, San Antonio, Texas, United States|Allergy Asthma Research Institute, Waco, Texas, United States|Immunology/allergy and asthma Care of Waco, Waco, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01915823"
211,"NCT01266876","Study of the Safety and Efficacy of REGN727/SAR236553 in Patients With HeFH Hypercholesterolemia",,"Completed","Has Results","Hypercholesterolemia","Drug: Alirocumab|Drug: Placebo","Percent Change From Baseline in Calculated LDL-C at Week 12 - On-treatment Analysis|Absolute Change From Baseline in Calculated LDL-C at Week 12 - On-treatment Analysis|Percentage of Participants Achieving Calculated LDL-C <100 mg/dL (2.59 mmol/L) at Week 12 - On-treatment Analysis|Percentage of Participants Achieving LDL-C < 70 mg/dL (1.81 mmol/L) at Week 12 - On-treatment Analysis|Percent Change From Baseline in Total Cholesterol at Week 12 - On-treatment Analysis|Absolute Change From Baseline in Total Cholesterol at Week 12 - On-treatment Analysis|Percent Change From Baseline in High Density Lipoprotein Cholesterol (HDL-C) at Week 12 - On-treatment Analysis|Absolute Change From Baseline in HDL-C at Week 12 - On-treatment Analysis|Percent Change From Baseline in Triglycerides at Week 12 - On-treatment Analysis|Absolute Change From Baseline in Triglycerides at Week at 12 - On-treatment Analysis|Percent Change From Baseline in Non-HDL-C at Week 12 - On-treatment Analysis|Absolute Change From Baseline in Non-HDL-C at Week 12 - On-treatment Analysis|Percent Change From Baseline in Apo Lipoprotein B (Apo-B) at Week 12 - On-treatment Analysis|Absolute Change From Baseline in Apo-B at Week 12 - On-treatment Analysis|Percent Change From Baseline in Apolipoprotein - A1 (Apo-A1) at Week 12 - On-treatment Analysis|Absolute Change From Baseline in Apo-A1 at Week 12 - On-treatment Analysis|Absolute Change in the Ratio ApoB/ApoA-1 From Baseline to Week 12 - On-treatment Analysis|Percent Change From Baseline in Lipoprotein(a) at Week 12 - On-treatment Analysis|Absolute Change From Baseline in Lipoprotein(a) at Week 12 - On-treatment Analysis","Regeneron Pharmaceuticals|Sanofi","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","77","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","R727-CL-1003","January 2011","November 2011","November 2011","December 24, 2010","September 22, 2015","September 22, 2015","Huntsville, Alabama, United States|Mission Viejo, California, United States|Newport Beach, California, United States|Bridgeport, Connecticut, United States|Jacksonville, Florida, United States|Miami, Florida, United States|Port Orange, Florida, United States|Chicago, Illinois, United States|Kansas City, Kansas, United States|Auburn, Maine, United States|Biddeford, Maine, United States|St. Louis, Missouri, United States|Concord, New Hampshire, United States|Durham, North Carolina, United States|Cincinnati, Ohio, United States|Nashville, Tennessee, United States|Houston, Texas, United States|Winnipeg, Manitoba, Canada|London, Ontario, Canada|Chicoutimi, Quebec, Canada|Montreal, Quebec, Canada|St. Foy, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT01266876"
212,"NCT02277769","Study of Dupilumab (REGN668/SAR231893) Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis","SOLO 2","Completed","Has Results","Dermatitis, Atopic","Drug: Dupilumab|Drug: Placebo (for Dupilumab)","Percentage of Participants With Investigator's Global Assessment (IGA) Score of ""0"" or ""1"" and Reduction From Baseline of ≥2 Points at Week 16|Percentage of Participants With Eczema Area and Severity Index-75 (EASI-75) (≥75% Improvement From Baseline) at Week 16|Percentage of Participants With Improvement (Reduction ≥4 Points) of Weekly Average of Peak Daily Pruritus Numerical Rating Scale (NRS) Score From Baseline to Week 16|Percentage of Participants With Improvement (Reduction ≥3 Points) in Weekly Average of Peak Daily Pruritus Numerical Rating Scale (NRS) Score From Baseline to Week 16|Percent Change From Baseline in Weekly Average of Peak Pruritus Numerical Rating Scale (NRS) Score to Week 16|Percentage of Participants With Improvement (Reduction ≥4 Points) of Pruritus Numerical Rating Scale (NRS) Score From Baseline to Week 4|Percentage of Participants With Improvement (Reduction ≥4 Points) of Pruritus Numerical Rating Scale (NRS) Score From Baseline to Week 2|Change From Baseline in Peak Daily Pruritus Numerical Rating Scale (NRS) Score to Week 16|Percent Change From Baseline in Eczema Area and Severity Index (EASI) Score to Week 16|Percentage of Participants With Eczema Area and Severity Index-50 (EASI-50) (≥50% Improvement From Baseline) at Week 16|Percentage of Participants With Eczema Area and Severity Index-90 (EASI-90) (≥90% Improvement From Baseline) at Week 16|Change From Baseline in Percent Body Surface Area (BSA) to Week 16|Percent Change From Baseline in the SCORing Atopic Dermatitis (SCORAD) Score to Week 16|Change From Baseline in Dermatology Life Quality Index (DLQI) to Week 16|Change From Baseline in Patient Oriented Eczema Measure (POEM) to Week 16|Change From Baseline in Hospital Anxiety Depression Scale (HADS) to Week 16|Percent Change From Baseline in Global Individual Signs Score (GISS) to Week 16|Percent Change From Baseline in Weekly Average of Peak Daily Pruritus NRS Score to Week 2|Percentage of Participants With Skin Infection Treatment Emergent Adverse Events (TEAEs) Requiring Systemic Treatment|Percentage of Participants With Treatment Emergent Serious Adverse Events (TESAEs) From Baseline Through Week 16|Percentage of Participants With Treatment Emergent Adverse Events (TEAEs) Leading to Treatment Discontinuation From Baseline Through Week 16","Regeneron Pharmaceuticals|Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 3","708","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","R668-AD-1416","November 2014","October 2015","January 2016","October 29, 2014","October 16, 2017","October 16, 2017","Anniston, Alabama, United States|Birmingham, Alabama, United States|Phoenix, Arizona, United States|Bakersfield, California, United States|Costa Mesa, California, United States|Fremont, California, United States|Long Beach, California, United States|Los Angeles, California, United States|Orange, California, United States|Roseville, California, United States|Temecula, California, United States|Trumbull, Connecticut, United States|Miami, Florida, United States|Oviedo, Florida, United States|Tampa, Florida, United States|West Palm Beach, Florida, United States|Alpharetta, Georgia, United States|Atlanta, Georgia, United States|Columbus, Georgia, United States|Buffalo Grove, Illinois, United States|Plainfield, Indiana, United States|West Des Moines, Iowa, United States|Overland Park, Kansas, United States|Rockville, Maryland, United States|Washington Park, Maryland, United States|Boston, Massachusetts, United States|Farmington Hills, Michigan, United States|Minneapolis, Minnesota, United States|Plymouth, Minnesota, United States|Saint Joseph, Missouri, United States|Saint Louis, Missouri, United States|Billings, Montana, United States|Bozeman, Montana, United States|Las Vegas, Nevada, United States|Verona, New Jersey, United States|Forest Hills, New York, United States|New York, New York, United States|Smithtown, New York, United States|Chapel Hill, North Carolina, United States|Raleigh, North Carolina, United States|Wilmington, North Carolina, United States|Winston-Salem, North Carolina, United States|Tulsa, Oklahoma, United States|Portland, Oregon, United States|Jenkintown, Pennsylvania, United States|Greer, South Carolina, United States|Arlington, Texas, United States|Austin, Texas, United States|Bellaire, Texas, United States|Houston, Texas, United States|San Antonio, Texas, United States|Richmond, Virginia, United States|Seattle, Washington, United States|Calgary, Alberta, Canada|Edmonton, Alberta, Canada|Surrey, British Columbia, Canada|St. John's, Newfoundland and Labrador, Canada|Ajax, Ontario, Canada|Mississauga, Ontario, Canada|Oakville, Ontario, Canada|Ottawa, Ontario, Canada|Peterborough, Ontario, Canada|Richmond Hill, Ontario, Canada|Montreal, Quebec, Canada|Lille Cedex, France|Marseille, France|Nantes, France|Berlin, Germany|Bochum, Germany|Darmstadt, Germany|Friedrichshafen, Germany|Hamburg, Germany|Kiel, Germany|Hong Kong, Hong Kong|Lucca, Italy|Pisa, Italy|Roma, Italy|Busan, Korea, Republic of|Gyeonggi-do, Korea, Republic of|Incheon, Korea, Republic of|Seoul, Korea, Republic of|Kaunas, Lithuania|Klaipeda, Lithuania|Vilnius, Lithuania|Elblag, Poland|Gdansk, Poland|Katowice, Poland|Poznan, Poland|Torun, Poland|Warsaw, Poland|Stockholm, Sweden|London, United Kingdom|Plymouth, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02277769"
213,"NCT01026519","A Safety and Tolerability Study of REGN88(SAR153191) in Subjects With Rheumatoid Arthritis",,"Completed","No Results Available","Rheumatoid Arthritis","Drug: REGN88|Other: Placebo","hs-C reactive protein (hs-CRP)|Subject's Assessment of Pain and Subject's Global Assessment of Disease activity","Regeneron Pharmaceuticals|Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 1","32","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","6R88-RA-0803","September 2008","March 2009","May 2009","December 4, 2009",,"September 30, 2013","Institute of Rheumatology under the Russian Academy of Medical Sciences, Moscow, Russian Federation",,"https://ClinicalTrials.gov/show/NCT01026519"
214,"NCT01385657","Safety and Tolerability of REGN668 (SAR231893) in Patients With Moderate to Severe Atopic Dermatitis",,"Completed","No Results Available","Atopic Dermatitis","Drug: REGN668 (SAR231893)","The primary endpoint in the study is the incidence of treatment-emergent adverse events (TEAEs) in patients treated with REGN668 or Placebo from baseline through Week 12.|The secondary endpoint in the study is to characterize PK profile of study drug REGN668 from baseline through Week 12.","Regeneron Pharmaceuticals|Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","37","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","R668-AD-1026","July 2011","March 2012","March 2012","June 30, 2011",,"October 28, 2013","Kogarah, New South Wales, Australia|Woolloongabba, Queensland, Australia|Carlton, Victoria, Australia|Nedlands, Western Australia, Australia|Hannover, Niedersachsen, Germany|Bonn, Nordrhein-Westfalen, Germany|Berlin, Germany|Berlin, Germany|Gera, Germany|Munster, Germany|Syndenham, Christchurch, New Zealand|Caversham, Dunedin, New Zealand|Auckland, New Zealand",,"https://ClinicalTrials.gov/show/NCT01385657"
215,"NCT02647086","Open Label, Drug-Drug Interaction (DDI) Study of Dupilumab (REGN668/SAR231893) in Patients With Moderate to Severe Atopic Dermatitis (AD)",,"Completed","No Results Available","Atopic Dermatitis","Drug: Dupilumab|Drug: Midazolam|Drug: Omeprazole|Drug: Warfarin|Drug: Caffeine|Drug: Metoprolol","Ratio of Area Under Curve last (AUClast) and maximum concentration (Cmax) for Cytochrome P450 substrates from pre-dupilumab administration at baseline (period 1, day 1)|Ratio of AUClast and Cmax for CYP substrates 4 weeks after initiating a weekly regimen of dupilumab (period 2, day 36)|Incidence of treatment-emergent adverse events (TEAEs) from day of first administration of dupilumab to end of study (day 50 for patients who enroll in the OLE study; day 134 for patients who decline participation in the OLE).","Regeneron Pharmaceuticals|Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 1","14","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","R668-AD-1433","December 2015","July 2016","July 2016","January 6, 2016",,"August 22, 2016","Regeneron Study Site, Little Rock, Arkansas, United States|Regeneron Study Site, Centennial, Colorado, United States|Regeneron Study Site, Minneapolis, Minnesota, United States|Regeneron Study Site, Berlin, New Jersey, United States|Regeneron Study Site, Raleigh, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT02647086"
216,"NCT01979016","Study to Determine the Safety and Effectiveness of Dupilumab (REGN668/SAR231893) for Treatment of Atopic Dermatitis (AD)",,"Completed","No Results Available","Atopic Dermatitis (AD)","Drug: dupilumab|Drug: placebo","Percent change in EASI score|Proportion of patients achieving IGA score of 0 or 1|Proportion of patients achieving IGA score reduction >/= 2|Change in pruritus NRS score|Change in EASI score|Change in SCORAD score|Proportion of patients achieving a 50 to 90% reduction in SCORAD score|Absolute and percent change in POEM score|Change in Global Individual Sign Score|Changes in GISS cumulative score|Incidence of TEAEs|Dupilumab serum concentrations","Regeneron Pharmaceuticals|Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 2","54","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","R668-AD-1307","December 2013","December 2014","January 2015","November 8, 2013",,"April 22, 2015","Chicago, Illinois, United States|New York (2 locations), New York, United States|Dallas, Texas, United States|Montreal, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT01979016"
217,"NCT01448304","Study of the Tolerability, Safety, Pharmacokinetics and Pharmacodynamics of Alirocumab SAR236553 (REGN727)",,"Completed","No Results Available","Hypercholesterolemia","Drug: alirocumab SAR236553 (REGN727)","Pain using present pain intensity (PPI) verbal questionnaire|Erythema at injection site by measuring diameter and qualitative assessment|Edema at injection site by measuring diameter and qualitative assessment|Assessment of PK parameter - time to maximum concentration (tmax)|Assessment of PK parameter - maximum concentration (Cmax)|Assessment of PK parameter - area under curve (AUC)|Assessment of PK parameter - cluster of differentiation (CD) biomarker (CD29)|Assessment of PK parameter - terminal elimination half-life (t1/2z)|Pharmacodynamics: Change in LDL-C from baseline|Number of participants with Adverse Events","Sanofi|Regeneron Pharmaceuticals","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","24","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","PKD12011|U1111-1119-3056","June 2011","September 2011","September 2011","October 7, 2011",,"June 28, 2013","Sanofi-Aventis Administrative Office, Bridgewater, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT01448304"
218,"NCT01074372","Ascending Dose Study of the Safety and Tolerability of REGN727 (SAR236553) in Healthy Volunteers",,"Completed","No Results Available","Healthy Volunteers","Drug: REGN727|Drug: Placebo","The incidence of treatment-emergent adverse events in subjects treated with REGN727 or placebo, reported from the administration of study drug on day 1 to the completion of the study on day 106","Regeneron Pharmaceuticals|Sanofi","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","32","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","R727-CL-0904","March 2010","November 2010","November 2010","February 24, 2010",,"January 27, 2015","Overland Park, Kansas, United States",,"https://ClinicalTrials.gov/show/NCT01074372"
219,"NCT01026597","Ascending Dose Study of the Safety and Tolerability of REGN727(SAR236553) in Healthy Volunteers",,"Completed","No Results Available","Healthy","Drug: REGN727|Drug: Placebo","The primary endpoint in the study is the incidence of treatment-emergent adverse events in subjects treated with REGN727 or placebo, reported from the administration of study drug on day 1 to the completion of the study on day 106.","Regeneron Pharmaceuticals|Sanofi","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","40","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","R727-CL-0902","November 2009","October 2010","October 2010","December 4, 2009",,"January 27, 2015","Overland Park, Kansas, United States",,"https://ClinicalTrials.gov/show/NCT01026597"
220,"NCT00856310","A Single-Dose Study of the Safety and Tolerability of REGN475(SAR164877) in Healthy Subjects",,"Completed","No Results Available","Healthy","Biological: REGN475 (SAR164877)","Incidence of treatment emergent adverse events in subjects treated with REGN475 or placebo.|Serum concentrations of REGN475.|The presence or absence of antibodies against REGN475.","Regeneron Pharmaceuticals|Sanofi","All","21 Years to 65 Years   (Adult, Older Adult)","Phase 1","56","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","R475-PN-0817","February 2009","November 2009","November 2009","March 5, 2009",,"May 10, 2012","Altoona, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT00856310"
221,"NCT01604824","A Study of Alirocumab (REGN727/SAR236553) in Patients With ADH and GOFm of the PCSK9 Gene or LOFm of the apoB Gene",,"Unknown status","No Results Available","Hypercholesterolemia","Drug: alirocumab|Drug: placebo","Percent change in serum LDL-C|TEAEs|Percent change in ApoB100|Percent change in non-HDL-C|Percent change in total cholesterol|Percent change in ApoB100/ApoA1 ratio|Trough concentrations of total alirocumab|Immunogenicity of repeat SC dosing","Regeneron Pharmaceuticals|Sanofi","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","23","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","R727-CL-1018","September 2012","May 2014","September 2016","May 24, 2012",,"January 30, 2015","Salt Lake City, Utah, United States|Lille, Cedex, France|Nante, Cedex, France|Paris, France",,"https://ClinicalTrials.gov/show/NCT01604824"
222,"NCT00777699","Safety Study of XL765 (SAR245409) in Combination With Erlotinib in Adults With Solid Tumors",,"Completed","No Results Available","Cancer|Non-Small Cell Lung Cancer","Drug: XL765 (SAR245409)|Drug: erlotinib","Safety, tolerability, and maximum tolerated dose of XL765 administered in combination with erlotinib|To evaluate plasma pharmacokinetics of XL765 and erlotinib when administered in combination|To evaluate preliminary efficacy of XL765 in combination with erlotinib in subjects with non-small-cell lung cancer (NSCLC) and other solid tumors","Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 1","80","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TED11442|2008-003219-11|XL765-003","August 2008","February 2011","February 2011","October 22, 2008",,"February 3, 2012","Investigational Site Number 168983, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT00777699"
223,"NCT01688960","Nesvacumab (REGN910/ SAR307746) and Aflibercept (""Ziv-aflibercept"" in the U.S.) in Patients With Advanced Solid Malignancies",,"Completed","No Results Available","Solid Tumors","Drug: nesvacumab (REGN910/ SAR307746)|Drug: aflibercept (ziv-aflibercept)","Maximum Tolerable Dose (MTD) or Recommended Phase 2 Dose (RP2D)|Pharmacokinetics (PK)|Immunogenicity|Antitumor activity|Pharmacodynamics (PD)","Regeneron Pharmaceuticals|Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 1","48","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","R910-ST-1114","October 2012","November 2014","November 2014","September 20, 2012",,"March 17, 2015","Indianapolis, Indiana, United States|New York, New York, United States|Oklahoma City, Oklahoma, United States|Philadelphia, Pennsylvania, United States|San Antonio, Texas, United States|Toronto, Canada",,"https://ClinicalTrials.gov/show/NCT01688960"
224,"NCT01015027","Ascending Dose Study of the Safety and Tolerability of REGN668(SAR231893) in Normal Healthy Volunteers",,"Completed","No Results Available","Healthy","Biological: REGN668","The primary endpoint in the study is the incidence of treatment-emergent adverse events in subjects treated with REGN668 or placebo, reported from the administration of study drug on day 1 to the completion of the study on day 85/visit 11.|Pharmacokinetics: Serum concentrations of REGN668 over time.","Regeneron Pharmaceuticals|Sanofi","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","48","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","R668-AS-0907","October 2009","July 2010","July 2010","November 17, 2009",,"June 17, 2013","Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT01015027"
225,"NCT00944892","A Study of the Safety and Efficacy of REGN475(SAR164877) in Patients With Osteoarthritis of the Knee",,"Completed","No Results Available","Osteoarthritis of the Knee","Drug: REGN475|Other: Placebo","The incidence of TEAEs in patients treated with REGN475 or placebo, reported between administration of study drug on Day 1 and the completion of study at the end of week 24 (Day 169).|Change from baseline in The Western Ontario and McMaster Osteoarthritis Index (WOMAC) (total score as well as all 3 subscales: pain, stiffness and function).|Patient assessment of response to treatment over time using the Patient Global Impression of Change.|Change from baseline in patient-rated QOL using the Short-Form 12-Item Questionnaire (SF-12).","Regeneron Pharmaceuticals|Sanofi","All","40 Years to 75 Years   (Adult, Older Adult)","Phase 1|Phase 2","200","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","R475-PN-0901","August 2009","May 2010","May 2010","July 23, 2009",,"December 8, 2011","Anaheim, California, United States|Tampa, Florida, United States|Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT00944892"
226,"NCT01458275","A Safety and Efficacy Study of Ciclesonide Nasal Aerosol in Subjects 6-11 Years With Seasonal Allergic Rhinitis (SAR)",,"Completed","Has Results","Seasonal Allergic Rhinitis","Drug: Ciclesonide nasal aerosol 37 mcg|Drug: ciclesonide nasal aerosol 74 mcg|Drug: Placebo","Change From Baseline in Average Daily Subject Reported AM and PM Reflective Total Nasal Symptom Scores (rTNSS) Over the 2-week Double-blind Treatment Period|Change From Baseline in Average Daily Subject-reported AM and PM Instantaneous Total Nasal Symptom Scores (iTNSS) Over the 2-week Double-blind Treatment Period|Change From Baseline in Average Daily Subject-reported AM and PM Reflective Total Ocular Symptom Scores (rTOSS) Over the 2-week Double-blind Treatment Period.|Change From Baseline in the Pediatric Rhinoconjunctivitis Quality of Life Questionnaire (PRQLQ) Overall Score at the End of the Double-blind Treatment Period.|Change From Baseline in Average Daily Subject Reported AM Instantaneous Total Nasal Symptom Scores (iTNSS) Over the 2-week Double-blind Treatment Period|Change From Baseline in Average Daily Subject-reported AM and PM Instantaneous Total Ocular Symptom Scores (iTOSS) Over the 2-week Double-blind Treatment Period.|Time to Maximal Effect in the AM and PM Reflective Total Nasal Symptom Scores (rTNSS) Over the 2-week Double-blind Treatment Period|Number of Subjects Experiencing Treatment-emergent AEs|Percentage of Subjects Experiencing Treatment-emergent AEs|Treatment-emergent AEs Causing Study Medication Discontinuation|Number of Subjects Experiencing Treatment-emergent Nasal AEs, Including Epistaxis, Nasal Ulceration, and Nasal Perforation|Percentage of Subjects Experiencing Treatment-emergent Nasal AEs, Including Epistaxis, Nasal Ulceration, and Nasal Perforation","Sunovion","All","6 Years to 11 Years   (Child)","Phase 3","847","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","SEP060-305","November 2011","March 2013","March 2013","October 24, 2011","May 15, 2014","May 15, 2014","Arkansas Pediatric Clinic, Little Rock, Arkansas, United States|San Jose Multispecialty Medical Group, Inc, Baldwin Park, California, United States|WCCT Global, LLC, Costa Mesa, California, United States|Premier Health Research Center, Downey, California, United States|Allergy, Asthma, Brochitis and Immunology Assoc Medical Group, Fountain Valley, California, United States|Pediatric Care Medical Group, Inc., Huntington Beach, California, United States|Pediatric Care Medical Group, Huntington Beach, California, United States|Allergy and Asthma Associates of Southern California, Mission Viejo, California, United States|CHOC, PSF, AMC, Division of Allergy, Asthma, and Immunology, Orange, California, United States|Center for Clinical Trials, LLC, Paramount, California, United States|Peninsula Research Associates, Rolling Hills Estates, California, United States|Capital Allergy & Respiratory Disease Center, Sacramento, California, United States|Allergy Associates Medical Group, San Diego, California, United States|Allergy & Asthma Medical Group and Research Center, APC, San Diego, California, United States|Bensch Research Associates, Stockton, California, United States|Asthma & Allergy Associates, PC, Colorado Springs, Colorado, United States|Storms Clinical Research Institute, Colorado Springs, Colorado, United States|Colorado Allergy and Asthma Centers, PC, Denver, Colorado, United States|Northeast Georgia Research Center, Gainesville, Georgia, United States|DataQuest Medical Research, LLC, Lawerenceville, Georgia, United States|Atlanta Allergy & Astma Clinic, Marietta, Georgia, United States|Aeroallergy Research Laboratories of Savannah, Inc, Savannah, Georgia, United States|Clinical Research Atlanta, Stockbridge, Georgia, United States|Alzein Pediatrics, Evergreen Park, Illinois, United States|Sneeze, Weeze, & Itch Associates, Normal, Illinois, United States|Gordon D. Raphael, MD, Berthesda, Maryland, United States|Clinical Research Institute, Plymouth, Minnesota, United States|Creighton University Medical Center, Omaha, Nebraska, United States|Atlantic Research Center, LLC, Ocean, New Jersey, United States|North Carolina Clinical Research, Raleigh, North Carolina, United States|Catalyst Medical Center, Fargo, North Dakota, United States|Toledo Center for Clinical Research, Sylvania, Ohio, United States|Baker Allergy Asthma and Dermatology Research Center LLC, Lake Oswego, Oregon, United States|Clinical Research Institute of Southern Oregon, PC, Medford, Oregon, United States|Allergy Associates Research Center, Portland, Oregon, United States|Asthma and Allergy Research Associates, Upland, Pennsylvania, United States|Asthma, Nasal Disease & Allergy Research Center of New England, Providence, Rhode Island, United States|National Allergy, Asthma, and Uticaria Centers of Charleston, PA, Charleston, South Carolina, United States|Spartanburg Medical Research, Spartanburg, South Carolina, United States|DCT - Anchor, LLC dba Discovery Clinical Trials, Arlington, Texas, United States|Discovery Clinical Trials, Arlington, Texas, United States|Benchmark Research, Austin, Texas, United States|Isis Clinical Research, LLC, Austin, Texas, United States|Sirius Clinical Research LLC, Austin, Texas, United States|TTS Research Center, Boeme, Texas, United States|Research Across America, Carroliton, Texas, United States|Dallas Allergy Immunology Research, Dallas, Texas, United States|Pharmaceutical Research and Consulting, Dallas, Texas, United States|Western Sky Medical Research, El Paso, Texas, United States|Benchmark Research, Fort Worth, Texas, United States|Kerrville Research Associates, Kerrville, Texas, United States|Live Oak Allergy and Asthma Clinic, Live Oak, Texas, United States|Central Texas Health Research, New Braunfels, Texas, United States|ACRC Trials, Plano, Texas, United States|North Texas Family Medicine, Plano, Texas, United States|Benchmark Research, San Angelo, Texas, United States|Sun Research Institute, San Antonio, Texas, United States|DCT - Barlite Dba Discovery Clinical Trials, San Antonio, Texas, United States|Allergy and Asthma Research Center, PA, San Antonio, Texas, United States|San Antonio Ear, Nose & Throat Research, San Antonio, Texas, United States|Sylvana Research Associates, San Antonio, Texas, United States|DCT-Westover Hills, Dba Discovery Clinical Trials, San Antonio, Texas, United States|Pediatric Healthcare of Northwest Houston, Tomball, Texas, United States|Allergy & Asthma Care of Waco, Waco, Texas, United States|Allergy Asthma Research Institute, Waco, Texas, United States|Ericksen Research and Development, Clinton, Utah, United States",,"https://ClinicalTrials.gov/show/NCT01458275"
227,"NCT00485719","Study of the Safety and Pharmacokinetics of XL765 (SAR245409) in Adults With Solid Tumors",,"Completed","No Results Available","Cancer","Drug: XL765 (SAR245409)","Safety, tolerability, and maximum tolerated dose (MTD) of daily oral administration of XL765 in two treatment schedules|Plasma pharmacokinetics of daily oral administration of XL765 in two treatment schedules|Pharmacodynamic effects of XL765 on tumor tissue when administered at the MTD in two treatment schedules","Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 1","83","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TED11440|2007-002437-36|XL765-001","June 2007","September 2012","September 2012","June 13, 2007",,"May 30, 2013","Investigational Site Number 1302, Detroit, Michigan, United States|Investigational Site Number 1435, Omaha, Nebraska, United States|Investigational Site Number 1402, San Antonio, Texas, United States|Investigational Site Number 3411, Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT00485719"
228,"NCT01053702","Study of the Safety and Efficacy of REGN475(SAR164877) in Patients With Pain Resulting From Thermal Injury",,"Withdrawn","No Results Available","Thermal Injury Pain","Drug: R475|Drug: Placebo","Change in procedural pain intensity|Cumulative analgesic usage|Weekly Patient-rated Global Impression of Change|Additional quality of life assessments","Regeneron Pharmaceuticals|Sanofi","All","18 Years to 50 Years   (Adult)","Phase 2","0","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","R475-PN-0909",,,,"January 21, 2010",,"April 19, 2011","Tampa, Florida, United States",,"https://ClinicalTrials.gov/show/NCT01053702"
229,"NCT02407756","A Study to Determine the Safety and Tolerability of Dupilumab (REGN668/SAR231893) in Patients Aged ≥6 to <18 Years With Atopic Dermatitis (Eczema)",,"Completed","No Results Available","Atopic Dermatitis","Drug: Dupilumab","Pharmacokinetic (PK) parameters|Incidence of treatment-emergent adverse events (TEAEs)|Percent change from baseline in Eczema Area and Severity Index (EASI)|Percent change from baseline in SCORing Atopic Dermatitis (SCORAD) score|Percent change from baseline in Pruritus Numerical Rating Scale (NRS)|Percentage of patients with an Investigator Global Assessment (IGA) score of 0 or 1","Regeneron Pharmaceuticals|Sanofi","All","6 Years to 17 Years   (Child)","Phase 2","78","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","R668-AD-1412","March 2015","March 2016","March 2016","April 3, 2015",,"August 22, 2016","Markham, Ontario, Canada|Peterborough, Ontario, Canada|Waterloo, Ontario, Canada|Windsor, Ontario, Canada|Kutna Hora, Czech Republic|Prague, Czech Republic|Dresden, Germany|Frankfurt, Germany|Gera, Germany|Hamburg, Germany|Kiel, Germany|Luebeck, Germany|Muenster, Germany|Munich, Germany|Tuebingen, Germany|Kaposvar, Hungary|Miskolc, Hungary|Szeged, Hungary|Szolnok, Hungary|Katowice, Poland|Krakow, Poland|Lodz, Poland|Warszawa, Poland|Wroclaw, Poland|Manchester, United Kingdom|Sheffield, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02407756"
230,"NCT01011959","A Multiple-dose Study of the Safety and Tolerability of REGN88(SAR153191) in Rheumatoid Arthritis Subjects",,"Completed","No Results Available","Rheumatoid Arthritis","Biological: REGN88","Incidence of treatment-emergent adverse events in patients treated with REGN88 and placebo|To evaluate exploratory efficacy endpoints","Regeneron Pharmaceuticals|Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 1","60","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","6R88-RA-0802","December 2008","August 2009","August 2009","November 11, 2009",,"September 30, 2013","Santa Maria, California, United States|Boca Raton, Florida, United States|Clearwater, Florida, United States|Daytona Beach, Florida, United States|Delray Beach, Florida, United States|Palm Harbor, Florida, United States|Idaho Falls, Idaho, United States|Worcester, Massachusetts, United States|Lansing, Michigan, United States|Flowood, Mississippi, United States|Kalamzaoo, Missouri, United States|St. Louis, Missouri, United States|Reno, Nevada, United States|Charlotte, North Carolina, United States|Cincinnati, Ohio, United States|Toledo, Ohio, United States|Oklahoma City, Oklahoma, United States|Duncansville, Pennsylvania, United States|Greenville, South Carolina, United States|Orangeburg, South Carolina, United States|Hixson, Tennessee, United States|Austin, Texas, United States|Houston, Texas, United States|San Antonio, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01011959"
231,"NCT02260986","Study to Assess the Efficacy and Long-term Safety of Dupilumab (REGN668/SAR231893) in Adult Participants With Moderate-to-Severe Atopic Dermatitis","CHRONOS","Completed","Has Results","Atopic Dermatitis","Drug: Dupilumab|Drug: Placebo (for Dupilumab)|Other: Topical Corticosteroid (TCS)","Percentage of Participants With Investigator's Global Assessment (IGA) Score of ""0"" or ""1"" and Reduction From Baseline of ≥2 Points at Week 16|Percentage of Participants With Eczema Area and Severity Index-75 (EASI-75) (≥75% Improvement From Baseline) at Week 16|Percentage of Participants With Improvement (Reduction ≥4 Points) of Weekly Average of Peak Daily Pruritus Numerical Rating Scale (NRS) Score From Baseline to Week 16|Percentage of Participants With Improvement (Reduction ≥3 Points) of Weekly Average of Peak Daily Pruritus Numerical Rating Scale (NRS) Score From Baseline to Week 16|Percentage of Participants With Investigator's Global Assessment (IGA) Score of ""0"" or ""1"" and Reduction From Baseline of ≥2 Points at Week 52|Percentage of Participants With Eczema Area and Severity Index-75 (EASI-75) (≥75% Improvement From Baseline) at Week 52|Percent Change From Baseline in Weekly Average of Peak Daily Pruritus Numerical Rating Scale (NRS) Score to Week 16|Percentage of Participants With Improvement (Reduction ≥4 Points) of Weekly Average of Peak Daily Pruritus Numerical Rating Scale (NRS) Score From Baseline to Week 52|Percentage of Participants With Improvement (Reduction ≥3 Points) of Weekly Average of Peak Daily Pruritus Numerical Rating Scale (NRS) Score From Baseline to Week 52|Percentage of Participants With Improvement (Reduction ≥4 Points) of Weekly Average of Peak Daily Pruritus Numerical Rating Scale (NRS) Score From Baseline to Week 24|Percentage of Participants With Improvement (Reduction ≥4 Points) of Weekly Average of Peak Daily Pruritus Numerical Rating Scale (NRS) Score From Baseline to Week 4|Percentage of Participants With Improvement (Reduction ≥4 Points) of Weekly Average of Peak Daily Pruritus Numerical Rating Scale (NRS) Score From Baseline to Week 2|Change From Baseline in Weekly Average of Peak Daily Pruritus Numerical Rating Scale (NRS) Score to Week 16|Percent Change From Baseline in Eczema Area and Severity Index (EASI) Score to Week 16|Change From Baseline in Percent Body Surface Area (BSA) Affected by Atopic Dermatitis to Week 16|Percent Change From Baseline in the SCORing Atopic Dermatitis (SCORAD) Score to Week 16|Change From Baseline in Dermatology Life Quality Index (DLQI) to Week 16|Change From Baseline in Patient Oriented Eczema Measure (POEM) to Week 16|Change From Baseline in Hospital Anxiety Depression Scale (HADS) to Week 16|Percent Change From Baseline in Total Global Individual Signs Score (GISS) to Week 16|Proportion of Topical Atopic Dermatitis Medication-Free Days Through Week 52|Percent Change From Baseline in Weekly Average of Peak Daily Pruritus Numerical Rating Scale (NRS) Score to Week 2|Percent Change From Baseline in Eczema Area and Severity Index (EASI) Score to Week 52|Change From Baseline in Percent Body Surface Area (BSA) Affected by Atopic Dermatitis to Week 52|Percent Change From Baseline in the SCORing Atopic Dermatitis (SCORAD) Score to Week 52|Percent Change From Baseline in Global Individual Signs Score (GISS) to Week 52|Change From Baseline in Dermatology Life Quality Index (DLQI) to Week 52|Change From Baseline in Patient Oriented Eczema Measure (POEM) to Week 52|Change From Baseline in Hospital Anxiety Depression Scale (HADS) to Week 52|Number of Flares Through Week 52|Number of Serious Treatment Emergent Adverse Events (TEAEs) Leading to Study Drug Discontinuation Through Week 52|Percentage of Participants With Skin Infection Treatment Emergent Adverse Events (TEAEs) (Excluding Herpetic Infections) From Baseline Through Week 52|Number of Skin Infection TEAEs (Excluding Herpetic Infections) From Baseline Through Week 52|Percentage of Participants With Skin Infection Treatment Emergent Adverse Events (TEAEs) (Excluding Herpetic Infections) Requiring Systemic Treatment From Baseline Through Week 52|Number of Skin Infection Treatment Emergent Adverse Events (TEAEs) (Excluding Herpetic Infections) Requiring Systemic Treatment From Baseline Through Week 52","Regeneron Pharmaceuticals|Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 3","740","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","R668-AD-1224","September 2014","August 2015","October 2016","October 9, 2014","October 17, 2017","October 17, 2017","Phoenix, Arizona, United States|Hot Springs, Arkansas, United States|Little Rock, Arkansas, United States|Encinitas, California, United States|Oceanside, California, United States|Palmdale, California, United States|San Diego, California, United States|New Haven, Connecticut, United States|Trumbull, Connecticut, United States|Edgewater, Florida, United States|Lake Worth, Florida, United States|Miami Lakes, Florida, United States|Orlando, Florida, United States|Tampa, Florida, United States|Alpharetta, Georgia, United States|Columbus, Georgia, United States|Savannah, Georgia, United States|West Dundee, Illinois, United States|Carmel, Indiana, United States|New Albany, Indiana, United States|Rockville, Maryland, United States|Ann Arbor, Michigan, United States|Bay City, Michigan, United States|Edina, Minnesota, United States|Fridley, Minnesota, United States|Saint Louis, Missouri, United States|Omaha, Nebraska, United States|Henderson, Nevada, United States|Verona, New Jersey, United States|Albuquerque, New Mexico, United States|Corning, New York, United States|New York, New York, United States|Smithtown, New York, United States|Stony Brook, New York, United States|Cincinnati, Ohio, United States|Norman, Oklahoma, United States|Oklahoma City, Oklahoma, United States|Lake Oswego, Oregon, United States|Portland, Oregon, United States|Exton, Pennsylvania, United States|Hazleton, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Austin, Texas, United States|Dallas, Texas, United States|West Jordan, Utah, United States|South Burlington, Vermont, United States|Henrico, Virginia, United States|Norfolk, Virginia, United States|Richmond, Virginia, United States|Spokane, Washington, United States|Phillip, Australian Capital Territory, Australia|Kogarah, New South Wales, Australia|Benowa, Queensland, Australia|Dulwich, Queensland, Australia|Hectorville, South Australia, Australia|Carlton, Victoria, Australia|Surrey, British Columbia, Canada|Vancouver, British Columbia, Canada|Ajax, Ontario, Canada|Barrie, Ontario, Canada|Hamilton, Ontario, Canada|Markham, Ontario, Canada|North Bay, Ontario, Canada|Oakville, Ontario, Canada|Ottawa, Ontario, Canada|Peterborough, Ontario, Canada|Richmond Hill, Ontario, Canada|Toronto, Ontario, Canada|Waterloo, Ontario, Canada|Windsor, Ontario, Canada|Drummondville, Quebec, Canada|Quebec, Canada|Hradec Kralove, Czechia|Nachod, Czechia|Praha 10, Czechia|Praha 5, Czechia|Svitavy, Czechia|Usti nad Labem, Czechia|Oroshaza, Békés, Hungary|Szolnok, Jász-Nagykun-Szolnok, Hungary|Veszprem, Veszprém, Hungary|Budapest, Hungary|Ancona, Italy|Bologna, Italy|Brescia, Italy|Novara, Italy|Pavia, Italy|Perugia, Italy|Roma, Italy|Kitakyushu, Fukuoka, Japan|Amagasaki, Hyôgo, Japan|Yokohama, Kanagawa, Japan|Kamimashiki-gun, Kumamoto, Japan|Saitama-shi, Saitama, Japan|Yaizu, Shizuoka, Japan|Koto-ku, Tokyo, Japan|Setagaya-ku, Tokyo, Japan|Adachi-ku, Tôkyô, Japan|Chiyoda-ku, Tôkyô, Japan|Nakano-ku, Tôkyô, Japan|Nerima-ku, Tôkyô, Japan|Shibuya-ku, Tôkyô, Japan|Shinagawa-ku, Tôkyô, Japan|Shinjuku-ku, Tôkyô, Japan|Suginami-ku, Tôkyô, Japan|Fukuoka, Japan|Bucheon-si, Gyeonggido, Korea, Republic of|Suwon, Gyeonggido, Korea, Republic of|Seoul, Seoul Teugbyeolsi, Korea, Republic of|Seodaemun-gu, Korea, Republic of|Uijeongbu-si, Korea, Republic of|Breda, Noord-Brabant, Netherlands|Amsterdam, Noord-Holland, Netherlands|Rotterdam, Zuid-Holland, Netherlands|Groningen, Netherlands|Utrecht, Netherlands|Dunedin, South Island, New Zealand|Auckland, New Zealand|Wroclaw, Dolnośląskie, Poland|Lublin, Lubelskie, Poland|Warszawa, Mazowieckie, Poland|Krakow, Małopolskie, Poland|Strzelce Opolskie, Opolskie, Poland|Iwonicz Zdroj, Podkarpackie, Poland|Bialystok, Podlaskie, Poland|Gdansk, Pomorskie, Poland|Poznan, Wielkopolskie, Poland|Szczecin, Zachodniopomorskie, Poland|Gdynia, Poland|Łódź, Łódzkie, Poland|Katowice, Śląskie, Poland|Skarzysko-Kamienna, Świętokrzyskie, Poland|Brasov, Braşov, Romania|Bucuresti, Bucureşti, Romania|Cluj-Napoca, Cluj, Romania|Craiova, Dolj, Romania|Targu Mures, Mureş, Romania|Barcelona, Cataluña, Spain|Alicante, Spain|Madrid, Spain|Dundee, Angus, United Kingdom|Edgbaston, Birmingham, United Kingdom|Glasgow, Glasgow City, United Kingdom|Sidcup, Kent, United Kingdom|Northwood, Middlesex, United Kingdom|Liverpool, United Kingdom|Manchester, United Kingdom|Reading, United Kingdom|Salford, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02260986"
232,"NCT01730053","Study of Alirocumab (REGN727/SAR236553) added-on to Rosuvastatin Versus Other Lipid Modifying Treatments (LMT) (ODYSSEY OPTIONS II)",,"Completed","Has Results","Hypercholesterolemia","Drug: Alirocumab|Drug: Rosuvastatin|Drug: Ezetimibe|Drug: Placebo","Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent-to-Treat (ITT) Analysis|Percent Change From Baseline in Calculated LDL-C at Week 24 - On-Treatment Analysis|Percent Change From Baseline in Calculated LDL-C at Week 12 - ITT Analysis|Percent Change From Baseline in Calculated LDL-C at Week 12 - On-Treatment Analysis|Percent Change From Baseline in Apolipoprotein (Apo) B at Week 24 - ITT Analysis|Percent Change From Baseline in Apo B at Week 24 - On-Treatment Analysis|Percent Change From Baseline in Non-High-density Lipoprotein Cholesterol (Non-HDL-C) at Week 24 - ITT Analysis|Percent Change From Baseline in Non-HDL-C at Week 24 - On-Treatment Analysis|Percent Change From Baseline in Total Cholesterol (Total-C) at Week 24 - ITT Analysis|Percent Change From Baseline in Apo B at Week 12 - ITT Analysis|Percent Change From Baseline in Non-HDL-C at Week 12 - ITT Analysis|Percent Change From Baseline in Total-C at Week 12 - ITT Analysis|Percentage of Very High CV Risk Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) or High CV Risk Participants Reaching Calculated LDL-C <100 mg/dL (2.59 mmol/L) at Week 24 - ITT Analysis|Percentage of Very High CV Risk Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) or High CV Risk Participants Reaching Calculated LDL-C <100 mg/dL (2.59 mmol/L) at Week 24 - On-Treatment Analysis|Percentage of Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - ITT Analysis|Percentage of Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - On-Treatment Analysis|Percent Change From Baseline in Lipoprotein(a) at Week 24 - ITT Analysis|Percent Change From Baseline in HDL-C at Week 24 - ITT Analysis|Percent Change From Baseline in Fasting Triglycerides at Week 24 - ITT Analysis|Percent Change From Baseline in Apo A-1 at Week 24 - ITT Analysis|Percent Change From Baseline in Lipoprotein (a) at Week 12 - ITT Analysis|Percent Change From Baseline in HDL-C at Week 12 - ITT Analysis|Percent Change From Baseline in Fasting Triglycerides at Week 12 - ITT Analysis|Percent Change From Baseline in Apo A-1 at Week 12 - ITT Analysis","Regeneron Pharmaceuticals|Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 3","305","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","R727-CL-1118","November 2012","April 2014","May 2014","November 21, 2012","October 28, 2015","October 28, 2015","Chandler, Arizona, United States|Tucson, Arizona, United States|Anaheim, California, United States|Beverly Hills, California, United States|Fair Oaks, California, United States|Newport Beach, California, United States|Northridge, California, United States|Sacramento, California, United States|Walnut Creek, California, United States|Milford, Connecticut, United States|Atlantis, Florida, United States|Bradenton, Florida, United States|Clearwater, Florida, United States|Fort Lauderdale, Florida, United States|Jacksonville, Florida, United States|Lakeland, Florida, United States|Miami (2 locations), Florida, United States|Oviedo, Florida, United States|Pinellas Park, Florida, United States|Port Orange, Florida, United States|Sarasota, Florida, United States|Tampa, Florida, United States|West Palm Beach, Florida, United States|Winter Park, Florida, United States|Boise, Idaho, United States|Morton, Illinois, United States|Evansville, Indiana, United States|Indianapolis, Indiana, United States|Newton, Kansas, United States|Overland Park, Kansas, United States|Wichita, Kansas, United States|Lexington, Kentucky, United States|Louisville, Kentucky, United States|Auburn, Maine, United States|Bethesda, Maryland, United States|Edina, Minnesota, United States|Rochester, Minnesota, United States|Olive Branch, Mississippi, United States|Port Gibson, Mississippi, United States|St. Louis, Missouri, United States|Butte, Montana, United States|Williamsville, New York, United States|Cincinatti, Ohio, United States|Marion, Ohio, United States|Portland, Oregon, United States|Warwick, Rhode Island, United States|Greer, South Carolina, United States|Summerville, South Carolina, United States|Kingsport, Tennessee, United States|Dallas (2 locations), Texas, United States|Fort Worth, Texas, United States|Houston, Texas, United States|Bountiful, Utah, United States|Salt Lake City, Utah, United States|Herston QLD, Australia|New Lambton Heights, Australia|Perth, Australia|Sherwood, Australia|Woolloongabba, Australia|Brampton, Ontario, Canada|Burlington, Ontario, Canada|Etobicoke, Ontario, Canada|London, Ontario, Canada|Newmarke, Ontario, Canada|Thornhill, Ontario, Canada|Toronto, Ontario, Canada|Chicoutimi, Quebec, Canada|Dijon, France|Lille, France|Bad Oeynhausen, Germany|Berlin, Germany|Koeln, Germany|Regensburg, Germany|Ulm, Germany|Chiete, Italy|Genova, Italy|Napoli, Italy|Palermo, Italy|Roma (2 locations), Italy|Distrito Federal, Mexico|Guadalajara Jalisco, Mexico|Guadalajara, Jal., Mexico|Guadalajara, Mexico|Monterrey Nuevo Leon, Mexico|Tijuana Baja California, Mexico|Zapopan Jalisco, Mexico|Alcalà de Henares (Madrid), Spain|Barcelona (2 locations), Spain|Santiago, Spain|Sevilla, Spain|Chester, United Kingdom|Peterborough, United Kingdom|Salford, United Kingdom|Stevenage, United Kingdom|West Bromwich, West Midlands, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01730053"
233,"NCT01328522","Comparison of the Safety and Pharmacokinetics of Two SAR153191 (REGN88) Drug Products in Rheumatoid Arthritis Patients",,"Completed","No Results Available","Rheumatoid Arthritis","Drug: SAR153191 (REGN88)","Occurrence of potentially clinically significant abnormalities in clinical laboratory test results|Occurrence of Adverse Events|Pain evaluation using the Present Pain Intensity (PPI) verbal questionnaire|Pain evaluation using Visual Analog Scale (VAS)|Diameter of the erythema at injection site|Diameter of the edema at injection site|Serum concentration of SAR153191: Maximum plasma concentration (Cmax), first time to reach Cmax (tmax), area under the plasma concentration (AUClast and AUC)","Sanofi|Regeneron Pharmaceuticals","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1","32","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","PKM12058|U1111-1119-2883","May 2011","September 2011","September 2011","April 4, 2011",,"October 24, 2011","Investigational Site Number 840003, Beverly Hills, California, United States|Investigational Site Number 840001, Ocala, Florida, United States|Investigational Site Number 840004, Duncansville, Pennsylvania, United States|Investigational Site Number 840002, Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01328522"
234,"NCT02097524","Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)",,"Completed","No Results Available","Rheumatoid Arthritis","Drug: Sarilumab|Drug: Tocilizumab","PD parameters|Percentage of TEAEs|PK parameters","Regeneron Pharmaceuticals|Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 1","105","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","6R88-RA-1309","March 2014","April 2015","April 2015","March 27, 2014",,"May 5, 2015","Birmingham, Alabama, United States|Orange, California, United States|Deland, Florida, United States|Edgewater, Florida, United States|Miami Lakes, Florida, United States|Miami, Florida, United States|Granger, Indiana, United States|Grand Blanc, Michigan, United States|Charlotte, North Carolina, United States|Cinicinnati, Ohio, United States|Memphis, Tennessee, United States|Austin, Texas, United States|Carrollton, Texas, United States|Channelview, Texas, United States|Dallas, Texas, United States|Houston, Texas, United States|Mesquite, Texas, United States|Plano, Texas, United States|San Antonio, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02097524"
235,"NCT00486135","Study of the Safety and Pharmacokinetics of XL147 (SAR245408) in Adults With Solid Tumors or Lymphoma",,"Completed","No Results Available","Cancer|Lymphoma","Drug: XL147 (SAR245408)","Safety, tolerability, and maximum tolerated dose of oral administration of two formulations of XL147 in two treatment schedules|Safety and tolerability of oral dosing with XL147 capsules in subjects with lymphoma, and of XL147 capsules and tablets in subjects with solid tumors|Plasma pharmacokinetics of daily oral administration of XL147 in two treatment schedules|Pharmacodynamic effects of XL147 on tumor tissue when administered at the maximum tolerated dose in two treatment schedules|Plasma pharmacokinetics of XL147 capsule and tablet formulations","Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 1","118","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TED11433|XL147-001","June 2007","October 2012","October 2012","June 13, 2007",,"February 1, 2013","Investigational Site Number 1241, Augusta, Georgia, United States|Investigational Site Number 1503, Boston, Massachusetts, United States|Investigational Site Number 1401, Dallas, Texas, United States|Investigational Site Number 3412, Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT00486135"
236,"NCT01259323","Sequential Ascending Dose Study to Assess the Safety and Tolerability of REGN668 (SAR231893) in Patients With Atopic Dermatitis",,"Completed","No Results Available","Dermatitis","Biological: REGN668","The primary endpoint in the study is the incidence of treatment-emergent adverse events (TEAEs) in patients treated with REGN668 or Placebo from baseline through week 12.|The secondary endpoint is to characterize PK profile of study drug REGN668 from baseline through week 12.","Regeneron Pharmaceuticals|Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 1","30","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","R668-AD-0914","December 2010","July 2012","July 2012","December 14, 2010",,"October 4, 2012","Los Angeles, California, United States|Riverside, California, United States|Miami, Florida, United States|Chicago, Illinois, United States|Troy, Michigan, United States|New York, New York, United States|﻿Rochester, New York, United States|Portland, Oregon, United States|Philadelphia, Pennsylvania, United States|Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01259323"
237,"NCT01730040","Study of the Efficacy and Safety of Alirocumab (REGN727/SAR236553) in Combination With Other Lipid-modifying Treatment (LMT) (ODYSSEY OPTIONS I)",,"Completed","Has Results","Hypercholesterolemia","Drug: Alirocumab|Drug: Atorvastatin|Drug: Ezetimibe|Drug: Rosuvastatin|Drug: Placebo","Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent-to-treat (ITT) Analysis|Percent Change From Baseline in Calculated LDL-C at Week 24 - On-Treatment Analysis|Percent Change From Baseline in Calculated LDL-C at Week 12 - ITT Analysis|Percent Change From Baseline in Calculated LDL-C at Week 12 - On-Treatment Analysis|Percent Change From Baseline in Apolipoprotein (Apo) B at Week 24 - ITT Analysis|Percent Change From Baseline in Apo B at Week 24 - On-Treatment Analysis|Percent Change From Baseline in Non-High-density Lipoprotein Cholesterol (Non-HDL-C) at Week 24 - ITT Analysis|Percent Change From Baseline in Non-HDL-C at Week 24 - On-Treatment Analysis|Percent Change From Baseline in Total Cholesterol (Total-C) at Week 24 - ITT Analysis|Percent Change From Baseline in Apo B at Week 12 - ITT Analysis|Percent Change From Baseline in Non-HDL-C at Week 12 - ITT Analysis|Percent Change From Baseline in Total-C at Week 12 - ITT Analysis|Percentage of Very High CV Risk Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) or High CV Risk Participants Reaching Calculated LDL-C <100 mg/dL (2.59 mmol/L) at Week 24 - ITT Analysis|Percentage of Very High CV Risk Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) or High CV Risk Participants Reaching Calculated LDL-C <100 mg/dL (2.59 mmol/L) at Week 24 - On-Treatment Analysis|Percentage of Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - ITT Analysis|Percentage of Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - On-Treatment Analysis|Percent Change From Baseline in Lipoprotein(a) at Week 24 - ITT Analysis|Percent Change From Baseline in HDL-C at Week 24 - ITT Analysis|Percent Change From Baseline in Fasting Triglycerides at Week 24 - ITT Analysis|Percent Change From Baseline in Apo A-1 at Week 24 - ITT Analysis|Percent Change From Baseline in Lipoprotein(a) at Week 12 - ITT Analysis|Percent Change From Baseline in HDL-C at Week 12 - ITT Analysis|Percent Change From Baseline in Fasting Triglycerides at Week 12 - ITT Analysis|Percent Change From Baseline in Apo A-1 at Week 12 - ITT Analysis","Regeneron Pharmaceuticals|Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 3","355","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","R727-CL-1110","October 2012","April 2014","May 2014","November 21, 2012","August 31, 2015","August 31, 2015","Mobile, Alabama, United States|Chandler, Arizona, United States|Tucson, Arizona, United States|Anaheim, California, United States|Beverly Hills, California, United States|Lakeland, California, United States|Newport Beach, California, United States|Northridge, California, United States|Sacramento, California, United States|Walnut Creek, California, United States|Milford, Connecticut, United States|Atlantis, Florida, United States|Boca Raton, Florida, United States|Clearwater, Florida, United States|Jacksonville, Florida, United States|Miami (2 locations), Florida, United States|Oviedo, Florida, United States|Pinellas Park, Florida, United States|Port Orange, Florida, United States|Sarasota, Florida, United States|Tampa, Florida, United States|West Palm Beach, Florida, United States|Boise, Idaho, United States|Meridian, Idaho, United States|Chicago, Illinois, United States|Morton, Illinois, United States|Indianapolis, Indiana, United States|Newton, Kansas, United States|Overland Park, Kansas, United States|Wichita, Kansas, United States|Lexington, Kentucky, United States|Louisville, Kentucky, United States|Auburn, Maine, United States|Bethesda, Maryland, United States|Edina, Minnesota, United States|Rochester, Minnesota, United States|Olive Branch, Mississippi, United States|Port Gibson, Mississippi, United States|St. Louis, Missouri, United States|Butte, Montana, United States|Las Vegas, Nevada, United States|Williamsville, New York, United States|Winston-Salem, North Carolina, United States|Cleveland, Ohio, United States|Oklahoma City, Oklahoma, United States|Warwick, Rhode Island, United States|Greer, South Carolina, United States|Summerville, South Carolina, United States|Kingsport, Tennessee, United States|Dallas (2 locations), Texas, United States|Fort Worth, Texas, United States|Houston, Texas, United States|Bountiful, Utah, United States|Marion, Utah, United States|Salt Lake City, Utah, United States|Renton, Washington, United States|Herston QLD, Australia|New Lambton Heights, Australia|Perth, Australia|Sherwood, Australia|Woolloongabba, Australia|Brampton, Ontario, Canada|Etobicoke, Ontario, Canada|London, Ontario, Canada|Newmarke, Ontario, Canada|Thornhill, Ontario, Canada|Toronto, Ontario, Canada|Chicoutimi, Quebec, Canada|Dijon, France|Lille, France|Venissieux, France|Bad Oeynhausen, Germany|Berlin, Germany|Koeln, Germany|Munich, Germany|Regensburg, Germany|Ulm, Germany|Chiete, Italy|Genova, Italy|Napoli, Italy|Palermo, Italy|Roma (2 locations), Italy|Distrito Federal, Mexico|Guadalajara, Jalisco, Mexico|Guadalajara, Mexico|Monterrey Nuevo Leon, Mexico|Tijuana Baja California, Mexico|Zapopan Jalisco, Mexico|Barcelona (3 locations), Spain|Madrid, Spain|Sant Joan Despi, Spain|Carmarthen, United Kingdom|Chester, United Kingdom|Peterborough, United Kingdom|Salford, United Kingdom|Stevenage, United Kingdom|West Bromwich, West Midlands, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01730040"
238,"NCT02326220","Study of Alirocumab (REGN727/SAR236553) in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) Undergoing Low-density Lipoprotein (LDL) Apheresis Therapy","ODYSSEY ESCAPE","Completed","No Results Available","Heterozygous Familial Hypercholesterolemia","Drug: Alirocumab|Drug: Placebo","Rate of apheresis treatments during a 12-week period normalized by the number of planned apheresis treatments according to each patient's established schedule at screening|Percent change from baseline in low-density lipoprotein cholesterol (LDL-C) (pre-apheresis)|Standardized rate of apheresis treatments during a 4-week period|Percent change from baseline in apolipoprotein B (ApoB) (pre-apheresis) (pre-apheresis) to week 6|Percent change from baseline in non-high-density lipoprotein cholesterol (HDL-C) (pre-apheresis)|Percent change from baseline in total cholesterol (pre-apheresis)|Percent change from baseline in ApoA-1 (pre-apheresis)|Proportion of patients with ≥30% reduction in LDL-C (pre-apheresis)|Proportion of patients with ≥50% reduction in LDL-C (pre-apheresis)|Percent change from baseline in LDL-C (pre-apheresis)|Percent change from baseline in ApoB (pre-apheresis)|Percent change from baseline in non-HDL-C (pre-apheresis) to week 18|Percent change from baseline in total cholesterol (pre-apheresis) to week 18|Percent change from baseline in ApoA-1(pre-apheresis) to week 18|Proportion of patients with ≥30% reduction in LDL-C (pre-apheresis) at week 18 (pre-apheresis)|Proportion of patients with ≥50% reduction in LDL-C (pre-apheresis) at week 18|Change of W-BQ22 (Well-Being Questionnaire 22-item version) from baseline to week 18|Percent change from baseline in lipoprotein (a) [Lp(a)] (pre-apheresis)|Percent change from baseline in HDL-C (pre-apheresis)|Percent change from baseline in triglyceride (TG) levels (pre-apheresis)|Percent change from baseline in Lp(a) (pre-apheresis) to week 18|Percent change from baseline in HDL-C (pre-apheresis) to week 18|Percent change from baseline in TG levels (pre-apheresis) to week 18","Regeneron Pharmaceuticals|Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 3","62","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","R727-CL-1216","March 2015","January 2016","April 2016","December 29, 2014",,"February 7, 2017","Aurora, Colorado, United States|Hartford, Connecticut, United States|Kansas City, Kansas, United States|Scarborough, Maine, United States|Rochester, Minnesota, United States|Portland, Oregon, United States|Philadelphia, Pennsylvania, United States|Dresden, Sachsen, Germany|Berlin, Germany|Goettlinger, Germany|Muenchen (2 locations), Germany|Passau, Germany|Rostock, Germany",,"https://ClinicalTrials.gov/show/NCT02326220"
239,"NCT00991172","A Study to Evaluate the Safety and Efficacy of Subcutaneously Administered REGN475(SAR164877) in Patients With Sciatic Pain",,"Completed","No Results Available","Sciatica","Drug: REGN475|Drug: Placebo Injection","Sciatic pain between baseline and end of week 4|Additional measures of sciatic pain.","Regeneron Pharmaceuticals|Sanofi","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","159","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","R475-PN-0908","November 2009","May 2010","May 2010","October 7, 2009",,"December 8, 2011","Regeneron Investigational Site, Birmingham, Alabama, United States|Regeneron Investigational Site, Mobile, Alabama, United States|Regeneron Investigational Site, Peoria, Arizona, United States|Regeneron Investigational Site, Anaheim, California, United States|Regeneron Investigational Site, Beverly Hills, California, United States|Regeneron Investigational Site, National City, California, United States|Regeneron Investigational Site, Santa Ana, California, United States|Regeneron Investigational Site, Milford, Connecticut, United States|Regeneron Investigational Site, Stamford, Connecticut, United States|Regeneron Investigational Site, Clearwater, Florida, United States|Regeneron Investigational Site, Hallandale Beach, Florida, United States|Regeneron Investigational Site, St. Petersburg, Florida, United States|Regeneron Investigational Site, Tampa, Florida, United States|Regeneron Investigational Site, West Palm Beach, Florida, United States|Regeneron Investigational Site, Atlanta, Georgia, United States|Regeneron Investigational Site, Sandy Springs, Georgia, United States|Regeneron Investigational Site, Overland Park, Kansas, United States|Regeneron Investigational Site, Rockville, Maryland, United States|Regeneron Investigational Site, Kansas City, Missouri, United States|Regeneron Investigational Site, Albuquerque, New Mexico, United States|Regeneron Investigational Site, Raleigh, North Carolina, United States|Regeneron Investigational Site, Cincinnati, Ohio, United States|Regeneron Investigational Site, Duncansville, Pennsylvania, United States|Regeneron Investigational Site, Tyrone, Pennsylvania, United States|Regeneron Investigational Site, Warwick, Rhode Island, United States|Regeneron Investigational Site, Greer, South Carolina, United States|Regeneron Investigational Site, Memphis, Tennessee, United States|Regeneron Investigational Site, El Paso, Texas, United States|Regeneron Investigational Site, San Antonio, Texas, United States|Regeneron Invesitgational Site, West Jordan, Utah, United States",,"https://ClinicalTrials.gov/show/NCT00991172"
240,"NCT01576484","Open-Label Extension of Study R727-CL-1003 to Evaluate the Long-Term Safety and Efficacy of REGN727 (SAR236553) in Patients With Hypercholesterolemia",,"Completed","No Results Available","Hypercholesterolemia","Drug: REGN727 (SAR236553)","Incidence of AEs from baseline to end of study|Percent change in LDL-C: Baseline to weeks 12, 24, 52 and 218|Changes in other lipids and other lipoproteins","Regeneron Pharmaceuticals|Sanofi","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","58","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","R727-CL-1032","March 2012","December 2016","December 2016","April 12, 2012",,"February 9, 2018","Mission Viejo, California, United States|Newport Beach, California, United States|Thousand Oaks, California, United States|Miami, Florida, United States|Port Orange, Florida, United States|Kansas City, Kansas, United States|Auburn, Maine, United States|Saint Louis, Missouri, United States|Durham, North Carolina, United States|Cincinnati, Ohio, United States|Houston, Texas, United States|Chicoutimi, Quebec, Canada|Montreal, Quebec, Canada|Sainte-Foy, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT01576484"
241,"NCT01709578","To Evaluate The Effect Of SAR153191 (REGN88) Added To Other RA Drugs In Patients With RA Who Are Not Responding To Or Intolerant Of Anti-TNF Therapy (SARIL-RA-TARGET)",,"Completed","Has Results","Rheumatoid Arthritis","Drug: Sarilumab|Drug: placebo|Drug: hydroxychloroquine|Drug: methotrexate|Drug: sulfasalazine|Drug: leflunomide","Percentage of Participants Who Achieved at Least 20% Improvement in the American College of Rheumatology (ACR20) Criteria at Week 24|Change From Baseline in the Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 12|Change From Baseline in Disease Activity Score for 28 Joints -C-Reactive Protein (DAS28--CRP) Score at Week 24|Percentage of Participants Achieving ACR50 Criteria at Week 24|Percentage of Participants Achieving ACR70 Criteria at Week 24|Percentage of Participants Achieving Clinical Remission Score (DAS28-CRP) <2.6 at Week 24|Change From Baseline in Clinical Disease Activity Index (CDAI) at Week 24|Change From Baseline in HAQ-DI at Week 24|Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Physical Component Summary Scores (PCS) at Week 24|Change From Baseline in SF-36 MCS at Week 24|Change From Baseline in the Functional Assessment of Chronic Illness Therapy Fatigue (FACIT-fatigue) Score at Week 24|Change From Baseline in Morning Stiffness VAS at Week 24|Change From Baseline in Work Productivity Survey - Rheumatoid Arthritis (WPS-RA) at Week 24: Work Days Missed Due to RA|Change From Baseline in WPS-RA at Week 24: Days With Work Productivity Reduced by ≥ 50% Due to RA|Change From Baseline in WPS-RA at Week 24: RA Interference With Work Productivity|Change From Baseline in WPS-RA at Week 24: House Work Days Missed Due to RA|Change From Baseline in WPS-RA at Week 24: Days With Household Work Productivity Reduced by ≥ 50% Due to RA|Change From Baseline in WPS-RA at Week 24: Days With Family/Social/Leisure Activities Missed Due to RA|Change From Baseline in WPS-RA at Week 24: Days With Outside Help Hired Due to RA|Change From Baseline in WPS-RA at Week 24: RA Interference With Household Work Productivity|Change From Baseline in Rheumatoid Arthritis Impact of Disease (RAID) Scores at Week 24|Change From Baseline in European Quality of Life-5 Dimension 3 Level (EQ-5D-3L) VAS Scores at Week 24|Percentage of Participants Achieving ACR20, ACR50 and ACR70 Criteria at Week 12|Change From Baseline in DAS28-CRP at Week 12|Percentage of Participants Achieving Clinical Remission Score (DAS28--CRP <2.6) at Week 12|Change From Baseline in SF-36 at Week 12|Change From Baseline in WPS-RA at Week 12: Work Days Missed Due to RA|Change From Baseline in WPS-RA at Week 12: Days With Work Productivity Reduced by ≥ 50% Due to RA|Change From Baseline in WPS-RA at Week 12: RA Interference With Work Productivity|Change From Baseline in WPS-RA at Week 12: House Work Days Missed Due to RA|Change From Baseline in WPS-RA at Week 12: Days With Household Work Productivity Reduced by ≥ 50% Due to RA|Change From Baseline in WPS-RA at Week 12: Days With Family/Social/Leisure Activities Missed Due to RA|Change From Baseline in WPS-RA at Week 12: Days With Outside Help Hired Due to RA|Change From Baseline in WPS-RA at Week 12: RA Interference With Household Work Productivity|Change From Baseline in the FACIT-fatigue at Week 12|Change From Baseline in EQ-5D-3L VAS Scores at Week 12|Change From Baseline in RAID Scores at Week 12|Change From Baseline in Individual ACR Components - TJC and SJC at Week 12 and Week 24|Change From Baseline in Individual ACR Component - Physician Global VAS, Participant Global VAS and Pain VAS at Week 12 and Week 24|Change From Baseline in Individual ACR Component - CRP Level at Week 12 and Week 24|Change From Baseline in Individual ACR Component - HAQ-DI at Week 12 and Week 24","Sanofi|Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 3","546","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","EFC10832|U1111-1115-8466|2011-003538-16","October 2012","March 2015","March 2015","October 18, 2012","August 8, 2017","August 8, 2017","Investigational Site Number 840070, Anniston, Alabama, United States|Investigational Site Number 840138, Birmingham, Alabama, United States|Investigational Site Number 840142, Phoenix, Arizona, United States|Investigational Site Number 840134, Fullerton, California, United States|Investigational Site Number 840141, Glendale, California, United States|Investigational Site Number 840111, La Jolla, California, United States|Investigational Site Number 840135, San Diego, California, United States|Investigational Site Number 840021, Santa Maria, California, United States|Investigational Site Number 840100, Stanford, California, United States|Investigational Site Number 840049, Upland, California, United States|Investigational Site Number 840131, Whittier, California, United States|Investigational Site Number 840201, Denver, Colorado, United States|Investigational Site Number 840130, Lewes, Delaware, United States|Investigational Site Number 840125, DeBary, Florida, United States|Investigational Site Number 840048, Miami, Florida, United States|Investigational Site Number 840024, Naples, Florida, United States|Investigational Site Number 840006, Orlando, Florida, United States|Investigational Site Number 840128, Ormond Beach, Florida, United States|Investigational Site Number 840063, Palm Harbor, Florida, United States|Investigational Site Number 840060, Sarasota, Florida, United States|Investigational Site Number 840140, Tampa, Florida, United States|Investigational Site Number 840126, Vero Beach, Florida, United States|Investigational Site Number 840018, Idaho Falls, Idaho, United States|Investigational Site Number 840110, Meridian, Idaho, United States|Investigational Site Number 840052, Kansas City, Kansas, United States|Investigational Site Number 840015, Lexington, Kentucky, United States|Investigational Site Number 840120, Baton Rouge, Louisiana, United States|Investigational Site Number 840109, Lake Charles, Louisiana, United States|Investigational Site Number 840055, Frederick, Maryland, United States|Investigational Site Number 840150, Lansing, Michigan, United States|Investigational Site Number 840137, Saint Clair Shores, Michigan, United States|Investigational Site Number 840037, Tupelo, Mississippi, United States|Investigational Site Number 840112, Lincoln, Nebraska, United States|Investigational Site Number 840106, Orchard Park, New York, United States|Investigational Site Number 840121, Rochester, New York, United States|Investigational Site Number 840115, Roslyn, New York, United States|Investigational Site Number 840118, Smithtown, New York, United States|Investigational Site Number 840139, Syracuse, New York, United States|Investigational Site Number 840123, Charlotte, North Carolina, United States|Investigational Site Number 840116, Wilmington, North Carolina, United States|Investigational Site Number 840127, Oklahoma City, Oklahoma, United States|Investigational Site Number 840011, Tulsa, Oklahoma, United States|Investigational Site Number 840009, Duncansville, Pennsylvania, United States|Investigational Site Number 840117, Pittsburgh, Pennsylvania, United States|Investigational Site Number 840062, Reading, Pennsylvania, United States|Investigational Site Number 840058, Columbia, South Carolina, United States|Investigational Site Number 840025, Jackson, Tennessee, United States|Investigational Site Number 840059, Memphis, Tennessee, United States|Investigational Site Number 840132, Austin, Texas, United States|Investigational Site Number 840022, Dallas, Texas, United States|Investigational Site Number 840114, El Paso, Texas, United States|Investigational Site Number 840133, Houston, Texas, United States|Investigational Site Number 840129, Houston, Texas, United States|Investigational Site Number 840074, Mesquite, Texas, United States|Investigational Site Number 840036, Spokane, Washington, United States|Investigational Site Number 840124, Clarksburg, West Virginia, United States|Investigational Site Number 032015, Buenos Aires, Argentina|Investigational Site Number 032008, Buenos Aires, Argentina|Investigational Site Number 032019, Caba, Argentina|Investigational Site Number 032006, Caba, Argentina|Investigational Site Number 032016, Capital Federal, Argentina|Investigational Site Number 032020, Cordoba, Argentina|Investigational Site Number 032017, La Plata, Argentina|Investigational Site Number 032010, Ramos Mejia, Argentina|Investigational Site Number 032013, Rosario, Argentina|Investigational Site Number 032004, San Miguel De Tucuman, Argentina|Investigational Site Number 032009, Zarate, Argentina|Investigational Site Number 036014, Victoria Park, Australia|Investigational Site Number 040004, Stockerau, Austria|Investigational Site Number 040003, Wien, Austria|Investigational Site Number 076001, Curitiba, Brazil|Investigational Site Number 076016, Curitiba, Brazil|Investigational Site Number 076006, Goiania, Brazil|Investigational Site Number 076010, Juiz De Fora, Brazil|Investigational Site Number 076005, Rio De Janeiro, Brazil|Investigational Site Number 076015, Rio De Janeiro, Brazil|Investigational Site Number 124005, Toronto, Canada|Investigational Site Number 124009, Trois-Rivières, Canada|Investigational Site Number 124104, Victoria, Canada|Investigational Site Number 152015, Temuco, Chile|Investigational Site Number 170001, Bogota, Colombia|Investigational Site Number 170012, Bogota, Colombia|Investigational Site Number 170006, Bogotá, Colombia|Investigational Site Number 170007, Bucaramanga, Colombia|Investigational Site Number 170009, Bucaramanga, Colombia|Investigational Site Number 170014, Chia, Colombia|Investigational Site Number 170019, Medellin, Colombia|Investigational Site Number 203008, Hostivice, Czechia|Investigational Site Number 203004, Ostrava, Czechia|Investigational Site Number 203007, Praha 2, Czechia|Investigational Site Number 203002, Uherske Hradiste, Czechia|Investigational Site Number 203006, Zlin, Czechia|Investigational Site Number 218003, Cuenca, Ecuador|Investigational Site Number 218001, Guayaquil, Ecuador|Investigational Site Number 218002, Quito, Ecuador|Investigational Site Number 276011, Bad Nauheim, Germany|Investigational Site Number 276010, Berlin, Germany|Investigational Site Number 276001, Berlin, Germany|Investigational Site Number 276014, Berlin, Germany|Investigational Site Number 276018, Deggingen, Germany|Investigational Site Number 276004, Erlangen, Germany|Investigational Site Number 276015, Halle/Saale, Germany|Investigational Site Number 276013, Hamburg, Germany|Investigational Site Number 276016, Leipzig, Germany|Investigational Site Number 276017, München, Germany|Investigational Site Number 276021, Osnabrück, Germany|Investigational Site Number 276020, Tübingen, Germany|Investigational Site Number 276019, Zerbst, Germany|Investigational Site Number 300002, Heraklion, Greece|Investigational Site Number 300005, Thessaloniki, Greece|Investigational Site Number 320002, Guatemala City, Guatemala|Investigational Site Number 320003, Guatemala City, Guatemala|Investigational Site Number 320001, Guatemala City, Guatemala|Investigational Site Number 348022, Budapest, Hungary|Investigational Site Number 348003, Debrecen, Hungary|Investigational Site Number 348004, Veszprém, Hungary|Investigational Site Number 348017, Veszprém, Hungary|Investigational Site Number 376001, Haifa, Israel|Investigational Site Number 376003, Petach Tikva, Israel|Investigational Site Number 376002, Tel Hashomer, Israel|Investigational Site Number 380011, Catania, Italy|Investigational Site Number 380002, Firenze, Italy|Investigational Site Number 380005, Genova, Italy|Investigational Site Number 380014, Milano, Italy|Investigational Site Number 380013, Udine, Italy|Investigational Site Number 410017, Daejeon, Korea, Republic of|Investigational Site Number 410016, Seoul, Korea, Republic of|Investigational Site Number 440005, Kaunas, Lithuania|Investigational Site Number 440006, Klaipeda, Lithuania|Investigational Site Number 440007, Vilnius, Lithuania|Investigational Site Number 484023, Chihuahua, Mexico|Investigational Site Number 484018, Guadalajara, Mexico|Investigational Site Number 484002, Guadalajara, Mexico|Investigational Site Number 484024, Guadalajara, Mexico|Investigational Site Number 484010, Mexicali, Mexico|Investigational Site Number 484019, Monterrey, Mexico|Investigational Site Number 484020, Monterrey, Mexico|Investigational Site Number 484005, Monterrey, Mexico|Investigational Site Number 484017, México, Mexico|Investigational Site Number 484021, Queretaro, Mexico|Investigational Site Number 554005, Hamilton, New Zealand|Investigational Site Number 554011, Nelson, New Zealand|Investigational Site Number 554007, Otahuhu, New Zealand|Investigational Site Number 554001, Timaru, New Zealand|Investigational Site Number 554006, Wellington, New Zealand|Investigational Site Number 604010, Lima, Peru|Investigational Site Number 604009, Lima, Peru|Investigational Site Number 604006, Lima, Peru|Investigational Site Number 604012, Lima, Peru|Investigational Site Number 604013, Lima, Peru|Investigational Site Number 604001, Lima, Peru|Investigational Site Number 604008, Lima, Peru|Investigational Site Number 604007, Lima, Peru|Investigational Site Number 604005, Lima, Peru|Investigational Site Number 604014, Lima, Peru|Investigational Site Number 616014, Bialystok, Poland|Investigational Site Number 616019, Bydgoszcz, Poland|Investigational Site Number 616015, Elblag, Poland|Investigational Site Number 616018, Poznan, Poland|Investigational Site Number 616016, Szczecin, Poland|Investigational Site Number 616004, Warszawa, Poland|Investigational Site Number 616017, Warszawa, Poland|Investigational Site Number 616020, Wroclaw, Poland|Investigational Site Number 620002, Lisboa, Portugal|Investigational Site Number 620004, Lisboa, Portugal|Investigational Site Number 620007, Ponte De Lima, Portugal|Investigational Site Number 642001, Bucuresti, Romania|Investigational Site Number 642012, Bucuresti, Romania|Investigational Site Number 642002, Bucuresti, Romania|Investigational Site Number 642014, Iasi, Romania|Investigational Site Number 643001, Moscow, Russian Federation|Investigational Site Number 643021, Moscow, Russian Federation|Investigational Site Number 643022, Novosibirsk, Russian Federation|Investigational Site Number 643008, Saint-Petersburg, Russian Federation|Investigational Site Number 643010, Samara, Russian Federation|Investigational Site Number 703001, Kosice, Slovakia|Investigational Site Number 724016, Barakaldo, Spain|Investigational Site Number 724015, Barcelona, Spain|Investigational Site Number 724014, Cadiz, Spain|Investigational Site Number 724009, La Coruña, Spain|Investigational Site Number 724001, Málaga, Spain|Investigational Site Number 724011, Sabadell, Spain|Investigational Site Number 724017, Santiago De Compostela, Spain|Investigational Site Number 724013, Santiago De Compostela, Spain|Investigational Site Number 724007, Sevilla, Spain|Investigational Site Number 158005, Kaohsiung, Taiwan|Investigational Site Number 158006, Taipei, Taiwan|Investigational Site Number 158002, Taoyuan County, Taiwan|Investigational Site Number 792007, Edirne, Turkey|Investigational Site Number 792008, Gaziantep, Turkey|Investigational Site Number 792009, Samsun, Turkey|Investigational Site Number 804013, Kharkiv, Ukraine|Investigational Site Number 804014, Kyiv, Ukraine|Investigational Site Number 804027, Kyiv, Ukraine|Investigational Site Number 804011, Vinnytsia, Ukraine|Investigational Site Number 804009, Zaporizhzhya, Ukraine",,"https://ClinicalTrials.gov/show/NCT01709578"
242,"NCT01240460","Exploratory Study of XL765 (SAR245409) or XL147 (SAR245408) in Subjects With Recurrent Glioblastoma Who Are Candidates for Surgical Resection",,"Completed","No Results Available","Glioblastoma|Astrocytoma, Grade IV","Drug: XL765 (SAR245409)|Drug: XL147 (SAR245408)","To explore the biological effect of XL765 and XL147 measured by modulation of PI3K/ mTOR pathway readouts in GB tumor tissue|To examine the safety profile of daily oral administration of XL765 and XL147 in subjects with recurrent GB|To determine the levels of XL765 and XL147 in plasma and GB tumor tissue|To assess the anti-proliferative and pro-apoptotic effects of XL765 and XL147 on tumor cells|To measure changes in tumor after surgery in subjects receiving XL765 and XL147|To conduct genetic analyses of GB tumor tissue comparing, where feasible, tumor tissue removed during the on-study resection with tissue removed during the initial surgical resection|To evaluate the pharmacodynamic effects of XL765 and XL147 in blood and/or blood cells for identification and characterization of surrogate biomarkers associated with the biological effects of XL765 and XL147|To explore the relationship between clinical response and genomic and proteomic biomarkers in the PI3K and EGFR pathways","Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 1","40","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TED11605|XL765-202","January 2011","June 2012","June 2012","November 15, 2010",,"July 27, 2012","Investigational Site Number 840001, Los Angeles, California, United States|Investigational Site Number 840003, San Francisco, California, United States|Investigational Site Number 840004, Boston, Massachusetts, United States|Investigational Site Number 840002, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT01240460"
243,"NCT00197262","Once-Daily Investigational Nasal Spray In Adults And Adolescents With Seasonal Allergic Rhinitis (SAR)",,"Completed","No Results Available","Rhinitis, Allergic, Seasonal","Drug: GW685698X Aqueous Nasal Spray","Mean change from baseline over the entire treatment period in daily, reflective total nasal symptom scores.|1) Mean change from baseline over the entire treatment period in AM, pre-dose, instantaneous total nasal symptom scores. 2) Mean change from baseline in daily reflective total ocular symptom scores. 3) overall evaluation of response to therapy.","GlaxoSmithKline","All","12 Years and older   (Child, Adult, Older Adult)","Phase 3","288","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","FFR104861","August 2005","October 2005","October 2005","September 20, 2005",,"January 19, 2017","GSK Investigational Site, Chicago, Illinois, United States|GSK Investigational Site, Indianapolis, Indiana, United States|GSK Investigational Site, Lafayette, Indiana, United States|GSK Investigational Site, Louisville, Kentucky, United States|GSK Investigational Site, Novi, Michigan, United States|GSK Investigational Site, Minneapolis, Minnesota, United States|GSK Investigational Site, Columbia, Missouri, United States|GSK Investigational Site, Rolla, Missouri, United States|GSK Investigational Site, St. Louis, Missouri, United States|GSK Investigational Site, Lincoln, Nebraska, United States|GSK Investigational Site, Papillion, Nebraska, United States|GSK Investigational Site, Canton, Ohio, United States|GSK Investigational Site, Sylvania, Ohio, United States|GSK Investigational Site, Spartanburg, South Carolina, United States|GSK Investigational Site, Dallas, Texas, United States|GSK Investigational Site, Dallas, Texas, United States|GSK Investigational Site, Greenfield, Wisconsin, United States|GSK Investigational Site, West Allis, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT00197262"
244,"NCT00871559","A Multiple-Ascending-Dose Study of the Safety and Tolerability of REGN421(SAR153192) in Patients With Advanced Solid Malignancies",,"Completed","No Results Available","Advanced Solid Malignancies","Drug: REGN421(SAR153192)","Safety and tolerability|Preliminary evidence of antitumor activity","Regeneron Pharmaceuticals|Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 1","83","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","R421-ST-0804","June 2009","February 2014","February 2014","March 30, 2009",,"March 26, 2014","Aurora, Colorado, United States|Indianapolis, Indiana, United States|Boston, Massachusetts, United States|Detroit, Michigan, United States|St. Louis, Missouri, United States|New York, New York, United States|Columbus, Ohio, United States|Oklahoma City, Oklahoma, United States",,"https://ClinicalTrials.gov/show/NCT00871559"
245,"NCT00521040","Efficacy and Safety of Levocetirizine 8 Weeks Prior and After the Onset of the Grass Pollen Season in Subjects With SAR",,"Completed","No Results Available","Rhinitis, Allergic, Seasonal","Drug: Levocetirizine dihydrochloride","T4SS (sum of the scores of the severity of sneezing, rhinorrhea, nasal pruritus and ocular pruritus)|Pollen-induced symptomatology of asthma; symptoms of rhinitis and asthma over the first 4 season weeks and during the entire observation period following the actual onset of the grass pollen season","UCB Pharma","All","12 Years and older   (Child, Adult, Older Adult)","Not Applicable","459","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","A00306","February 2004","July 2004","July 2004","August 27, 2007",,"December 12, 2013",,,"https://ClinicalTrials.gov/show/NCT00521040"
246,"NCT01448239","Injection Site Tolerability, Safety, Pharmacokinetics and Pharmacodynamics Study After a Single Dose Subcutaneous Treatment of Alirocumab SAR236553 (REGN727)",,"Completed","No Results Available","Hypercholesterolemia","Drug: alirocumab SAR236553 (REGN727)","Pain using present pain intensity (PPI) verbal questionnaire|Erythema at injection site by measuring diameter and qualitative assessment|Edema at injection site by measuring diameter and qualitative assessment|Assessment of PK parameter - time to maximum concentration (tmax)|Assessment of PK parameter - maximum concentration (Cmax)|Assessment of PK parameter - area under curve (AUC)|Assessment of PK parameter - cluster of differentiation (CD) biomarker (CD29)|Assessment of PK parameter - terminal elimination half-life (t1/2z)|Pharmacodynamics: Change in LDL-C from baseline|Number of participants with Adverse Events","Sanofi|Regeneron Pharmaceuticals","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","24","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","PKD12010|U1111-1118-2935","February 2011","May 2011","May 2011","October 7, 2011",,"June 28, 2013","Sanofi-Aventis Administrative Office, Bridgewater, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT01448239"
247,"NCT01926782","Study to Evaluate the Efficacy and Safety of an Every Four Weeks Treatment Regimen of Alirocumab (REGN727/ SAR236553) in Patients With Primary Hypercholesterolemia (ODYSSEY CHOICE 1)",,"Completed","Has Results","Hypercholesterolemia","Drug: Placebo (for alirocumab)|Drug: Alirocumab|Drug: Statin","Percent Change From Baseline in Calculated LDL-C in Participants Not Receiving Concomitant Statin Therapy - ITT Analysis|Percent Change From Baseline in Calculated LDL-C in Participants Receiving Concomitant Statin Therapy - Intent-to-Treat (ITT Analysis)|Percent Change From Baseline in Calculated LDL-C at Week 24 in Participants Not Receiving Concomitant Statin Therapy - On-Treatment Analysis|Percent Change From Baseline in Calculated LDL-C at Week 24 in Participants Receiving Concomitant Statin Therapy - On-Treatment Analysis|Percent Change From Baseline in Calculated LDL-C at Week 12 in Participants Not Receiving Concomitant Statin Therapy - ITT Analysis|Percent Change From Baseline in Calculated LDL-C at Week 12 in Participants Receiving Concomitant Statin Therapy - ITT Analysis|Percent Change From Baseline in Calculated LDL-C at Week 12 in Participants Not Receiving Concomitant Statin Therapy - On-treatment Analysis|Percent Change From Baseline in Calculated LDL-C at Week 12 in Participants Receiving Concomitant Statin Therapy - On-treatment Analysis|Percent Change From Baseline in Apolipoprotein (Apo) B at Week 24 in Participants Not Receiving Concomitant Statin Therapy - ITT Analysis|Percent Change From Baseline in Apo B at Week 24 in Participants Receiving Concomitant Statin Therapy - ITT Analysis|Percent Change From Baseline in Apo B at Week 24 in Participants Not Receiving Concomitant Statin Therapy - On-Treatment Analysis|Percent Change From Baseline in Apo B at Week 24 in Participants Receiving Concomitant Statin Therapy - On-Treatment Analysis|Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 24 in Participants Not Receiving Concomitant Statin Therapy - ITT Analysis|Percent Change From Baseline in Non-HDL-C at Week 24 in Participants Receiving Concomitant Statin Therapy - ITT Analysis|Percent Change From Baseline in Non-HDL-C at Week 24 in Participants Not Receiving Concomitant Statin Therapy - On-Treatment Analysis|Percent Change From Baseline in Non-HDL-C at Week 24 in Participants Receiving Concomitant Statin Therapy - On-Treatment Analysis|Percent Change From Baseline in Total Cholesterol (Total-C) at Week 24 in Participants Not Receiving Concomitant Statin Therapy - ITT Analysis|Percent Change From Baseline in Total-C at Week 24 in Participants Receiving Concomitant Statin Therapy - ITT Analysis|Percent Change From Baseline in Apo B at Week 12 in Participants Not Receiving Concomitant Statin Therapy - ITT Analysis|Percent Change From Baseline in Apo B at Week 12 in Participants Receiving Concomitant Statin Therapy - ITT Analysis|Percent Change From Baseline in Non-HDL-C at Week 12 in Participants Not Receiving Concomitant Statin Therapy - ITT Analysis|Percent Change From Baseline in Non-HDL-C at Week 12 in Participants Receiving Concomitant Statin Therapy - ITT Analysis|Percent Change From Baseline in Total-C at Week 12 in Participants Not Receiving Concomitant Statin Therapy - ITT Analysis|Percent Change From Baseline in Total-C at Week 12 in Participants Receiving Concomitant Statin Therapy - ITT Analysis|Percentage of Very High CV Risk Participants Reaching Calculated LDL-C<70 mg/dL or Moderate or High CV Risk Participants Reaching Calculated LDL-C<100 mg/dL (Without Concomitant Statin Therapy) at Week 24 - ITT Analysis|Percentage of Very High Cardiovascular (CV) Risk Participants Reaching Calculated LDL-C <70 mg/dL or Moderate or High CV Risk Participants Reaching Calculated LDL-C <100 mg/dL (With Concomitant Statin Therapy) at Week 24 - ITT Analysis|Percentage of Very High CV Risk Participants Reaching Calculated LDL-C<70 mg/dL (1.81 mmol/L) or Moderate or High CV Risk Participants Reaching Calculated LDL-C<100 mg/dL(2.59 mmol/L) (Without Concomitant Statin Therapy) at Week 24 - On-Treatment Analysis|Percentage of Very High CV Risk Participants Reaching Calculated LDL-C <70 mg/dL(1.81 mmol/L) or Moderate or High CV Risk Participants Reaching Calculated LDL-C <100 mg/dL(2.59 mmol/L) (With Concomitant Statin Therapy) at Week 24 - On-Treatment Analysis|Percentage of Participants (Without Concomitant Statin Therapy) Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - ITT Analysis|Percentage of Participants (With Concomitant Statin Therapy) Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - ITT Analysis|Percentage of Participants (Without Concomitant Statin Therapy) Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - On-Treatment Analysis|Percentage of Participants (With Concomitant Statin Therapy) Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - On-Treatment Analysis|Percent Change From Baseline in Lipoprotein (a) in Participants Not Receiving Concomitant Statin Therapy at Week 24 - ITT Analysis|Percent Change From Baseline in Lipoprotein (a) in Participants Receiving Concomitant Statin Therapy at Week 24 - ITT Analysis|Percent Change From Baseline in Lipoprotein (a) in Participants Not Receiving Concomitant Statin Therapy at Week 12 - ITT Analysis|Percent Change From Baseline in Lipoprotein (a) in Participants Receiving Concomitant Statin Therapy at Week 12 - ITT Analysis|Percent Change From Baseline in HDL-C in Participants Not Receiving Concomitant Statin Therapy at Week 24 - ITT Analysis|Percent Change From Baseline in HDL-C in Participants Receiving Concomitant Statin Therapy at Week 24 - ITT Analysis|Percent Change From Baseline in HDL-C in Participants Not Receiving Concomitant Statin Therapy at Week 12 - ITT Analysis|Percent Change From Baseline in HDL-C in Participants Receiving Concomitant Statin Therapy at Week 12 - ITT Analysis|Percent Change From Baseline in Fasting Triglycerides in Participants Not Receiving Concomitant Statin Therapy at Week 24 - ITT Analysis|Percent Change From Baseline in Fasting Triglycerides in Participants Receiving Concomitant Statin Therapy at Week 24 - ITT Analysis|Percent Change From Baseline in Fasting Triglycerides in Participants Not Receiving Concomitant Statin Therapy at Week 12 - ITT Analysis|Percent Change From Baseline in Fasting Triglycerides in Participants Receiving Concomitant Statin Therapy at Week 12 - ITT Analysis|Percent Change From Baseline in Apo A1 in Participants Not Receiving Concomitant Statin Therapy at Week 24 - ITT Analysis|Percent Change From Baseline in Apo A1 in Participants Receiving Concomitant Statin Therapy at Week 24 - ITT Analysis|Percent Change From Baseline in Apo A1 in Participants Not Receiving Concomitant Statin Therapy at Week 12 - ITT Analysis|Percent Change From Baseline in Apo A1 in Participants Receiving Concomitant Statin Therapy at Week 12 - ITT Analysis","Regeneron Pharmaceuticals|Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 3","803","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","R727-CL-1308","September 2013","September 2014","April 2015","August 21, 2013","March 21, 2017","March 21, 2017","Chandler, Arizona, United States|Goodyear, Arizona, United States|Carmichael, California, United States|Fresno, California, United States|West Hills, California, United States|Wildomar, California, United States|Colorado Springs, Colorado, United States|Golden, Colorado, United States|Boynton Beach, Florida, United States|Jacksonville, Florida, United States|Safety Harbor, Florida, United States|Atlanta, Georgia, United States|Boise, Idaho, United States|Meridian, Idaho, United States|Chicago, Illinois, United States|Gurnee, Illinois, United States|Evansville, Indiana, United States|Indianapolis, Indiana, United States|Iowa City, Iowa, United States|Kansas City, Kansas, United States|Louisville, Kentucky, United States|Monroe, Louisiana, United States|Auburn, Maine, United States|Methuen, Massachusetts, United States|Minneapolis, Minnesota, United States|St. Louis, Missouri, United States|Rochester, New York, United States|Farmville, North Carolina, United States|Greensboro, North Carolina, United States|Greenville, North Carolina, United States|Raleigh, North Carolina, United States|Wilson, North Carolina, United States|Cincinnati, Ohio, United States|Marion, Ohio, United States|Tulsa, Oklahoma, United States|Philadelphia, Pennsylvania, United States|Wyomissing, Pennsylvania, United States|Knoxville, Tennessee, United States|Dallas, Texas, United States|Houston, Texas, United States|San Antonio, Texas, United States|Orem, Utah, United States|Salt Lake City, Utah, United States|South Jordan, Utah, United States|Norfolk, Virginia, United States|Richmond, Virginia, United States|Spokane, Washington, United States|Tacoma, Washington, United States|Kenosha, Wisconsin, United States|Sofia, Bulgaria|Varna, Bulgaria|Victoria, British Columbia, Canada|Oshawa, Ontario, Canada|Toronto, Ontario, Canada|Woodstock, Ontario, Canada|Montreal, Quebec, Canada|Trois-Rivieres, Quebec, Canada|Quebec, Canada|Budapest, Becsi ut, Hungary|Debrecen, HBM, Hungary|Nyiregyhaza, Sz-sz-b_m, Hungary|Ajka, VeszprÃ©m, Hungary|Nagykanizsa, Zala, Hungary|Zalaegerszeg, Zala, Hungary|Tel Hashomer, IL, Israel|Safed, ISR, Israel|Ofakim, South, Israel|Holon, Israel|Tel Hashomer, Israel|Skedsmokorset, Akershus, Norway|Oslo, Norway|Svidnik, Presov, Slovakia|Bratislava, SK, Slovakia|Bratislava, SR, Slovakia|Lucenec, Slovakia|PovaÅ¾skÃ¡ Bystrica, Slovakia|Worton Grange, Reading, Berkshire, United Kingdom|Edgbaston, Birmingham, United Kingdom|Llanishen, Cardiff, United Kingdom|Choley, Lancashire, United Kingdom|Waterloo, Liverpool, United Kingdom|Lloyd Street North, Manchester, United Kingdom|Glasgow, Scotland, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01926782"
248,"NCT01768572","To Evaluate The Safety of SAR153191 (REGN88) and Tocilizumab Added to Other RA Drugs in Patients With RA Who Are Not Responding to or Intolerant of Anti-TNF Therapy (SARIL-RA-ASCERTAIN)",,"Completed","Has Results","Rheumatoid Arthritis","Drug: sarilumab SAR153191 (REGN88)|Drug: tocilizumab|Drug: hydroxychloroquine|Drug: methotrexate|Drug: sulfasalazine|Drug: leflunomide|Drug: subcutaneous placebo|Drug: intravenous placebo","Number of Participants With Treatment Emergent Adverse Events (TEAEs)","Sanofi|Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 3","202","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","SFY13370|2012-003536-23|U1111-1133-7839","March 2013","October 2014","October 2014","January 15, 2013","June 26, 2017","June 26, 2017","Investigational Site Number 840152, Huntsville, Alabama, United States|Investigational Site Number 840151, Colorado Springs, Colorado, United States|Investigational Site Number 840153, Aventura, Florida, United States|Investigational Site Number 840033, Fort Lauderdale, Florida, United States|Investigational Site Number 840048, Miami, Florida, United States|Investigational Site Number 840155, Palm Harbor, Florida, United States|Investigational Site Number 840013, Wheaton, Maryland, United States|Investigational Site Number 840154, Boston, Massachusetts, United States|Investigational Site Number 840150, Lansing, Michigan, United States|Investigational Site Number 840062, Reading, Pennsylvania, United States|Investigational Site Number 840038, Austin, Texas, United States|Investigational Site Number 840022, Dallas, Texas, United States|Investigational Site Number 840156, Dallas, Texas, United States|Investigational Site Number 840074, Mesquite, Texas, United States|Investigational Site Number 032006, Caba, Argentina|Investigational Site Number 032010, Ramos Mejia, Argentina|Investigational Site Number 032013, Rosario, Argentina|Investigational Site Number 032015, San Fernando, Argentina|Investigational Site Number 032004, San Miguel De Tucuman, Argentina|Investigational Site Number 032005, Tucuman, Argentina|Investigational Site Number 056010, Leuven, Belgium|Investigational Site Number 076001, Curitiba, Brazil|Investigational Site Number 076030, Sao Jose Do Rio Preto, Brazil|Investigational Site Number 203009, Liberec, Czechia|Investigational Site Number 203011, Praha 2, Czechia|Investigational Site Number 203010, Praha 4, Czechia|Investigational Site Number 233010, Tallinn, Estonia|Investigational Site Number 233002, Tallinn, Estonia|Investigational Site Number 246001, Helsinki, Finland|Investigational Site Number 246010, Riihimäki, Finland|Investigational Site Number 348014, Budapest, Hungary|Investigational Site Number 348022, Budapest, Hungary|Investigational Site Number 348021, Esztergom, Hungary|Investigational Site Number 348016, Kistarcsa, Hungary|Investigational Site Number 348009, Szolnok, Hungary|Investigational Site Number 348015, Szombathely, Hungary|Investigational Site Number 376010, Haifa, Israel|Investigational Site Number 376011, Tel Aviv, Israel|Investigational Site Number 380002, Firenze, Italy|Investigational Site Number 380005, Genova, Italy|Investigational Site Number 484008, Durango, Mexico|Investigational Site Number 484035, Leon, Mexico|Investigational Site Number 484009, Merida, Mexico|Investigational Site Number 484001, México, D.F., Mexico|Investigational Site Number 484036, Zapopan, Mexico|Investigational Site Number 528010, Amsterdam, Netherlands|Investigational Site Number 528001, Leiden, Netherlands|Investigational Site Number 578010, Kristiansand, Norway|Investigational Site Number 578006, Tønsberg, Norway|Investigational Site Number 616019, Bydgoszcz, Poland|Investigational Site Number 616054, Bytom, Poland|Investigational Site Number 616030, Lublin, Poland|Investigational Site Number 616031, Warszawa, Poland|Investigational Site Number 616017, Warszawa, Poland|Investigational Site Number 642006, Braila, Romania|Investigational Site Number 642020, Bucharest, Romania|Investigational Site Number 642010, Bucharest, Romania|Investigational Site Number 642021, Bucuresti, Romania|Investigational Site Number 642001, Bucuresti, Romania|Investigational Site Number 642022, Targoviste, Romania|Investigational Site Number 643017, Kemerovo, Russian Federation|Investigational Site Number 643020, Moscow, Russian Federation|Investigational Site Number 643001, Moscow, Russian Federation|Investigational Site Number 643002, Moscow, Russian Federation|Investigational Site Number 643031, Moscow, Russian Federation|Investigational Site Number 643030, Moscow, Russian Federation|Investigational Site Number 643032, St-Petersburg, Russian Federation|Investigational Site Number 724020, Barcelona, Spain|Investigational Site Number 724021, Santander, Spain|Investigational Site Number 724022, Sevilla, Spain|Investigational Site Number 752004, Malmö, Sweden|Investigational Site Number 752002, Uppsala, Sweden|Investigational Site Number 826004, Doncaster, United Kingdom|Investigational Site Number 826006, Edinburgh, United Kingdom|Investigational Site Number 826001, Leeds, United Kingdom|Investigational Site Number 826002, London, United Kingdom|Investigational Site Number 826005, Southampton, United Kingdom|Investigational Site Number 826025, Wigan, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01768572"
249,"NCT00574379","Efficacy, Safety and PK of Once or Twice Daily Bilastine (10 or 20 mg) Compared With Placebo in the Symptomatic Treatment of SAR",,"Completed","No Results Available","Seasonal Allergic Rhinitis|Hay Fever|Allergic Conjunctivitis|Hypersensitivity","Drug: Bilastine|Drug: Placebo","Change in nasal symptom scores|Change in ocular symptom scores and quality of life scores; standard safety assessments","Faes Farma, S.A.|Merck Sharp & Dohme Corp.|Allied Research International","All","12 Years and older   (Child, Adult, Older Adult)","Phase 2","805","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","BILA 2607/RAE|CTFZ07001","December 2007","March 2008","March 2008","December 17, 2007",,"February 15, 2019","Oklahoma Allergy and Asthma Clinic, Oklahoma City, Oklahoma, United States|MetaClin Research Inc., Austin, Texas, United States|Austin Clinical Research, Austin, Texas, United States|Lovelace Scientific Resources, Austin, Texas, United States|Kerrville Research Associates, Kerrville, Texas, United States|Biogenics Research Institute, San Antonio, Texas, United States|DGD Research, San Antonio, Texas, United States|Diagnostics Research Group, San Antonio, Texas, United States|Southwest Allergy and Asthma Centre, San Antonio, Texas, United States|Sylvana Research Associates, San Antonio, Texas, United States|Live Oak Allergy and Asthma, San Antonio, Texas, United States|Allergy & Asthma Care of Waco, Waco, Texas, United States|Allergy Asthma Research Institute, Waco, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00574379"
250,"NCT01639040","Study to Assess the Safety of Dupilumab (REGN668/SAR231893) Administered Concomitantly With Topical Corticosteroids (TCS) in Patients With Moderate-to-severe Atopic Dermatitis (AD)",,"Completed","Has Results","Atopic Dermatitis","Drug: Dupilumab|Drug: Placebo (for Dupilumab)|Other: Topical Corticosteroid (TCS)","Percentage of Participants With Treatment Emergent Adverse Events (TEAEs)","Regeneron Pharmaceuticals|Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 2","31","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","R668-AD-1121","July 2012","December 2012","December 2012","July 12, 2012","October 13, 2017","October 13, 2017","Berlin, Germany|Dresden, Germany|Duelmen, Germany|Frankfurt, Germany|Gera, Germany|Langenau, Germany|Munster, Germany|Szeged-Hungary, Hungary|Szolnok, Hungary|Gdansk, Poland|Lodz, Poland|Lublin, Poland|Warszawa, Poland",,"https://ClinicalTrials.gov/show/NCT01639040"
251,"NCT00818805","Efficacy Investigation Study of Olopatadine Hydrochloride Ophthalmic Solution Using OHIO Chamber in Patients With Seasonal Allergic Rhinitis (SAR)",,"Completed","Has Results","Allergic Conjunctivitis","Drug: Olopatadine 0.1%|Drug: Tranilast 0.5%|Drug: Placebo (Olopatadine)|Drug: Placebo (Tranilast)","Change in ""Ocular Itching"" Score (5-point Scale) in Subjective Symptom Questionnaire|Change in Total Score in Ocular Symptom Questionnaire","Alcon Research","All","20 Years and older   (Adult, Older Adult)","Phase 4","50","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","AL-292ET","July 2008","July 2008",,"January 8, 2009","March 15, 2010","June 4, 2012",,,"https://ClinicalTrials.gov/show/NCT00818805"
252,"NCT01673659","A Safety and Bioequivalence of a Mometasone Nasal Spray, 50 Mcg/Actuation Compared With Nasonex® Nasal Spray 50 Mcg/Actuation in the Relief of the Symptoms of Seasonal Allergic Rhinitis (SAR)",,"Completed","No Results Available","Seasonal Allergic Rhinitis","Drug: Mometasone furoate|Drug: Nasonex Nasal Spray|Drug: Placebo nasal spray","Mean Change from Baseline for mean reflective Total Nasal Symptom Score (rTNSS)|Mean Change from Baseline in the mean Instantaneous Total Nasal Symptom Score (iTNSS)","Perrigo Company","All","12 Years to 65 Years   (Child, Adult, Older Adult)","Phase 3","1220","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","PRG-NY-12-008","August 2012","October 2012","October 2012","August 28, 2012",,"October 1, 2013","San Antonio, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01673659"
253,"NCT03723148","Individual Patient Compassionate Use of Fedratinib",,"Available","No Results Available","Myelofibrosis","Drug: Oral Fedratinib",,"Celgene|Impact Biomedicines, Inc., a wholly owned subsidiary of Celgene Corporation","All","18 Years and older   (Adult, Older Adult)",,,"Industry|Other","Expanded Access:Individual Patients",,"FEDR",,,,"October 29, 2018",,"October 22, 2019","Celgene, Summit, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT03723148"
254,"NCT03499808","S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis",,"Recruiting","No Results Available","Amorphous, Eosinophilic, and Acellular Deposit|Constipation|Diarrhea|Early Satiety|Gastrointestinal Hemorrhage|Hepatomegaly|Lymphadenopathy|Macroglossia|Nausea|Primary Systemic Amyloidosis|Purpura|Recurrent Primary Amyloidosis|Refractory Primary Amyloidosis","Biological: Isatuximab|Other: Laboratory Biomarker Analysis","Overall confirmed hematologic response rate|Incidence of adverse events|Organ response|Overall survival|Progression free survival","Southwest Oncology Group|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 2","39","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","S1702|NCI-2017-01375|U10CA180888","March 8, 2018","October 30, 2021","July 31, 2025","April 17, 2018",,"July 2, 2019","Anchorage Associates in Radiation Medicine, Anchorage, Alaska, United States|Anchorage Radiation Therapy Center, Anchorage, Alaska, United States|Alaska Breast Care and Surgery LLC, Anchorage, Alaska, United States|Alaska Oncology and Hematology LLC, Anchorage, Alaska, United States|Alaska Women's Cancer Care, Anchorage, Alaska, United States|Anchorage Oncology Centre, Anchorage, Alaska, United States|Katmai Oncology Group, Anchorage, Alaska, United States|Providence Alaska Medical Center, Anchorage, Alaska, United States|CHI Saint Vincent Cancer Center Hot Springs, Hot Springs, Arkansas, United States|Providence Saint Joseph Medical Center/Disney Family Cancer Center, Burbank, California, United States|Fremont - Rideout Cancer Center, Marysville, California, United States|UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California, United States|University of California Davis Comprehensive Cancer Center, Sacramento, California, United States|Rocky Mountain Cancer Centers-Aurora, Aurora, Colorado, United States|The Medical Center of Aurora, Aurora, Colorado, United States|University of Colorado Hospital, Aurora, Colorado, United States|Boulder Community Hospital, Boulder, Colorado, United States|Rocky Mountain Cancer Centers-Boulder, Boulder, Colorado, United States|Penrose-Saint Francis Healthcare, Colorado Springs, Colorado, United States|Rocky Mountain Cancer Centers-Penrose, Colorado Springs, Colorado, United States|Denver Health Medical Center, Denver, Colorado, United States|National Jewish Health-Main Campus, Denver, Colorado, United States|The Women's Imaging Center, Denver, Colorado, United States|Porter Adventist Hospital, Denver, Colorado, United States|Colorado Blood Cancer Institute, Denver, Colorado, United States|Presbyterian - Saint Lukes Medical Center - Health One, Denver, Colorado, United States|Rocky Mountain Cancer Centers-Midtown, Denver, Colorado, United States|SCL Health Saint Joseph Hospital, Denver, Colorado, United States|Rocky Mountain Cancer Centers-Rose, Denver, Colorado, United States|Rose Medical Center, Denver, Colorado, United States|Western Surgical Care, Denver, Colorado, United States|Mercy Medical Center, Durango, Colorado, United States|Southwest Oncology PC, Durango, Colorado, United States|Comprehensive Cancer Care and Research Institute of Colorado LLC, Englewood, Colorado, United States|Swedish Medical Center, Englewood, Colorado, United States|Poudre Valley Hospital, Fort Collins, Colorado, United States|Mountain Blue Cancer Care Center, Golden, Colorado, United States|National Jewish Health-Western Hematology Oncology, Golden, Colorado, United States|Saint Mary's Hospital and Regional Medical Center, Grand Junction, Colorado, United States|North Colorado Medical Center, Greeley, Colorado, United States|Good Samaritan Medical Center, Lafayette, Colorado, United States|Rocky Mountain Cancer Centers-Lakewood, Lakewood, Colorado, United States|Saint Anthony Hospital, Lakewood, Colorado, United States|Rocky Mountain Cancer Centers-Littleton, Littleton, Colorado, United States|Littleton Adventist Hospital, Littleton, Colorado, United States|Rocky Mountain Cancer Centers-Sky Ridge, Lone Tree, Colorado, United States|Sky Ridge Medical Center, Lone Tree, Colorado, United States|Longmont United Hospital, Longmont, Colorado, United States|Rocky Mountain Cancer Centers-Longmont, Longmont, Colorado, United States|McKee Medical Center, Loveland, Colorado, United States|Parker Adventist Hospital, Parker, Colorado, United States|Rocky Mountain Cancer Centers-Parker, Parker, Colorado, United States|Saint Mary Corwin Medical Center, Pueblo, Colorado, United States|Rocky Mountain Cancer Centers - Pueblo, Pueblo, Colorado, United States|National Jewish Health-Northern Hematology Oncology, Thornton, Colorado, United States|Rocky Mountain Cancer Centers-Thornton, Thornton, Colorado, United States|SCL Health Lutheran Medical Center, Wheat Ridge, Colorado, United States|Smilow Cancer Hospital-Derby Care Center, Derby, Connecticut, United States|Smilow Cancer Hospital Care Center-Fairfield, Fairfield, Connecticut, United States|Smilow Cancer Hospital Care Center at Saint Francis, Hartford, Connecticut, United States|Smilow Cancer Center/Yale-New Haven Hospital, New Haven, Connecticut, United States|Yale University, New Haven, Connecticut, United States|Yale-New Haven Hospital North Haven Medical Center, North Haven, Connecticut, United States|Smilow Cancer Hospital-Orange Care Center, Orange, Connecticut, United States|Smilow Cancer Hospital-Torrington Care Center, Torrington, Connecticut, United States|Smilow Cancer Hospital Care Center-Trumbull, Trumbull, Connecticut, United States|Smilow Cancer Hospital-Waterbury Care Center, Waterbury, Connecticut, United States|Mayo Clinic in Florida, Jacksonville, Florida, United States|Cleveland Clinic-Weston, Weston, Florida, United States|Saint Alphonsus Cancer Care Center-Boise, Boise, Idaho, United States|Saint Luke's Mountain States Tumor Institute, Boise, Idaho, United States|Saint Alphonsus Cancer Care Center-Caldwell, Caldwell, Idaho, United States|Kootenai Medical Center, Coeur d'Alene, Idaho, United States|Walter Knox Memorial Hospital, Emmett, Idaho, United States|Saint Luke's Mountain States Tumor Institute - Fruitland, Fruitland, Idaho, United States|Idaho Urologic Institute-Meridian, Meridian, Idaho, United States|Saint Luke's Mountain States Tumor Institute - Meridian, Meridian, Idaho, United States|Saint Alphonsus Medical Center-Nampa, Nampa, Idaho, United States|Saint Luke's Mountain States Tumor Institute - Nampa, Nampa, Idaho, United States|Kootenai Cancer Center, Post Falls, Idaho, United States|Kootenai Cancer Clinic, Sandpoint, Idaho, United States|Saint Luke's Mountain States Tumor Institute-Twin Falls, Twin Falls, Idaho, United States|Rush - Copley Medical Center, Aurora, Illinois, United States|Illinois CancerCare-Bloomington, Bloomington, Illinois, United States|Illinois CancerCare-Canton, Canton, Illinois, United States|Memorial Hospital of Carbondale, Carbondale, Illinois, United States|SIH Cancer Institute, Carterville, Illinois, United States|Illinois CancerCare-Carthage, Carthage, Illinois, United States|Centralia Oncology Clinic, Centralia, Illinois, United States|Carle on Vermilion, Danville, Illinois, United States|Cancer Care Specialists of Illinois - Decatur, Decatur, Illinois, United States|Decatur Memorial Hospital, Decatur, Illinois, United States|Carle Physician Group-Effingham, Effingham, Illinois, United States|Crossroads Cancer Center, Effingham, Illinois, United States|Illinois CancerCare-Eureka, Eureka, Illinois, United States|Illinois CancerCare-Galesburg, Galesburg, Illinois, United States|Western Illinois Cancer Treatment Center, Galesburg, Illinois, United States|Illinois CancerCare-Kewanee Clinic, Kewanee, Illinois, United States|Illinois CancerCare-Macomb, Macomb, Illinois, United States|Carle Physician Group-Mattoon/Charleston, Mattoon, Illinois, United States|Loyola University Medical Center, Maywood, Illinois, United States|Marjorie Weinberg Cancer Center at Loyola-Gottlieb, Melrose Park, Illinois, United States|Illinois CancerCare-Ottawa Clinic, Ottawa, Illinois, United States|Illinois CancerCare-Pekin, Pekin, Illinois, United States|Illinois CancerCare-Peoria, Peoria, Illinois, United States|Methodist Medical Center of Illinois, Peoria, Illinois, United States|Illinois CancerCare-Peru, Peru, Illinois, United States|Valley Radiation Oncology, Peru, Illinois, United States|Illinois CancerCare-Princeton, Princeton, Illinois, United States|Southern Illinois University School of Medicine, Springfield, Illinois, United States|Springfield Clinic, Springfield, Illinois, United States|Memorial Medical Center, Springfield, Illinois, United States|Cancer Care Specialists of Illinois-Swansea, Swansea, Illinois, United States|Southwest Illinois Health Services LLP, Swansea, Illinois, United States|Carle Cancer Center, Urbana, Illinois, United States|The Carle Foundation Hospital, Urbana, Illinois, United States|Rush-Copley Healthcare Center, Yorkville, Illinois, United States|Medical Oncology and Hematology Associates-West Des Moines, Clive, Iowa, United States|Mercy Cancer Center-West Lakes, Clive, Iowa, United States|Alegent Health Mercy Hospital, Council Bluffs, Iowa, United States|Greater Regional Medical Center, Creston, Iowa, United States|Medical Oncology and Hematology Associates-Laurel, Des Moines, Iowa, United States|Mercy Medical Center - Des Moines, Des Moines, Iowa, United States|Mercy Medical Center-West Lakes, West Des Moines, Iowa, United States|Central Care Cancer Center - Garden City, Garden City, Kansas, United States|Central Care Cancer Center - Great Bend, Great Bend, Kansas, United States|Lawrence Memorial Hospital, Lawrence, Kansas, United States|Kansas Institute of Medicine Cancer and Blood Center, Lenexa, Kansas, United States|Minimally Invasive Surgery Hospital, Lenexa, Kansas, United States|Menorah Medical Center, Overland Park, Kansas, United States|Saint Luke's South Hospital, Overland Park, Kansas, United States|Cancer Center of Kansas-Wichita Medical Arts Tower, Wichita, Kansas, United States|Cancer Center of Kansas - Wichita, Wichita, Kansas, United States|Flaget Memorial Hospital, Bardstown, Kentucky, United States|Commonwealth Cancer Center-Corbin, Corbin, Kentucky, United States|Saint Joseph Radiation Oncology Resource Center, Lexington, Kentucky, United States|Saint Joseph Hospital East, Lexington, Kentucky, United States|Saint Joseph London, London, Kentucky, United States|Jewish Hospital, Louisville, Kentucky, United States|Saints Mary and Elizabeth Hospital, Louisville, Kentucky, United States|Jewish Hospital Medical Center Northeast, Louisville, Kentucky, United States|Jewish Hospital Medical Center South, Shepherdsville, Kentucky, United States|Ochsner Medical Center Jefferson, New Orleans, Louisiana, United States|Harold Alfond Center for Cancer Care, Augusta, Maine, United States|Eastern Maine Medical Center, Bangor, Maine, United States|Waldo County General Hospital, Belfast, Maine, United States|MaineHealth/SMHC Cancer Care and Blood Disorders-Biddeford, Biddeford, Maine, United States|Lafayette Family Cancer Center-EMMC, Brewer, Maine, United States|Stephens Memorial Hospital, Norway, Maine, United States|MaineHealth/SMHC Cancer Care and Blood Disorders-Sanford, Sanford, Maine, United States|Boston Medical Center, Boston, Massachusetts, United States|Mercy Medical Center, Springfield, Massachusetts, United States|Saint Joseph Mercy Hospital, Ann Arbor, Michigan, United States|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States|IHA Hematology Oncology Consultants-Brighton, Brighton, Michigan, United States|Saint Joseph Mercy Brighton, Brighton, Michigan, United States|IHA Hematology Oncology Consultants-Canton, Canton, Michigan, United States|Saint Joseph Mercy Canton, Canton, Michigan, United States|Caro Cancer Center, Caro, Michigan, United States|IHA Hematology Oncology Consultants-Chelsea, Chelsea, Michigan, United States|Saint Joseph Mercy Chelsea, Chelsea, Michigan, United States|Hematology Oncology Consultants-Clarkston, Clarkston, Michigan, United States|Newland Medical Associates-Clarkston, Clarkston, Michigan, United States|Wayne State University/Karmanos Cancer Institute, Detroit, Michigan, United States|Ascension Saint John Hospital, Detroit, Michigan, United States|Great Lakes Cancer Management Specialists-Doctors Park, East China Township, Michigan, United States|Weisberg Cancer Treatment Center, Farmington Hills, Michigan, United States|Genesee Cancer and Blood Disease Treatment Center, Flint, Michigan, United States|Genesee Hematology Oncology PC, Flint, Michigan, United States|Genesys Hurley Cancer Institute, Flint, Michigan, United States|Hurley Medical Center, Flint, Michigan, United States|Academic Hematology Oncology Specialists, Grosse Pointe Woods, Michigan, United States|Great Lakes Cancer Management Specialists-Van Elslander Cancer Center, Grosse Pointe Woods, Michigan, United States|Michigan Breast Specialists-Grosse Pointe Woods, Grosse Pointe Woods, Michigan, United States|Sparrow Hospital, Lansing, Michigan, United States|Hope Cancer Clinic, Livonia, Michigan, United States|Saint Mary Mercy Hospital, Livonia, Michigan, United States|Great Lakes Cancer Management Specialists-Macomb Medical Campus, Macomb, Michigan, United States|Michigan Breast Specialists-Macomb Township, Macomb, Michigan, United States|Saint Mary's Oncology/Hematology Associates of Marlette, Marlette, Michigan, United States|21st Century Oncology-Pontiac, Pontiac, Michigan, United States|Hope Cancer Center, Pontiac, Michigan, United States|Newland Medical Associates-Pontiac, Pontiac, Michigan, United States|Saint Joseph Mercy Oakland, Pontiac, Michigan, United States|Great Lakes Cancer Management Specialists-Rochester Hills, Rochester Hills, Michigan, United States|Ascension Saint Mary's Hospital, Saginaw, Michigan, United States|Oncology Hematology Associates of Saginaw Valley PC, Saginaw, Michigan, United States|Bhadresh Nayak MD PC-Sterling Heights, Sterling Heights, Michigan, United States|Ascension Saint Joseph Hospital, Tawas City, Michigan, United States|Advanced Breast Care Center PLLC, Warren, Michigan, United States|Great Lakes Cancer Management Specialists-Macomb Professional Building, Warren, Michigan, United States|Macomb Hematology Oncology PC, Warren, Michigan, United States|Michigan Breast Specialists-Warren, Warren, Michigan, United States|Saint John Macomb-Oakland Hospital, Warren, Michigan, United States|Saint Mary's Oncology/Hematology Associates of West Branch, West Branch, Michigan, United States|Huron Gastroenterology PC, Ypsilanti, Michigan, United States|IHA Hematology Oncology Consultants-Ann Arbor, Ypsilanti, Michigan, United States|Fairview Ridges Hospital, Burnsville, Minnesota, United States|Cambridge Medical Center, Cambridge, Minnesota, United States|Mercy Hospital, Coon Rapids, Minnesota, United States|Fairview-Southdale Hospital, Edina, Minnesota, United States|Unity Hospital, Fridley, Minnesota, United States|Fairview Maple Grove Medical Center, Maple Grove, Minnesota, United States|Minnesota Oncology Hematology PA-Maplewood, Maplewood, Minnesota, United States|Saint John's Hospital - Healtheast, Maplewood, Minnesota, United States|Abbott-Northwestern Hospital, Minneapolis, Minnesota, United States|Hennepin County Medical Center, Minneapolis, Minnesota, United States|Health Partners Inc, Minneapolis, Minnesota, United States|Monticello Cancer Center, Monticello, Minnesota, United States|New Ulm Medical Center, New Ulm, Minnesota, United States|Fairview Northland Medical Center, Princeton, Minnesota, United States|North Memorial Medical Health Center, Robbinsdale, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|Park Nicollet Clinic - Saint Louis Park, Saint Louis Park, Minnesota, United States|Regions Hospital, Saint Paul, Minnesota, United States|United Hospital, Saint Paul, Minnesota, United States|Saint Francis Regional Medical Center, Shakopee, Minnesota, United States|Lakeview Hospital, Stillwater, Minnesota, United States|Ridgeview Medical Center, Waconia, Minnesota, United States|Rice Memorial Hospital, Willmar, Minnesota, United States|Minnesota Oncology Hematology PA-Woodbury, Woodbury, Minnesota, United States|Fairview Lakes Medical Center, Wyoming, Minnesota, United States|Central Care Cancer Center - Bolivar, Bolivar, Missouri, United States|Parkland Health Center-Bonne Terre, Bonne Terre, Missouri, United States|Saint Francis Medical Center, Cape Girardeau, Missouri, United States|Southeast Cancer Center, Cape Girardeau, Missouri, United States|Centerpoint Medical Center LLC, Independence, Missouri, United States|Capital Region Southwest Campus, Jefferson City, Missouri, United States|Saint Luke's Hospital of Kansas City, Kansas City, Missouri, United States|Research Medical Center, Kansas City, Missouri, United States|Saint Luke's East - Lee's Summit, Lee's Summit, Missouri, United States|Heartland Regional Medical Center, Saint Joseph, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Siteman Cancer Center-South County, Saint Louis, Missouri, United States|Missouri Baptist Medical Center, Saint Louis, Missouri, United States|Sainte Genevieve County Memorial Hospital, Sainte Genevieve, Missouri, United States|Missouri Baptist Sullivan Hospital, Sullivan, Missouri, United States|Missouri Baptist Outpatient Center-Sunset Hills, Sunset Hills, Missouri, United States|Community Hospital of Anaconda, Anaconda, Montana, United States|Billings Clinic Cancer Center, Billings, Montana, United States|Saint Vincent Healthcare, Billings, Montana, United States|Saint Vincent Frontier Cancer Center, Billings, Montana, United States|Bozeman Deaconess Hospital, Bozeman, Montana, United States|Saint James Community Hospital and Cancer Treatment Center, Butte, Montana, United States|Benefis Healthcare- Sletten Cancer Institute, Great Falls, Montana, United States|Great Falls Clinic, Great Falls, Montana, United States|Saint Peter's Community Hospital, Helena, Montana, United States|Kalispell Regional Medical Center, Kalispell, Montana, United States|Saint Patrick Hospital - Community Hospital, Missoula, Montana, United States|Community Medical Hospital, Missoula, Montana, United States|CHI Health Saint Francis, Grand Island, Nebraska, United States|Heartland Hematology and Oncology, Kearney, Nebraska, United States|CHI Health Good Samaritan, Kearney, Nebraska, United States|Saint Elizabeth Regional Medical Center, Lincoln, Nebraska, United States|Alegent Health Immanuel Medical Center, Omaha, Nebraska, United States|Hematology and Oncology Consultants PC, Omaha, Nebraska, United States|Alegent Health Bergan Mercy Medical Center, Omaha, Nebraska, United States|Alegent Health Lakeside Hospital, Omaha, Nebraska, United States|Creighton University Medical Center, Omaha, Nebraska, United States|Midlands Community Hospital, Papillion, Nebraska, United States|Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States|Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States|Memorial Sloan Kettering Commack, Commack, New York, United States|Memorial Sloan Kettering Westchester, Harrison, New York, United States|NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|University of Rochester, Rochester, New York, United States|Memorial Sloan Kettering Nassau, Uniondale, New York, United States|UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States|Carolinas Medical Center/Levine Cancer Institute, Charlotte, North Carolina, United States|Southeastern Medical Oncology Center-Clinton, Clinton, North Carolina, United States|Southeastern Medical Oncology Center-Goldsboro, Goldsboro, North Carolina, United States|Wayne Memorial Hospital, Goldsboro, North Carolina, United States|East Carolina University, Greenville, North Carolina, United States|Onslow Memorial Hospital, Jacksonville, North Carolina, United States|Southeastern Medical Oncology Center-Jacksonville, Jacksonville, North Carolina, United States|Good Samaritan Hospital - Cincinnati, Cincinnati, Ohio, United States|Bethesda North Hospital, Cincinnati, Ohio, United States|TriHealth Cancer Institute-Westside, Cincinnati, Ohio, United States|TriHealth Cancer Institute-Anderson, Cincinnati, Ohio, United States|Case Western Reserve University, Cleveland, Ohio, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States|Saint Alphonsus Medical Center-Baker City, Baker City, Oregon, United States|Saint Charles Health System, Bend, Oregon, United States|Clackamas Radiation Oncology Center, Clackamas, Oregon, United States|Providence Oncology and Hematology Care Southeast, Clackamas, Oregon, United States|Bay Area Hospital, Coos Bay, Oregon, United States|Providence Newberg Medical Center, Newberg, Oregon, United States|Saint Alphonsus Medical Center-Ontario, Ontario, Oregon, United States|Providence Portland Medical Center, Portland, Oregon, United States|Providence Saint Vincent Medical Center, Portland, Oregon, United States|Kaiser Permanente Northwest, Portland, Oregon, United States|Oregon Health and Science University, Portland, Oregon, United States|Saint Charles Health System-Redmond, Redmond, Oregon, United States|Lehigh Valley Hospital-Cedar Crest, Allentown, Pennsylvania, United States|Lehigh Valley Hospital - Muhlenberg, Bethlehem, Pennsylvania, United States|Pocono Medical Center, East Stroudsburg, Pennsylvania, United States|Lehigh Valley Hospital-Hazleton, Hazleton, Pennsylvania, United States|Memorial Hospital, Chattanooga, Tennessee, United States|Pulmonary Medicine Center of Chattanooga-Hixson, Hixson, Tennessee, United States|Memorial GYN Plus, Ooltewah, Tennessee, United States|Saint Joseph Regional Cancer Center, Bryan, Texas, United States|Providence Regional Cancer System-Aberdeen, Aberdeen, Washington, United States|PeaceHealth Saint Joseph Medical Center, Bellingham, Washington, United States|Harrison HealthPartners Hematology and Oncology-Bremerton, Bremerton, Washington, United States|Harrison Medical Center, Bremerton, Washington, United States|Highline Medical Center-Main Campus, Burien, Washington, United States|Providence Regional Cancer System-Centralia, Centralia, Washington, United States|Swedish Cancer Institute-Edmonds, Edmonds, Washington, United States|Saint Elizabeth Hospital, Enumclaw, Washington, United States|Providence Regional Cancer Partnership, Everett, Washington, United States|Saint Francis Hospital, Federal Way, Washington, United States|Swedish Cancer Institute-Issaquah, Issaquah, Washington, United States|Kadlec Clinic Hematology and Oncology, Kennewick, Washington, United States|Providence Regional Cancer System-Lacey, Lacey, Washington, United States|Saint Clare Hospital, Lakewood, Washington, United States|PeaceHealth Saint John Medical Center, Longview, Washington, United States|Harrison HealthPartners Hematology and Oncology-Poulsbo, Poulsbo, Washington, United States|Pacific Gynecology Specialists, Seattle, Washington, United States|Swedish Medical Center-Ballard Campus, Seattle, Washington, United States|Kaiser Permanente Washington, Seattle, Washington, United States|Swedish Medical Center-First Hill, Seattle, Washington, United States|Swedish Medical Center-Cherry Hill, Seattle, Washington, United States|PeaceHealth United General Medical Center, Sedro-Woolley, Washington, United States|Providence Regional Cancer System-Shelton, Shelton, Washington, United States|Franciscan Research Center-Northwest Medical Plaza, Tacoma, Washington, United States|Northwest Medical Specialties PLLC, Tacoma, Washington, United States|PeaceHealth Southwest Medical Center, Vancouver, Washington, United States|Providence Saint Mary Regional Cancer Center, Walla Walla, Washington, United States|Providence Regional Cancer System-Yelm, Yelm, Washington, United States|United Hospital Center, Bridgeport, West Virginia, United States|WVUH-Berkely Medical Center, Martinsburg, West Virginia, United States|West Virginia University Healthcare, Morgantown, West Virginia, United States|Camden Clark Medical Center, Parkersburg, West Virginia, United States|Marshfield Medical Center-EC Cancer Center, Eau Claire, Wisconsin, United States|Marshfield Medical Center-Marshfield, Marshfield, Wisconsin, United States|Marshfield Clinic-Minocqua Center, Minocqua, Wisconsin, United States|Cancer Center of Western Wisconsin, New Richmond, Wisconsin, United States|Marshfield Medical Center-Rice Lake, Rice Lake, Wisconsin, United States|Marshfield Clinic Stevens Point Center, Stevens Point, Wisconsin, United States|Marshfield Clinic - Weston Center, Weston, Wisconsin, United States|Cheyenne Regional Medical Center-West, Cheyenne, Wyoming, United States|Billings Clinic-Cody, Cody, Wyoming, United States|Welch Cancer Center, Sheridan, Wyoming, United States",,"https://ClinicalTrials.gov/show/NCT03499808"
255,"NCT02960555","Isatuximab in Treating Patients With High Risk Smoldering Plasma Cell Myeloma",,"Active, not recruiting","No Results Available","Smoldering Plasma Cell Myeloma","Biological: Isatuximab|Other: Laboratory Biomarker Analysis","Overall response (>= partial response)|Progression free survival|Overall survival|Incidence of adverse events","M.D. Anderson Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 2","48","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2015-0148|NCI-2016-01922|P30CA016672","February 8, 2017","February 1, 2022","February 1, 2022","November 9, 2016",,"January 3, 2020","Mount Sinai Hospital, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|M D Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02960555"
256,"NCT02400814","MPDL3280A and Stereotactic Ablative Radiotherapy in Patients With Non-small Cell Lung Cancer",,"Active, not recruiting","No Results Available","Recurrent Non-Small Cell Lung Carcinoma|Stage IV Non-Small Cell Lung Cancer","Drug: Anti-PD-L1 Monoclonal Antibody MPDL3280A|Radiation: Stereotactic Body Radiation Therapy","Incidence of adverse events|Response rate using irRECIST|Progression free survival using RECIST 1.1 and irRECIST","University of California, Davis|National Cancer Institute (NCI)|Genentech, Inc.","All","19 Years and older   (Adult, Older Adult)","Phase 1","27","Other|NIH|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","685389|UCDCC#251|ML29551|P30CA093373|NCI-2014-02629","December 2015","April 2020","April 2021","March 27, 2015",,"October 28, 2019","University of California Davis, Sacramento, California, United States",,"https://ClinicalTrials.gov/show/NCT02400814"
257,"NCT01123252","Seasonal Allergic Rhinitis Study","SAR","Completed","No Results Available","Seasonal Affective Rhinitis|Asthma|Grass Allergy","Dietary Supplement: Lactobacillus casei Shirota (LcS)|Dietary Supplement: Placebo","Total nasal symptom score|Area under the curve for nasal symptoms scores for 12 hours following nasal allergen challenge|• Area under the curve for peak nasal inspiratory flow for 12 hours following nasal allergen challenge|Phenotype of nasal epithelial cells from scrapings|Nasal lavage inflammatory mediator profile","University of East Anglia|Quadram Institute Bioscience|Norfolk and Norwich University Hospitals NHS Foundation Trust|Yakult Honsha Co., LTD","All","16 Years and older   (Child, Adult, Older Adult)","Phase 2","60","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Supportive Care","UEA SAR 1","September 2010","April 2011","April 2011","May 14, 2010",,"August 23, 2012","Institute of Food Research, Norwich, Norfolk, United Kingdom|Norfolk and Norwich University Hospital, Norwich, Norfolk, United Kingdom|CRTU University of East Anglia, Norwich, Norfolk, United Kingdom|University of East Anglia, Norwich, Norfolk, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01123252"
258,"NCT03367819","Isatuximab in Combination With REGN2810 (Cemiplimab) in Patients With Advanced Malignancies",,"Active, not recruiting","No Results Available","Prostate Cancer|Non-small Cell Lung Cancer","Drug: Isatuximab SAR650984|Drug: Cemiplimab REGN2810","Dose Limiting Toxicities (DLTs)|AEs|Response Rate|Immunogenicity: isatuximab|Pharmacokinetic (PK) parameters: area under the curve (AUC)|Tumor burden change|Duration of response|Progression-free survival|Assessment of PK parameter: Cmax|Immunogenicity: REGN2810|Disease control rate","Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","134","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ACT15319|2017-002846-61|U1111-1197-7792","January 4, 2018","June 2021","June 2021","December 11, 2017",,"December 19, 2019","Investigational Site Number 8400003, Birmingham, Alabama, United States|Investigational Site Number 8400009, Santa Monica, California, United States|Investigational Site Number 8400007, Atlanta, Georgia, United States|Investigational Site Number 8400002, Hackensack, New Jersey, United States|Investigational Site Number 8400005, Nashville, Tennessee, United States|Investigational Site Number 8400004, Houston, Texas, United States|Investigational Site Number 2500002, Bordeaux Cedex, France|Investigational Site Number 2500001, Villejuif Cedex, France|Investigational Site Number 3800006, Napoli, Italy|Investigational Site Number 3800001, Orbassano, Italy|Investigational Site Number 3800004, Padova, Italy|Investigational Site Number 3800002, Pavia, Italy|Investigational Site Number 3800003, Rozzano, Italy|Investigational Site Number 3800005, Verona, Italy|Investigational Site Number 1580002, Tainan, Taiwan|Investigational Site Number 1580001, Taipei 100, Taiwan|Investigational Site Number 8260002, Newcastle Upon Tyne, United Kingdom|Investigational Site Number 8260001, Sutton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03367819"
259,"NCT02514668","A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Isatuximab in Patients With Multiple Myeloma",,"Active, not recruiting","No Results Available","Plasma Cell Myeloma","Drug: Isatuximab","Part A: Dose Limiting Toxicities (DLTs)|Part A: Number of patients with adverse events (AEs) and changes in laboratory tests and vital signs according to the National Cancer Institute - Common Toxicity Criteria (NCI-CTC) version 4.03 grade scaling|Part B: Overall Response Rate (ORR)|Assessment of PK parameters: partial area under the serum concentration time curve (AUC)|Assessment of PK parameters: maximum observed concentration (Cmax)|Part B: Number of patients with AEs and changes in laboratory tests and vital signs according to the National Cancer Institute - Common Toxicity Criteria (NCI-CTC) version 4.03 grade scaling|Part B: Duration of Response (DOR)|Part B: Clinical Benefit Rate (CBR)|Part B: Progression Free Survival (PFS)|Part B: Levels of isatuximab antibodies","Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 1","55","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TED14154|U1111-1163-1073","September 1, 2015","June 2020","June 2020","August 4, 2015",,"December 10, 2019","Investigational Site Number 840003, Scottsdale, Arizona, United States|Investigational Site Number 840004, San Francisco, California, United States|Investigational Site Number 840011, Detroit, Michigan, United States|Investigational Site Number 840015, Saint Louis, Missouri, United States|Investigational Site Number 840005, Hackensack, New Jersey, United States|Investigational Site Number 840010, Durham, North Carolina, United States|Investigational Site Number 840013, Canton, Ohio, United States|Investigational Site Number 840001, Nashville, Tennessee, United States|Investigational Site Number 840002, Salt Lake City, Utah, United States|Investigational Site Number 840006, Milwaukee, Wisconsin, United States|Investigational Site Number 203002, Brno, Czechia|Investigational Site Number 203001, Praha 2, Czechia|Investigational Site Number 250008, Creteil Cedex, France|Investigational Site Number 250005, Montpellier Cedex 5, France|Investigational Site Number 250002, Nantes Cedex 01, France|Investigational Site Number 250004, Pessac, France|Investigational Site Number 250001, Poitiers, France|Investigational Site Number 250006, Vandoeuvre-Les-Nancy Cedex, France",,"https://ClinicalTrials.gov/show/NCT02514668"
260,"NCT01146652","Long Term Evaluation of Sarilumab in Rheumatoid Arthritis Patients (SARIL-RA-EXTEND)",,"Active, not recruiting","No Results Available","Rheumatoid Arthritis","Drug: SAR153191 (REGN88)","Number of patients with adverse events|Percentage of patients who achieve 20% improvement response according to the American College of Rheumatology criteria (ACR20)|Disease Activity Score (DAS28-CRP)|European League Against Rheumatism (EULAR) response","Sanofi|Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 3","2000","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LTS11210|2010-019262-86","June 2010","December 2020","December 2020","June 17, 2010",,"January 29, 2020","Investigational Site Number 840070, Anniston, Alabama, United States|Investigational Site Number 840138, Birmingham, Alabama, United States|Investigational Site Number 840152, Huntsville, Alabama, United States|Investigational Site Number 840072, Gilbert, Arizona, United States|Investigational Site Number 840141, Glendale, Arizona, United States|Investigational Site Number 840134, Fullerton, California, United States|Investigational Site Number 840008, La Jolla, California, United States|Investigational Site Number 840135, San Diego, California, United States|Investigational Site Number 840021, Santa Maria, California, United States|Investigational Site Number 840100, Stanford, California, United States|Investigational Site Number 840049, Upland, California, United States|Investigational Site Number 840151, Colorado Springs, Colorado, United States|Investigational Site Number 840130, Lewes, Delaware, United States|Investigational Site Number 840153, Aventura, Florida, United States|Investigational Site Number 840050, Clearwater, Florida, United States|Investigational Site Number 840033, Fort Lauderdale, Florida, United States|Investigational Site Number 840041, Gainesville, Florida, United States|Investigational Site Number 840067, Jupiter, Florida, United States|Investigational Site Number 840048, Miami, Florida, United States|Investigational Site Number 840024, Naples, Florida, United States|Investigational Site Number 840006, Orlando, Florida, United States|Investigational Site Number 840128, Ormond Beach, Florida, United States|Investigational Site Number 840063, Palm Harbor, Florida, United States|Investigational Site Number 840155, Palm Harbor, Florida, United States|Investigational Site Number 840060, Sarasota, Florida, United States|Investigational Site Number 840140, Tampa, Florida, United States|Investigational Site Number 840126, Vero Beach, Florida, United States|Investigational Site Number 840003, Atlanta, Georgia, United States|Investigational Site Number 840028, Decatur, Georgia, United States|Investigational Site Number 840027, Marietta, Georgia, United States|Investigational Site Number 840018, Idaho Falls, Idaho, United States|Investigational Site Number 840046, Chicago, Illinois, United States|Investigational Site Number 840052, Kansas City, Kansas, United States|Investigational Site Number 840230, Elizabethtown, Kentucky, United States|Investigational Site Number 840015, Lexington, Kentucky, United States|Investigational Site Number 840120, Baton Rouge, Louisiana, United States|Investigational Site Number 840109, Lake Charles, Louisiana, United States|Investigational Site Number 840055, Frederick, Maryland, United States|Investigational Site Number 840013, Wheaton, Maryland, United States|Investigational Site Number 840154, Boston, Massachusetts, United States|Investigational Site Number 840150, Lansing, Michigan, United States|Investigational Site Number 840137, Saint Clair Shores, Michigan, United States|Investigational Site Number 840112, Lincoln, Nebraska, United States|Investigational Site Number 840026, Freehold, New Jersey, United States|Investigational Site Number 840115, Lake Success, New York, United States|Investigational Site Number 840056, New York, New York, United States|Investigational Site Number 840043, New York, New York, United States|Investigational Site Number 840106, Orchard Park, New York, United States|Investigational Site Number 840118, Smithtown, New York, United States|Investigational Site Number 840116, Wilmington, North Carolina, United States|Investigational Site Number 840233, Minot, North Dakota, United States|Investigational Site Number 840002, Oklahoma City, Oklahoma, United States|Investigational Site Number 840127, Oklahoma City, Oklahoma, United States|Investigational Site Number 840011, Tulsa, Oklahoma, United States|Investigational Site Number 840065, Tulsa, Oklahoma, United States|Investigational Site Number 840010, Bethlehem, Pennsylvania, United States|Investigational Site Number 840009, Duncansville, Pennsylvania, United States|Investigational Site Number 840062, Reading, Pennsylvania, United States|Investigational Site Number 840058, Columbia, South Carolina, United States|Investigational Site Number 840016, North Charleston, South Carolina, United States|Investigational Site Number 840025, Jackson, Tennessee, United States|Investigational Site Number 840059, Memphis, Tennessee, United States|Investigational Site Number 840032, Amarillo, Texas, United States|Investigational Site Number 840038, Austin, Texas, United States|Investigational Site Number 840001, Dallas, Texas, United States|Investigational Site Number 840022, Dallas, Texas, United States|Investigational Site Number 840012, Dallas, Texas, United States|Investigational Site Number 840129, Houston, Texas, United States|Investigational Site Number 840069, Lubbock, Texas, United States|Investigational Site Number 840074, Mesquite, Texas, United States|Investigational Site Number 840020, Nassau Bay, Texas, United States|Investigational Site Number 840103, San Antonio, Texas, United States|Investigational Site Number 840036, Spokane, Washington, United States|Investigational Site Number 840061, Tacoma, Washington, United States|Investigational Site Number 840124, Clarksburg, West Virginia, United States|Investigational Site Number 032006, Caba, Argentina|Investigational Site Number 032007, Caba, Argentina|Investigational Site Number 032008, Caba, Argentina|Investigational Site Number 032019, Capital Federal, Argentina|Investigational Site Number 032016, Capital Federal, Argentina|Investigational Site Number 032002, Cordoba, Argentina|Investigational Site Number 032020, Cordoba, Argentina|Investigational Site Number 032003, Córdoba, Argentina|Investigational Site Number 032017, La Plata, Argentina|Investigational Site Number 032012, Mar Del Plata, Argentina|Investigational Site Number 032011, Quilmes, Argentina|Investigational Site Number 032010, Ramos Mejia, Argentina|Investigational Site Number 032001, Rosario, Argentina|Investigational Site Number 032013, Rosario, Argentina|Investigational Site Number 032015, San Fernando, Argentina|Investigational Site Number 032005, San Miguel De Tucuman, Argentina|Investigational Site Number 032004, San Miguel De Tucuman, Argentina|Investigational Site Number 032009, Zarate, Argentina|Investigational Site Number 036003, Camperdown, Australia|Investigational Site Number 036012, Fitzroy, Australia|Investigational Site Number 036010, Garran, Australia|Investigational Site Number 036004, Heidelberg West, Australia|Investigational Site Number 036001, Maroochydore, Australia|Investigational Site Number 036014, Victoria Park, Australia|Investigational Site Number 036007, Woodville, Australia|Investigational Site Number 040001, Graz, Austria|Investigational Site Number 112002, Minsk, Belarus|Investigational Site Number 112001, Minsk, Belarus|Investigational Site Number 056010, Leuven, Belgium|Investigational Site Number 076001, Curitiba, Brazil|Investigational Site Number 076006, Goiania, Brazil|Investigational Site Number 076010, Juiz De Fora, Brazil|Investigational Site Number 076004, Porto Alegre, Brazil|Investigational Site Number 076005, Rio De Janeiro, Brazil|Investigational Site Number 076015, Rio De Janeiro, Brazil|Investigational Site Number 076011, Salvador, Brazil|Investigational Site Number 076002, Sao Paulo, Brazil|Investigational Site Number 076003, Sao Paulo, Brazil|Investigational Site Number 076013, Vitoria, Brazil|Investigational Site Number 124003, Mississauga, Canada|Investigational Site Number 124002, St. Catharines, Canada|Investigational Site Number 124005, Toronto, Canada|Investigational Site Number 124009, Trois-Rivières, Canada|Investigational Site Number 124104, Victoria, Canada|Investigational Site Number 124012, Winnipeg, Canada|Investigational Site Number 152005, Osorno, Chile|Investigational Site Number 152012, Santiago, Chile|Investigational Site Number 152002, Santiago, Chile|Investigational Site Number 152011, Santiago, Chile|Investigational Site Number 152009, Santiago, Chile|Investigational Site Number 152001, Santiago, Chile|Investigational Site Number 152013, Santiago, Chile|Investigational Site Number 152008, Santiago, Chile|Investigational Site Number 152014, Talca, Chile|Investigational Site Number 152015, Temuco IX Region, Chile|Investigational Site Number 152004, Valdivia, Chile|Investigational Site Number 152006, Vina Del Mar, Chile|Investigational Site Number 152007, Viña Del Mar, Chile|Investigational Site Number 170005, Barranquilla, Colombia|Investigational Site Number 170004, Barranquilla, Colombia|Investigational Site Number 170001, Bogota, Colombia|Investigational Site Number 170008, Bogota, Colombia|Investigational Site Number 170006, Bogotá, Colombia|Investigational Site Number 170003, Bogotá, Colombia|Investigational Site Number 170007, Bucaramanga, Colombia|Investigational Site Number 170009, Bucaramanga, Colombia|Investigational Site Number 203009, Liberec, Czechia|Investigational Site Number 203004, Ostrava, Czechia|Investigational Site Number 203034, Pardubice, Czechia|Investigational Site Number 203001, Praha 2, Czechia|Investigational Site Number 203007, Praha 2, Czechia|Investigational Site Number 203011, Praha 2, Czechia|Investigational Site Number 203010, Praha 4, Czechia|Investigational Site Number 203002, Uherske Hradiste, Czechia|Investigational Site Number 203006, Zlin, Czechia|Investigational Site Number 218003, Cuenca, Ecuador|Investigational Site Number 218001, Guayaquil, Ecuador|Investigational Site Number 218002, Quito, Ecuador|Investigational Site Number 233001, Tallinn, Estonia|Investigational Site Number 233010, Tallinn, Estonia|Investigational Site Number 233002, Tallinn, Estonia|Investigational Site Number 246001, Helsinki, Finland|Investigational Site Number 246002, Hyvinkää, Finland|Investigational Site Number 246003, Pori, Finland|Investigational Site Number 246010, Riihimäki, Finland|Investigational Site Number 276011, Bad Nauheim, Germany|Investigational Site Number 276010, Berlin, Germany|Investigational Site Number 276007, Berlin, Germany|Investigational Site Number 276008, Berlin, Germany|Investigational Site Number 276014, Berlin, Germany|Investigational Site Number 276018, Deggingen, Germany|Investigational Site Number 276015, Halle/Saale, Germany|Investigational Site Number 276005, Hamburg, Germany|Investigational Site Number 276013, Hamburg, Germany|Investigational Site Number 276001, Herne, Germany|Investigational Site Number 276016, Leipzig, Germany|Investigational Site Number 276017, München, Germany|Investigational Site Number 276021, Osnabrück, Germany|Investigational Site Number 276020, Tübingen, Germany|Investigational Site Number 276019, Zerbst, Germany|Investigational Site Number 300002, Heraklion, Greece|Investigational Site Number 300003, Thessaloniki, Greece|Investigational Site Number 300005, Thessaloniki, Greece|Investigational Site Number 320002, Guatemala City, Guatemala|Investigational Site Number 320003, Guatemala City, Guatemala|Investigational Site Number 320001, Guatemala, Guatemala|Investigational Site Number 348006, Budapest, Hungary|Investigational Site Number 348014, Budapest, Hungary|Investigational Site Number 348025, Budapest, Hungary|Investigational Site Number 348022, Budapest, Hungary|Investigational Site Number 348010, Debrecen, Hungary|Investigational Site Number 348003, Debrecen, Hungary|Investigational Site Number 348021, Esztergom, Hungary|Investigational Site Number 348013, Györ, Hungary|Investigational Site Number 348009, Szolnok, Hungary|Investigational Site Number 348015, Szombathely, Hungary|Investigational Site Number 348004, Székesfehérvár, Hungary|Investigational Site Number 348005, Sátoraljaújhely, Hungary|Investigational Site Number 376001, Haifa, Israel|Investigational Site Number 376010, Haifa, Israel|Investigational Site Number 376011, Tel Aviv, Israel|Investigational Site Number 376002, Tel Hashomer, Israel|Investigational Site Number 380005, Genova, Italy|Investigational Site Number 410014, Anyang-Si, Korea, Republic of|Investigational Site Number 410006, Busan, Korea, Republic of|Investigational Site Number 410004, Daegu, Korea, Republic of|Investigational Site Number 410017, Daejeon, Korea, Republic of|Investigational Site Number 410005, Daejeon, Korea, Republic of|Investigational Site Number 410010, Gwangju, Korea, Republic of|Investigational Site Number 410001, Incheon, Korea, Republic of|Investigational Site Number 410009, Incheon, Korea, Republic of|Investigational Site Number 410011, Jeonju, Korea, Republic of|Investigational Site Number 410007, Seoul, Korea, Republic of|Investigational Site Number 410012, Seoul, Korea, Republic of|Investigational Site Number 410016, Seoul, Korea, Republic of|Investigational Site Number 410003, Seoul, Korea, Republic of|Investigational Site Number 410008, Suwon, Korea, Republic of|Investigational Site Number 440001, Kaunas, Lithuania|Investigational Site Number 440006, Klaipeda, Lithuania|Investigational Site Number 440002, Vilnius, Lithuania|Investigational Site Number 440007, Vilnius, Lithuania|Investigational Site Number 458001, Ipoh, Malaysia|Investigational Site Number 458002, Kuching, Malaysia|Investigational Site Number 484023, Chihuahua, Mexico|Investigational Site Number 484008, Durango, Mexico|Investigational Site Number 484018, Guadalajara, Mexico|Investigational Site Number 484002, Guadalajara, Mexico|Investigational Site Number 484035, Leon, Mexico|Investigational Site Number 484009, Merida, Mexico|Investigational Site Number 484007, Metepec, Mexico|Investigational Site Number 484010, Mexicali, Mexico|Investigational Site Number 484003, Mexico City, Mexico|Investigational Site Number 484019, Monterrey, Mexico|Investigational Site Number 484020, Monterrey, Mexico|Investigational Site Number 484005, Monterrey, Mexico|Investigational Site Number 484004, Mérida, Mexico|Investigational Site Number 484001, México, D.F., Mexico|Investigational Site Number 484017, México, Mexico|Investigational Site Number 484021, Queretaro, Mexico|Investigational Site Number 528010, Amsterdam, Netherlands|Investigational Site Number 554004, Christchurch, New Zealand|Investigational Site Number 554011, Nelson, New Zealand|Investigational Site Number 554007, Otahuhu, New Zealand|Investigational Site Number 554002, Rotorua, New Zealand|Investigational Site Number 554001, Timaru, New Zealand|Investigational Site Number 604001, Lima, Peru|Investigational Site Number 604010, Lima, Peru|Investigational Site Number 604008, Lima, Peru|Investigational Site Number 604009, Lima, Peru|Investigational Site Number 604006, Lima, Peru|Investigational Site Number 604012, Lima, Peru|Investigational Site Number 604013, Lima, Peru|Investigational Site Number 604007, Lima, Peru|Investigational Site Number 604005, Lima, Peru|Investigational Site Number 608003, Cebu City, Philippines|Investigational Site Number 608001, Manila, Philippines|Investigational Site Number 616014, Bialystok, Poland|Investigational Site Number 616002, Bialystok, Poland|Investigational Site Number 616003, Bialystok, Poland|Investigational Site Number 616019, Bydgoszcz, Poland|Investigational Site Number 616054, Bytom, Poland|Investigational Site Number 616015, Elblag, Poland|Investigational Site Number 616001, Krakow, Poland|Investigational Site Number 616005, Lublin, Poland|Investigational Site Number 616030, Lublin, Poland|Investigational Site Number 616018, Poznan, Poland|Investigational Site Number 616016, Szczecin, Poland|Investigational Site Number 616006, Torun, Poland|Investigational Site Number 616031, Warszawa, Poland|Investigational Site Number 616004, Warszawa, Poland|Investigational Site Number 616017, Warszawa, Poland|Investigational Site Number 616020, Wroclaw, Poland|Investigational Site Number 616012, Wroclaw, Poland|Investigational Site Number 620002, Lisboa, Portugal|Investigational Site Number 642006, Braila, Romania|Investigational Site Number 642010, Bucharest, Romania|Investigational Site Number 642021, Bucuresti, Romania|Investigational Site Number 642001, Bucuresti, Romania|Investigational Site Number 642020, Bucuresti, Romania|Investigational Site Number 642002, Bucuresti, Romania|Investigational Site Number 642005, Galati, Romania|Investigational Site Number 643006, Kemerovo, Russian Federation|Investigational Site Number 643017, Kemerovo, Russian Federation|Investigational Site Number 643020, Moscow, Russian Federation|Investigational Site Number 643001, Moscow, Russian Federation|Investigational Site Number 643002, Moscow, Russian Federation|Investigational Site Number 643021, Moscow, Russian Federation|Investigational Site Number 643004, Moscow, Russian Federation|Investigational Site Number 643012, Moscow, Russian Federation|Investigational Site Number 643031, Moscow, Russian Federation|Investigational Site Number 643030, Moscow, Russian Federation|Investigational Site Number 643009, Novosibirsk, Russian Federation|Investigational Site Number 643016, Ryazan, Russian Federation|Investigational Site Number 643008, Saint-Petersburg, Russian Federation|Investigational Site Number 643010, Samara, Russian Federation|Investigational Site Number 643011, Saratov, Russian Federation|Investigational Site Number 643007, St-Petersburg, Russian Federation|Investigational Site Number 643032, St-Petersburg, Russian Federation|Investigational Site Number 643014, St-Petersburg, Russian Federation|Investigational Site Number 643013, Ufa, Russian Federation|Investigational Site Number 710011, Cape Town, South Africa|Investigational Site Number 710007, Cape Town, South Africa|Investigational Site Number 710009, Cape Town, South Africa|Investigational Site Number 710003, Durban, South Africa|Investigational Site Number 710002, Durban, South Africa|Investigational Site Number 710001, Johannesburg, South Africa|Investigational Site Number 710004, Kempton Park, South Africa|Investigational Site Number 710005, Pretoria, South Africa|Investigational Site Number 710006, Pretoria, South Africa|Investigational Site Number 710010, Stellenbosch, South Africa|Investigational Site Number 724016, Barakaldo, Spain|Investigational Site Number 724015, Barcelona, Spain|Investigational Site Number 724014, Cádiz, Spain|Investigational Site Number 724009, La Coruña, Spain|Investigational Site Number 724001, Málaga, Spain|Investigational Site Number 724011, Sabadell, Spain|Investigational Site Number 724012, Santiago De Compostela, Spain|Investigational Site Number 724013, Santiago De Compostela, Spain|Investigational Site Number 724022, Sevilla, Spain|Investigational Site Number 724007, Sevilla, Spain|Investigational Site Number 752002, Uppsala, Sweden|Investigational Site Number 158006, Taichung, Taiwan|Investigational Site Number 158002, Taoyuan County, Taiwan|Investigational Site Number 764001, Bangkok, Thailand|Investigational Site Number 764003, Bangkok, Thailand|Investigational Site Number 792008, Gaziantep, Turkey|Investigational Site Number 804003, Dnipro, Ukraine|Investigational Site Number 804010, Kharkiv, Ukraine|Investigational Site Number 804013, Kharkiv, Ukraine|Investigational Site Number 804014, Kyiv, Ukraine|Investigational Site Number 804004, Kyiv, Ukraine|Investigational Site Number 804027, Kyiv, Ukraine|Investigational Site Number 804005, Lviv, Ukraine|Investigational Site Number 804006, Simferopol, Ukraine|Investigational Site Number 804011, Vinnytsya, Ukraine|Investigational Site Number 804009, Zaporizhzhya, Ukraine|Investigational Site Number 826004, Doncaster, United Kingdom|Investigational Site Number 826006, Edinburgh, United Kingdom|Investigational Site Number 826002, Leytonstone, United Kingdom|Investigational Site Number 826005, Southampton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01146652"
261,"NCT02082054","StahistRx Phase 2, Five-arm, Parallel Group, Active vs Active, Double-blind Study",,"Unknown status","No Results Available","Rhinitis, Seasonal, Allergic","Drug: PSE 120 mg, CM 8 mg, Atr 0.36 mg|Drug: PSE 120 mg, CM 8 mg, Atr 0.24 mg|Drug: PSE 120 mg, CM 8 mg, Atr 0.12 mg|Drug: PSE 120 mg, CM 8 mg|Drug: Atropine 0.24 mg","Dose-ranging data for atropin|Establish effect size for determining power and TNSS efficacy endpoint","Magna Pharmaceuticals, Inc.","All","12 Years to 60 Years   (Child, Adult)","Phase 2","125","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","MAGNA2014-001","March 2014","May 2014","May 2014","March 10, 2014",,"May 30, 2014","Clinical Research Atlanta, Stockbridge, Georgia, United States|Family Allergy and Asthma Institute, Louisville, Kentucky, United States|National Allergy, Asthma & Urticaria Centers of Charleston, PA, Charleston, South Carolina, United States|Central Texas Health Research, New Braunfels, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02082054"
262,"NCT04045795","Multi-center, Open-label, Phase 1b Study in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)",,"Recruiting","No Results Available","Multiple Myeloma","Drug: isatuximab SAR650984|Drug: pomalidomide|Drug: dexamethasone","Assessment of adverse events (AEs)|Pharmacokinetic (PK) assessment: Ceoi|PK assessment: Cmax|PK assessment: tmax|PK assessment: Clast|PK assessment: tlast|PK assessment: Ctrough|PK assessment: AUClast|PK assessment: AUC0 T|Estimation of absolute bioavailability of isatuximab|Overall response rate (ORR)|Duration of response (DOR)|Time to response (TTR)|Time to progression (TTP)|Overall survival (OS)|Clinical benefit rate (CBR)|Progression free survival (PFS)|Comparison of patient expectations and satisfaction: Patient Expectations and Satisfaction Questionnaires|Immunogenicity: Anti drug antibody levels|Biomarker: Change in CD38 receptor occupancy","Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 1","46","Industry","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TCD15484|2018‐001996‐19|U1111-1211-9525","August 6, 2019","September 2020","August 2022","August 6, 2019",,"August 9, 2019","Investigational Site Number 0360003, Richmond, Australia",,"https://ClinicalTrials.gov/show/NCT04045795"
263,"NCT01390818","Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumors",,"Completed","Has Results","Locally Advanced Solid Tumor|Metastatic Solid Tumor|Breast Cancer|Non Small Cell Lung Cancer|Melanoma|Colorectal Cancer","Drug: MSC1936369B (pimasertib)|Drug: SAR245409 (PI3K and mTOR inhibitor)","Number of Subjects With Dose Limiting Toxicities (DLT)|Number of Subjects Experiencing Any Treatment-Emergent Adverse Events (TEAEs)|Maximum Observed Plasma Concentration (Cmax) for Pimasertib (MSC1936369B)|Time to Reach Maximum Plasma Concentration (Tmax) of Pimasertib (MSC1936369B)|Area Under the Plasma Concentration-Time Curve (AUC) From Time Zero to the Last Sampling Time (0-24 Hours) of Pimasertib (MSC1936369B)|Area Under the Plasma Concentration-Time Curve From Time Zero to Infinity (AUC 0-inf) of Pimasertib (MSC1936369B) at Day 1|Area Under the Concentration-Time Curve (AUC) During a Dosing Interval (Tau) of Pimasertib (MSC1936369B)|Half-Life (t1/2) of MSC1936369B (Pimasertib)|Total Body Clearance (CL/f) of Pimasertib (MSC1936369B)|Apparent Volume of Distribution of Total Pimasertib During the Terminal Phase Following Oral Administration (Vz/f) of Pimasertib|Accumulation Ratio (Racc) for AUCtau of Pimasertib (MSC1936369B): Day 15|Accumulation Ratio (Racc) for Cmax of Pimasertib (MSC1936369B): Day 15|Maximum Observed Plasma Concentration (Cmax) for SAR245409|Time to Reach Maximum Plasma Concentration (Tmax) of SAR245409|Area Under the Plasma Concentration-Time Curve (AUC) From Time Zero to the Last Sampling Time (0-24 Hours) of SAR245409|Area Under the Concentration-Time Curve (AUC) During a Dosing Interval (Tau) of SAR245409|Area Under the Plasma Concentration-Time Curve (AUC) From Time Zero to Infinity (0-inf) of SAR245409: Day 1|Apparent Terminal Half-Life (t1/2) of SAR245409|Total Body Clearance (CL/f) of SAR245409|Apparent Volume of Distribution of Total SAR245409 During the Terminal Phase Following Oral Administration (Vz/f)|Accumulation Ratio (Racc) for AUCtau of SAR245409: Day 15|Accumulation Ratio (Racc) for Cmax of SAR245409: Day 15|pS6 Concentrations in Peripheral Blood Mononuclear Cells (PBMCs)|pERK Concentrations in PBMCs|Number of Subjects With Complete Tumor Response (CR), Partial Tumor Response (PR), or Stable Disease (SD)","EMD Serono|Sanofi","All","18 Years to 82 Years   (Adult, Older Adult)","Phase 1","146","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EMR 200066-006","May 2011","April 2015","April 2015","July 11, 2011","March 7, 2017","March 7, 2017","Pinnacle Oncology Hematology, Scottsdale, Arizona, United States|Cedars Sinai Medical Center, Los Angeles, California, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States|Cancer Therapy and Research Center, San Antonio, Texas, United States|Merck Serono Research Site, Milan, Italy|Merck Serono Research Site, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT01390818"
264,"NCT03104842","Evaluation iNduction, Consolidation and Maintenance Treatment With Isatuximab , Carfilzomib, LEnalidomide and Dexamethasone",,"Recruiting","No Results Available","Multiple Myeloma","Drug: Isatuximab|Drug: Carfilzomib|Drug: Lenalidomide|Drug: Dexamethasone","MRD negativity","University Hospital Tuebingen","All","18 Years and older   (Adult, Older Adult)","Phase 2","153","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GMMG-CONCEPT","August 15, 2017","July 2023","July 2024","April 7, 2017",,"July 12, 2019","Vivantes Am Urban, Berlin, Germany|Campus Benjamin Franklin Charite Berlin, Berlin, Germany|Vivantes Klinikum Neukölln, Berlin, Germany|Städt. Kliniken Bielefeld Klinikum Mitte, Bielefeld, Germany|University Hospital Bochum, Bochum, Germany|Johanniter-Krankenhaus Bonn, Bonn, Germany|Uniklinikum Chemnitz, Chemnitz, Germany|St. Antonius Hospital, Eschweiler, Germany|Universitätsklinikum Essen, Essen, Germany|Asklepios Altona, Hamburg, Germany|University Hospital Hamburg Eppendorf, Hamburg, Germany|University Hospital Heidelberg, Heidelberg, Germany|Uniklinik Köln, Koln, Germany|Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Mainz, Germany|Philipps-Universität Marburg, Marburg, Germany|Klinik für Hämatologie, Onkologie und GastroenterologieKliniken Maria Hilf GmbH, Mönchengladbach, Germany|University Hospital Münster, Münster, Germany|Zentrum für Tumordiagnostik und -therapieHämatologie/Int. Onkologie, Osnabruck, Germany|Universitätsklinikum Tuebingen, Tuebingen, Germany",,"https://ClinicalTrials.gov/show/NCT03104842"
265,"NCT01455532","A Dose Escalation Study of Iniparib as a Single Agent and in Combination in Solid Tumors",,"Completed","No Results Available","Neoplasm Malignant","Drug: Iniparib (SAR240550-BSI-201)|Drug: Gemcitabine|Drug: Carboplatin|Drug: Placlitaxel|Drug: Pegylated liposomal doxorubicin","Assessment of iniparib as single agent and in combination with chemotherapeutic agents related dose limiting toxicities (DLTs) observed at first cycle|To assess the antitumor effect of iniparib according to the Response Evaluation Criteria in Solid Tumors [RECIST]) Version 1.1 in patients with measurable disease|Pharmakokinetic (PK) parameters: Cmax|Pharmakokinetic (PK) parameters : tmax|Pharmakokinetic (PK) parameters: tlast|Pharmakokinetic (PK) parameters: AUC|Pharmakokinetic (PK) parameters : t1/2z","Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 1","59","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TED11746|U1111-1118-6091","November 2011","May 2013","April 2014","October 20, 2011",,"October 22, 2014","Investigational Site Number 840002, Scottsdale, Arizona, United States|Investigational Site Number 840004, Los Angeles, California, United States|Investigational Site Number 840010, Augusta, Georgia, United States|Investigational Site Number 840007, St Louis, Missouri, United States|Investigational Site Number 840001, Cincinnati, Ohio, United States|Investigational Site Number 840006, San Antonio, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01455532"
266,"NCT03523728","A Medical Research Study Designed to Determine if Venglustat Can be a Future Treatment for ADPKD Patients","STAGED-PKD","Recruiting","No Results Available","Polycystic Kidney, Autosomal Dominant","Drug: Venglustat GZ402671|Drug: Placebo","Rate of change in of total kidney volume (TKV)|Rate of change in eGFR|Rate of change in TKV|Change in urine osmolality|Change in nocturia|Adverse events|Assessment of plasma concentration of venglustat|Change in lens clarity|Change in score of Beck Depression Inventory-II (BDI-II)","Genzyme, a Sanofi Company|Sanofi","All","18 Years to 55 Years   (Adult)","Phase 2|Phase 3","640","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","EFC15392|2017‐004084‐12|U1111-1202-0775","October 4, 2018","January 2023","January 2023","May 14, 2018",,"January 27, 2020","Investigational Site Number 8400002, Birmingham, Alabama, United States|Investigational Site Number 8400017, Los Angeles, California, United States|Investigational Site Number 8400001, San Francisco, California, United States|Investigational Site Number 8400008, Aurora, Colorado, United States|Investigational Site Number 8400010, New Haven, Connecticut, United States|Investigational Site Number 8400004, Atlanta, Georgia, United States|Investigational Site Number 8400007, Chicago, Illinois, United States|Investigational Site Number 8400014, Iowa City, Iowa, United States|Investigational Site Number 8400003, Kansas City, Kansas, United States|Investigational Site Number 8400021, Baltimore, Maryland, United States|Investigational Site Number 8400016, Boston, Massachusetts, United States|Investigational Site Number 8400020, Rochester, Minnesota, United States|Investigational Site Number 8400011, Philadelphia, Pennsylvania, United States|Investigational Site Number 8400015, San Antonio, Texas, United States|Investigational Site Number 8400019, Morgantown, West Virginia, United States|Investigational Site Number 8400005, Madison, Wisconsin, United States|Investigational Site Number 8400006, Milwaukee, Wisconsin, United States|Investigational Site Number 0360002, Herston, Australia|Investigational Site Number 0360001, Westmead, Australia|Investigational Site Number 0400001, Graz, Austria|Investigational Site Number 0400004, Wien, Austria|Investigational Site Number 0560001, Bruxelles, Belgium|Investigational Site Number 0560002, Leuven, Belgium|Investigational Site Number 1240002, Edmonton, Canada|Investigational Site Number 1240003, Montreal, Canada|Investigational Site Number 1240001, Toronto, Canada|Investigational Site Number 1560005, Beijing, China|Investigational Site Number 1560004, Chengdu, China|Investigational Site Number 1560002, Hefei, China|Investigational Site Number 1560001, Shanghai, China|Investigational Site Number 1560003, Shenyang, China|Investigational Site Number 2030001, Praha 2, Czechia|Investigational Site Number 2030002, Praha 4, Czechia|Investigational Site Number 2080001, København Ø, Denmark|Investigational Site Number 2080002, Roskilde, Denmark|Investigational Site Number 2500004, Bordeaux, France|Investigational Site Number 2500003, Brest, France|Investigational Site Number 2500002, Paris, France|Investigational Site Number 2500001, Toulouse, France|Investigational Site Number 2760001, Berlin, Germany|Investigational Site Number 2760002, Dresden, Germany|Investigational Site Number 2760010, Dresden, Germany|Investigational Site Number 2760007, Düsseldorf, Germany|Investigational Site Number 2760009, Essen, Germany|Investigational Site Number 2760005, Hannover, Germany|Investigational Site Number 2760003, Köln, Germany|Investigational Site Number 2760011, Leipzig, Germany|Investigational Site Number 2760004, München, Germany|Investigational Site Number 3800002, Milano, Italy|Investigational Site Number 3800001, Montichiari, Italy|Investigational Site Number 3920002, Bunkyo-Ku, Japan|Investigational Site Number 3920005, Kamakura-Shi, Japan|Investigational Site Number 3920006, Kawasaki-Shi, Japan|Investigational Site Number 3920010, Kyoto-Shi, Japan|Investigational Site Number 3920009, Nagoya-Shi, Japan|Investigational Site Number 3920003, Niigata-Shi, Japan|Investigational Site Number 3920007, Osaka-Shi, Japan|Investigational Site Number 3920001, Sapporo-Shi, Japan|Investigational Site Number 3920004, Shinjuku-Ku, Japan|Investigational Site Number 3920008, Toyoake-Shi, Japan|Investigational Site Number 4100001, Seoul, Korea, Republic of|Investigational Site Number 4100002, Seoul, Korea, Republic of|Investigational Site Number 5280001, Groningen, Netherlands|Investigational Site Number 5280002, Nijmegen, Netherlands|Investigational Site Number 6200004, Almada, Portugal|Investigational Site Number 6200001, Loures, Portugal|Investigational Site Number 6420002, Bucuresti, Romania|Investigational Site Number 6420001, Timisoara, Romania|Investigational Site Number 7240003, Barcelona, Spain|Investigational Site Number 7240001, Barcelona, Spain|Investigational Site Number 7240002, Madrid, Spain|Investigational Site Number 1580001, Taichung, Taiwan|Investigational Site Number 1580002, Taipei, Taiwan|Investigational Site Number 8260001, Sheffield, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03523728"
267,"NCT01230619","Vienna Challenge Chamber Study Using RV658 in Subjects With Allergic Rhinitis",,"Completed","No Results Available","Seasonal Allergic Rhinitis","Drug: RV568|Drug: Placebo","Total nasal symptom score (TNSS)|Eye symptom score|Global symptom score|Nasal airflow resistance|Safety parameters","Respivert Ltd","Male","18 Years to 55 Years   (Adult)","Phase 2","75","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","RVH002|2010-022113-25","October 2010","November 2010","December 2010","October 29, 2010",,"December 6, 2010","Institute for Allergy Research, Vienna Challenge Chamber, Vienna, Austria",,"https://ClinicalTrials.gov/show/NCT01230619"
268,"NCT02990338","Multinational Clinical Study Comparing Isatuximab, Pomalidomide, and Dexamethasone to Pomalidomide and Dexamethasone in Refractory or Relapsed and Refractory Multiple Myeloma Patients","ICARIA-MM","Active, not recruiting","Has Results","Plasma Cell Myeloma","Drug: Isatuximab|Drug: Pomalidomide|Drug: Dexamethasone","Progression Free Survival (PFS)|Overall Response Rate (ORR): Percentage of Participants With Overall Response|Overall Survival (OS)|Time to Progression (TTP)|Progression Free Survival in High Risk Cytogenetic Population|Duration of Response (DOR)|Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)|Pharmacokinetics (PK) Parameter: Plasma Concentration of Isatuximab at End of Infusion (CEOI)|Pharmacokinetic Parameter: Accumulation Ratio of Isatuximab at Concentration at the End of Infusion (CEOI)|Pharmacokinetic Parameter: Plasma Concentration of Isatuximab at 1 Hour After End of Infusion (CEOI+1 Hour)|PK Parameter: Plasma Concentration of Isatuximab at Ctrough|PK Parameter: Accumulation Ratio of Isatuximab at Trough Concentration (Ctrough)|Number of Participants With Anti-drug Antibodies (ADA)|Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Cancer Specific Questionnaire With 30 Items (EORTC QLQ-C30): Global Health Status (GHS)/Quality of Life (QOL) Score|Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Multiple Myeloma Specific Module With 20 Items (EORTC QLQ-MY20): Disease Symptoms Domain Score|Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Multiple Myeloma Specific Module With 20 Items (EORTC QLQ-MY20): Side Effects of Treatment Domain Score|Change From Baseline in European Quality of Life Working Group Health Status Measure 5 Dimensions (5D), 5 Levels (5L) (EQ-5D-5L) Score: Health State Utility Index Value|Change From Baseline in European Quality of Life Working Group Health Status Measure 5 Dimensions, 5 Levels (EQ-5D-5L) Score: Visual Analogic Scale (VAS)|Percentage of Participants With Best Overall Response (BOR)|Clinical Benefit Rate (CBR): Percentage of Participants With Clinical Benefit|Percentage of Participants With Very Good Partial Response (VGPR)|Time to First Response (TT1R)|Time to Best Response (TTBR)|Number of Participants With Minimal Residual Disease (MRD)","Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 3","307","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EFC14335|2016-003097-41|U1111-1180-6262","December 22, 2016","November 22, 2018","March 2021","December 13, 2016","December 6, 2019","January 28, 2020","Investigational Site Number 8400002, Plantation, Florida, United States|Investigational Site Number 8400006, Boston, Massachusetts, United States|Investigational Site Number 0360005, Melbourne, Australia|Investigational Site Number 0360002, Prahran, Australia|Investigational Site Number 0360006, Richmond, Australia|Investigational Site Number 0360004, St Leonards, Australia|Investigational Site Number 0360001, Waratah, Australia|Investigational Site Number 0560003, Antwerpen, Belgium|Investigational Site Number 0560002, Brussel, Belgium|Investigational Site Number 0560004, Gent, Belgium|Investigational Site Number 0560001, Leuven, Belgium|Investigational Site Number 1240001, Montreal, Canada|Investigational Site Number 1240004, Montreal, Canada|Investigational Site Number 1240005, Sherbrooke, Canada|Investigational Site Number 2030005, Brno, Czechia|Investigational Site Number 2030004, Hradec Kralove, Czechia|Investigational Site Number 2030001, Olomouc, Czechia|Investigational Site Number 2030002, Ostrava - Poruba, Czechia|Investigational Site Number 2030003, Praha 2, Czechia|Investigational Site Number 2080002, Ålborg, Denmark|Investigational Site Number 2500021, Bayonne, France|Investigational Site Number 2500008, Caen, France|Investigational Site Number 2500009, Dijon, France|Investigational Site Number 2500017, Grenoble, France|Investigational Site Number 2500013, La Roche Sur Yon, France|Investigational Site Number 2500003, Lille, France|Investigational Site Number 2500023, Limoges, France|Investigational Site Number 2500019, Montpellier Cedex, France|Investigational Site Number 2500002, Nantes Cedex 01, France|Investigational Site Number 2500015, Paris, France|Investigational Site Number 2500016, Paris, France|Investigational Site Number 2500005, Pessac, France|Investigational Site Number 2500004, Pierre Benite, France|Investigational Site Number 2500007, Poitiers Cedex, France|Investigational Site Number 2500025, Reims, France|Investigational Site Number 2500014, Rennes, France|Investigational Site Number 2500001, Toulouse Cedex 9, France|Investigational Site Number 2500012, Tours, France|Investigational Site Number 2500018, Vandoeuvre-Les-Nancy Cedex, France|Investigational Site Number 2760001, Leipzig, Germany|Investigational Site Number 3000002, Athens, Greece|Investigational Site Number 3000005, Athens, Greece|Investigational Site Number 3000001, Athens, Greece|Investigational Site Number 3000004, Patra, Greece|Investigational Site Number 3000003, Thessaloniki, Greece|Investigational Site Number 3480001, Budapest, Hungary|Investigational Site Number 3480003, Budapest, Hungary|Investigational Site Number 3480002, Debrecen, Hungary|Investigational Site Number 3800001, Bologna, Italy|Investigational Site Number 3800010, Catania, Italy|Investigational Site Number 3800009, Firenze, Italy|Investigational Site Number 3800008, Genova, Italy|Investigational Site Number 3800007, Milano, Italy|Investigational Site Number 3800002, Milano, Italy|Investigational Site Number 3800006, Padova, Italy|Investigational Site Number 3800004, Terni, Italy|Investigational Site Number 3800003, Torino, Italy|Investigational Site Number 3920006, Kyoto-Shi, Japan|Investigational Site Number 3920001, Nagoya-Shi, Japan|Investigational Site Number 3920003, Okayama-Shi, Japan|Investigational Site Number 3920004, Sapporo-Shi, Japan|Investigational Site Number 3920005, Shibukawa-Shi, Japan|Investigational Site Number 3920002, Shibuya-Ku, Japan|Investigational Site Number 3920007, Sunto-Gun, Japan|Investigational Site Number 3920008, Suwa-Shi, Japan|Investigational Site Number 4100007, Hwasun-Gun, Korea, Republic of|Investigational Site Number 4100006, Incheon, Korea, Republic of|Investigational Site Number 4100001, Seoul, Korea, Republic of|Investigational Site Number 4100002, Seoul, Korea, Republic of|Investigational Site Number 4100005, Seoul, Korea, Republic of|Investigational Site Number 5540002, Auckland, New Zealand|Investigational Site Number 5540004, Dunedin, New Zealand|Investigational Site Number 5540003, Hamilton, New Zealand|Investigational Site Number 5540001, Takapuna, New Zealand|Investigational Site Number 5780001, Oslo, Norway|Investigational Site Number 6160002, Chorzow, Poland|Investigational Site Number 6160005, Krakow, Poland|Investigational Site Number 6160003, Lublin, Poland|Investigational Site Number 6160001, Warszawa, Poland|Investigational Site Number 6200004, Coimbra, Portugal|Investigational Site Number 6200002, Lisboa, Portugal|Investigational Site Number 6200001, Porto, Portugal|Investigational Site Number 6430004, Moscow, Russian Federation|Investigational Site Number 6430001, Moscow, Russian Federation|Investigational Site Number 6430002, Moscow, Russian Federation|Investigational Site Number 7030001, Bratislava, Slovakia|Investigational Site Number 7240001, Barcelona, Spain|Investigational Site Number 7240003, Madrid, Spain|Investigational Site Number 7240002, Pamplona, Spain|Investigational Site Number 7240004, Salamanca, Spain|Investigational Site Number 7240006, Santander, Spain|Investigational Site Number 7240005, Santiago De Compostela, Spain|Investigational Site Number 7520004, Luleå, Sweden|Investigational Site Number 7520005, Uddevalla, Sweden|Investigational Site Number 1580004, Kaohsiung, Taiwan|Investigational Site Number 1580002, Taichung, Taiwan|Investigational Site Number 1580001, Taipei, Taiwan|Investigational Site Number 1580003, Taoyuan, Taiwan|Investigational Site Number 7920001, Ankara, Turkey|Investigational Site Number 7920002, Antalya, Turkey|Investigational Site Number 7920005, Istanbul, Turkey|Investigational Site Number 7920003, Istanbul, Turkey|Investigational Site Number 7920004, Istanbul, Turkey|Investigational Site Number 7920006, İstanbul, Turkey|Investigational Site Number 7920008, Izmir, Turkey|Investigational Site Number 7920010, Izmir, Turkey|Investigational Site Number 7920009, Kayseri, Turkey|Investigational Site Number 7920007, Kocaeli, Turkey|Investigational Site Number 8260002, London, United Kingdom|Investigational Site Number 8260003, London, United Kingdom|Investigational Site Number 8260001, London, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/38/NCT02990338/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/38/NCT02990338/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02990338"
269,"NCT00733005","Study of Nasonex in the Relief of Nasal Congestion in Patients With Seasonal Allergic Rhinitis (Study P05528)(COMPLETED)",,"Completed","Has Results","Allergic Rhinitis","Drug: Mometasone furoate nasal spray (MFNS)|Drug: Matching placebo nasal spray","The Change From Baseline in Average AM/PM PRIOR Nasal Congestion Score Over 15 Days.|The Change From Baseline in Average AM/PM PRIOR Total Nasal Symptom Score Over 15 Days","Merck Sharp & Dohme Corp.","All","12 Years and older   (Child, Adult, Older Adult)","Phase 3","324","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","P05528","July 2008","October 2008","October 2008","August 12, 2008","November 19, 2009","April 12, 2017",,,"https://ClinicalTrials.gov/show/NCT00733005"
270,"NCT00732381","Study of Nasonex in the Relief of Nasal Congestion in Patients With Seasonal Allergic Rhinitis (Study P05529)",,"Completed","Has Results","Allergic Rhinitis","Drug: Mometasone furoate nasal spray (MFNS)|Drug: Matching placebo nasal spray","The Change From Baseline in Average AM/PM PRIOR Nasal Congestion Score Over 15 Days|The Change From Baseline in Average AM/PM PRIOR Total Nasal Symptom Score Over 15 Days","Merck Sharp & Dohme Corp.","All","12 Years and older   (Child, Adult, Older Adult)","Phase 3","351","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","P05529","August 2008","November 2008","November 2008","August 12, 2008","November 13, 2009","April 13, 2017",,,"https://ClinicalTrials.gov/show/NCT00732381"
271,"NCT00728416","Study of Nasonex in the Relief of Nasal Congestion in Patients With Seasonal Allergic Rhinitis (Study P05583)",,"Completed","Has Results","Allergic Rhinitis","Drug: Mometasone furoate nasal spray (MFNS)|Drug: Matching placebo nasal spray","Change From Baseline in Average AM/PM PRIOR Nasal Congestion Score Over 15 Days|Change From Baseline in Average AM/PM PRIOR Total Nasal Symptom Score Over 15 Days","Merck Sharp & Dohme Corp.","All","12 Years and older   (Child, Adult, Older Adult)","Phase 3","333","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","P05583|MK-0887-160","August 2008","October 2008","October 2008","August 5, 2008","November 19, 2009","September 16, 2016",,,"https://ClinicalTrials.gov/show/NCT00728416"
272,"NCT02715726","Evaluation of Alirocumab Versus Ezetimibe on Top of Statin in Asia in High Cardiovascular Risk Patients With Hypercholesterolemia","ODYSSEY EAST","Completed","Has Results","Hypercholesterolemia","Drug: Alirocumab|Drug: Placebo for alirocumab|Drug: ezetimibe|Drug: placebo for ezetimibe|Drug: atorvastatin|Drug: rosuvastatin|Drug: simvastatin","Percent Change From Baseline in Calculated Low Density Lipoprotein Cholesterol at Week 24: Intent-to-treat (ITT) Analysis|Percent Change From Baseline in Calculated Low Density Lipoprotein Cholesterol at Week 24: On-Treatment Analysis|Percent Change From Baseline in Calculated Low Density Lipoprotein Cholesterol at Week 12: ITT Analysis|Percent Change From Baseline in Calculated Low Density Lipoprotein Cholesterol at Week 12: On-Treatment Analysis|Percent Change From Baseline in Apolipoprotein B (Apo B) at Week 24: ITT Analysis|Percent Change From Baseline in Apolipoprotein B at Week 24: On-Treatment Analysis|Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 24: ITT Analysis|Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol at Week 24: On-Treatment Analysis|Percent Change From Baseline in Total Cholesterol (Total-C) at Week 24: ITT Analysis|Percent Change From Baseline in Apolipoprotein B at Week 12: ITT Analysis|Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol at Week 12: ITT Analysis|Percent Change From Baseline in Total Cholesterol at Week 12: ITT Analysis|Percentage of Participants Reaching Calculated Low Density Lipoprotein Cholesterol <70 mg/dL (1.81 mmol/L) at Week 24: ITT Analysis|Percentage of Participants Reaching Calculated Low Density Lipoprotein Cholesterol <70 mg/dL (1.81 mmol/L) at Week 24: On-Treatment Analysis|Percent Change From Baseline in Lipoprotein (a) (Lp[a]) at Week 24: ITT Analysis|Percent Change From Baseline in High Density Lipoprotein Cholesterol at Week 24: ITT Analysis|Percent Change From Baseline in Fasting Triglycerides (TG) at Week 24: ITT Analysis|Percent Change From Baseline in Apolipoprotein A-1 (Apo A-1) at Week 24: ITT Analysis|Percent Change From Baseline in Lipoprotein (a) at Week 12: ITT Analysis|Percent Change From Baseline in High Density Lipoprotein Cholesterol at Week 12: ITT Analysis|Percent Change From Baseline in Fasting Triglycerides at Week 12: ITT Analysis|Percent Change From Baseline in Apolipoprotein A-1 at Week 12 : ITT Analysis","Sanofi|Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 3","615","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","EFC13889|U1111-1150-8859","July 27, 2016","August 6, 2018","August 6, 2018","March 22, 2016","September 30, 2019","September 30, 2019","Investigational Site Number 1560027, Beijing, China|Investigational Site Number 1560043, Beijing, China|Investigational Site Number 1560039, Beijing, China|Investigational Site Number 1560012, Beijing, China|Investigational Site Number 1560018, Beijing, China|Investigational Site Number 1560006, Changchun, China|Investigational Site Number 1560020, Changchun, China|Investigational Site Number 1560023, Changsha, China|Investigational Site Number 1560030, Fuzhou, China|Investigational Site Number 1560005, Guangzhou, China|Investigational Site Number 1560040, Guangzhou, China|Investigational Site Number 1560025, Guangzhou, China|Investigational Site Number 1560048, Hangzhou, China|Investigational Site Number 1560037, Hangzhou, China|Investigational Site Number 1560008, Hangzhou, China|Investigational Site Number 1560014, Hohhot, China|Investigational Site Number 1560016, Jinan, China|Investigational Site Number 1560044, Lanzhou, China|Investigational Site Number 1560028, Nanchang, China|Investigational Site Number 1560045, Nanjing, China|Investigational Site Number 1560017, Nanjing, China|Investigational Site Number 1560031, Nanjing, China|Investigational Site Number 1560035, Nanning, China|Investigational Site Number 1560029, Shanghai, China|Investigational Site Number 1560041, Shanghai, China|Investigational Site Number 1560053, Shanghai, China|Investigational Site Number 1560009, Shenyang, China|Investigational Site Number 1560001, Shenyang, China|Investigational Site Number 1560042, Shenyang, China|Investigational Site Number 1560036, Shenzhen, China|Investigational Site Number 1560056, Siping, China|Investigational Site Number 1560021, Taiyuan, China|Investigational Site Number 1560002, Tianjin, China|Investigational Site Number 1560022, Tianjin, China|Investigational Site Number 1560052, Tianjin, China|Investigational Site Number 1560055, Wenzhou, China|Investigational Site Number 1560003, Wuhan, China|Investigational Site Number 1560004, Xi'An, China|Investigational Site Number 1560019, Xuzhou, China|Investigational Site Number 1560054, Yinchuan, China|Investigational Site Number 1560057, Zhanjiang, China|Investigational Site Number 3560017, Belgaum, India|Investigational Site Number 3560001, Gurgaon, India|Investigational Site Number 3560003, Hubli, India|Investigational Site Number 3560010, Kolkata, India|Investigational Site Number 3560019, Kolkata, India|Investigational Site Number 3560020, Mangalore, India|Investigational Site Number 3560006, Mumbai, India|Investigational Site Number 3560007, Nagpur, India|Investigational Site Number 3560004, Nagpur, India|Investigational Site Number 3560008, Nagpur, India|Investigational Site Number 3560016, Nagpur, India|Investigational Site Number 3560014, New Delhi, India|Investigational Site Number 3560005, Pune, India|Investigational Site Number 3560011, Pune, India|Investigational Site Number 3560013, Surat, India|Investigational Site Number 3560015, Vijayawada, India|Investigational Site Number 3560012, Vijaywada, India|Investigational Site Number 7640003, Bangkok-Noi, Thailand|Investigational Site Number 7640004, Bangkok, Thailand|Investigational Site Number 7640001, Muang, Thailand|Investigational Site Number 7640002, Pratumwan, Thailand","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/26/NCT02715726/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/26/NCT02715726/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT02715726"
273,"NCT00464568","A 5-way Treatment Period Trial of Single Doses of Intranasal GSK256066 in Patients With Rhinitis",,"Completed","Has Results","Rhinitis, Allergic, Seasonal","Drug: GSK256066","Mean Messenger Ribonucleic Acid (mRNA) Concentrations as a Measure of Gene Expression|Mean Forced Expiratory Volume in One Second (FEV1)|Mean Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) Over Study Period|Mean Heart Rate Over Study Period|Change From Baseline in Electrocardiogram (ECG) Values|Number of Participants With Adverse Events (AE) and Serious Adverse Events (SAE)|Number of Participants With Hematology Values of Potential Clinical Concern|Number of Participants With Clinical Chemistry Values of Potential Clinical Concern|Area Under the Plasma Drug Concentration Versus Time Curve (AUC0-last) of GSK256066|AUC (0-last) of Active Metabolite GSK614917|Maximum Observed Plasma Drug Concentration (Cmax) of GSK256066|Cmax of Active Metabolite GSK614917|Time to Maximum Observed Plasma Drug Concentration (Tmax) and Time to Last Observed Plasma Drug Concentration (Tlast) of GSK256066|Tmax and Tlast of Active Metabolite GSK614917|Nasal Lavage Concentrations of GSK256066|Mean Levels of Total Vasodilator Stimulated Phosphoprotein (VASP) Protein, Phosphorylated(Phospho)157 VASP (pVASP) and phospho239 VASP in Lavage Cells","GlaxoSmithKline","All","18 Years to 50 Years   (Adult)","Phase 2","32","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Primary Purpose: Treatment","IPR109764","March 28, 2007","May 16, 2007","May 16, 2007","April 23, 2007","August 21, 2017","August 20, 2018","GSK Investigational Site, Berlin, Germany",,"https://ClinicalTrials.gov/show/NCT00464568"
274,"NCT00805584","Study of Nasal Symptom Relief and Side Effects in Hayfever Patients Treated With Aerius (Desloratadine)(P03442)",,"Completed","No Results Available","Rhinitis, Allergic, Seasonal","Drug: desloratadine","Relief of allergy symptoms|Global therapeutic response|Adverse events","Merck Sharp & Dohme Corp.","All","18 Years and older   (Adult, Older Adult)","Phase 4","311","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","P03442","May 2003","June 2003","June 2003","December 9, 2008",,"April 21, 2015",,,"https://ClinicalTrials.gov/show/NCT00805584"
275,"NCT02411825","Multiple Ascending Dose Study in Healthy Male Subjects and Overweight to Obese Male and Female Type 2 Diabetes Mellitus (T2DM) Patients",,"Completed","No Results Available","Type 2 Diabetes Mellitus","Drug: SAR425899|Drug: placebo|Drug: metformin","Number of adverse events|Changes in vital signs|Changes in physical examination|Changes in ECG|Changes in clinical laboratory parameters (hematology)|Changes in clinical laboratory parameters (biochemistry)|Changes in body temperature|Change from baseline in biomarkers (FGF21)|Change from baseline in biomarkers (lipid biomarker)|Change from baseline in biomarkers (incretins)|Assessment of pharmacokinetic parameters in blood (AUC)|Assessment of pharmacokinetic parameters in blood (Cmax)|Assessment of pharmacokinetic parameters in blood (t1/2)|Assessment of pharmacokinetic parameters in urine (Ae0-24)|Assessment of pharmacokinetic parameters in urine (fe0-24)|Change from baseline in Body weight|Change from baseline in Fasting Blood Glucose|Change from baseline in Postprandial Blood Glucose|Change from baseline in postprandial Insulin|Change from baseline in postprandial C-peptide profiles|Change from baseline in HbA1c","Sanofi","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1","76","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","TDR13700|2014-004216-10|U1111-1163-1209","March 2015","January 2016","January 2016","April 8, 2015",,"June 15, 2018","Investigational Site Number 276001, Berlin, Germany",,"https://ClinicalTrials.gov/show/NCT02411825"
276,"NCT01663402","ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab",,"Completed","Has Results","Atherosclerotic Cardiovascular Disease","Drug: Alirocumab|Drug: Placebo|Drug: LMT","Time to First Occurrence of Major Adverse Cardiovascular Event (MACE); Percentage of Observed Participants With Outcome Measure Events During the Study|Time to First Occurrence of Any Coronary Heart Disease Event; Percentage of Observed Participants With Outcome Measure Events During the Study|Time to First Occurrence of Any Major Coronary Heart Disease Event; Percentage of Observed Participants With Outcome Measure Events During the Study|Time to First Occurrence of Any Cardiovascular Event; Percentage of Observed Participants With Outcome Measure Events During the Study|Time to First Occurrence of All-Cause Mortality, Non-Fatal Myocardial Infarction, Non-Fatal Ischemic Stroke; Percentage of Observed Participants With Outcome Measure Events During the Study|Time to Coronary Heart Disease Death; Percentage of Observed Participants With Outcome Measure Events During the Study|Time to Cardiovascular Death; Percentage of Observed Participants With Outcome Measure Events During the Study|Time to All-Cause Death; Percentage of Observed Participants With Outcome Measure Events During the Study|Time to First Occurrence of Any Non-Fatal Myocardial Infarction; Percentage of Observed Participants With Outcome Measure Events During the Study|Time to First Occurrence of Fatal or Any Non-Fatal Ischemic Stroke; Percentage of Observed Participants With Outcome Measure Events During the Study|Time to First Occurrence of Any Unstable Angina Requiring Hospitalization; Percentage of Observed Participants With Outcome Measure Events During the Study|Time to First Occurrence of Any Ischemia-Driven Coronary Revascularization Procedure; Percentage of Observed Participants With Outcome Measure Events During the Study|Time to First Occurrence of Any Congestive Heart Failure (CHF) Requiring Hospitalization; Percentage of Observed Participants With Outcome Measure Events During the Study","Sanofi|Regeneron Pharmaceuticals","All","40 Years and older   (Adult, Older Adult)","Phase 3","18924","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","EFC11570|2011-005698-21|U1111-1127-4323","October 2012","January 23, 2018","January 23, 2018","August 13, 2012","March 18, 2019","March 18, 2019","Investigational Site Number 840163, Birmingham, Alabama, United States|Investigational Site Number 840060, Birmingham, Alabama, United States|Investigational Site Number 840117, Huntsville, Alabama, United States|Investigational Site Number 840192, Huntsville, Alabama, United States|Investigational Site Number 840121, Mobile, Alabama, United States|Investigational Site Number 840319, Mobile, Alabama, United States|Investigational Site Number 840332, Atlantis, Arizona, United States|Investigational Site Number 840320, Newport Beach, Arizona, United States|Investigational Site Number 840103, Tucson, Arizona, United States|Investigational Site Number 840084, Tucson, Arizona, United States|Investigational Site Number 840139, Banning, California, United States|Investigational Site Number 840286, Beverly Hills, California, United States|Investigational Site Number 840246, Beverly Hills, California, United States|Investigational Site Number 840353, Beverly Hills, California, United States|Investigational Site Number 840341, Carmichael, California, United States|Investigational Site Number 840299, Chula Vista, California, United States|Investigational Site Number 840164, Fresno, California, United States|Investigational Site Number 840076, Fullerton, California, United States|Investigational Site Number 840073, Huntington Beach, California, United States|Investigational Site Number 840092, La Jolla, California, United States|Investigational Site Number 840208, Long Beach, California, United States|Investigational Site Number 840068, Long Beach, California, United States|Investigational Site Number 840269, Los Alamitos, California, United States|Investigational Site Number 840009, Los Angeles, California, United States|Investigational Site Number 840282, Los Angeles, California, United States|Investigational Site Number 840019, Mission Viejo, California, United States|Investigational Site Number 840336, Moreno Valley, California, United States|Investigational Site Number 840124, Northridge, California, United States|Investigational Site Number 840251, Pasadena, California, United States|Investigational Site Number 840289, Pasadena, California, United States|Investigational Site Number 840312, Port Hueneme, California, United States|Investigational Site Number 840261, San Diego, California, United States|Investigational Site Number 840310, San Diego, California, United States|Investigational Site Number 840024, San Diego, California, United States|Investigational Site Number 840071, Santa Ana, California, United States|Investigational Site Number 840236, Santa Rosa, California, United States|Investigational Site Number 840012, Torrance, California, United States|Investigational Site Number 840096, Aurora, Colorado, United States|Investigational Site Number 840037, Colorado Springs, Colorado, United States|Investigational Site Number 840189, Denver, Colorado, United States|Investigational Site Number 840122, Bridgeport, Connecticut, United States|Investigational Site Number 840219, Guilford, Connecticut, United States|Investigational Site Number 840347, Altamonte Springs, Florida, United States|Investigational Site Number 840066, Clearwater, Florida, United States|Investigational Site Number 840079, Daytona Beach, Florida, United States|Investigational Site Number 840051, Daytona Beach, Florida, United States|Investigational Site Number 840368, Delray Beach, Florida, United States|Investigational Site Number 840242, Fort Lauderdale, Florida, United States|Investigational Site Number 840134, Gainesville, Florida, United States|Investigational Site Number 840327, Hollywood, Florida, United States|Investigational Site Number 840153, Hudson, Florida, United States|Investigational Site Number 840105, Hudson, Florida, United States|Investigational Site Number 840253, Jacksonville, Florida, United States|Investigational Site Number 840141, Jacksonville, Florida, United States|Investigational Site Number 840042, Jacksonville, Florida, United States|Investigational Site Number 840206, Jacksonville, Florida, United States|Investigational Site Number 840063, Jacksonville, Florida, United States|Investigational Site Number 840002, Jupiter, Florida, United States|Investigational Site Number 840119, Largo, Florida, United States|Investigational Site Number 840241, Miami Beach, Florida, United States|Investigational Site Number 840210, Mount Clemens, Florida, United States|Investigational Site Number 840366, New Port Richey, Florida, United States|Investigational Site Number 840311, Palm Beach Gardens, Florida, United States|Investigational Site Number 840280, Palm Harbor, Florida, United States|Investigational Site Number 840054, Panama City, Florida, United States|Investigational Site Number 840239, Pembroke Pines, Florida, United States|Investigational Site Number 840044, Pensacola, Florida, United States|Investigational Site Number 840367, Plantation, Florida, United States|Investigational Site Number 840132, Safety Harbor, Florida, United States|Investigational Site Number 840061, Safety Harbor, Florida, United States|Investigational Site Number 840247, Sarasota, Florida, United States|Investigational Site Number 840264, Tampa, Florida, United States|Investigational Site Number 840082, Tampa, Florida, United States|Investigational Site Number 840213, Trinity, Florida, United States|Investigational Site Number 840165, Wellington, Florida, United States|Investigational Site Number 840323, West Palm Beach, Florida, United States|Investigational Site Number 840075, Atlanta, Georgia, United States|Investigational Site Number 840176, Augusta, Georgia, United States|Investigational Site Number 840048, Covington, Georgia, United States|Investigational Site Number 840065, Cumming, Georgia, United States|Investigational Site Number 840356, Thomasville, Georgia, United States|Investigational Site Number 840114, Tucker, Georgia, United States|Investigational Site Number 840211, Idaho Falls, Idaho, United States|Investigational Site Number 840237, Arlington Heights, Illinois, United States|Investigational Site Number 840292, Chicago, Illinois, United States|Investigational Site Number 840146, Harvey, Illinois, United States|Investigational Site Number 840340, Joliet, Illinois, United States|Investigational Site Number 840196, Peoria, Illinois, United States|Investigational Site Number 840081, Rock Island, Illinois, United States|Investigational Site Number 840090, Rock Island, Illinois, United States|Investigational Site Number 840358, Elkhart, Indiana, United States|Investigational Site Number 840036, Hammond, Indiana, United States|Investigational Site Number 840026, Indianapolis, Indiana, United States|Investigational Site Number 840102, Muncie, Indiana, United States|Investigational Site Number 840145, South Bend, Indiana, United States|Investigational Site Number 840154, Ames, Iowa, United States|Investigational Site Number 840345, Iowa City, Iowa, United States|Investigational Site Number 840283, West Des Moines, Iowa, United States|Investigational Site Number 840335, Kansas City, Kansas, United States|Investigational Site Number 840089, Kansas City, Kansas, United States|Investigational Site Number 840218, Kansas City, Kansas, United States|Investigational Site Number 840140, Overland Park, Kansas, United States|Investigational Site Number 840030, Lexington, Kentucky, United States|Investigational Site Number 840023, Louisville, Kentucky, United States|Investigational Site Number 840007, Louisville, Kentucky, United States|Investigational Site Number 840279, Owensboro, Kentucky, United States|Investigational Site Number 840308, Pikeville, Kentucky, United States|Investigational Site Number 840181, Saint Paul, Kentucky, United States|Investigational Site Number 840254, Alexandria, Louisiana, United States|Investigational Site Number 840344, Lafayette, Louisiana, United States|Investigational Site Number 840187, Lake Charles, Louisiana, United States|Investigational Site Number 840291, Minden, Louisiana, United States|Investigational Site Number 840278, New Orleans, Louisiana, United States|Investigational Site Number 840290, Shreveport, Louisiana, United States|Investigational Site Number 840142, Auburn, Maine, United States|Investigational Site Number 840148, Auburn, Maine, United States|Investigational Site Number 840097, Bangor, Maine, United States|Investigational Site Number 840234, Framingham, Maine, United States|Investigational Site Number 840276, Scarborough, Maine, United States|Investigational Site Number 840351, Annapolis, Maryland, United States|Investigational Site Number 840072, Beltsville, Maryland, United States|Investigational Site Number 840193, Bethesda, Maryland, United States|Investigational Site Number 840200, Columbia, Maryland, United States|Investigational Site Number 840349, Rockville, Maryland, United States|Investigational Site Number 840111, Winfield, Maryland, United States|Investigational Site Number 840056, Boston, Massachusetts, United States|Investigational Site Number 840144, Flint, Michigan, United States|Investigational Site Number 840365, Grandville, Michigan, United States|Investigational Site Number 840093, Kalamazoo, Michigan, United States|Investigational Site Number 840198, Lansing, Michigan, United States|Investigational Site Number 840087, Rochester Hills, Michigan, United States|Investigational Site Number 840004, Springfield, Michigan, United States|Investigational Site Number 840267, Springfield, Michigan, United States|Investigational Site Number 840035, Ypsilanti, Michigan, United States|Investigational Site Number 840199, Duluth, Minnesota, United States|Investigational Site Number 840116, Edina, Minnesota, United States|Investigational Site Number 840281, Minneapolis, Minnesota, United States|Investigational Site Number 840094, Saint Cloud, Minnesota, United States|Investigational Site Number 840324, Saint Paul, Minnesota, United States|Investigational Site Number 840046, Columbia, Missouri, United States|Investigational Site Number 840180, Independence, Missouri, United States|Investigational Site Number 840274, Little Rock, Missouri, United States|Investigational Site Number 840013, Marquette, Missouri, United States|Investigational Site Number 840179, Overland, Missouri, United States|Investigational Site Number 840228, Saint Louis, Missouri, United States|Investigational Site Number 840233, Saint Louis, Missouri, United States|Investigational Site Number 840235, Saint Louis, Missouri, United States|Investigational Site Number 840175, Saint Louis, Missouri, United States|Investigational Site Number 840125, Saint Louis, Missouri, United States|Investigational Site Number 840168, Saint Louis, Missouri, United States|Investigational Site Number 840032, Kalispell, Montana, United States|Investigational Site Number 840033, Grand Island, Nebraska, United States|Investigational Site Number 840015, Omaha, Nebraska, United States|Investigational Site Number 840021, Omaha, Nebraska, United States|Investigational Site Number 840001, Omaha, Nebraska, United States|Investigational Site Number 840221, Las Vegas, Nevada, United States|Investigational Site Number 840062, Nashua, New Hampshire, United States|Investigational Site Number 840077, Bridgewater, New Jersey, United States|Investigational Site Number 840173, Bridgewater, New Jersey, United States|Investigational Site Number 840127, Flemington, New Jersey, United States|Investigational Site Number 840359, Hackensack, New Jersey, United States|Investigational Site Number 840348, Moorestown, New Jersey, United States|Investigational Site Number 840128, New Brunswick, New Jersey, United States|Investigational Site Number 840167, Pomona, New Jersey, United States|Investigational Site Number 840067, Ridgewood, New Jersey, United States|Investigational Site Number 840250, Somerset, New Jersey, United States|Investigational Site Number 840277, Voorhees, New Jersey, United States|Investigational Site Number 840083, Westwood, New Jersey, United States|Investigational Site Number 840222, Bronx, New York, United States|Investigational Site Number 840322, Buffalo, New York, United States|Investigational Site Number 840248, New York, New York, United States|Investigational Site Number 840371, New York, New York, United States|Investigational Site Number 840333, Newburgh, New York, United States|Investigational Site Number 840017, Poughkeepsie, New York, United States|Investigational Site Number 840166, Valhalla, New York, United States|Investigational Site Number 840354, Williamsville, New York, United States|Investigational Site Number 840070, Elizabeth City, North Carolina, United States|Investigational Site Number 840303, Greenville, North Carolina, United States|Investigational Site Number 840182, Greenville, North Carolina, United States|Investigational Site Number 840243, Raleigh, North Carolina, United States|Investigational Site Number 840342, Raleigh, North Carolina, United States|Investigational Site Number 840293, Rocky Mount, North Carolina, United States|Investigational Site Number 840088, Statesville, North Carolina, United States|Investigational Site Number 840052, Wilmington, North Carolina, United States|Investigational Site Number 840306, Baltimore, North Dakota, United States|Investigational Site Number 840214, Fargo, North Dakota, United States|Investigational Site Number 840095, Minot, North Dakota, United States|Investigational Site Number 840257, Mountain Lakes, North Dakota, United States|Investigational Site Number 840364, Akron, Ohio, United States|Investigational Site Number 840131, Cincinnati, Ohio, United States|Investigational Site Number 840045, Columbus, Ohio, United States|Investigational Site Number 840265, Columbus, Ohio, United States|Investigational Site Number 840113, Lorain, Ohio, United States|Investigational Site Number 840115, Lorain, Ohio, United States|Investigational Site Number 840309, Maumee, Ohio, United States|Investigational Site Number 840297, Springfield, Ohio, United States|Investigational Site Number 840172, Toledo, Ohio, United States|Investigational Site Number 840263, Youngstown, Ohio, United States|Investigational Site Number 840334, Oklahoma City, Oklahoma, United States|Investigational Site Number 840337, Oklahoma City, Oklahoma, United States|Investigational Site Number 840018, Tulsa, Oklahoma, United States|Investigational Site Number 840184, Portland, Oregon, United States|Investigational Site Number 840133, Allentown, Pennsylvania, United States|Investigational Site Number 840104, Beaver, Pennsylvania, United States|Investigational Site Number 840170, Camp Hill, Pennsylvania, United States|Investigational Site Number 840020, Doylestown, Pennsylvania, United States|Investigational Site Number 840016, Erie, Pennsylvania, United States|Investigational Site Number 840329, Goodyear, Pennsylvania, United States|Investigational Site Number 840126, Knoxville, Pennsylvania, United States|Investigational Site Number 840249, Lancaster, Pennsylvania, United States|Investigational Site Number 840150, Lancaster, Pennsylvania, United States|Investigational Site Number 840231, Philadelphia, Pennsylvania, United States|Investigational Site Number 840339, Philadelphia, Pennsylvania, United States|Investigational Site Number 840230, Pittsburgh, Pennsylvania, United States|Investigational Site Number 840028, Sayre, Pennsylvania, United States|Investigational Site Number 840069, Scranton, Pennsylvania, United States|Investigational Site Number 840316, Scranton, Pennsylvania, United States|Investigational Site Number 840273, Seven Fields, Pennsylvania, United States|Investigational Site Number 840227, Washington, Pennsylvania, United States|Investigational Site Number 840129, Pawtucket, Rhode Island, United States|Investigational Site Number 840118, Anderson, South Carolina, United States|Investigational Site Number 840190, Greenwood, South Carolina, United States|Investigational Site Number 840360, Lancaster, South Carolina, United States|Investigational Site Number 840314, Myrtle Beach, South Carolina, United States|Investigational Site Number 840008, Rapid City, South Dakota, United States|Investigational Site Number 840285, Chattanooga, Tennessee, United States|Investigational Site Number 840287, Jackson, Tennessee, United States|Investigational Site Number 840040, Johnson City, Tennessee, United States|Investigational Site Number 840238, Knoxville, Tennessee, United States|Investigational Site Number 840195, Oak Ridge, Tennessee, United States|Investigational Site Number 840205, Amarillo, Texas, United States|Investigational Site Number 840352, Amarillo, Texas, United States|Investigational Site Number 840135, Austin, Texas, United States|Investigational Site Number 840301, Dallas, Texas, United States|Investigational Site Number 840152, Dallas, Texas, United States|Investigational Site Number 840157, Dallas, Texas, United States|Investigational Site Number 840229, Fort Worth, Texas, United States|Investigational Site Number 840120, Fort Worth, Texas, United States|Investigational Site Number 840258, Fort Worth, Texas, United States|Investigational Site Number 840136, Kingwood, Texas, United States|Investigational Site Number 840027, Lubbock, Texas, United States|Investigational Site Number 840202, Lufkin, Texas, United States|Investigational Site Number 840270, Odessa, Texas, United States|Investigational Site Number 840162, San Antonio, Texas, United States|Investigational Site Number 840232, San Antonio, Texas, United States|Investigational Site Number 840328, Schertz, Texas, United States|Investigational Site Number 840158, Tyler, Texas, United States|Investigational Site Number 840318, Victoria, Texas, United States|Investigational Site Number 840245, Wichita Falls, Texas, United States|Investigational Site Number 840256, Orem, Utah, United States|Investigational Site Number 840296, Salt Lake City, Utah, United States|Investigational Site Number 840053, Burlington, Vermont, United States|Investigational Site Number 840049, Charlottesville, Virginia, United States|Investigational Site Number 840260, Charlottesville, Virginia, United States|Investigational Site Number 840350, Harrisonburg, Virginia, United States|Investigational Site Number 840215, Leesburg, Virginia, United States|Investigational Site Number 840010, Lynchburg, Virginia, United States|Investigational Site Number 840225, Manassas, Virginia, United States|Investigational Site Number 840022, Richmond, Virginia, United States|Investigational Site Number 840078, Richmond, Virginia, United States|Investigational Site Number 840110, Richmond, Virginia, United States|Investigational Site Number 840149, Roanoke, Virginia, United States|Investigational Site Number 840223, Winchester, Virginia, United States|Investigational Site Number 840025, Bellevue, Washington, United States|Investigational Site Number 840321, Everett, Washington, United States|Investigational Site Number 840326, Spokane, Washington, United States|Investigational Site Number 840086, Tacoma, Washington, United States|Investigational Site Number 840295, Walla Walla, Washington, United States|Investigational Site Number 840262, Burlington, Wisconsin, United States|Investigational Site Number 840298, Green Bay, Wisconsin, United States|Investigational Site Number 840059, Green Bay, Wisconsin, United States|Investigational Site Number 840177, La Crosse, Wisconsin, United States|Investigational Site Number 840300, Manitowoc, Wisconsin, United States|Investigational Site Number 032012, Adrogue, Argentina|Investigational Site Number 032018, Bahia Blanca, Argentina|Investigational Site Number 032050, Caba, Argentina|Investigational Site Number 032048, Caba, Argentina|Investigational Site Number 032023, Caba, Argentina|Investigational Site Number 032020, Caba, Argentina|Investigational Site Number 032041, Caba, Argentina|Investigational Site Number 032011, Caba, Argentina|Investigational Site Number 032045, Caba, Argentina|Investigational Site Number 032010, Ciudad De Buenos Aires, Argentina|Investigational Site Number 032046, Ciudadela, Argentina|Investigational Site Number 032032, Cordoba, Argentina|Investigational Site Number 032019, Cordoba, Argentina|Investigational Site Number 032021, Cordoba, Argentina|Investigational Site Number 032008, Cordoba, Argentina|Investigational Site Number 032042, Cordoba, Argentina|Investigational Site Number 032038, Cordoba, Argentina|Investigational Site Number 032031, Cordoba, Argentina|Investigational Site Number 032017, Coronel Suarez, Argentina|Investigational Site Number 032009, Corrientes, Argentina|Investigational Site Number 032026, Córdoba, Argentina|Investigational Site Number 032049, Córdoba, Argentina|Investigational Site Number 032005, Junin, Argentina|Investigational Site Number 032001, La Plata, Argentina|Investigational Site Number 032040, La Plata, Argentina|Investigational Site Number 032033, Mar Del Plata, Argentina|Investigational Site Number 032014, Mar Del Plata, Argentina|Investigational Site Number 032016, Mendoza, Argentina|Investigational Site Number 032030, Merlo, Argentina|Investigational Site Number 032036, Moron, Argentina|Investigational Site Number 032007, Olivos, Argentina|Investigational Site Number 032044, Olivos, Argentina|Investigational Site Number 032004, Quilmes, Argentina|Investigational Site Number 032025, Rafaela, Argentina|Investigational Site Number 032035, Ramos Mejia, Argentina|Investigational Site Number 032039, Resistencia, Argentina|Investigational Site Number 032028, Rosario, Argentina|Investigational Site Number 032024, Rosario, Argentina|Investigational Site Number 032053, Salta, Argentina|Investigational Site Number 032037, San Isidro, Argentina|Investigational Site Number 032052, San Martin, Argentina|Investigational Site Number 032013, San Martin, Argentina|Investigational Site Number 032002, San Miguel De Tucuman, Argentina|Investigational Site Number 032034, San Miguel De Tucuman, Argentina|Investigational Site Number 032006, San Nicolas, Argentina|Investigational Site Number 032043, Santa Fe, Argentina|Investigational Site Number 032003, Santa Fe, Argentina|Investigational Site Number 032051, Santa Rosa, Argentina|Investigational Site Number 032047, Santiago Del Estero, Argentina|Investigational Site Number 032029, Venado Tuerto, Argentina|Investigational Site Number 032022, Villa Maria, Argentina|Investigational Site Number 032015, Zarate, Argentina|Investigational Site Number 036002, Ashford, Australia|Investigational Site Number 036023, Auchenflower, Australia|Investigational Site Number 036024, Ballarat, Australia|Investigational Site Number 036020, Bedford Park, Australia|Investigational Site Number 036015, Bruce, Australia|Investigational Site Number 036026, Cairns, Australia|Investigational Site Number 036005, Chermside, Australia|Investigational Site Number 036008, Chermside, Australia|Investigational Site Number 036011, Coffs Harbour, Australia|Investigational Site Number 036003, Concord, Australia|Investigational Site Number 036017, Elizabeth Vale, Australia|Investigational Site Number 036006, Fullarton, Australia|Investigational Site Number 036004, Gosford, Australia|Investigational Site Number 036019, Heidelberg West, Australia|Investigational Site Number 036027, Hobart, Australia|Investigational Site Number 036009, Kogarah, Australia|Investigational Site Number 036012, Mildura, Australia|Investigational Site Number 036028, Nambour, Australia|Investigational Site Number 036013, New Lambton, Australia|Investigational Site Number 036010, Perth, Australia|Investigational Site Number 036014, Prahran, Australia|Investigational Site Number 036018, Redcliffe, Australia|Investigational Site Number 036022, Richmond, Australia|Investigational Site Number 036025, Woodville South, Australia|Investigational Site Number 036021, Woolloongabba, Australia|Investigational Site Number 040004, Feldkirch, Austria|Investigational Site Number 040007, Graz, Austria|Investigational Site Number 040001, Salzburg, Austria|Investigational Site Number 040006, Wien, Austria|Investigational Site Number 040003, Wien, Austria|Investigational Site Number 040002, Wien, Austria|Investigational Site Number 056016, Aalst, Belgium|Investigational Site Number 056003, Antwerpen, Belgium|Investigational Site Number 056002, Antwerpen, Belgium|Investigational Site Number 056008, Bonheiden, Belgium|Investigational Site Number 056014, Brasschaat, Belgium|Investigational Site Number 056021, Brussels, Belgium|Investigational Site Number 056005, Bruxelles, Belgium|Investigational Site Number 056004, Bruxelles, Belgium|Investigational Site Number 056017, Edegem, Belgium|Investigational Site Number 056024, Genk, Belgium|Investigational Site Number 056007, Gent, Belgium|Investigational Site Number 056018, Gent, Belgium|Investigational Site Number 056020, La Louviere, Belgium|Investigational Site Number 056009, Leuven, Belgium|Investigational Site Number 056015, Liège, Belgium|Investigational Site Number 056010, Mechelen, Belgium|Investigational Site Number 056013, Mol, Belgium|Investigational Site Number 056001, Ottignies, Belgium|Investigational Site Number 056012, Overpelt, Belgium|Investigational Site Number 056006, Roeselare, Belgium|Investigational Site Number 056019, Tienen, Belgium|Investigational Site Number 070001, Banja Luka, Bosnia and Herzegovina|Investigational Site Number 070002, Banja Luka, Bosnia and Herzegovina|Investigational Site Number 070011, Bihac, Bosnia and Herzegovina|Investigational Site Number 070003, Mostar, Bosnia and Herzegovina|Investigational Site Number 070004, Mostar, Bosnia and Herzegovina|Investigational Site Number 070005, Sarajevo, Bosnia and Herzegovina|Investigational Site Number 070007, Sarajevo, Bosnia and Herzegovina|Investigational Site Number 070010, Sarajevo, Bosnia and Herzegovina|Investigational Site Number 070008, Tuzla, Bosnia and Herzegovina|Investigational Site Number 070009, Tuzla, Bosnia and Herzegovina|Investigational Site Number 070006, Zenica, Bosnia and Herzegovina|Investigational Site Number 076029, Aparecida De Goiania, Brazil|Investigational Site Number 076032, Belem, Brazil|Investigational Site Number 076017, Belo Horizonte, Brazil|Investigational Site Number 076004, Belo Horizonte, Brazil|Investigational Site Number 076022, Belo Horizonte, Brazil|Investigational Site Number 076038, Belo Horizonte, Brazil|Investigational Site Number 076002, Blumenau, Brazil|Investigational Site Number 076011, Brasilia, Brazil|Investigational Site Number 076007, Brasilia, Brazil|Investigational Site Number 076003, Campina Grande Do Sul, Brazil|Investigational Site Number 076006, Campinas, Brazil|Investigational Site Number 076040, Canoas, Brazil|Investigational Site Number 076033, Curitiba, Brazil|Investigational Site Number 076005, Curitiba, Brazil|Investigational Site Number 076009, Fortaleza, Brazil|Investigational Site Number 076008, Fortaleza, Brazil|Investigational Site Number 076012, Goiania, Brazil|Investigational Site Number 076021, Goiania, Brazil|Investigational Site Number 076019, Passo Fundo, Brazil|Investigational Site Number 076018, Pelotas, Brazil|Investigational Site Number 076024, Porto Alegre, Brazil|Investigational Site Number 076026, Porto Alegre, Brazil|Investigational Site Number 076014, Porto Alegre, Brazil|Investigational Site Number 076001, Porto Alegre, Brazil|Investigational Site Number 076027, Porto Alegre, Brazil|Investigational Site Number 076035, Riberao Preto, Brazil|Investigational Site Number 076010, Rio De Janeiro, Brazil|Investigational Site Number 076015, Salvador, Brazil|Investigational Site Number 076041, Salvador, Brazil|Investigational Site Number 076036, Santo Andre, Brazil|Investigational Site Number 076031, Sao Bernardo Do Campo, Brazil|Investigational Site Number 076030, Sao Jose Do Rio Preto, Brazil|Investigational Site Number 076020, Sao Jose Do Rio Preto, Brazil|Investigational Site Number 076025, Sao Paulo, Brazil|Investigational Site Number 076042, Sao Paulo, Brazil|Investigational Site Number 076039, Sao Paulo, Brazil|Investigational Site Number 076013, Sao Paulo, Brazil|Investigational Site Number 076023, Sao Paulo, Brazil|Investigational Site Number 076028, Sao Paulo, Brazil|Investigational Site Number 076016, Tatuí, Brazil|Investigational Site Number 076034, Uberlandia, Brazil|Investigational Site Number 100020, Blagoevgrad, Bulgaria|Investigational Site Number 100012, Burgas, Bulgaria|Investigational Site Number 100011, Pazardzhik, Bulgaria|Investigational Site Number 100013, Pleven, Bulgaria|Investigational Site Number 100018, Pleven, Bulgaria|Investigational Site Number 100005, Plovdiv, Bulgaria|Investigational Site Number 100015, Sandanski, Bulgaria|Investigational Site Number 100023, Smoljan, Bulgaria|Investigational Site Number 100017, Sofia, Bulgaria|Investigational Site Number 100007, Sofia, Bulgaria|Investigational Site Number 100001, Sofia, Bulgaria|Investigational Site Number 100004, Sofia, Bulgaria|Investigational Site Number 100010, Sofia, Bulgaria|Investigational Site Number 100019, Sofia, Bulgaria|Investigational Site Number 100016, Sofia, Bulgaria|Investigational Site Number 100003, Sofia, Bulgaria|Investigational Site Number 100022, Varna, Bulgaria|Investigational Site Number 100014, Veliko Tarnovo, Bulgaria|Investigational Site Number 124033, Calgary, Canada|Investigational Site Number 124017, Cambridge, Canada|Investigational Site Number 124013, Cambridge, Canada|Investigational Site Number 124026, Edmonton, Canada|Investigational Site Number 124019, Edmonton, Canada|Investigational Site Number 124016, Edmonton, Canada|Investigational Site Number 124027, Granby, Canada|Investigational Site Number 124002, Halifax, Canada|Investigational Site Number 124051, Hamilton, Canada|Investigational Site Number 124043, Joliette, Canada|Investigational Site Number 124045, Kitchener, Canada|Investigational Site Number 124053, Levis, Canada|Investigational Site Number 124015, Longueuil, Canada|Investigational Site Number 124004, Moncton, Canada|Investigational Site Number 124040, Montreal, Canada|Investigational Site Number 124032, Montreal, Canada|Investigational Site Number 124036, Montreal, Canada|Investigational Site Number 124042, Montreal, Canada|Investigational Site Number 124028, New Westminster, Canada|Investigational Site Number 124008, Newmarket, Canada|Investigational Site Number 124005, Oshawa, Canada|Investigational Site Number 124007, Ottawa, Canada|Investigational Site Number 124006, Penticton, Canada|Investigational Site Number 124012, Red Deer, Canada|Investigational Site Number 124054, Saint-Jerome, Canada|Investigational Site Number 124024, Sainte-Foy, Canada|Investigational Site Number 124035, Scarborough, Canada|Investigational Site Number 124047, Sherbrooke, Canada|Investigational Site Number 124025, St-Georges, Canada|Investigational Site Number 124044, St. Catherines, Canada|Investigational Site Number 124034, St. John'S, Canada|Investigational Site Number 124021, St. John, Canada|Investigational Site Number 124009, Surrey, Canada|Investigational Site Number 124022, Sydney, Canada|Investigational Site Number 124048, Thetford Mines, Canada|Investigational Site Number 124037, Thunder Bay, Canada|Investigational Site Number 124001, Toronto, Canada|Investigational Site Number 124049, Trois-Rivieres, Canada|Investigational Site Number 124039, Vancouver, Canada|Investigational Site Number 124023, Victoria, Canada|Investigational Site Number 124041, Victoria, Canada|Investigational Site Number 124038, Winnipeg, Canada|Investigational Site Number 152013, Concepcion, Chile|Investigational Site Number 152003, Osorno, Chile|Investigational Site Number 152017, Punta Arenas, Chile|Investigational Site Number 152004, Santiago, Chile|Investigational Site Number 152014, Santiago, Chile|Investigational Site Number 152001, Santiago, Chile|Investigational Site Number 152019, Santiago, Chile|Investigational Site Number 152007, Santiago, Chile|Investigational Site Number 152012, Santiago, Chile|Investigational Site Number 152011, Santiago, Chile|Investigational Site Number 152006, Santiago, Chile|Investigational Site Number 152016, Santiago, Chile|Investigational Site Number 152015, Santiago, Chile|Investigational Site Number 152009, Talca, Chile|Investigational Site Number 152002, Temuco, Chile|Investigational Site Number 152008, Valdivia, Chile|Investigational Site Number 152010, Viña Del Mar, Chile|Investigational Site Number 152018, Viña Del Mar, Chile|Investigational Site Number 156022, Baotou, China|Investigational Site Number 156004, Beijing, China|Investigational Site Number 156005, Beijing, China|Investigational Site Number 156006, Beijing, China|Investigational Site Number 156001, Beijing, China|Investigational Site Number 156082, Beijing, China|Investigational Site Number 156009, Beijing, China|Investigational Site Number 156003, Beijing, China|Investigational Site Number 156002, Beijing, China|Investigational Site Number 156013, Changchun, China|Investigational Site Number 156064, Changchun, China|Investigational Site Number 156052, Changsha, China|Investigational Site Number 156053, Changsha, China|Investigational Site Number 156088, Changsha, China|Investigational Site Number 156057, Chongqing, China|Investigational Site Number 156070, Fuzhou, China|Investigational Site Number 156079, Fuzhou, China|Investigational Site Number 156059, Guangzhou, China|Investigational Site Number 156060, Guangzhou, China|Investigational Site Number 156071, Guangzhou, China|Investigational Site Number 156061, Guangzhou, China|Investigational Site Number 156072, Guiyang, China|Investigational Site Number 156047, Hangzhou, China|Investigational Site Number 156077, Hangzhou, China|Investigational Site Number 156048, Hangzhou, China|Investigational Site Number 156068, Hangzhou, China|Investigational Site Number 156078, Hangzhou, China|Investigational Site Number 156046, Hangzhou, China|Investigational Site Number 156020, Hohhot, China|Investigational Site Number 156032, Jinan, China|Investigational Site Number 156031, Jinan, China|Investigational Site Number 156027, Lanzhou, China|Investigational Site Number 156074, Lanzhou, China|Investigational Site Number 156081, Luzhou, China|Investigational Site Number 156054, Nanchang, China|Investigational Site Number 156055, Nanchang, China|Investigational Site Number 156034, Nanjing, China|Investigational Site Number 156035, Nanjing, China|Investigational Site Number 156039, Shanghai, China|Investigational Site Number 156076, Shanghai, China|Investigational Site Number 156044, Shanghai, China|Investigational Site Number 156043, Shanghai, China|Investigational Site Number 156038, Shanghai, China|Investigational Site Number 156040, Shanghai, China|Investigational Site Number 156016, Shenyang, China|Investigational Site Number 156017, Shenyang, China|Investigational Site Number 156073, Shenzhen, China|Investigational Site Number 156084, Shenzhen, China|Investigational Site Number 156063, Siping, China|Investigational Site Number 156037, Suzhou, China|Investigational Site Number 156066, Tianjin, China|Investigational Site Number 156067, Tianjin, China|Investigational Site Number 156083, Tianjin, China|Investigational Site Number 156025, Tianjin, China|Investigational Site Number 156065, Wenzhou, China|Investigational Site Number 156051, Wuhan, China|Investigational Site Number 156087, Wuhan, China|Investigational Site Number 156029, Xi'An, China|Investigational Site Number 156086, Xi'An, China|Investigational Site Number 156062, Xuzhou, China|Investigational Site Number 156014, Yanji, China|Investigational Site Number 156075, Yueyang, China|Investigational Site Number 156080, Zhanjiang, China|Investigational Site Number 170006, Armenia, Colombia|Investigational Site Number 170003, Barranquilla, Colombia|Investigational Site Number 170011, Barranquilla, Colombia|Investigational Site Number 170013, Barranquilla, Colombia|Investigational Site Number 170022, Bogota D.C., Colombia|Investigational Site Number 170018, Bogota, Colombia|Investigational Site Number 170016, Bogota, Colombia|Investigational Site Number 170010, Cali, Colombia|Investigational Site Number 170001, Cali, Colombia|Investigational Site Number 170017, Cartagena, Colombia|Investigational Site Number 170004, Cartagena, Colombia|Investigational Site Number 170008, Espinal - Tolima, Colombia|Investigational Site Number 170005, Floridablanca, Colombia|Investigational Site Number 170002, Manizales, Colombia|Investigational Site Number 170007, Medellin, Colombia|Investigational Site Number 170009, Medellin, Colombia|Investigational Site Number 170021, Medellin, Colombia|Investigational Site Number 191013, Dubrovnik, Croatia|Investigational Site Number 191017, Krapinske Toplice, Croatia|Investigational Site Number 191009, Opatija, Croatia|Investigational Site Number 191006, Rijeka, Croatia|Investigational Site Number 191012, Slavonski Brod, Croatia|Investigational Site Number 191003, Varazdin, Croatia|Investigational Site Number 191001, Zagreb, Croatia|Investigational Site Number 191002, Zagreb, Croatia|Investigational Site Number 191005, Zagreb, Croatia|Investigational Site Number 191007, Zagreb, Croatia|Investigational Site Number 191008, Zagreb, Croatia|Investigational Site Number 191010, Zagreb, Croatia|Investigational Site Number 191011, Zagreb, Croatia|Investigational Site Number 191015, Zagreb, Croatia|Investigational Site Number 191016, Zagreb, Croatia|Investigational Site Number 191018, Zagreb, Croatia|Investigational Site Number 203003, Brno, Czechia|Investigational Site Number 203020, Ceska Lipa, Czechia|Investigational Site Number 203025, Cesky Krumlov, Czechia|Investigational Site Number 203023, Hodonin, Czechia|Investigational Site Number 203006, Hradec Kralove, Czechia|Investigational Site Number 203019, Kladno, Czechia|Investigational Site Number 203005, Kladno, Czechia|Investigational Site Number 203008, Kromeriz, Czechia|Investigational Site Number 203015, Liberec, Czechia|Investigational Site Number 203024, Marianske Lazne, Czechia|Investigational Site Number 203013, Olomouc, Czechia|Investigational Site Number 203016, Ostrava, Czechia|Investigational Site Number 203014, Pardubice, Czechia|Investigational Site Number 203018, Plzen, Czechia|Investigational Site Number 203011, Praha 10, Czechia|Investigational Site Number 203017, Praha 2, Czechia|Investigational Site Number 203004, Praha 4, Czechia|Investigational Site Number 203021, Praha 4, Czechia|Investigational Site Number 203007, Praha 5 - Motol, Czechia|Investigational Site Number 203012, Praha 5, Czechia|Investigational Site Number 203009, Rakovnik, Czechia|Investigational Site Number 203010, Zlin, Czechia|Investigational Site Number 208016, Aabenraa, Denmark|Investigational Site Number 208012, Aalborg, Denmark|Investigational Site Number 208011, Aarhus N, Denmark|Investigational Site Number 208002, Copenhagen, Denmark|Investigational Site Number 208003, Glostrup, Denmark|Investigational Site Number 208007, Hellerup, Denmark|Investigational Site Number 208006, Herning, Denmark|Investigational Site Number 208018, Hillerød, Denmark|Investigational Site Number 208014, Holbaek, Denmark|Investigational Site Number 208013, Hvidovre, Denmark|Investigational Site Number 208004, Køge, Denmark|Investigational Site Number 208017, Næstved, Denmark|Investigational Site Number 208009, Odense C, Denmark|Investigational Site Number 208015, Silkeborg, Denmark|Investigational Site Number 208008, Slagelse, Denmark|Investigational Site Number 208001, Vejle, Denmark|Investigational Site Number 208010, Viborg, Denmark|Investigational Site Number 233007, Pärnu, Estonia|Investigational Site Number 233004, Tallinn, Estonia|Investigational Site Number 233002, Tallinn, Estonia|Investigational Site Number 233001, Tallinn, Estonia|Investigational Site Number 233005, Tallinn, Estonia|Investigational Site Number 233003, Tartu, Estonia|Investigational Site Number 233006, Viljandimaa, Estonia|Investigational Site Number 246004, Helsinki, Finland|Investigational Site Number 246001, Oulu, Finland|Investigational Site Number 246003, Tampere, Finland|Investigational Site Number 246002, Turku, Finland|Investigational Site Number 250003, Besancon, France|Investigational Site Number 250007, Brest Cedex, France|Investigational Site Number 250010, Cambrai Cedex, France|Investigational Site Number 250018, Clermont-Ferrand Cedex 1, France|Investigational Site Number 250021, Compiegne, France|Investigational Site Number 250002, Dijon, France|Investigational Site Number 250001, Grenoble, France|Investigational Site Number 250009, Limoges Cedex 1, France|Investigational Site Number 250019, Marseille, France|Investigational Site Number 250008, Massy, France|Investigational Site Number 250005, Montfermeil, France|Investigational Site Number 250023, Montpellier Cedex 5, France|Investigational Site Number 250025, Nantes, France|Investigational Site Number 250017, Nice Cedex 01, France|Investigational Site Number 250015, Paris Cedex 12, France|Investigational Site Number 250020, Paris, France|Investigational Site Number 250012, Paris, France|Investigational Site Number 250004, Paris, France|Investigational Site Number 250011, Pau, France|Investigational Site Number 250016, Pessac, France|Investigational Site Number 250026, Rouen, France|Investigational Site Number 250022, Strasbourg Cedex, France|Investigational Site Number 268004, Batumi, Georgia|Investigational Site Number 268001, Kutaisi, Georgia|Investigational Site Number 268005, Tbilisi, Georgia|Investigational Site Number 268002, Tbilisi, Georgia|Investigational Site Number 268003, Tbilisi, Georgia|Investigational Site Number 268008, Tbilisi, Georgia|Investigational Site Number 268009, Tbilisi, Georgia|Investigational Site Number 276013, Aachen, Germany|Investigational Site Number 276019, Bad Krozingen, Germany|Investigational Site Number 276008, Berlin, Germany|Investigational Site Number 276040, Berlin, Germany|Investigational Site Number 276051, Berlin, Germany|Investigational Site Number 276039, Berlin, Germany|Investigational Site Number 276025, Berlin, Germany|Investigational Site Number 276054, Bernau, Germany|Investigational Site Number 276037, Bielefeld, Germany|Investigational Site Number 276016, Bonn, Germany|Investigational Site Number 276009, Bonn, Germany|Investigational Site Number 276001, Dortmund, Germany|Investigational Site Number 276006, Dortmund, Germany|Investigational Site Number 276031, Dortmund, Germany|Investigational Site Number 276050, Dresden, Germany|Investigational Site Number 276024, Eschweiler, Germany|Investigational Site Number 276028, Essen, Germany|Investigational Site Number 276036, Frankfurt Am Main, Germany|Investigational Site Number 276012, Freiburg, Germany|Investigational Site Number 276030, Halle/Saale, Germany|Investigational Site Number 276032, Hamburg, Germany|Investigational Site Number 276017, Hamburg, Germany|Investigational Site Number 276027, Hamburg, Germany|Investigational Site Number 276029, Hamm, Germany|Investigational Site Number 276052, Haßloch, Germany|Investigational Site Number 276014, Heidelberg, Germany|Investigational Site Number 276023, Homburg/Saar, Germany|Investigational Site Number 276035, Kassel, Germany|Investigational Site Number 276046, Leipzig, Germany|Investigational Site Number 276020, Limburg, Germany|Investigational Site Number 276026, Lippstadt, Germany|Investigational Site Number 276044, Lübeck, Germany|Investigational Site Number 276021, Magdeburg, Germany|Investigational Site Number 276015, Mainz, Germany|Investigational Site Number 276010, Marburg, Germany|Investigational Site Number 276018, Münster, Germany|Investigational Site Number 276042, Nürnberg, Germany|Investigational Site Number 276048, Peine, Germany|Investigational Site Number 276053, Rotenburg An Der Fulda, Germany|Investigational Site Number 276045, Rüdersdorf Bei Berlin, Germany|Investigational Site Number 276002, Stuttgart, Germany|Investigational Site Number 276033, Warendorf, Germany|Investigational Site Number 300001, Athens, Greece|Investigational Site Number 300002, Athens, Greece|Investigational Site Number 300007, Athens, Greece|Investigational Site Number 300008, Chios, Greece|Investigational Site Number 300013, Haidari, Greece|Investigational Site Number 300010, Heraklion, Greece|Investigational Site Number 300005, Ioannina, Greece|Investigational Site Number 300003, Marousi, Greece|Investigational Site Number 300006, N. Ionia, Greece|Investigational Site Number 300004, Patra, Greece|Investigational Site Number 300011, Thessaloniki, Greece|Investigational Site Number 300009, Thessaloniki, Greece|Investigational Site Number 320003, Guatemala, Guatemala|Investigational Site Number 320001, Guatemala, Guatemala|Investigational Site Number 320002, Guatemala, Guatemala|Investigational Site Number 320004, Guatemala, Guatemala|Investigational Site Number 344003, Hong Kong, Hong Kong|Investigational Site Number 344001, Shatin, Nt, Hong Kong|Investigational Site Number 348013, Balatonfüred, Hungary|Investigational Site Number 348002, Budapest, Hungary|Investigational Site Number 348012, Budapest, Hungary|Investigational Site Number 348005, Budapest, Hungary|Investigational Site Number 348006, Budapest, Hungary|Investigational Site Number 348008, Debrecen, Hungary|Investigational Site Number 348004, Eger, Hungary|Investigational Site Number 348003, Gyula, Hungary|Investigational Site Number 348010, Pécs, Hungary|Investigational Site Number 348009, Szeged, Hungary|Investigational Site Number 348007, Szekesfehervar, Hungary|Investigational Site Number 348011, Szombathely, Hungary|Investigational Site Number 348001, Zalaegerszeg, Hungary|Investigational Site Number 356060, Ahmedabad, India|Investigational Site Number 356056, Aurangabad, India|Investigational Site Number 356025, Bangalore, India|Investigational Site Number 356028, Bangalore, India|Investigational Site Number 356083, Bangalore, India|Investigational Site Number 356018, Bangalore, India|Investigational Site Number 356026, Bangalore, India|Investigational Site Number 356084, Bangalore, India|Investigational Site Number 356103, Belgaum, India|Investigational Site Number 356019, Bikaner, India|Investigational Site Number 356013, Chennai, India|Investigational Site Number 356012, Chennai, India|Investigational Site Number 356081, Chennai, India|Investigational Site Number 356093, Delhi, India|Investigational Site Number 356038, Delhi, India|Investigational Site Number 356101, Gurgaon, India|Investigational Site Number 356100, Gurgaon, India|Investigational Site Number 356035, Hyderabad, India|Investigational Site Number 356082, Hyderabad, India|Investigational Site Number 356015, Jaipur, India|Investigational Site Number 356053, Karad, India|Investigational Site Number 356102, Karamsad, India|Investigational Site Number 356022, Kochi, India|Investigational Site Number 356106, Kolhapur, India|Investigational Site Number 356067, Kolkata, India|Investigational Site Number 356079, Kolkata, India|Investigational Site Number 356069, Kolkata, India|Investigational Site Number 356089, Ludhiana, India|Investigational Site Number 356095, Mangalore, India|Investigational Site Number 356071, Mumbai, India|Investigational Site Number 356057, Mumbai, India|Investigational Site Number 356007, Mysore, India|Investigational Site Number 356087, Nagpur, India|Investigational Site Number 356098, Nagpur, India|Investigational Site Number 356097, Nagpur, India|Investigational Site Number 356096, Nashik, India|Investigational Site Number 356055, New Delhi, India|Investigational Site Number 356031, New Delhi, India|Investigational Site Number 356041, Panaji, India|Investigational Site Number 356077, Pune, India|Investigational Site Number 356099, Pune, India|Investigational Site Number 356048, Pune, India|Investigational Site Number 356049, Pune, India|Investigational Site Number 356050, Pune, India|Investigational Site Number 356045, Pune, India|Investigational Site Number 356046, Pune, India|Investigational Site Number 356094, Pune, India|Investigational Site Number 356042, Secunderabad, Hyderabad, India|Investigational Site Number 356009, Secunderabad, India|Investigational Site Number 356032, Secunderabad, India|Investigational Site Number 356091, Surat, India|Investigational Site Number 356002, Vijayawada, India|Investigational Site Number 356105, Vijaywada, India|Investigational Site Number 356033, Visakhapatnam, India|Investigational Site Number 356039, Vishkhapattanam, India|Investigational Site Number 356104, Wardha, India|Investigational Site Number 376006, Afula, Israel|Investigational Site Number 376024, Afula, Israel|Investigational Site Number 376009, Ashkelon, Israel|Investigational Site Number 376012, Beer Sheva, Israel|Investigational Site Number 376011, Haifa, Israel|Investigational Site Number 376017, Haifa, Israel|Investigational Site Number 376025, Haifa, Israel|Investigational Site Number 376018, Haifa, Israel|Investigational Site Number 376007, Holon, Israel|Investigational Site Number 376021, Holon, Israel|Investigational Site Number 376016, Jerusalem, Israel|Investigational Site Number 376005, Jerusalem, Israel|Investigational Site Number 376027, Jerusalem, Israel|Investigational Site Number 376002, Kfar Saba, Israel|Investigational Site Number 376013, Kfar Saba, Israel|Investigational Site Number 376004, Nahariya, Israel|Investigational Site Number 376015, Nazareth, Israel|Investigational Site Number 376001, Petah-Tikva, Israel|Investigational Site Number 376019, Petah-Tikva, Israel|Investigational Site Number 376020, Rehovot, Israel|Investigational Site Number 376003, Safed, Israel|Investigational Site Number 376008, Safed, Israel|Investigational Site Number 376010, Tel Aviv, Israel|Investigational Site Number 376014, Tel Aviv, Israel|Investigational Site Number 376022, Tel Hashomer, Israel|Investigational Site Number 376023, Tiberias, Israel|Investigational Site Number 376026, Tzrifin, Israel|Investigational Site Number 380019, Augusta, Italy|Investigational Site Number 380017, Bergamo, Italy|Investigational Site Number 380026, Brescia, Italy|Investigational Site Number 380008, Brescia, Italy|Investigational Site Number 380012, Ferrara, Italy|Investigational Site Number 380027, Forlì, Italy|Investigational Site Number 380015, Livorno, Italy|Investigational Site Number 380033, Massa, Italy|Investigational Site Number 380030, Milano, Italy|Investigational Site Number 380005, Milano, Italy|Investigational Site Number 380003, Milano, Italy|Investigational Site Number 380025, Monza, Italy|Investigational Site Number 380001, Napoli, Italy|Investigational Site Number 380002, Napoli, Italy|Investigational Site Number 380021, Novara, Italy|Investigational Site Number 380009, Osio Sotto, Italy|Investigational Site Number 380007, Palermo, Italy|Investigational Site Number 380013, Perugia, Italy|Investigational Site Number 380031, Rho, Italy|Investigational Site Number 380014, Rimini, Italy|Investigational Site Number 380024, Roma, Italy|Investigational Site Number 380028, Seriate, Italy|Investigational Site Number 380032, Treviso, Italy|Investigational Site Number 380020, Vittorio Veneto, Italy|Investigational Site Number 392013, Amagasaki-Shi, Japan|Investigational Site Number 392041, Amagasaki-Shi, Japan|Investigational Site Number 392029, Fukuoka-Shi, Japan|Investigational Site Number 392019, Hachioji-Shi, Japan|Investigational Site Number 392026, Higashihiroshima-Shi, Japan|Investigational Site Number 392024, Higashiibaraki-Gun, Japan|Investigational Site Number 392003, Hiroshima-Shi, Japan|Investigational Site Number 392002, Itabashi-Ku, Japan|Investigational Site Number 392014, Itabashi-Ku, Japan|Investigational Site Number 392033, Izumisano-Shi, Japan|Investigational Site Number 392020, Kanazawa-Shi, Japan|Investigational Site Number 392015, Kitakyushu-Shi, Japan|Investigational Site Number 392017, Kobe-Shi, Japan|Investigational Site Number 392028, Kobe-Shi, Japan|Investigational Site Number 392037, Kobe-Shi, Japan|Investigational Site Number 392025, Koga-Shi, Japan|Investigational Site Number 392010, Komatsu-Shi, Japan|Investigational Site Number 392035, Komatsushima-Shi, Japan|Investigational Site Number 392023, Kumamoto-Shi, Japan|Investigational Site Number 392031, Kumamoto-Shi, Japan|Investigational Site Number 392039, Kure-Shi, Japan|Investigational Site Number 392012, Kurume-Shi, Japan|Investigational Site Number 392032, Kusatsu-Shi, Japan|Investigational Site Number 392001, Kyoto City, Japan|Investigational Site Number 392027, Minato-Ku, Japan|Investigational Site Number 392016, Morioka-Shi, Japan|Investigational Site Number 392005, Nagoya-Shi, Japan|Investigational Site Number 392022, Nerima-Ku, Japan|Investigational Site Number 392009, Osaka-Shi, Japan|Investigational Site Number 392011, Osaka-Shi, Japan|Investigational Site Number 392040, Osaka-Shi, Japan|Investigational Site Number 392004, Sagamihara-Shi, Japan|Investigational Site Number 392036, Sapporo-Shi, Japan|Investigational Site Number 392034, Shinagawa-Ku, Japan|Investigational Site Number 392018, Suita-Shi, Japan|Investigational Site Number 392030, Tokushima-Shi, Japan|Investigational Site Number 392008, Urasoe-Shi, Japan|Investigational Site Number 392006, Yokohama-Shi, Japan|Investigational Site Number 392021, Yokohama-Shi, Japan|Investigational Site Number 410013, Busan, Korea, Republic of|Investigational Site Number 410003, Busan, Korea, Republic of|Investigational Site Number 410002, Daegu, Korea, Republic of|Investigational Site Number 410012, Goyang-Si, Korea, Republic of|Investigational Site Number 410001, Gwangju, Korea, Republic of|Investigational Site Number 410008, Seongnam, Korea, Republic of|Investigational Site Number 410004, Seoul, Korea, Republic of|Investigational Site Number 410007, Seoul, Korea, Republic of|Investigational Site Number 410010, Seoul, Korea, Republic of|Investigational Site Number 410011, Seoul, Korea, Republic of|Investigational Site Number 410006, Seoul, Korea, Republic of|Investigational Site Number 410009, Suwon, Korea, Republic of|Investigational Site Number 410005, Wonju, Korea, Republic of|Investigational Site Number 428004, Daugavpils, Latvia|Investigational Site Number 428002, Liepaja, Latvia|Investigational Site Number 428006, Riga, Latvia|Investigational Site Number 428001, Riga, Latvia|Investigational Site Number 428005, Riga, Latvia|Investigational Site Number 428003, Ventspils, Latvia|Investigational Site Number 440004, Kaunas, Lithuania|Investigational Site Number 440005, Kaunas, Lithuania|Investigational Site Number 440009, Kaunas, Lithuania|Investigational Site Number 440008, Kaunas, Lithuania|Investigational Site Number 440001, Klaipeda, Lithuania|Investigational Site Number 440006, Klaipeda, Lithuania|Investigational Site Number 440002, Vilnius, Lithuania|Investigational Site Number 440007, Vilnius, Lithuania|Investigational Site Number 440003, Vilnius, Lithuania|Investigational Site Number 807005, Bitola, Macedonia, The Former Yugoslav Republic of|Investigational Site Number 807004, Shtip, Macedonia, The Former Yugoslav Republic of|Investigational Site Number 807002, Skopje, Macedonia, The Former Yugoslav Republic of|Investigational Site Number 807001, Skopje, Macedonia, The Former Yugoslav Republic of|Investigational Site Number 807003, Tetovo, Macedonia, The Former Yugoslav Republic of|Investigational Site Number 458004, Batu Caves, Malaysia|Investigational Site Number 458007, Kota Bharu, Malaysia|Investigational Site Number 458006, Kota Kinabalu, Malaysia|Investigational Site Number 458002, Kuala Lumpur, Malaysia|Investigational Site Number 458005, Kuala Lumpur, Malaysia|Investigational Site Number 458003, Kuching, Malaysia|Investigational Site Number 458001, Sungai Buloh, Malaysia|Investigational Site Number 484005, Aguascalientes, Mexico|Investigational Site Number 484015, Aguascalientes, Mexico|Investigational Site Number 484004, Culiacan, Mexico|Investigational Site Number 484003, Durango, Mexico|Investigational Site Number 484010, Guadalajara, Mexico|Investigational Site Number 484006, Guadalajara, Mexico|Investigational Site Number 484008, Jalapa, Mexico|Investigational Site Number 484019, Mexico D.F., Mexico|Investigational Site Number 484023, Mexico Df, Mexico|Investigational Site Number 484027, Mexico, Mexico|Investigational Site Number 484013, Monterrey, Mexico|Investigational Site Number 484018, Monterrey, Mexico|Investigational Site Number 484011, Monterrey, Mexico|Investigational Site Number 484007, Monterrey, Mexico|Investigational Site Number 484017, Morelia, Mexico|Investigational Site Number 484012, Oaxaca, Mexico|Investigational Site Number 484014, Querétaro, Mexico|Investigational Site Number 484009, San Luis Potosi, Mexico|Investigational Site Number 484002, Tijuana, Mexico|Investigational Site Number 484020, Toluca, Mexico|Investigational Site Number 528006, Alkmaar, Netherlands|Investigational Site Number 528022, Amsterdam, Netherlands|Investigational Site Number 528026, Amsterdam, Netherlands|Investigational Site Number 528021, Apeldoorn, Netherlands|Investigational Site Number 528029, Arnhem, Netherlands|Investigational Site Number 528004, Breda, Netherlands|Investigational Site Number 528002, Delft, Netherlands|Investigational Site Number 528007, Eindhoven, Netherlands|Investigational Site Number 528032, Goes, Netherlands|Investigational Site Number 528012, Gouda, Netherlands|Investigational Site Number 528001, Groningen, Netherlands|Investigational Site Number 528025, Haarlem, Netherlands|Investigational Site Number 528023, Hardenberg, Netherlands|Investigational Site Number 528024, Heerenveen, Netherlands|Investigational Site Number 528016, Hoorn, Netherlands|Investigational Site Number 528019, Leeuwarden, Netherlands|Investigational Site Number 528008, Leiden, Netherlands|Investigational Site Number 528017, Meppel, Netherlands|Investigational Site Number 528030, Nieuwegein, Netherlands|Investigational Site Number 528011, Nijmegen, Netherlands|Investigational Site Number 528015, Purmerend, Netherlands|Investigational Site Number 528018, Roosendaal, Netherlands|Investigational Site Number 528014, Rotterdam, Netherlands|Investigational Site Number 528027, Rotterdam, Netherlands|Investigational Site Number 528005, Sneek, Netherlands|Investigational Site Number 528034, Tiel, Netherlands|Investigational Site Number 528013, Tilburg, Netherlands|Investigational Site Number 528028, Uden, Netherlands|Investigational Site Number 528009, Venlo, Netherlands|Investigational Site Number 528033, Zaandam, Netherlands|Investigational Site Number 528031, Zutphen, Netherlands|Investigational Site Number 528020, Zwolle, Netherlands|Investigational Site Number 554010, Auckland, New Zealand|Investigational Site Number 554001, Christchurch, New Zealand|Investigational Site Number 554006, Dunedin, New Zealand|Investigational Site Number 554004, Hamilton, New Zealand|Investigational Site Number 554011, Lower Hutt, New Zealand|Investigational Site Number 554005, Nelson, New Zealand|Investigational Site Number 554007, New Plymouth, New Zealand|Investigational Site Number 554002, Otahuhu, New Zealand|Investigational Site Number 554008, Palmerston North, New Zealand|Investigational Site Number 554012, Rotorua, New Zealand|Investigational Site Number 554009, Takapuna, New Zealand|Investigational Site Number 554003, Wellington, New Zealand|Investigational Site Number 578004, Arendal, Norway|Investigational Site Number 578013, Bergen, Norway|Investigational Site Number 578009, Hamar, Norway|Investigational Site Number 578006, Kongsvinger, Norway|Investigational Site Number 578003, Oslo, Norway|Investigational Site Number 578005, Oslo, Norway|Investigational Site Number 578012, Stavanger, Norway|Investigational Site Number 578002, Svelvik, Norway|Investigational Site Number 578011, Tynset, Norway|Investigational Site Number 604018, Arequipa, Peru|Investigational Site Number 604004, Callao, Peru|Investigational Site Number 604025, Callao, Peru|Investigational Site Number 604022, Cuzco, Peru|Investigational Site Number 604013, Ica, Peru|Investigational Site Number 604010, Lima, Peru|Investigational Site Number 604008, Lima, Peru|Investigational Site Number 604001, Lima, Peru|Investigational Site Number 604007, Lima, Peru|Investigational Site Number 604005, Lima, Peru|Investigational Site Number 604006, Lima, Peru|Investigational Site Number 604015, Lima, Peru|Investigational Site Number 604016, Lima, Peru|Investigational Site Number 604017, Lima, Peru|Investigational Site Number 604019, Lima, Peru|Investigational Site Number 604003, Lima, Peru|Investigational Site Number 604024, Lima, Peru|Investigational Site Number 604012, Lima, Peru|Investigational Site Number 604020, Piura, Peru|Investigational Site Number 604023, Trujillo, Peru|Investigational Site Number 608012, Cavite, Philippines|Investigational Site Number 608003, Cebu City, Philippines|Investigational Site Number 608013, Cebu City, Philippines|Investigational Site Number 608011, Davao City, Philippines|Investigational Site Number 608010, Davao, Philippines|Investigational Site Number 608006, Iloilo City, Philippines|Investigational Site Number 608002, Makati City, Philippines|Investigational Site Number 608004, Manila, Philippines|Investigational Site Number 608014, Manila, Philippines|Investigational Site Number 608001, Quezon City, Philippines|Investigational Site Number 608009, Quezon City, Philippines|Investigational Site Number 608005, Quezon, Philippines|Investigational Site Number 608008, San Juan, Philippines|Investigational Site Number 616026, Bydgoszcz, Poland|Investigational Site Number 616029, Bydgoszcz, Poland|Investigational Site Number 616010, Chrzanow, Poland|Investigational Site Number 616036, Czeladz, Poland|Investigational Site Number 616034, Gdansk, Poland|Investigational Site Number 616015, Gdansk, Poland|Investigational Site Number 616035, Gdynia, Poland|Investigational Site Number 616005, Gdynia, Poland|Investigational Site Number 616033, Gdynia, Poland|Investigational Site Number 616037, Grodzisk Mazowiecki, Poland|Investigational Site Number 616030, Jelenia Gora, Poland|Investigational Site Number 616031, Krakow, Poland|Investigational Site Number 616002, Krakow, Poland|Investigational Site Number 616012, Leczna, Poland|Investigational Site Number 616017, Legnica, Poland|Investigational Site Number 616019, Lodz, Poland|Investigational Site Number 616016, Lubin, Poland|Investigational Site Number 616021, Olawa, Poland|Investigational Site Number 616039, Olsztyn, Poland|Investigational Site Number 616003, Plock, Poland|Investigational Site Number 616011, Poznan, Poland|Investigational Site Number 616018, Pulawy, Poland|Investigational Site Number 616006, Skierniewice, Poland|Investigational Site Number 616027, Sobotka, Poland|Investigational Site Number 616007, Sokolka, Poland|Investigational Site Number 616022, Swidnik, Poland|Investigational Site Number 616024, Szczecin, Poland|Investigational Site Number 616004, Torun, Poland|Investigational Site Number 616013, Torun, Poland|Investigational Site Number 616025, Torun, Poland|Investigational Site Number 616032, W?Grów, Poland|Investigational Site Number 616040, Warszawa, Poland|Investigational Site Number 616020, Warszawa, Poland|Investigational Site Number 616038, Warszawa, Poland|Investigational Site Number 616008, Warszawa, Poland|Investigational Site Number 616041, Wroclaw, Poland|Investigational Site Number 620004, Almada, Portugal|Investigational Site Number 620005, Aveiro, Portugal|Investigational Site Number 620011, Coimbra, Portugal|Investigational Site Number 620008, Coimbra, Portugal|Investigational Site Number 620001, Leiria, Portugal|Investigational Site Number 620003, Ponta Delgada, Portugal|Investigational Site Number 620002, Setubal, Portugal|Investigational Site Number 620010, Vila Franca De Xira, Portugal|Investigational Site Number 620006, Vila Nova Gaia, Portugal|Investigational Site Number 642001, Braila, Romania|Investigational Site Number 642003, Bucharest, Romania|Investigational Site Number 642012, Bucuresti, Romania|Investigational Site Number 642021, Bucuresti, Romania|Investigational Site Number 642007, Bucuresti, Romania|Investigational Site Number 642008, Bucuresti, Romania|Investigational Site Number 642005, Buzau, Romania|Investigational Site Number 642013, Codlea, Romania|Investigational Site Number 642004, Constanta, Romania|Investigational Site Number 642002, Craiova, Romania|Investigational Site Number 642016, Craiova, Romania|Investigational Site Number 642010, Focsani, Romania|Investigational Site Number 642017, Iasi, Romania|Investigational Site Number 642006, Targoviste, Romania|Investigational Site Number 642019, Targu Mures, Romania|Investigational Site Number 642015, Targu Mures, Romania|Investigational Site Number 642018, Timisoara, Romania|Investigational Site Number 643027, Barnaul, Russian Federation|Investigational Site Number 643037, Kazan, Russian Federation|Investigational Site Number 643013, Kemerovo, Russian Federation|Investigational Site Number 643020, Krasnodar, Russian Federation|Investigational Site Number 643053, Krasnodar, Russian Federation|Investigational Site Number 643033, Moscow, Russian Federation|Investigational Site Number 643002, Moscow, Russian Federation|Investigational Site Number 643011, Moscow, Russian Federation|Investigational Site Number 643029, Moscow, Russian Federation|Investigational Site Number 643028, Moscow, Russian Federation|Investigational Site Number 643004, Moscow, Russian Federation|Investigational Site Number 643016, Moscow, Russian Federation|Investigational Site Number 643023, Moscow, Russian Federation|Investigational Site Number 643044, Moscow, Russian Federation|Investigational Site Number 643022, Moscow, Russian Federation|Investigational Site Number 643031, Moscow, Russian Federation|Investigational Site Number 643043, Nizhny Novgorod, Russian Federation|Investigational Site Number 643034, Novosibirsk, Russian Federation|Investigational Site Number 643052, Novosibirsk, Russian Federation|Investigational Site Number 643050, Novosibirsk, Russian Federation|Investigational Site Number 643035, Omsk, Russian Federation|Investigational Site Number 643039, Perm, Russian Federation|Investigational Site Number 643008, Rostov-Na-Donu, Russian Federation|Investigational Site Number 643017, Ryazan, Russian Federation|Investigational Site Number 643006, Saint - Petersburg, Russian Federation|Investigational Site Number 643015, Saint - Petersburg, Russian Federation|Investigational Site Number 643001, Saint Petersburg, Russian Federation|Investigational Site Number 643007, Saint Petersburg, Russian Federation|Investigational Site Number 643051, Saint-Petersburg, Russian Federation|Investigational Site Number 643042, Saint-Petersburg, Russian Federation|Investigational Site Number 643040, Saint-Petersburg, Russian Federation|Investigational Site Number 643012, Saratov, Russian Federation|Investigational Site Number 643021, Saratov, Russian Federation|Investigational Site Number 643003, Saratov, Russian Federation|Investigational Site Number 643014, Saratov, Russian Federation|Investigational Site Number 643030, St-Petersburg, Russian Federation|Investigational Site Number 643010, St-Petersburg, Russian Federation|Investigational Site Number 643054, St-Petersburg, Russian Federation|Investigational Site Number 643049, Tomsk, Russian Federation|Investigational Site Number 643019, Tyumen, Russian Federation|Investigational Site Number 643025, Tyumen, Russian Federation|Investigational Site Number 643045, Voronezh, Russian Federation|Investigational Site Number 643009, Yaroslavl, Russian Federation|Investigational Site Number 688003, Belgrade, Serbia|Investigational Site Number 688005, Belgrade, Serbia|Investigational Site Number 688006, Belgrade, Serbia|Investigational Site Number 688007, Belgrade, Serbia|Investigational Site Number 688008, Belgrade, Serbia|Investigational Site Number 688010, Belgrade, Serbia|Investigational Site Number 688011, Belgrade, Serbia|Investigational Site Number 688013, Belgrade, Serbia|Investigational Site Number 688015, Belgrade, Serbia|Investigational Site Number 688002, Belgrade, Serbia|Investigational Site Number 688012, Kragujevac, Serbia|Investigational Site Number 688016, Leskovac, Serbia|Investigational Site Number 688001, Niska Banja, Serbia|Investigational Site Number 688004, Nis, Serbia|Investigational Site Number 688018, Pancevo, Serbia|Investigational Site Number 688009, Sremska Kamenica, Serbia|Investigational Site Number 688017, Sremska Mitrovica, Serbia|Investigational Site Number 688014, Valjevo, Serbia|Investigational Site Number 702002, Singapore, Singapore|Investigational Site Number 702003, Singapore, Singapore|Investigational Site Number 702001, Singapore, Singapore|Investigational Site Number 703001, Bardejov, Slovakia|Investigational Site Number 703008, Bratislava, Slovakia|Investigational Site Number 703020, Bratislava, Slovakia|Investigational Site Number 703014, Bratislava, Slovakia|Investigational Site Number 703013, Bratislava, Slovakia|Investigational Site Number 703023, Dolny Kubin, Slovakia|Investigational Site Number 703002, Kosice, Slovakia|Investigational Site Number 703009, Kosice, Slovakia|Investigational Site Number 703016, Kosice, Slovakia|Investigational Site Number 703019, Kosice, Slovakia|Investigational Site Number 703007, Kosice, Slovakia|Investigational Site Number 703012, Kralovsky Chlmec, Slovakia|Investigational Site Number 703006, Lucenec, Slovakia|Investigational Site Number 703010, Lucenec, Slovakia|Investigational Site Number 703003, Nitra, Slovakia|Investigational Site Number 703004, Presov, Slovakia|Investigational Site Number 703018, Svidnik, Slovakia|Investigational Site Number 703022, Trebisov, Slovakia|Investigational Site Number 703005, Zilina, Slovakia|Investigational Site Number 705001, Celje, Slovenia|Investigational Site Number 705004, Izola, Slovenia|Investigational Site Number 705002, Jesenice, Slovenia|Investigational Site Number 705005, Ljubljana, Slovenia|Investigational Site Number 705006, Ljubljana, Slovenia|Investigational Site Number 710017, Alberton, South Africa|Investigational Site Number 710007, Bellville, South Africa|Investigational Site Number 710015, Bloemfontein, South Africa|Investigational Site Number 710009, Cape Town, South Africa|Investigational Site Number 710010, Cape Town, South Africa|Investigational Site Number 710005, Chatsworth, South Africa|Investigational Site Number 710006, Durban, South Africa|Investigational Site Number 710004, Durban, South Africa|Investigational Site Number 710002, Durban, South Africa|Investigational Site Number 710012, Johannesburg, South Africa|Investigational Site Number 710014, Johannesburg, South Africa|Investigational Site Number 710019, Kempton Park, South Africa|Investigational Site Number 710011, Kimberley, South Africa|Investigational Site Number 710021, Kuils River, South Africa|Investigational Site Number 710018, Parow, South Africa|Investigational Site Number 710008, Pretoria, South Africa|Investigational Site Number 710016, Pretoria, South Africa|Investigational Site Number 710020, Stellenbosch, South Africa|Investigational Site Number 710013, Tongaat, South Africa|Investigational Site Number 710022, Western Cape, South Africa|Investigational Site Number 710003, Worcester, South Africa|Investigational Site Number 724010, Alcalá De Henares, Spain|Investigational Site Number 724007, Almería, Spain|Investigational Site Number 724037, Barcelona, Spain|Investigational Site Number 724041, Barcelona, Spain|Investigational Site Number 724038, Barcelona, Spain|Investigational Site Number 724008, Barcelona, Spain|Investigational Site Number 724039, Cáceres, Spain|Investigational Site Number 724042, Córdoba, Spain|Investigational Site Number 724027, Fuenlabrada, Spain|Investigational Site Number 724002, Girona, Spain|Investigational Site Number 724013, Granada, Spain|Investigational Site Number 724032, Guadalajara, Spain|Investigational Site Number 724025, Hospitalet De Llobregat, Spain|Investigational Site Number 724003, Huelva, Spain|Investigational Site Number 724021, León, Spain|Investigational Site Number 724026, Lleida, Spain|Investigational Site Number 724006, Lugo, Spain|Investigational Site Number 724030, Madrid, Spain|Investigational Site Number 724020, Madrid, Spain|Investigational Site Number 724015, Madrid, Spain|Investigational Site Number 724031, Madrid, Spain|Investigational Site Number 724033, Madrid, Spain|Investigational Site Number 724017, Madrid, Spain|Investigational Site Number 724035, Majadahonda, Spain|Investigational Site Number 724036, Murcia, Spain|Investigational Site Number 724016, Málaga, Spain|Investigational Site Number 724043, Málaga, Spain|Investigational Site Number 724001, Oviedo, Spain|Investigational Site Number 724022, Sabadell, Spain|Investigational Site Number 724029, San Sebastian De Los Reyes, Spain|Investigational Site Number 724028, Santander, Spain|Investigational Site Number 724034, Santiago De Compostela, Spain|Investigational Site Number 724014, Sevilla, Spain|Investigational Site Number 724024, Tarragona, Spain|Investigational Site Number 724019, Valencia, Spain|Investigational Site Number 724009, Valencia, Spain|Investigational Site Number 724011, Valencia, Spain|Investigational Site Number 724023, Valladolid, Spain|Investigational Site Number 724005, Vigo, Spain|Investigational Site Number 724040, Zaragoza, Spain|Investigational Site Number 144002, Colombo 7, Sri Lanka|Investigational Site Number 144004, Colombo 8, Sri Lanka|Investigational Site Number 144003, Colombo, Sri Lanka|Investigational Site Number 144010, Colombo, Sri Lanka|Investigational Site Number 144005, Colombo, Sri Lanka|Investigational Site Number 144006, Colombo, Sri Lanka|Investigational Site Number 144001, Colombo, Sri Lanka|Investigational Site Number 144008, Kandy, Sri Lanka|Investigational Site Number 144009, Kurunegala, Sri Lanka|Investigational Site Number 144007, Ragama, Sri Lanka|Investigational Site Number 752001, Falun, Sweden|Investigational Site Number 752016, Göteborg, Sweden|Investigational Site Number 752011, Halmstad, Sweden|Investigational Site Number 752006, Karlshamn, Sweden|Investigational Site Number 752008, Karlskrona, Sweden|Investigational Site Number 752004, Kristianstad, Sweden|Investigational Site Number 752013, Köping, Sweden|Investigational Site Number 752015, Malmö, Sweden|Investigational Site Number 752012, Mölndal, Sweden|Investigational Site Number 752009, Stockholm, Sweden|Investigational Site Number 752002, Stockholm, Sweden|Investigational Site Number 752014, Sundsvall, Sweden|Investigational Site Number 752007, Uppsala, Sweden|Investigational Site Number 756005, Basel, Switzerland|Investigational Site Number 756003, Geneve, Switzerland|Investigational Site Number 756004, Lugano, Switzerland|Investigational Site Number 756002, Zürich, Switzerland|Investigational Site Number 158003, Changhua, Taiwan|Investigational Site Number 158008, Division Of Cardiology, Taiwan|Investigational Site Number 158014, Hsinchu, Taiwan|Investigational Site Number 158013, Kaohsiung, Taiwan|Investigational Site Number 158004, Taichung, Taiwan|Investigational Site Number 158009, Tainan, Taiwan|Investigational Site Number 158011, Tainan, Taiwan|Investigational Site Number 158005, Taipei, Taiwan|Investigational Site Number 158001, Taipei, Taiwan|Investigational Site Number 158010, Taipei, Taiwan|Investigational Site Number 158007, Taipei, Taiwan|Investigational Site Number 158012, Taoyuan Hsien, Taiwan|Investigational Site Number 158002, Yunlin, Taiwan|Investigational Site Number 764009, Bangkok-Noi, Thailand|Investigational Site Number 764001, Bangkok, Thailand|Investigational Site Number 764011, Bangkok, Thailand|Investigational Site Number 764007, Bangkok, Thailand|Investigational Site Number 764012, Bangkok, Thailand|Investigational Site Number 764005, Hat Yai, Thailand|Investigational Site Number 764008, Klong Luang, Thailand|Investigational Site Number 764002, Moung, Thailand|Investigational Site Number 764003, Muang, Thailand|Investigational Site Number 764010, Nonthaburi, Thailand|Investigational Site Number 764006, Pratumwan, Thailand|Investigational Site Number 792007, Adana, Turkey|Investigational Site Number 792009, Ankara, Turkey|Investigational Site Number 792006, Bursa, Turkey|Investigational Site Number 792016, Eskisehir, Turkey|Investigational Site Number 792014, Istanbul, Turkey|Investigational Site Number 792005, Istanbul, Turkey|Investigational Site Number 792011, Istanbul, Turkey|Investigational Site Number 792013, Istanbul, Turkey|Investigational Site Number 792004, Izmir, Turkey|Investigational Site Number 792003, Izmir, Turkey|Investigational Site Number 792015, Kocaeli, Turkey|Investigational Site Number 792010, Mersin, Turkey|Investigational Site Number 804015, Chernivtsi, Ukraine|Investigational Site Number 804018, Dnipropetrovsk, Ukraine|Investigational Site Number 804027, Donetsk, Ukraine|Investigational Site Number 804012, Donetsk, Ukraine|Investigational Site Number 804010, Ivano-Frankivsk, Ukraine|Investigational Site Number 804006, Kharkiv, Ukraine|Investigational Site Number 804003, Kharkiv, Ukraine|Investigational Site Number 804009, Kharkiv, Ukraine|Investigational Site Number 804020, Khmelnytskyi, Ukraine|Investigational Site Number 804001, Kiev, Ukraine|Investigational Site Number 804002, Kiev, Ukraine|Investigational Site Number 804011, Kyiv, Ukraine|Investigational Site Number 804014, Kyiv, Ukraine|Investigational Site Number 804025, Kyiv, Ukraine|Investigational Site Number 804034, Kyiv, Ukraine|Investigational Site Number 804036, Kyiv, Ukraine|Investigational Site Number 804016, Kyiv, Ukraine|Investigational Site Number 804030, Kyiv, Ukraine|Investigational Site Number 804028, Lutsk, Ukraine|Investigational Site Number 804033, Lviv, Ukraine|Investigational Site Number 804031, Lviv, Ukraine|Investigational Site Number 804029, Mykolaiv, Ukraine|Investigational Site Number 804013, Odesa, Ukraine|Investigational Site Number 804004, Odessa, Ukraine|Investigational Site Number 804017, Simferopol, Ukraine|Investigational Site Number 804035, Sumy, Ukraine|Investigational Site Number 804007, Uzhgorod, Ukraine|Investigational Site Number 804005, Vinnitsya, Ukraine|Investigational Site Number 804008, Vinnytsia, Ukraine|Investigational Site Number 804026, Zaporizhia, Ukraine|Investigational Site Number 804024, Zhytomyr, Ukraine|Investigational Site Number 804032, Zhytomyr, Ukraine|Investigational Site Number 826018, Basildon, United Kingdom|Investigational Site Number 826015, Birmingham, United Kingdom|Investigational Site Number 826030, Birmingham, United Kingdom|Investigational Site Number 826038, Bournemouth, United Kingdom|Investigational Site Number 826025, Bradford, United Kingdom|Investigational Site Number 826027, Burton On Trent, United Kingdom|Investigational Site Number 826017, Cardiff, United Kingdom|Investigational Site Number 826010, Chertsey, United Kingdom|Investigational Site Number 826012, Chesterfield, United Kingdom|Investigational Site Number 826039, Chichester, United Kingdom|Investigational Site Number 826024, Cumbria, United Kingdom|Investigational Site Number 826041, Dudley, United Kingdom|Investigational Site Number 826021, Harrow, United Kingdom|Investigational Site Number 826026, High Wycombe, United Kingdom|Investigational Site Number 826028, Hull, United Kingdom|Investigational Site Number 826034, London, United Kingdom|Investigational Site Number 826004, Manchester, United Kingdom|Investigational Site Number 826011, Newcastle Upon Tyne, United Kingdom|Investigational Site Number 826036, Northampton, United Kingdom|Investigational Site Number 826019, Peterborough, United Kingdom|Investigational Site Number 826020, Plymouth, United Kingdom|Investigational Site Number 826040, Portadown, United Kingdom|Investigational Site Number 826016, Portsmouth, United Kingdom|Investigational Site Number 826014, Redhill, United Kingdom|Investigational Site Number 826007, Rhyl, United Kingdom|Investigational Site Number 826001, Romford, United Kingdom|Investigational Site Number 826009, Rotherham, United Kingdom|Investigational Site Number 826002, Sheffield, United Kingdom|Investigational Site Number 826032, South Shields, United Kingdom|Investigational Site Number 826013, St Leonards, United Kingdom|Investigational Site Number 826005, Stoke-On-Trent, United Kingdom|Investigational Site Number 826031, Sunderland, United Kingdom|Investigational Site Number 826022, Truro, United Kingdom|Investigational Site Number 826035, Wigan, United Kingdom|Investigational Site Number 826003, Worcester, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/02/NCT01663402/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/02/NCT01663402/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT01663402"
277,"NCT01916226","A Comparator Study of Fluticasone Propionate Nasal Spray Verses (vs) Cetirizine in the Treatment of Seasonal Allergic Rhinitis",,"Completed","Has Results","Rhinitis, Allergic, Perennial and Seasonal","Drug: FPNS|Drug: FPNS Placebo|Drug: Cetirizine|Drug: Cetirizine Placebo","Mean Change From Baseline (CFB) in the Individual AM Reflective Total Nasal Symptom Scores (rTNSS) Over the Entire Treatment Period|Mean Change From Baseline in the Individual AM Reflective Nasal Symptom Scores for Rhinorrhea, Nasal Congestion, Nasal Itching, and Sneezing Over the Entire Treatment Period|Mean Change From Baseline in the Nocturnal Rhinoconjunctivitis Quality of Life Questionnaire (NRQLQ) Overall Score at Visit 3/Early Withdrawal.|Mean Change From Baseline in the AM Pre-dose Instantaneous Total Nasal Symptom Score (iTNSS) Over the Entire Treatment Period|Mean Change From Baseline in the AM Pre-dose Reflective Total Ocular Symptom Score (rTOSS) Over the Entire Treatment Period|Mean Change From Baseline in the AM Pre-dose Instantaneous Total Ocular Symptom Score (iTOSS) Over the Entire Treatment Period|Mean Change From Baseline in the Combined Nasal and Ocular Reflective Total Symptom Score (rTSS = rTNSS+rTOSS) Over the Entire Treatment Period","GlaxoSmithKline","All","18 Years and older   (Adult, Older Adult)","Phase 4","682","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","200165","August 1, 2013","October 1, 2013","October 17, 2013","August 5, 2013","August 27, 2014","June 20, 2018","GSK Investigational Site, Little Rock, Arkansas, United States|GSK Investigational Site, Denver, Colorado, United States|GSK Investigational Site, Aventura, Florida, United States|GSK Investigational Site, Miami, Florida, United States|GSK Investigational Site, Indianapolis, Indiana, United States|GSK Investigational Site, Lenexa, Kansas, United States|GSK Investigational Site, Overland Park, Kansas, United States|GSK Investigational Site, Owensboro, Kentucky, United States|GSK Investigational Site, Baltimore, Maryland, United States|GSK Investigational Site, Bethesda, Maryland, United States|GSK Investigational Site, North Dartmouth, Massachusetts, United States|GSK Investigational Site, Ypsilanti, Michigan, United States|GSK Investigational Site, Minneapolis, Minnesota, United States|GSK Investigational Site, Columbia, Missouri, United States|GSK Investigational Site, Rolla, Missouri, United States|GSK Investigational Site, Saint Louis, Missouri, United States|GSK Investigational Site, Bellevue, Nebraska, United States|GSK Investigational Site, Canton, Ohio, United States|GSK Investigational Site, Cincinnati, Ohio, United States|GSK Investigational Site, Oklahoma City, Oklahoma, United States|GSK Investigational Site, Pittsburgh, Pennsylvania, United States|GSK Investigational Site, Orangeburg, South Carolina, United States|GSK Investigational Site, Spartanburg, South Carolina, United States|GSK Investigational Site, Austin, Texas, United States|GSK Investigational Site, Austin, Texas, United States|GSK Investigational Site, Dallas, Texas, United States|GSK Investigational Site, Kerrville, Texas, United States|GSK Investigational Site, San Antonio, Texas, United States|GSK Investigational Site, Waco, Texas, United States|GSK Investigational Site, South Burlington, Vermont, United States|GSK Investigational Site, Greenfield, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT01916226"
278,"NCT00525278","To Evaluate the Efficacy and Safety of Levocetirizine Versus Loratadine for Treatment of Seasonal Allergic Rhinitis",,"Completed","No Results Available","Rhinitis|Allergic|Seasonal","Drug: Levocetirizine dihydrochloride","Investigator rated T5SS (Total 5 symptom Score) over 2 weeks|Investigator's global efficacy evaluation at 2 weeks; the patient's mean T5SS and 5 individual symptoms (over the last 24 hours) over the first week and over the 2 weeks of treatment; the Symptoms Score Reducing Index (SSRI).","UCB Pharma","All","18 Years to 60 Years   (Adult)","Phase 3","67","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single|Primary Purpose: Treatment","A00348","August 2003","October 2003","October 2003","September 5, 2007",,"December 16, 2013",,,"https://ClinicalTrials.gov/show/NCT00525278"
279,"NCT00867191","Comparison of the Effects of Desloratadine and Placebo in the Relief of Nasal Symptom Scores in Subjects With Seasonal Allergic Rhinitis to Cypress Pollen (Study P02836)",,"Completed","No Results Available","Seasonal Allergic Rhinitis","Drug: Placebo|Drug: Desloratadine","The primary objective was to demonstrate the efficacy (as percentage of change from baseline) of desloratadine to improve the nasal total symptom score of SAR to cypress pollen.","Merck Sharp & Dohme Corp.","All","18 Years and older   (Adult, Older Adult)","Phase 4","233","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","P02836","February 1, 2002","April 1, 2003","April 1, 2003","March 23, 2009",,"March 23, 2017",,,"https://ClinicalTrials.gov/show/NCT00867191"
280,"NCT01084252","Phase 1/2 Dose Escalation and Efficacy Study of Anti-CD38 Monoclonal Antibody in Patients With Selected CD38+ Hematological Malignancies",,"Active, not recruiting","No Results Available","Hematological Malignancy","Drug: Isatuximab SAR650984|Drug: Dexamethasone","Dose Limiting Toxicities (DLTs)|Overall Response Rate|Safety as assessed from adverse events reporting, laboratory tests, vital signs according to the National Cancer Institute - Common Toxicity Criteria (NCI-CTC) version 4.0 grade scaling|Main PK parameters : Partial area under the serum concentration time curve (AUC), maximum observed concentration (Cmax), Time to reach Cmax (tmax)|Main PD Biomarker : CD38 receptor occupancy and receptor density|Immune response : levels of human anti-human antibodies|Duration of Response|Patient reported outcomes|Overall Survival|Clinical Benefit Rate|Progression Free Survival","Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","341","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TED10893|U1111-1116-5472","May 11, 2010","December 21, 2018","December 2020","March 10, 2010",,"December 10, 2019","Investigational Site Number 840003, Scottsdale, Arizona, United States|Investigational Site Number 840005, San Francisco, California, United States|Investigational Site Number 840009, Atlanta, Georgia, United States|Investigational Site Number 840010, Chicago, Illinois, United States|Investigational Site Number 840022, Ann Arbor, Michigan, United States|Investigational Site Number 840027, Detroit, Michigan, United States|Investigational Site Number 840018, Rochester, Minnesota, United States|Investigational Site Number 840013, Saint Louis, Missouri, United States|Investigational Site Number 840011, Hackensack, New Jersey, United States|Investigational Site Number 840014, New York, New York, United States|Investigational Site Number 840016, Durham, North Carolina, United States|Investigational Site Number 840004, Cincinnati, Ohio, United States|Investigational Site Number 840001, Nashville, Tennessee, United States|Investigational Site Number 840002, Salt Lake City, Utah, United States|Investigational Site Number 840012, Seattle, Washington, United States|Investigational Site Number 840017, Milwaukee, Wisconsin, United States|Investigational Site Number 032002, Caba, Argentina|Investigational Site Number 032003, Capital Federal, Argentina|Investigational Site Number 032001, Ciudad De Buenos Aires, Argentina|Investigational Site Number 056001, Antwerpen, Belgium|Investigational Site Number 076001, Barretos, Brazil|Investigational Site Number 076003, Porto Alegre, Brazil|Investigational Site Number 076004, Rio De Janeiro, Brazil|Investigational Site Number 076002, Sao Paulo, Brazil|Investigational Site Number 152001, Temuco, Chile|Investigational Site Number 246001, Helsinki, Finland|Investigational Site Number 246002, Turku, Finland|Investigational Site Number 250003, Nantes Cedex 01, France|Investigational Site Number 250004, Pierre Benite, France|Investigational Site Number 250001, Toulouse Cedex 9, France|Investigational Site Number 300001, Athens, Greece|Investigational Site Number 376004, Jerusalem, Israel|Investigational Site Number 376002, Tel Hashomer, Israel|Investigational Site Number 380001, Bologna, Italy|Investigational Site Number 380002, Torino, Italy|Investigational Site Number 484001, Monterrey, Mexico|Investigational Site Number 484003, San Luis Potosi, Mexico|Investigational Site Number 604001, Arequipa, Peru|Investigational Site Number 604002, Lima, Peru|Investigational Site Number 643002, Moscow, Russian Federation|Investigational Site Number 643003, Novosibirsk, Russian Federation|Investigational Site Number 643001, Petrozavodsk, Russian Federation|Investigational Site Number 643004, Saint-Petersburg, Russian Federation|Investigational Site Number 724007, Badalona, Spain|Investigational Site Number 724005, Barcelona, Spain|Investigational Site Number 724004, Madrid, Spain|Investigational Site Number 724002, Pamplona, Spain|Investigational Site Number 724001, Salamanca, Spain|Investigational Site Number 724008, Sevilla, Spain|Investigational Site Number 724006, Valencia, Spain|Investigational Site Number 792002, Ankara, Turkey|Investigational Site Number 792005, Ankara, Turkey|Investigational Site Number 792001, İstanbul, Turkey|Investigational Site Number 792004, Samsun, Turkey|Investigational Site Number 804001, Kyiv, Ukraine|Investigational Site Number 804004, Vinnitsya, Ukraine|Investigational Site Number 804002, Zaporizhzhya, Ukraine|Investigational Site Number 826001, Nottingham, United Kingdom|Investigational Site Number 826002, Southampton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01084252"
281,"NCT02513186","Study of Isatuximab Combined With Bortezomib + Cyclophosphamide + Dexamethasone (VCD) and Bortezomib + Lenalidomide + Dexamethasone (VRD) in Newly Diagnosed Multiple Myeloma (MM) Non Eligible for Transplant or No Intent for Immediate Transplantation",,"Recruiting","No Results Available","Plasma Cell Myeloma","Drug: lenalidomide|Drug: bortezomib|Drug: cyclophosphamide|Drug: dexamethasone|Drug: isatuximab SAR650984","Assessment of dose-limiting toxicities (DLTs) in VCDI cohort|Overall response rate (VCDI)|Complete response rate (VCDI)|Complete response rate (VRDI)|Number of patients with adverse events (AEs), clinically significant changes in laboratory tests and vital signs according to the National Cancer Institute - Common Toxicity Criteria (NCI-CTC) version 4.03 grade scaling|Overall response rate (VRDI)|Infusion duration|Assessment of PK parameter: Partial area under the serum concentration time curve (AUC)|Assessment of PK parameter: Maximum observed concentration (Cmax)|Levels of human antidrug antibodies (ADA)|Duration of response - time|Progression-free survival for VCDI|Progression-free survival for VRDI|MRD negativity rate","Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 1","88","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TCD13983|2014-001251-23|U1111-1154-6102","September 30, 2015","December 2022","December 2022","July 31, 2015",,"December 13, 2019","Investigational Site Number 250002, Nantes Cedex 01, France|Investigational Site Number 250003, Pierre Benite, France|Investigational Site Number 250001, Toulouse Cedex 9, France|Investigational Site Number 276003, Berlin, Germany|Investigational Site Number 276002, Leipzig, Germany|Investigational Site Number 380003, Milano, Italy|Investigational Site Number 380002, Roma, Italy|Investigational Site Number 380001, Torino, Italy|Investigational Site Number 724003, Madrid, Spain|Investigational Site Number 724001, Pamplona, Spain|Investigational Site Number 724002, Salamanca, Spain|Investigational Site Number 724004, Santander, Spain",,"https://ClinicalTrials.gov/show/NCT02513186"
282,"NCT00673062","Study of the Effect of SCH 900538 on Congestion in Subjects With Seasonal Allergic Rhinitis (Study P05031)(COMPLETED)",,"Completed","No Results Available","Seasonal Allergic Rhinitis","Drug: SCH 900538|Drug: Pseudoephedrine|Drug: Placebo Capsules","Average change from baseline in nasal congestion scores over the first 4-hour observation period.|Average change from baseline in nasal congestion at each evaluation time point.|Average change from baseline in total symptoms, total symptoms minus congestion, total nasal symptoms, total nasal symptoms minus congestion, total non-nasal symptoms, and individual symptoms scores.|Onset of action: defined as the first time point at which a sustained, statistically significant (P<=0.05) reduction relative to placebo in an efficacy variable (eg, nasal congestion) up to a pre-specified time point.|Average change from baseline in PNIF over the first 4-hour and 12-hour study periods and at each time point.","Merck Sharp & Dohme Corp.","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","265","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","P05031","May 2008","July 2008","July 2008","May 7, 2008",,"November 2, 2015",,,"https://ClinicalTrials.gov/show/NCT00673062"
283,"NCT01692366","Phase 2 Study in Japanese Patients With Intermediate-2 or High Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis With Splenomegaly",,"Completed","No Results Available","Myelofibrosis","Drug: SAR302503","Response Rate (RR), defined as the proportion of subjects who have a ≥35% reduction as measured by MRI (or CT scan in subjects with contraindications for MRI). - Time Frame:|Number of patients with Serious Adverse events using NCI CTCAE v4.03, clinical parameters and vital signs|Measurements of SAR302503 pharmacokinetic endpoints including Cmax, Tmax, and AUC0-24|Symptom Response Rate (SRR): Proportion of subjects with a ≥50% reduction in the total symptom score using the modified MFSAF|Duration of maintenance of ≥35% reduction in spleen volume|Percent change from baseline in spleen volume measured by MRI|Percent change from baseline in spleen size measured by palpation|Proportion of patients with any grade reduction in reticulin fibrosis","Sanofi","All","20 Years and older   (Adult, Older Adult)","Phase 2","8","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ARD12888|U1111-1130-3710","November 2012","March 2014","March 2014","September 25, 2012",,"September 22, 2014","Investigational Site Number 392010, Akita-Shi, Japan|Investigational Site Number 392002, Bunkyo-Ku, Japan|Investigational Site Number 392006, Bunkyo-Ku, Japan|Investigational Site Number 392004, Sendai-Shi, Japan|Investigational Site Number 392008, Shinjuku-Ku, Japan|Investigational Site Number 392009, Shinjuku-Ku, Japan|Investigational Site Number 392003, Suita-Shi, Japan",,"https://ClinicalTrials.gov/show/NCT01692366"
284,"NCT00612118","A Phase II Study Evaluating Intranasal GSK256066 and Azelastine Hydrochloride in Subjects With Seasonal Allergic Rhinitis",,"Completed","No Results Available","Allergic Rhinitis|Rhinitis, Allergic, Seasonal","Drug: GSK256066|Drug: azelastine hydrochloride","Investigate effect of repeat intranasal doses of azelastine hydrochloride alone vs. GSK256066 + azelastine hydrochloride on nasal symptoms of allergic rhinitis provoked by spending 4h in the Vienna Challenge Chamber after morning dosing on Day 8.|Weighted mean eye symptom score (watery eyes, itchy eyes, red eyes)|Weighted mean global symptom score (sneeze, itch, rhinorrhoea, obstruction, cough, itchy throat, itchy ears, watery eyes, itchy eyes and red eyes)|Weighted mean nasal airflow (measured using active anterior rhinomanometry) and secretion weight (measured by weighing tissues)|Weighted mean components of TNSS (sneeze, itch, rhinorrhoea and obstruction)|FEV1, ECGs, Vital signs, AEs, and laboratory safety parameters.","GlaxoSmithKline","All","18 Years to 50 Years   (Adult)","Phase 2","70","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IPR110982","February 2008","May 2008","May 2008","February 11, 2008",,"June 5, 2012","GSK Investigational Site, Vienna, Austria",,"https://ClinicalTrials.gov/show/NCT00612118"
285,"NCT01485900","Repeated Dosing Study to Assess Safety and Tolerability in CKD-3 Patients on Stable ACE-I Treatment",,"Completed","No Results Available","Chronic Kidney Disease","Drug: SAR407899A","Number of patients reporting Adverse Events (AEs)|Clinical safety laboratory measurement including hematology and biochemistry|urine and blood renal function markers|ECG, vital signs measurements (Heart rate and systolic and diastolic blood pressure)|AcSDKP (tetrapeptide of the composition N-Acetyl-Ser-Asp-Lys-Pro)|AUC|Cmax|t1/2z|24-hr ambulatory blood pressure","Sanofi","All","18 Years to 79 Years   (Adult, Older Adult)","Phase 1","20","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","TDR12446|2011-003793-83|U1111-1123-5699","November 2011","August 2012","August 2012","December 6, 2011",,"August 23, 2012","Investigational Site Number 498002, Chisinau, Moldova, Republic of|Investigational Site Number 642001, Bucuresti, Romania",,"https://ClinicalTrials.gov/show/NCT01485900"
286,"NCT00430157","Trial With Allergic Rhinitis Patients Taking GSK256066 Versus Placebo In A Pollen Challenge Chamber",,"Completed","No Results Available","Rhinitis, Allergic, Seasonal|Seasonal Allergic Rhinitis","Drug: GSK256066","Weighted mean total nasal symptom score (TNSS) (sneeze, itch, rhinorrhoea and obstruction)","GlaxoSmithKline","All","18 Years to 50 Years   (Adult)","Phase 2","45","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double|Primary Purpose: Treatment","IPR107498","January 2007",,,"February 1, 2007",,"June 4, 2012","GSK Investigational Site, Vienna, Austria",,"https://ClinicalTrials.gov/show/NCT00430157"
287,"NCT02318303","To Study GSP 301 in Patients With Seasonal Allergic Rhinitis",,"Completed","Has Results","Seasonal Allergic Rhinitis","Drug: GSP 301-1 NS (QD)|Drug: GSP 301-2 NS (BID)|Drug: GSP 301 Placebo NS|Drug: Olopatadine HCl-1 NS (QD)|Drug: Olopatadine HCl-2 NS (BID)|Drug: Mometasone Furoate-1 NS (QD)|Drug: Mometasone Furoate-2 NS (BID)","Change in rTNSS From Baseline to End of Treatment","Glenmark Pharmaceuticals Ltd. India","All","12 Years and older   (Child, Adult, Older Adult)","Phase 2","1111","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","GPL/CT/2014/004/II|IND Number: 123164|Study Number (GSP 301-201)","December 2014","February 2015","February 2015","December 17, 2014","June 28, 2017","June 28, 2017","Glenmark Investigational Site 10, Austin, Texas, United States|Glenmark Investigational Site 5, Austin, Texas, United States|Glenmark Investigational Site 6, Austin, Texas, United States|Glenmark Investigational Site 2, Kerrville, Texas, United States|Glenmark Investigational Site 7, New Braunfels, Texas, United States|Glenmark Investigational Site 3, San Antonio, Texas, United States|Glenmark Investigational Site 4, San Antonio, Texas, United States|Glenmark Investigational Site 8, San Antonio, Texas, United States|Glenmark Investigational Site 9, San Antonio, Texas, United States|Glenmark Investigational Site 1, Waco, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02318303"
288,"NCT01876784","Evaluation of Efficacy, Safety of Vandetanib in Patients With Differentiated Thyroid Cancer","VERIFY","Unknown status","Has Results","Differentiated Thyroid Cancer","Drug: Vandetanib (SAR390530)|Drug: Placebo","Progression-Free Survival (PFS)|Determination of the Efficacy of Vandetanib When Compared to Placebo in the Patient Population as Assessed by Efficacy Variables Including Duration of Response.|Demonstration of an Improvement in Time to Worsening of Pain in Patients Treated With Vandetanib When Compared to Placebo in the Patient Population.|Evaluation of the Safety and Tolerability of Vandetanib Treatment in the Patient Population by Assessment of Adverse Events, Vital Signs, Laboratory Parameters and Electrocardiography.|Determination of the Efficacy of Vandetanib When Compared to Placebo in the Patient Population as Assessed by Efficacy Variables Including Objective Response Rate.|Determination of the Efficacy of Vandetanib When Compared to Placebo in the Patient Population as Assessed by Efficacy Variables Including Change in Tumour Size|Determination of the Efficacy of Vandetanib When Compared to Placebo in the Patient Population as Assessed by Efficacy Variables Including Overall Survival|Evaluation of the Pharmacokinetics of Vandetanib in the Patient Population by Assessment of V/F.|Evaluation of the Pharmacokinetics of Vandetanib in the Patient Population by Assessment of Cmax|Evaluation of the Pharmacokinetics of Vandetanib in the Patient Population by Assessment of AUCss|Evaluation of the Pharmacokinetics of Vandetanib in the Patient Population by Assessment of CL/F","Genzyme, a Sanofi Company|Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 3","243","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","D4203C00011|2013-000422-58|LPS14813","September 17, 2013","August 30, 2015","December 31, 2019","June 13, 2013","March 13, 2017","December 11, 2017","Research Site, Little Rock, Arkansas, United States|Research Site, Torrance, California, United States|Research Site, Lexington, Kentucky, United States|Research Site, Boston, Massachusetts, United States|Research Site, Ann Arbor, Michigan, United States|Washington University, Saint Louis, Missouri, United States|Research Site, Omaha, Nebraska, United States|Research Site, New York, New York, United States|Research Site, Portland, Oregon, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Porto Alegre, Brazil|Research Site, Ribeirão Preto, Brazil|Research Site, Rio de Janeiro, Brazil|Research Site, São José do Rio Preto, Brazil|Research Site, São Paulo, Brazil|Research Site, Beijing, China|Research Site, Changchun, China|Research Site, Chengdu, China|Research Site, Huangzhou, China|Research Site, Shanghai, China|Research Site, Tianjin, China|Research Site, Wuhan, China|Research Site, Olomouc, Czechia|Research Site, Praha, Czechia|Research Site, Odense, Denmark|Research Site, Angers Cedex 01, France|Research Site, Bordeaux Cedex, France|Research Site, Caen Cedex 5, France|Research Site, Paris Cedex 13, France|Research Site, Villejuif Cedex, France|Research Site, Catania, Italy|Research Site, Milano, Italy|Research Site, Napoli, Italy|Research Site, Pisa, Italy|Research Site, Roma, Italy|Research Site, Siena, Italy|Research Site, Bunkyo-ku, Japan|Research Site, Fukuoka-shi, Japan|Research Site, Fukushima-shi, Japan|Research Site, Kashiwa-shi, Japan|Research Site, Kobe-shi, Japan|Research Site, Koto-ku, Japan|Research Site, Matsumoto-shi, Japan|Research Site, Nagasaki-shi, Japan|Research Site, Nagoya-shi, Japan|Research Site, Niigata-shi, Japan|Research Site, Osaka-shi, Japan|Research Site, Shinjuku-ku, Japan|Research Site, Yokohama-shi, Japan|Research Site, Gliwice, Poland|Research Site, Kielce, Poland|Research Site, Warszawa, Poland|Research Site, Zgierz, Poland|Research Site, Barnaul, Russian Federation|Research Site, Obninsk, Russian Federation|Research Site, Barcelona, Spain|Research Site, Gerona, Spain|Research Site, Hospitalet de Llobregat(Barcel, Spain|Research Site, Madrid, Spain|Research Site, Lund, Sweden|Research Site, Stockholm, Sweden",,"https://ClinicalTrials.gov/show/NCT01876784"
289,"NCT00377728","Trial With Rhinitic Patients Taking GSK256066 Versus Placebo In A Pollen Challenge Chamber",,"Completed","No Results Available","Rhinitis, Allergic, Seasonal|Seasonal Allergic Rhinitis","Drug: GSK256066","Weighted mean total nasal symptom score (TNSS) (sneeze, itch, rhinorrhoea and obstruction) 0-6h post-dose period spent in the Vienna Challenge Chamber on Day 8 or 14|Weighted mean nasal, eye and global symptom score and weighted mean nasal airflow resistance and secretion weight over 0-6 hours and 22-26h post dose on Day 8 (period 2 only) or Day 14 (period 1 only). FEV1, ECGs, AEs, and lab safety parameters","GlaxoSmithKline","All","18 Years to 50 Years   (Adult)","Phase 2","44","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double|Primary Purpose: Treatment","IPR101987","March 2006","May 2006","May 2006","September 18, 2006",,"April 15, 2015","GSK Investigational Site, Vienna, Austria",,"https://ClinicalTrials.gov/show/NCT00377728"
290,"NCT00641979","New Nasal Applicator / New Formulation - User Study",,"Completed","No Results Available","Seasonal Allergic Rhinitis","Drug: budesonide|Device: Budesonide|Drug: Placebo","Assessment of Total Nasal Symptom scores (Rhinorrhea, Congestion, Itching & Sneezing)|Durability of device|Safety assessment via adverse events and clinical measurements","AstraZeneca","All","6 Years and older   (Child, Adult, Older Adult)","Phase 2","200","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","SD-005-0698|D5360C00698","April 2002","August 2002","August 2002","March 24, 2008",,"January 24, 2011",,,"https://ClinicalTrials.gov/show/NCT00641979"
291,"NCT01312961","Efficacy, Safety, and Tolerability of Dupilumab in Patients With Persistent Moderate to Severe Eosinophilic Asthma",,"Completed","Has Results","Asthma","Drug: Dupilumab|Drug: Placebo (for Dupilumab)|Drug: Fluticasone/Salmeterol combination therapy|Drug: Fluticasone monotherapy|Drug: Albuterol|Drug: Levalbuterol","Percentage of Participants With Asthma Exacerbation|Time to First Asthma Exacerbation: Kaplan-Meier Estimates at Week 4, Week 8 and Week 12|Percentage of Participants With Composite Asthma Events|Change From Baseline in Forced Expiratory Flow in One Second (FEV1) to Week 12|Change From Baseline in Peak Expiratory Flow (PEF) to Week 12|Change From Baseline in Asthma Control Questionnaire (5-question Version [ACQ-5]) to Week 12|Change From Baseline in 22-item Sinonasal Outcome Test (SNOT-22) Score to Week 12|Change From Baseline in Morning Asthma Symptom Scores to Week 12|Change From Baseline in Evening Asthma Symptom Scores to Week 12|Change From Baseline in Number of Nocturnal Awakenings Per Day to Week 12|Change From Baseline in Number of Inhalations Per Day of Albuterol or Levalbuterol to Week 12","Sanofi|Regeneron Pharmaceuticals","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","104","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","ACT11457|U1111-1117-7826","March 2011","October 2012","October 2012","March 11, 2011","June 8, 2017","June 8, 2017","Investigational Site Number 840047, Anaheim, California, United States|Investigational Site Number 840046, Long Beach, California, United States|Investigational Site Number 840032, Los Angeles, California, United States|Investigational Site Number 840036, Los Angeles, California, United States|Investigational Site Number 840005, Mission Viejo, California, United States|Investigational Site Number 840007, Orange, California, United States|Investigational Site Number 840048, Riverside, California, United States|Investigational Site Number 840035, Rolling Hills Estates, California, United States|Investigational Site Number 840041, San Francisco, California, United States|Investigational Site Number 840042, San Francisco, California, United States|Investigational Site Number 840039, San Jose, California, United States|Investigational Site Number 840024, Santa Rosa, California, United States|Investigational Site Number 840002, Stockton, California, United States|Investigational Site Number 840031, Colorado Springs, Colorado, United States|Investigational Site Number 840011, Denver, Colorado, United States|Investigational Site Number 840017, Denver, Colorado, United States|Investigational Site Number 840026, New Haven, Connecticut, United States|Investigational Site Number 840044, Tallahassee, Florida, United States|Investigational Site Number 840029, Tampa, Florida, United States|Investigational Site Number 840028, Indianapolis, Indiana, United States|Investigational Site Number 840038, Iowa City, Iowa, United States|Investigational Site Number 840021, Overland Park, Kansas, United States|Investigational Site Number 840053, Owensboro, Kentucky, United States|Investigational Site Number 840014, Baltimore, Maryland, United States|Investigational Site Number 840015, North Dartmouth, Massachusetts, United States|Investigational Site Number 840003, Minneapolis, Minnesota, United States|Investigational Site Number 840010, Minneapolis, Minnesota, United States|Investigational Site Number 840006, Saint Louis, Missouri, United States|Investigational Site Number 840013, Saint Louis, Missouri, United States|Investigational Site Number 840022, Bozeman, Montana, United States|Investigational Site Number 840025, Omaha, Nebraska, United States|Investigational Site Number 840008, Papillion, Nebraska, United States|Investigational Site Number 840018, Princeton, New Jersey, United States|Investigational Site Number 840004, Winston-Salem, North Carolina, United States|Investigational Site Number 840023, Sylvania, Ohio, United States|Investigational Site Number 840045, Oklahoma City, Oklahoma, United States|Investigational Site Number 840001, Lake Oswego, Oregon, United States|Investigational Site Number 840012, Medford, Oregon, United States|Investigational Site Number 840016, Portland, Oregon, United States|Investigational Site Number 840040, Hershey, Pennsylvania, United States|Investigational Site Number 840037, Pittsburgh, Pennsylvania, United States|Investigational Site Number 840009, Upland, Pennsylvania, United States|Investigational Site Number 840027, Charleston, South Carolina, United States|Investigational Site Number 840030, El Paso, Texas, United States|Investigational Site Number 840050, San Antonio, Texas, United States|Investigational Site Number 840052, South Burlington, Vermont, United States|Investigational Site Number 840049, Richmond, Virginia, United States|Investigational Site Number 840020, Seattle, Washington, United States|Investigational Site Number 840019, Tacoma, Washington, United States|Investigational Site Number 840034, Madison, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT01312961"
292,"NCT00305487","Safety and Efficacy of Ciclesonide in Pediatric Patients (6 to 11 Years of Age) With Seasonal Allergic Rhinitis (BY9010/M1-417)",,"Completed","No Results Available","Hay Fever|Seasonal Allergic Rhinitis","Drug: Ciclesonide nasal spray","Average of morning and evening parent/caregiver reported reflective total nasal symptoms score over the two weeks of treatment|Physician assessment of nasal symptoms score at endpoint|average of morning and evening parent/caregiver reported instantaneous total nasal symptom score over the two weeks of treatment|safety","AstraZeneca","All","6 Years to 11 Years   (Child)","Phase 3","660","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","BY9010/M1-417","March 2006","October 2006","October 2006","March 22, 2006",,"November 30, 2016","Altana Pharma/Nycomed, Birmingham, Alabama, United States|Altana Pharma/Nycomed, Hot Springs, Arkansas, United States|Altana Pharma/Nycomed, Costa Mesa, California, United States|Altana Pharma/Nycomed, Huntington Beach, California, United States|Altana Pharma/Nycomed, Long Beach, California, United States|Altana Pharma/Nycomed, Los Alamitos, California, United States|Altana Pharma/Nycomed, Mission Viejo, California, United States|Altana Pharma/Nycomed, Orange, California, United States|Altana Pharma/Nycomed, Roseville, California, United States|Altana Pharma/Nycomed, San Diego, California, United States|Altana Pharma/Nycomed, San Diego, California, United States|Altana Pharma/Nycomed, San Jose, California, United States|Altana Pharma/Nycomed, Stockton, California, United States|Altana Pharma/Nycomed, Colorado Springs, Colorado, United States|Altana Pharma/Nycomed, Denver, Colorado, United States|Altana Pharma/Nycomed, Englewood, Colorado, United States|Altana Pharma/Nycomed, Lakewood, CO, Colorado, United States|Altana Pharma/Nycomed, Atlanta, Georgia, United States|Altana Pharma/Nycomed, Gainesville, Georgia, United States|Altana Pharma/Nycomed, Savannah, Georgia, United States|Altana Pharma/Nycomed, Woodstock, GA, Georgia, United States|Altana Pharma/Nycomed, Normal, Illinois, United States|Altana Pharma/Nycomed, Indianapolis, Indiana, United States|Altana Pharma/Nycomed, Overland Park, Kansas, United States|Altana Pharma/Nycomed, Louisville, KY, Kentucky, United States|Altana Pharma/Nycomed, Metairie, Louisiana, United States|Altana Pharma/Nycomed, Shreveport, Louisiana, United States|Altana Pharma/Nycomed, Bethesda, Maryland, United States|Altana Pharma/Nycomed, North Dartmouth, Massachusetts, United States|Altana Pharma/Nycomed, Minneapolis, Minnesota, United States|Altana Pharma/Nycomed, Jefferson City, Missouri, United States|Altana Pharma/Nycomed, Rolla, Missouri, United States|Altana Pharma/Nycomed, St. Louis, Missouri, United States|Altana Pharma/Nycomed, Lincoln, NE, Nebraska, United States|Altana Pharma/Nycomed, Papillion, Nebraska, United States|Altana Pharma/Nycomed, Brick, New Jersey, United States|Altana Pharma/Nycomed, Forked River, New Jersey, United States|Altana Pharma/Nycomed, Red Bank, New Jersey, United States|Altana Pharma/Nycomed, Skillman, New Jersey, United States|Altana Pharma/Nycomed, Warren, New Jersey, United States|Altana Pharma/Nycomed, Rochester, NY, New York, United States|Altana Pharma/Nycomed, Rockville Centre, New York, United States|Altana Pharma/Nycomed, Raleigh, North Carolina, United States|Altana Pharma/Nycomed, Cincinnati, OH, Ohio, United States|Altana Pharma/Nycomed, Cincinnati, Ohio, United States|Altana Pharma/Nycomed, Ashland, Oregon, United States|Altana Pharma/Nycomed, Lake Oswego, Oregon, United States|Altana Pharma/Nycomed, Medford, OR, Oregon, United States|Altana Pharma/Nycomed, Portland, Oregon, United States|Altana Pharma/Nycomed, Blue Bell, Pennsylvania, United States|Altana Pharma/Nycomed, Eerie, Pennsylvania, United States|Altana Pharma/Nycomed, Pittsburgh, Pennsylvania, United States|Altana Pharma/Nycomed, Pittsburgh, Pennsylvania, United States|Altana Pharma/Nycomed, Upland, Pennsylvania, United States|Altana Pharma/Nycomed, Charleston, SC, South Carolina, United States|Altana Pharma/Nycomed, Charleston, South Carolina, United States|Altana Pharma/Nycomed, Germantown, Tennessee, United States|Altana Pharma/Nycomed, Jackson, Tennessee, United States|Altana Pharma/Nycomed, Austin, Texas, United States|Altana Pharma/Nycomed, Austin, Texas, United States|Altana Pharma/Nycomed, Dallas, Texas, United States|Altana Pharma/Nycomed, El Paso, Texas, United States|Altana Pharma/Nycomed, Kerrville, Texas, United States|Altana Pharma/Nycomed, New Braunfels, Texas, United States|Altana Pharma/Nycomed, San Antonio, Texas, United States|Altana Pharma/Nycomed, Salt Lake City, Utah, United States|Altana Pharma/Nycomed, South Burlington, Vermont, United States|Altana Pharma/Nycomed, Burke, Virginia, United States|Altana Pharma/Nycomed, Charlottesville, Virginia, United States|Altana Pharma/Nycomed, Richmond, Virginia, United States|Altana Pharma/Nycomed, Milwaukee, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT00305487"
293,"NCT00107757","Seasonal Allergic Rhinitis In Pediatric Subjects",,"Completed","No Results Available","Rhinitis, Allergic, Perennial","Drug: GW685698X","Improvement in daily, reflective total nasal symptom scores after 2 weeks of treatment in subjects ages 6 to <12 years.|Improvement in AM, pre-dose, instantaneous total nasal symptom scores after 2 weeks of treatment, overall evaluation of response to therapy after 2 weeks of treatment for subjects ages 6 to <12 years.","GlaxoSmithKline","All","2 Years to 12 Years   (Child)","Phase 3","576","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","FFR100010","March 2005",,"November 2005","April 8, 2005",,"September 15, 2016","GSK Investigational Site, Scottsdale, Arizona, United States|GSK Investigational Site, Little Rock, Arkansas, United States|GSK Investigational Site, Costa Mesa, California, United States|GSK Investigational Site, Cudahy, California, United States|GSK Investigational Site, Huntington Beach, California, United States|GSK Investigational Site, Long Beach, California, United States|GSK Investigational Site, Long Beach, California, United States|GSK Investigational Site, Mission Viejo, California, United States|GSK Investigational Site, Orange, California, United States|GSK Investigational Site, Riverside, California, United States|GSK Investigational Site, San Diego, California, United States|GSK Investigational Site, Walnut Creek, California, United States|GSK Investigational Site, Centennial, Colorado, United States|GSK Investigational Site, Denver, Colorado, United States|GSK Investigational Site, Denver, Colorado, United States|GSK Investigational Site, Englewood, Colorado, United States|GSK Investigational Site, Fort Collins, Colorado, United States|GSK Investigational Site, Lakewood, Colorado, United States|GSK Investigational Site, Miami, Florida, United States|GSK Investigational Site, Tampa, Florida, United States|GSK Investigational Site, Gainesville, Georgia, United States|GSK Investigational Site, Lawrenceville, Georgia, United States|GSK Investigational Site, Lilburn, Georgia, United States|GSK Investigational Site, Stockbridge, Georgia, United States|GSK Investigational Site, Woodstock, Georgia, United States|GSK Investigational Site, Indianapolis, Indiana, United States|GSK Investigational Site, Topeka, Kansas, United States|GSK Investigational Site, Metairie, Louisiana, United States|GSK Investigational Site, Shreveport, Louisiana, United States|GSK Investigational Site, Baltimore, Maryland, United States|GSK Investigational Site, Bethesda, Maryland, United States|GSK Investigational Site, Brockton, Massachusetts, United States|GSK Investigational Site, North Andover, Massachusetts, United States|GSK Investigational Site, North Dartmouth, Massachusetts, United States|GSK Investigational Site, Springfield, Massachusetts, United States|GSK Investigational Site, Richland, Michigan, United States|GSK Investigational Site, Ypsilanti, Michigan, United States|GSK Investigational Site, Jackson, Mississippi, United States|GSK Investigational Site, Kansas City, Missouri, United States|GSK Investigational Site, Rolla, Missouri, United States|GSK Investigational Site, Warrensburg, Missouri, United States|GSK Investigational Site, Omaha, Nebraska, United States|GSK Investigational Site, Hackensack, New Jersey, United States|GSK Investigational Site, Ocean, New Jersey, United States|GSK Investigational Site, Ithaca, New York, United States|GSK Investigational Site, Mineola, New York, United States|GSK Investigational Site, Utica, New York, United States|GSK Investigational Site, Durham, North Carolina, United States|GSK Investigational Site, Raleigh, North Carolina, United States|GSK Investigational Site, Canton, Ohio, United States|GSK Investigational Site, Cincinnati, Ohio, United States|GSK Investigational Site, Oklahoma City, Oklahoma, United States|GSK Investigational Site, Lake Oswego, Oregon, United States|GSK Investigational Site, Altoona, Pennsylvania, United States|GSK Investigational Site, Cranberry Township, Pennsylvania, United States|GSK Investigational Site, Pittsburgh, Pennsylvania, United States|GSK Investigational Site, Charleston, South Carolina, United States|GSK Investigational Site, Knoxville, Tennessee, United States|GSK Investigational Site, Nashville, Tennessee, United States|GSK Investigational Site, Dallas, Texas, United States|GSK Investigational Site, Dallas, Texas, United States|GSK Investigational Site, El Paso, Texas, United States|GSK Investigational Site, El Paso, Texas, United States|GSK Investigational Site, Greenfield, Wisconsin, United States|GSK Investigational Site, Madison, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT00107757"
294,"NCT04246242","A Randomized Multicenter Controlled Clinical Trial of Arbidol in Patients With 2019 Novel Coronavirus (2019-nCoV)",,"Not yet recruiting","No Results Available","2019 Novel Coronavirus","Drug: Conventional treatment group|Drug: arbidol,200mg,tid|Drug: arbidol,400mg,tid","mortality|mechanical ventilation time","Xiangya Hospital of Central South University","All","Child, Adult, Older Adult","Phase 4","500","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","81770083","January 25, 2020","April 30, 2020","May 30, 2021","January 29, 2020",,"January 29, 2020",,,"https://ClinicalTrials.gov/show/NCT04246242"
295,"NCT04245631","Development of a Simple, Fast and Portable Recombinase Aided Amplification Assay for 2019-nCoV",,"Recruiting","No Results Available","New Coronavirus","Diagnostic Test: Recombinase aided amplification (RAA) assay","Detection sensitivity is greater than 95%|Detection specificity is greater than 95%|Consistent with existing universal reagent detection rates greater than 95%","Beijing Ditan Hospital","All","1 Year to 90 Years   (Child, Adult, Older Adult)",,"50","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","DTXY022","January 1, 2020","December 31, 2020","December 31, 2020","January 29, 2020",,"January 29, 2020","Department of Hepatology Division 2, Beijing Ditan Hospital, Beijing, Beijing, China",,"https://ClinicalTrials.gov/show/NCT04245631"
296,"NCT04119440","Randomized, Double-blind, Placebo-controlled, Phase Ib Study to Assess the Safety and Immunogenicity of MVA-MERS-S_DF-1",,"Not yet recruiting","No Results Available","MERS (Middle East Respiratory Syndrome)","Biological: MVA-MERS-S_DF1 - Low Dose|Biological: MVA-MERS-S_DF1 - High Dose|Other: Placebo","Frequency of adverse events associated with MVA-MERS-S_DF-1.|Frequency and severity of local injection site reactogenicity signs and symptoms|Immunogenicity","Universitätsklinikum Hamburg-Eppendorf|Coalition for Epidemic Preparedness Innovations|IDT Biologika Dessau.Rossau|German Center for Infection Research|CR2O|Clinical Trial Center North (CTC North GmbH & Co. KG)|Erasmus Medical Center","All","18 Years to 55 Years   (Adult)","Phase 1","160","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","CEPI-MVA-MERS-S-Phase1b","May 2020","December 2021","December 2021","October 8, 2019",,"October 8, 2019","CTC North, Hamburg, Germany|Erasmus Medical Centre, Rotterdam, Netherlands",,"https://ClinicalTrials.gov/show/NCT04119440"
297,"NCT03615911","Safety, Tolerability and Immunogenicity of Vaccine Candidate MVA-MERS-S",,"Completed","No Results Available","MERS (Middle East Respiratory Syndrome)","Biological: vaccine candidate MVA-MERS-S","Occurrence of solicited local and systemic reactogenicity as defined by the study protocol|Occurrence of unsolicited adverse events|Change from baseline of safety laboratory measures as assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4|Occurrence of serious adverse events|Measures of immunogenicity to the MVA-MERS-S vaccine","Marylyn Addo|Philipps University Marburg Medical Center|Ludwig-Maximilians - University of Munich|Charite University, Berlin, Germany|Bernhard Nocht Institute for Tropical Medicine|University of Cologne|Universitätsklinikum Hamburg-Eppendorf","All","18 Years to 55 Years   (Adult)","Phase 1","26","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","UKE-DZIF1-MVA-MERS-S","November 28, 2017","April 15, 2019","May 10, 2019","August 6, 2018",,"October 2, 2019","CTC North GmbH & Co. KG at the University Medical Center Hamburg-Eppendorf, Hamburg, Germany",,"https://ClinicalTrials.gov/show/NCT03615911"
298,"NCT02845843","MERS-CoV Infection tReated With A Combination of Lopinavir /Ritonavir and Interferon Beta-1b","MIRACLE","Recruiting","No Results Available","Middle East Respiratory Syndrome Coronavirus (MERS-CoV)","Drug: Combination of Lopinavir /Ritonavir and Interferon beta-1b|Drug: Placebo","90-day mortality|Organ support-free days (e.g., supplemental O2, ventilator, extracorporeal membrane oxygenation (ECMO), renal replacement and vasopressors)|RT-PCR cycle threshold value in the lower respiratory samples|Sequential organ failure assessment (SOFA) scores|Length of stay in ICU|Length of stay in hospital|Duration of mechanical ventilation|Hospital-acquired infections as assessed by the NHSN 2016 definitions|Serial chest radiograph findings|Number of Patients with Adverse drug reactions related to the treatment|Karnofsky Performance Scale|ICU mortality|Hospital mortality|28-day mortality","King Abdullah International Medical Research Center","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","194","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","KingAbdullahIMRC","July 2016","December 2020","December 2020","July 27, 2016",,"March 7, 2019","Intensive Care Unit, King Abdulaziz Medical City, National Guard Health Affairs, Riyadh, Saudi Arabia|King Abdullah International Medical Research Center, Riyadh, Saudi Arabia",,"https://ClinicalTrials.gov/show/NCT02845843"
299,"NCT02788188","Safety, Tolerability, and Pharmacokinetics of SAB-301 in Healthy Adults",,"Completed","Has Results","Middle East Respiratory Syndrome Coronavirus","Biological: SAB-301|Other: Normal (9%) Saline","Number of Participants Having Adverse Events","National Institute of Allergy and Infectious Diseases (NIAID)|Naval Medical Research Center|SAB Biotherapeutics Inc.|National Institutes of Health Clinical Center (CC)","All","18 Years to 60 Years   (Adult)","Phase 1","38","NIH|U.S. Fed|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","160119|16-I-0119","May 28, 2016","April 10, 2018","April 30, 2018","June 2, 2016","June 12, 2018","June 12, 2018","National Institutes of Health Clinical Center, Bethesda, Maryland, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/88/NCT02788188/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02788188"
300,"NCT00938613","Compare CE-Budesonide Nasal Solution & Rhinocort Aqua in an EEC Study of AR",,"Completed","No Results Available","Seasonal Allergic Rhinitis","Drug: Budesonide|Drug: Placebo","Total Nasal Symptom Score|Onset of action of active treatments as compared to placebo|Compare the tolerance as measured by subject questionnaire and adverse events of Captisol-Enabled Budesonide nasal solution, Rhinocort Aqua and Placebo|Compare the effect and of the three treatments on an EEC-Specific Quality of Life questionnaire","Ligand Pharmaceuticals","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","65","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CDX947CT001|P2DS06001","February 2007","April 2007","April 2007","July 14, 2009",,"October 4, 2012","Allied Research International - Cetero Research, Mississauga, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT00938613"
301,"NCT04170829","A Clinical Trial to Determine the Safety and Immunogenicity of Healthy Candidate MERS-CoV Vaccine (MERS002)",,"Recruiting","No Results Available","Middle East Respiratory Syndrome Coronavirus","Biological: ChAdOx1 MERS","Occurrence of solicited and unsolicited local and systemic adverse events|Measures of immunogenicity to the ChAdOx1 MERS vaccine","King Abdullah International Medical Research Center|University of Oxford","All","18 Years to 50 Years   (Adult)","Phase 1","24","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","CT18/004/R|MERS002","January 1, 2020","September 1, 2020","January 1, 2021","November 20, 2019",,"November 26, 2019","King Abdulaziz Medical City, National Guard Health Affairs, Riyadh, Saudi Arabia",,"https://ClinicalTrials.gov/show/NCT04170829"
302,"NCT04130594","Study of Safety and Immunogenicity of BVRS-GamVac",,"Recruiting","No Results Available","MERS (Middle East Respiratory Syndrome)|MERS","Biological: BVRS-GamVac|Other: placebo","Number of Participants With Adverse Events|Number of Participants With Serious Adverse Events|Number of Participants with Solicited Local and Systemic Adverse Events|Antibody levels against the MERS-CoV glycoprotein S measured by an enzyme-linked immunosorbent assay (ELISA)|Assessment of antigen-specific cell-mediated immune response|Neutralizing antibody levels","Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation","All","18 Years to 55 Years   (Adult)","Phase 1|Phase 2","162","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention","01-BVRS-GamVac-2019","November 7, 2019","December 1, 2020","December 31, 2020","October 17, 2019",,"November 8, 2019","Research Institute of Influenza, Sankt-Peterburg, Russian Federation",,"https://ClinicalTrials.gov/show/NCT04130594"
303,"NCT04128059","Study of Safety and Immunogenicity of BVRS-GamVac-Combi",,"Recruiting","No Results Available","MERS (Middle East Respiratory Syndrome)|MERS","Drug: BVRS-GamVac-Combi|Other: placebo","Number of Participants With Adverse Events|Number of Participants With Serious Adverse Events|Number of Participants with Solicited Local and Systemic Adverse Events|Antibody levels against the MERS-CoV glycoprotein S measured by an enzyme-linked immunosorbent assay (ELISA)|Assessment of antigen-specific cell-mediated immune response|Neutralizing antibody levels","Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation|Acellena Contract Drug Research and Development","All","18 Years to 55 Years   (Adult)","Phase 1|Phase 2","268","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","02-BVRS-GamVac-Combi-2019","November 6, 2019","December 1, 2020","December 31, 2020","October 16, 2019",,"November 8, 2019","ECO-Safety, Sankt-Peterburg, Russian Federation",,"https://ClinicalTrials.gov/show/NCT04128059"
304,"NCT03399578","Safety and Immunogenicity of a Candidate MERS-CoV Vaccine (MERS001)",,"Recruiting","No Results Available","MERS (Middle East Respiratory Syndrome)","Biological: ChAdOx1 MERS","Occurrence of solicited and unsolicited local and systemic adverse events|Measures of immunogenicity to the ChAdOx1 MERS vaccine","University of Oxford","All","18 Years to 50 Years   (Adult)","Phase 1","48","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","MERS001","March 14, 2018","July 2021","July 2021","January 16, 2018",,"October 21, 2019","Centre for Clinical Vaccinology and Tropical Medicine, Churchill Hospital, Oxford, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03399578"
305,"NCT01743729","A Phase 3 Study to Evaluate the Efficacy of Lifitegrast in Subjects With Dry Eye",,"Completed","Has Results","Dry Eye Disease","Drug: Lifitegrast|Drug: Placebo","Change From Baseline in Inferior Corneal Fluorescein Staining Score to Day 84|Change From Baseline in Eye Dryness Score (Visual Analogue Scale) to Day 84","Shire","All","18 Years and older   (Adult, Older Adult)","Phase 3","720","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","1118-DRY-300","December 7, 2012","October 1, 2013","October 1, 2013","December 6, 2012","February 24, 2017","December 19, 2018","OPUS-2 Investigational Site, Artesia, California, United States|OPUS-2 Investigational Site, Hemet, California, United States|OPUS-2 Investigational Site, Lancaster, California, United States|OPUS-2 Investigational Site, Mission Hills, California, United States|OPUS-2 Investigational Site, Montebello, California, United States|OPUS-2 Investigational Site, Newport Beach, California, United States|OPUS-2 Investigational Site, Petaluma, California, United States|OPUS-2 Investigational SIte, Rancho Cordova, California, United States|OPUS-2 Investigational Site, Danbury, Connecticut, United States|OPUS-2 Investigational Site, Fort Myers, Florida, United States|OPUS-2 Investigational Site, Hoffman Estates, Illinois, United States|OPUS-2 Investigational Site, Indianapolis, Indiana, United States|OPUS-2 Investigational Site, New Albany, Indiana, United States|OPUS-2 Investigational Site, Lexington, Kentucky, United States|OPUS-2 Investigational Site, Saint Paul, Minnesota, United States|OPUS-2 Investigational Site, Chesterfield, Missouri, United States|OPUS-2 Investigational Site, Des Peres, Missouri, United States|OPUS-2 Investigational Site, Independence, Missouri, United States|OPUS-2 Investigational Site, Kansas City, Missouri, United States|OPUS-2 Investigational Site, Washington, Missouri, United States|OPUS-2 Investigational Site, New York, New York, United States|OPUS-2 Investigational Site, New York, New York, United States|OPUS-2 Investigational Site, Wantagh, New York, United States|OPUS-2 Investigational Site, Cleveland, Ohio, United States|OPUS-2 Investigational Site, Philadelphia, Pennsylvania, United States|OPUS-2 Investigational Site, Houston, Texas, United States|OPUS-2 Investigational Site, Houston, Texas, United States|OPUS-2 Investigational Site, League City, Texas, United States|OPUS-2 Investigational Site, San Antonio, Texas, United States|OPUS-2 Investigational Site, San Antonio, Texas, United States|OPUS-2 Investigational Site, Norfolk, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT01743729"
306,"NCT00247520","Safety and Efficacy Study of rEV131 in Allergic Rhinitis",,"Unknown status","No Results Available","Hay Fever","Drug: topical nasal rEV131","Sum of symptom scores at 15 minutes post allergen challenge|Sum of symptom scores at 30 and 45 minutes post allergen challenge|Individual symptom scores at 15, 30 and 45 minutes post challenge|Pre and post treatment responder analysis|Change in nasal volume as assessed by acoustic rhinometry","Evolutec Group","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1|Phase 2","112","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Prevention","EV-71-004","May 2005",,"August 2005","November 2, 2005",,"November 2, 2005","Diagnostics Research Group, San Antonio, Texas, United States|Sylvana Research Associates, San Antonio, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00247520"
307,"NCT01293201","Trial of STAHIST in Seasonal Allergic Rhinitis",,"Completed","No Results Available","Seasonal Allergic Rhinitis","Drug: STAHIST|Drug: Placebo","Total Symptom Scores (TSS)|Adverse Events (AEs) Assessment","Magna Pharmaceuticals, Inc.","All","12 Years to 60 Years   (Child, Adult)","Phase 3","290","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","105781-3","March 2011","June 2011","August 2011","February 10, 2011",,"September 2, 2011","Clinical Research Atlanta, Stockbridge, Georgia, United States|The South Bend Clinic, South Bend, Indiana, United States|Family Allergy and Asthma Institute, Louisville, Kentucky, United States|Family Allergy and Asthma, Somerset, Kentucky, United States|New Horizons Clinical Research, Cincinnati, Ohio, United States|National Allergy, Asthma & Urticaria Centers of Charleston, PA, Charleston, South Carolina, United States|Pharmaceutical Research and Consulting, Inc, Dallas, Texas, United States|Central Texas Health Research, New Braunfels, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01293201"
308,"NCT03225807","Implementation of Lung Protective Ventilation in Patients With Acute Respiratory Failure","IMPROVENT","Recruiting","No Results Available","Acute Respiratory Distress Syndrome|ARDS|Respiratory Distress Syndrome, Acute|Respiratory Insufficiency|Respiratory Distress Syndrome|Shock Lung|Severe Acute Respiratory Syndrome",,"Ventilator free days to day 28|30 day mortality|90 day mortality|Hospital discharge disposition|Hospital mortality|Time to first ICU activity","Intermountain Health Care, Inc.","All","18 Years and older   (Adult, Older Adult)",,"8000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","1050159","March 2016","July 2020","December 2020","July 21, 2017",,"August 14, 2019","Colin Grissom, Murray, Utah, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/07/NCT03225807/Prot_000.pdf","https://ClinicalTrials.gov/show/NCT03225807"
309,"NCT03158883","UCDCC#270: Avelumab and Stereotactic Ablative Radiotherapy in Non-responding and Progressing NSCLC Patients",,"Recruiting","No Results Available","Metastatic Non-small Cell Lung Cancer (NSCLC)","Drug: Avelumab|Radiation: Stereotactic ablative radiotherapy (SAR)","Overall Response Rate|Overall Survival (OS)|Progression-Free Survival (PFS)|Disease Control Rate (DCR)|Duration of Stable Disease|Duration of Overall Response|Confirmation|Immune Related Response Criteria|Evaluation of Best Overall Response","Megan Daly, MD|EMD Serono|University of California, Davis","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","26","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1054028|UCDCC#270","May 17, 2017","June 1, 2020","June 1, 2021","May 18, 2017",,"May 1, 2019","UC Davis, Sacramento, California, United States",,"https://ClinicalTrials.gov/show/NCT03158883"
310,"NCT01241214","Study of ACT-129968 in Adult Patients With Seasonal Allergic Rhinitis","SAR","Completed","No Results Available","Seasonal Allergic Rhinitis","Drug: ACT-129968|Drug: Cetirizine|Drug: Placebo","To demonstrate a change in Daytime Nasal Symptom Score while taking Dose 3 of ACT-129968 versus placebo|To demonstrate a change in Daytime Nasal Symptom Score while taking either Dose 1, Dose 2, or Dose 4 of ACT-129968 verses placebo.","Idorsia Pharmaceuticals Ltd.","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","579","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","AC-060B202","November 2010","February 2011","February 2011","November 16, 2010",,"May 15, 2019","Clinical Investigative Site 7905, Austin, Texas, United States|Clinical Investigative Site 7907, Kerrville, Texas, United States|Clinical Investigative Site 7903, New Braunfels, Texas, United States|Clinical Investigative Site 7901, San Antonio, Texas, United States|Clinical Investigative Site 7902, San Antonio, Texas, United States|Clinical Investigative Site 7904, San Antonio, Texas, United States|Clinical Investigative Site 7906, San Antonio, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01241214"
311,"NCT00517946","A Study To Investigate If MRI Scanning Is Effective At Seeing What Hayfever Drugs Do In Nasal Passage.",,"Completed","No Results Available","Seasonal Allergic Rhinitis|Sinusitis","Drug: pseudoephedrine hydrochloride|Drug: cetirizine hydrochloride","Cross-sectional airspace area (and thus also airspace volume) of the nasal passages|Volume of fluid identified adjacent to the airspace. Mucosal surface area. Nasal cavity volume. Nasal tissue volume derived from the nasal cavity volume less airspace and fluid volumes.","GlaxoSmithKline","All","18 Years to 60 Years   (Adult)",,"21","Industry","Observational",,"RES101509","March 2007","April 2007","April 2007","August 17, 2007",,"September 2, 2013","GSK Investigational Site, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00517946"
312,"NCT00670384","Phase 2 Study in Adults Sensitized to Short Ragweed",,"Withdrawn","No Results Available","Allergic Rhinitis","Biological: Standardized Allergenic Extract, Short Ragweed (Ambrosia artemisiifolia)|Biological: Placebo","Average of Total Symptom Scores","Antigen Laboratories, Inc.","All","18 Years to 55 Years   (Adult)","Phase 2","0","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ALI001-08",,,,"May 1, 2008",,"January 9, 2014",,,"https://ClinicalTrials.gov/show/NCT00670384"
313,"NCT01302418","Collection and Testing of Respiratory Samples",,"Completed","Has Results","QIAGEN ResPlex II Advanced Panel|Influenza A|Respiratory Syncytial Virus Infections|Infection Due to Human Parainfluenza Virus 1|Parainfluenza Type 2|Parainfluenza Type 3|Parainfluenza Type 4|Human Metapneumovirus A/B|Rhinovirus|Coxsackie Virus/Echovirus|Adenovirus Types B/C/E|Coronavirus Subtypes 229E|Coronavirus Subtype NL63|Coronavirus Subtype OC43|Coronavirus Subtype HKU1|Human Bocavirus|Artus Influenza A/B RT-PCR Test|Influenza B","Device: artus Influenza A/B RT-PCR Test","Detection of Respiratory Viruses","QIAGEN Gaithersburg, Inc","All","Child, Adult, Older Adult",,"272","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","C10-INFLUENZA-001","February 2011","July 2011","November 2011","February 24, 2011","June 28, 2012","May 10, 2017","University of Arizona, Tuscon, Arizona, United States|Albany Medical College, Albany, New York, United States|Wadsworth Center, New York State Department of Health, Albany, New York, United States|The University of North Carolina, Chapel Hill, North Carolina, United States|Ohio State University, Columbus, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT01302418"
314,"NCT00646152","Poly-ICLC to Prevent Respiratory Viral Infections A Safety Study",,"Completed","No Results Available","Influenza|Severe Acute Respiratory Distress Syndrome|Smallpox|Ebola|Unknown Respiratory Viruses","Drug: Poly-ICLC","Frequency of AE greater than or equal to grade 2 by subjects who receive drug|Intranasal cytokines, nasal NO production, inflammatory cells in nasal wash","National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC)","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1","57","NIH","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Primary Purpose: Treatment","080093|08-I-0093","March 24, 2008","December 16, 2009","December 16, 2009","March 28, 2008",,"July 5, 2018","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00646152"
315,"NCT01056354","Respiratory Virus Outpatient Study (FLU 002 Plus)",,"Completed","No Results Available","Influenza and Other Novel Respiratory Viruses",,"Death or Hospitalization|Days of work/school lost, duration of symptoms, use of antivirals","University of Minnesota|National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health (NIH)","All","18 Years and older   (Adult, Older Adult)",,"11719","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","0603M83587 FLU 002|HHSN261200800001E ; 29XS214","August 2009","May 12, 2017","May 12, 2017","January 26, 2010",,"August 18, 2017","UCSD Antiviral Research Center, San Diego, California, United States|Denver Public Health, Denver, Colorado, United States|George Washington Medical Faculty Associates, Washington, D.C., District of Columbia, United States|Washington DC VA Medical Center, Washington, D.C., District of Columbia, United States|Infectious Diseases Associates NW FL, PA, Pensacola, Florida, United States|University of Illinois at Chicago, Chicago, Illinois, United States|Henry Ford Health System, Detroit, Michigan, United States|Newland Immunology Center of Excellence (NICE), Southfield, Michigan, United States|New Jersey Medical School Adult Clinical Research Center, Newark, New Jersey, United States|Cornell CRS, New York, New York, United States|Bronx-Lebanon Hospital Center, The Bronx, New York, United States|UNC AIDS Clinical Trials Unit, Chapel Hill, North Carolina, United States|Duke University, Durham, North Carolina, United States|University of Tennessee College of Medicine, Chattanooga, Tennessee, United States|University of North Texas Health Science Center, Fort Worth, Texas, United States|Houston AIDS Research Team, Houston, Texas, United States|Virginia Commonwealth University, Richmond, Virginia, United States|Hospital Nacional Profesor Alejandro Posadas, El Palomar, Buenos Aires, Argentina|Hospital Interzonal General de Agudos Dr. Diego Paroissien, La Matanza, Buenos Aires, Argentina|Instituto Medico Platense, La Plata, Buenos Aires, Argentina|Hospital Profesor Bernardo Houssay, Vicente Lopez, Buenos Aires, Argentina|CAICI (Instituto Centralizado de Assistencia e Investigacion Clinica Integral), Rosario, Santa Fe, Argentina|Sanatorio Britanico, Rosario, Santa Fe, Argentina|CEMIC, Buenos Aires, Argentina|FUNCEI, Buenos Aires, Argentina|Hospital General de Agudos JM Ramos Mejia, Buenos Aires, Argentina|Hospital Italiano de Buenos Aires, Buenos Aires, Argentina|Hospital Privado Centro Medico de Cordoba, Cordoba, Argentina|Hospital Rawson, Cordoba, Argentina|Interchange General Practice, Canberra, Australian Capital Territory, Australia|Holdsworth House Medical Practice, Darlinghurst, New South Wales, Australia|Westmead Hospital, Westmead, New South Wales, Australia|Prahran Market Clinic, Melbourne, Victoria, Australia|Northside Clinic, North Fitzroy, Victoria, Australia|Centre Hospitalier Universitaire St. Pierre (C.H.U. St. Pierre), Brussels, Belgium|Practimed Medisch Centrum Tessenderlo, Tessenderlo, Belgium|Clinica Alemana, Santiago, Chile|Fundacion Arriaran, Santiago, Chile|Pontificia Universidad Catolica de Chile, Santiago, Chile|Arhus Universitetshospital, Skejby, Aarhus, Denmark|CHIP, Copenhagen, Denmark|Rigshospitalet, Infektionsmedicinsk ambulatorium 8622, Copenhagen, Denmark|University Clinic of General Practice, Copenhagen, Denmark|West Tallinn Central Hospital Infectious Diseases, Tallinn, Estonia|Medizinische Universitatsklinik - Bonn, Immunologische Ambulanz CRS, Bonn, Germany|Klinik I fur Innere Medizin der Universitat zu Koln, Studienburo fur Infektiologie u. HIV, Cologne, Germany|Johann Wolfgang Goethe - University Hospital, Infektionsambulanz CRS, Frankfurt, Germany|Ifi - Studien und Projekte GmbH, Hamburg, Germany|1st Dept of Critical Care Medicine and Pulmonary Services, Evangelismos Hospital, Athens, Greece|1st Respiratory Medicine Dept, Athens Hosp for Diseases of the Chest ""Sotiria Hospital"", Athens, Greece|Evangelismos General Hospital, Athens, Greece|Hippokration University General Hospital of Athens, Athens, Greece|National Hospital Organization Nagoya Medical Center, Nagoya, Japan|Hospital Nacional Arzobispo Loayza, Lima, Peru|Asociacion Civil IMPACTA Salud y Educacion, Lima, Peru|Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru|Hospital Nacional Guillermo Almenara Irigoyen, Lima, Peru|Wojewodzki Szpital Zakazny, Warsaw, Poland|EMC Instytut Medyczny SA, Wroclaw, Poland|Hospital Universitario y Politécnico La Fe, Valencia, Spain|Hospital Txagorritxu, Vitoria-Gasteiz, Spain|Chulalongkorn University Hospital, Bangkok, Thailand|Khon Kaen University, Srinagarind Hospital, Khon Kaen, Thailand|Bamrasnaradura Institute, Nonthaburi, Thailand|Norfolk and Norwich University Hospital, Norwich, Norfolk, United Kingdom|Churchill Hospital, Headington, Oxford, United Kingdom|Bradford Teaching Hospitals NHS Foundation Trust, Bradford, West Yorkshire, United Kingdom|St James's University Hospital, Leeds, West Yorkshire, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01056354"
